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Abstract 
 
Growing evidence suggests an association between attention-deficit/hyperactivity disorder 
(ADHD) and obesity, although very little is understood about the nature of this link. The aims 
of this thesis were to examine the following aspects of the ADHD-obesity association: (1) the 
directionality of the link from childhood to adolescence, (2) behavioural mediators during 
childhood and adolescence, and (3) prenatal risk factors common for both disorders.   
 
Participants were from the Northern Finland Birth Cohort (NFBC) 1986 (N=9479). Data 
were obtained on pregnancy and birth factors, and child/adolescent mental health, obesity, 
and lifestyle factors.  
 
Regression analyses showed that ADHD symptoms significantly predicted obesity, rather 
than in the opposite direction, from childhood to adolescence. Mediation analyses examined 
potential underlying behavioural factors – physical activity and binge-eating, and showed that 
physical inactivity mediated the longitudinal ADHD symptom-obesity association. Further, 
there was a bidirectional, longitudinal association between physical inactivity and ADHD 
symptoms.  
 
ADHD and obesity may share common prenatal risk factors, including prenatal exposure to 
cortisol. This was studied using a quasi-experimental approach by examining the impact of 
prenatal exposure to synthetic glucocorticoids (sGC). Results from propensity-score and 
mixed-effects methods showed that prenatal sGC increased the risk for general psychiatric 
disturbance and inattention symptoms, but not obesity, in childhood. Placental size may 
represent another common prenatal contributing factor; placental size was positively 
associated with behaviour problems, including ADHD symptoms, in child and adolescent 
boys, but was not associated with obesity.  
 
This thesis addresses important unexplored aspects of the association between ADHD and 
obesity, and provides insight into risk factors for both disorders. The direction of the 
association was driven from ADHD symptoms to obesity, and physical inactivity was a 
behavioural mediator underlying the link. Although there was no evidence that both disorders 
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share common prenatal risk, prenatal sGC and placental size were positively associated with 
ADHD symptoms.  
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PTSD Post-traumatic stress disorder  
RCT Randomised controlled trial 
ROC Receiver Operating Characteristic  
SAD Seasonal affective disorder 
SD Standard deviation 
SDQ Strengths and Difficulties Questionnaire  
SDS Standard deviation score 
sGC Synthetic glucocorticoid 
SNP Single-nucleotide polymorphism  
SSRI Selective serotonin reuptake inhibitors  
SWAN Strengths and Weaknesses of ADHD symptoms and Normal behaviour 
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VEGF Vascular endothelial growth factor  
WHR Waist-hip ratio  
WW2 World War 2 
YSL Youth Self Report 
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1. Introduction  
 
Attention-deficit/hyperactivity disorder (ADHD) symptoms and obesity are both highly 
prevalent with wide-ranging clinical implications, and typically persist throughout life [1,2]. 
Recent research suggesting a connection between ADHD and obesity [3] warrants further 
investigation since individuals with both conditions represent a proportion of the population 
who may be particularly vulnerable from a medical and psychological viewpoint. 
 
The period of childhood and adolescence will be the focus of study because both disorders 
typically manifest early in life [4,5], and thus this is a key stage for potential future 
intervention strategies. This chapter provides an overview of the aetiology and clinical 
implications of ADHD and obesity, and introduces how these two disorders may be related, 
including potential common prenatal origins.   
 
1.1 ADHD in children and adolescents  
 
ADHD is the most common behavioural disorder in young people, with an estimated 
worldwide prevalence of approximately 5% [6]. According to the Diagnostic and Statistical 
Manual of Mental Disorders V (DSM-V), the disorder is characterised by age-inappropriate 
levels of inattention and/or hyperactivity-impulsivity, which have persisted for at least 6 
months and interfere with functioning or development [7]. Inattention in ADHD manifests 
behaviourally as wandering off task, having difficulty sustaining focus and being 
disorganised [7]. Hyperactivity refers to excessive fidgeting and talking, and restlessness [7]. 
Impulsivity is expressed as hasty behaviour that lacks foresight, with a desire for immediate 
rewards, and can have a high potential for harm to the individual [7]. These symptoms of 
ADHD may persist into adulthood in up to 60% of cases [5]; hyperactivity-impulsivity 
symptoms tend to wane early in life though, while inattention symptoms tend to prevail over 
the long-term [8].   
 
In terms of aetiology, ADHD is a complex and multifactorial disorder, encompassing both 
genetic and environmental (e.g. biological and psychosocial adversity) underpinnings [1]. 
Genetic factors account for the greatest proportion in the aetiology of ADHD, estimated as 
approximately 80% [9]. The gene most strongly linked with ADHD is the 7-repeat allele of 
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the dopamine receptor 4 gene (DRD4) [10], and there are other dopamine-related genes e.g. 
DRD2, DRD5, dopamine transporter (DAT) and dopamine   β-hydroxylase (DBH) also 
associated with ADHD [11-14]; this corroborates consistent neurobiological findings that 
implicate the dopaminergic system in the pathogenesis of ADHD [1]. It is suggested that 
hypo-dopaminergic brain functioning contributes to ADHD pathology, and the most 
convincing evidence for this is demonstrated by the effective treatment of ADHD through use 
of psychostimulants, such as methylphenidate, which inhibit dopamine reuptake [15-18]. 
ADHD and other disorders that share a common genetic basis for deficient dopamine 
transmission  have  been  classified  under  an  umbrella  syndrome  known  as  “reward  deficiency  
syndrome”,  which  denotes  a  dysfunction  of   the  brain   reward  cascade   [18,19]. There is also 
evidence indicating that imbalances in the noradrenergic system is linked with ADHD 
pathology [1].   
 
The functional impairments related to ADHD are  manifold,   affecting   all   areas   of   a   child’s  
life, including social and scholastic aspects [20]. Children with ADHD are more likely to 
experience peer problems (e.g. rejection or teasing) and suffer from poor self-esteem, as well 
as attain lower academic grades and later experience poorer occupational attainment [7,20-
22]. Furthermore, individuals with ADHD are at increased risk of accidental injury; for 
example, traffic accidents are more frequent in drivers with ADHD [7]. Comorbid disorders 
are common in clinically diagnosed ADHD, and these most frequently include oppositional 
defiant disorder (ODD) - which is characterised by angry/irritable mood, 
argumentative/defiant behaviour, or vindictiveness, and conduct disorder (CD) - which 
presents as violating either the rights of others or major societal norms [7]. To a less extent, 
anxiety and depression co-occur with ADHD [7]. There is also a well-established 
comorbidity between ADHD and substance abuse e.g. drugs, alcohol and smoking [7,23]. 
The increased vulnerability to addiction is understood to stem from the symptomatology and 
hypo-dopaminergic functioning linked with ADHD; the impulsive desire for immediate 
rewards may be satisfied through use of drugs or other substances that can activate dopamine 
release [18]. Over the last decade, there have been a growing number of studies reporting a 
link between ADHD and obesity [3]; given the rewarding and potentially addictive properties 
of food, it is hypothesised that the obesogenic environment of our modern society may 
promote such an association [24,25]. Despite these findings, this field of research is still in its 
infancy, and only the minority of ADHD outcome studies have examined obesity as an 
outcome of ADHD, according to a recent review (Figure 1.1) [26]. This thesis aims to 
27 
 
Figure 1.1: Number of studies according to ADHD outcome group.  Reproduction of the figure 
from Shaw et al. (2012) [26], permitted under the Creative Commons Attribution Licence 2.0.   
 
address this gap in research, which is of particular public health significance in light of the 
current obesity epidemic which calls for further investigation of groups at risk of obesity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 Obesity in children and adolescents  
 
Childhood and adolescent obesity have increased dramatically over the past 30 years, in both 
developed and developing nations, such that now approximately 10% of school-aged children 
worldwide are overweight, a quarter of which are obese [27]. This trend poses significant 
public health implications, given that childhood obesity is associated with both immediate 
and long-term clinical consequences. Well-known physical conditions related to childhood 
obesity include endocrine, metabolic and cardiovascular disorders [28]. The psychological 
consequences, including depression, anxiety and behavioural problems [29], have received 
comparatively less research attention [27]. Obesity frequently tracks from childhood into 
adulthood, with up to 80% of obese children becoming obese adults [2].  In children and 
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adolescents, body mass index (BMI) based on age and sex-specific percentiles is commonly 
used to define obesity; child BMI correlates reasonably well with measures of body fatness 
and metabolic outcomes e.g. blood pressure and blood lipids [28].  
 
The escalating prevalence and impact of childhood obesity has prompted further investigation 
into the potential causes of this so-called epidemic. Most research attention has focused on 
environmental risk factors, given the dramatic transition in  modern society over recent years, 
where food and drink are in superfluity and lifestyle has become increasingly more sedentary 
[27]. Genetic studies have found that the heritability of BMI is high, estimated to be around 
70% [30]. Despite the considerable genetic component to BMI, it is suggested that only 
around  10%  of   obesity   cases   are   attributable   “purely”   to   genes   [30].  The majority – over 
90% of cases, are believed to be idiopathic [31], where it is likely that an interplay between 
multiple factors e.g. genes, environment, and behaviour, contribute to obesity [32]. There is 
some evidence that children with psychological problems represent a group particularly at 
risk for obesity [27]. In line with this, obesity is often characterised by compulsive 
consumption of food and an inability to control eating, with symptoms similar to those 
described in DSM-V for substance abuse and drug dependence, and thus there appears to be a 
significant psychological element to obesity [33]. It has been suggested that in certain cases 
obesity  may  be  regarded  as  a  ‘food  addiction’  and  should  perhaps  be  recognised as a mental 
disorder in DSM-V [33]. Given that both obesity and ADHD can be characterised by 
addictive and impulsive behaviours, it is important to examine the nature of the link between 
the two disorders.  
 
1.3 Foetal origins of ADHD and obesity 
 
To improve understanding of aetiology and enhance potential prevention strategies, it is 
important to examine ADHD and obesity using a life course approach, studying these chronic 
disorders from the earliest possible stage, foetal development, when the risk for such 
conditions may be established. Although genetic and environmental/lifestyle factors are 
traditionally associated with the development of disease, including obesity and ADHD, 
accumulating evidence over recent years has revealed that life in utero is another powerful 
source of influence, in accordance with the foetal programming phenomenon [34]. The 
hypothesis of foetal programming states that adverse prenatal conditions can result in 
29 
 
permanent changes to the structure, physiology and function of developing organs, thereby 
increasing  the  risk  for  disease  later  in  life;;  this  is  typically  referred  to  as  the  “Developmental  
Origins  of  Health  and  Disease  (DOHaD)”  model  [34-36]. The prenatal environment has been 
independently associated with ADHD and obesity [37,38]; however it remains unevaluated 
whether common prenatal pathways confer risk for these disorders.  
 
Prenatal maternal stress has been linked with ADHD and obesity [39,40], and as such may 
represent a common risk factor for both disorders. Considering the available evidence, it is 
possible to speculate that excess prenatal exposure to maternal glucocorticoids (GC) – 
released in response to stress, may underlie these associations [41,42]. This hypothesis can be 
explored via a quasi-experimental approach, through studying the impact of prenatal 
synthetic glucocorticoid (sGC) treatment (routinely administered in threatened preterm birth) 
on later mental health and obesity. Little is understood about the potential GC programming 
pathway. The placenta, which regulates foetal exposure to maternal GC, has been suggested 
as one potential factor mediating the pathway [43]. Various maternal factors can affect 
placental growth, which in turn is an important determinant of foetal growth and 
development, and has been linked with later disease risk [44,45]. As such, it is possible that 
altered placental size may underlie the link between prenatal exposures and later disease risk. 
Altered placental size has been associated with both prenatal maternal stress and prenatal 
sGC [46,47], but it remains unknown whether placental size may represent a common risk 
factor for both ADHD and obesity. Research into potential common prenatal pathways 
underlying both disorders is needed in order to provide insight into whether the risk for the 
ADHD-obesity association may originate in utero. 
 
1.4 Themes and aims of the thesis in brief 
 
This thesis will address critical gaps in knowledge relating to the association between ADHD 
symptoms and obesity, namely the direction of the link and potential underlying behavioural 
and prenatal pathways. As such, the aims of this thesis can be divided into two themes of 
study:  
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Theme I: 
Exploring directionality and underlying behavioural mediators of the association between 
ADHD symptoms and obesity 
 
1. To examine concurrent and longitudinal associations between ADHD symptoms and 
obesity over the period of childhood to adolescence.  
2. To examine binge-eating and physical inactivity as potential behavioural mediators 
underlying the ADHD symptom-obesity association.  
 
Theme II:  
Investigating whether prenatal factors confer common risk for mental health and obesity 
 
3. To examine whether prenatal sGC and placental size each confer common risk for mental 
health and obesity in childhood and adolescence.   
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2. Literature review 
2.1 Association between ADHD and obesity 
 
Over the past decade, a growing number of studies report an association between ADHD and 
obesity [48,49]. However, very little is known about this association in the general population 
of children and adolescents; since both ADHD and obesity are frequently manifested in 
childhood [4,5], it is important to study the possible comorbidity and causality between these 
disorders at an early stage to enhance prevention strategies. Whilst great emphasis has been 
placed on the long-term health consequences of childhood obesity, the concurrent risk of 
psychopathology at the time of childhood tends to be overlooked [3]. Indeed, one study 
observed that the ADHD diagnosis was missed in approximately 60% of obese patients [49].  
 
2.1.1 Review of the literature 
 
In 2008, Cortese et al. published a systematic review [50] of studies that examined the 
association between ADHD and obesity, from the period of January 1980 (when the 
American Psychiatric Association first published the DSM-III) to January 2007. In this thesis, 
a subsequent literature review of articles published from February 2007 to February 2014 is 
performed (Figure 2.1) to cover the latest research. In accordance with the Cortese et al. 
review [50], a similar selection process was used to identify further publications. Thus, 
studies were searched for that examined (1) the prevalence of ADHD or ADHD symptoms in 
obese individuals, and (2) the weight status of individuals with ADHD or ADHD symptoms. 
To do so, a PubMed search was performed, using the following keywords in various 
combinations: ADHD, attention-deficit/hyperactivity disorder, inattenti*, hyperactiv*, 
impulsiv*, obes*, overweight and weight. Additionally, the keywords psychiatr*, 
psychopatholog* and psycholog* were individually cross-referenced with obes* and 
overweight. The inclusion criteria for reviewing articles were as follows: (1) English 
language, (2) human studies (in children, adolescents or adults), (3) assessment of ADHD or 
ADHD symptoms based on standardised criteria, (4) studies that applied statistical analyses 
to data (i.e. exclude descriptive studies), and (5) studies that accounted for ADHD treatment. 
Stimulant medications commonly used to treat ADHD could impact weight because these 
drugs may have complex effects on energy intake and expenditure. Indeed, methylphenidate 
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– the most commonly prescribed ADHD medication [51], can supress appetite for a few 
hours [52,53], yet parents commonly report that their child has increased appetite and food 
intake after the effect of the drug diminishes [54]. Furthermore, methylphenidate may reduce 
the resting metabolic rate, as well as decrease spontaneous physical activity [55]. Thus, the 
ultimate effect of the drug may be an increase, decrease, or no change in weight – contingent 
on the net energy balance. Furthermore, long-term use of methylphenidate can reduce growth 
and final height [56].    
 
The following section discuses articles collectively identified by the Cortese et al. review [50] 
(from January 1980 to January 2007) and by the present literature review (February 2007 to 
February 2014); the results of all these articles are summarised in Table 2.1. Studies that did 
not meet the inclusion criteria but which are of interest, e.g. examine potential mediating 
factors or study very large samples, are also discussed in brief within the text.  
 
NB. Informants (e.g. parents, teachers, self-report or clinical examination) of weight/height 
and ADHD are detailed in the review, only when this information is available.  
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26,495 articles identified from 
electronic database search  
Combination search results:  
ADHD and obes*: 206; Attention-deficit/hyperactivity disorder and obes*: 1; Inattenti* and obes*: 16; 
Hyperactiv* and obes*: 177; Impulsiv* and obes*: 140; ADHD and overweight: 13; Attention-
deficit/hyperactivity disorder and overweight: 9;  Inattenti* and overweight: 1; Hyperactiv* and overweight: 
6; Impulsiv* and overweight: 11; ADHD and weight: 528; Attention-deficit/hyperactivity disorder and 
weight: 1; Inattenti* and weight: 33; Hyperactiv* and weight: 360; Impulsiv* and weight: 159; Obes* and 
psychiatr*: 2715; Obes* and psychol*: 7707; Obes* and psychopatholog*: 28; Overweight and psychiatr*: 
188; Overweight and psychol*: 750; Overweight and psychopatholog*: 0 
 
 
 
 
13,049 articles of potential 
relevance  
54 articles reviewed 
 
15 articles included in literature 
review which meet inclusion 
criteria 
13,446 duplicate articles  
12,995 articles excluded that do not examine the prevalence of ADHD in obese 
individuals or the weight status of individuals with ADHD  
17 articles of further interest 
included in literature review 
which do not meet inclusion 
criteria  
39 articles excluded that do not meet inclusion criteriaa 
Figure 2.1: Flowchart showing review and selection process of articles, from 
the period of February 2007 to February 2014. aInclusion criteria: (1) English 
language, (2) human studies (in children, adolescents or adults), (3) assessment 
of ADHD or ADHD symptoms based on standardised criteria, (4) studies that 
applied statistical analyses to data (i.e. exclude descriptive studies), and (5) 
studies that accounted for ADHD treatment. 
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Table 2.1: Summary of articles that examined the association between ADHD and obesity, which meet inclusion criteria,a from the period of January 1980 to February 
2014.  
Reference Study design Sample (size, type) Age range 
(years) or 
Mean age (SD) 
Key results 
Cross-sectional studies 
Studies examining prevalence of ADHD in obese individuals  
Children and adolescents 
Erermis et al. (2004) [57] Clinical cases (obese)   
vs. non-clinical cases 
(obese) & controls 
(normal weight) 
30 clinically obese  
30 non-clinically obese  
30 normal weight  
12-16 ADHD rates: 
(1) Clinical obese group: 13.3% 
(2) Non-clinical obese group: 3.3%  
(3) Control group: 3.3% 
ADHD rate in group (1) significantly higher than 
in groups (2) & (3) 
 
Agranat-Meged et al. (2005) [49] Clinical 26 obese  8-17  ADHD rate: 57.7%; significantly higher than the 
10% estimate in the general population in the same 
age  group:  χ2=65.71, p<.0001 
 
Erhart et al. (2012) [58] Population  2414  7-17  Overweight/obesity increased the risk of ADHD: 
OR=1.663, 95% CI: 1.008-2.744 
 
Delgado-Rico et al. (2012) [59] Population 63  12-17  BMI significantly predicted impulsivity:  
e.g. for negative urgency, R2 change when BMI 
added to model=.106, p=.002 
Adults     
Altfas (2002) [48] Clinical 215 obese  43.4 (10.9) ADHD rates:  
(1) Full sample: 27.4% 
(2) Extreme obese group: 42.6%  
(3) Obese group: 22.8%  
(4) Overweight group: 18.9%  
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ADHD rate in group (2) significantly higher than 
in groups (3) & (4): χ2=9.86, p=.002 
 
BMI: 
Obese ADHD vs. obese non-ADHD groups:  
39.2±10 vs. 34.6±7.1, p=.01 
 
Fleming et al. (2005) [60] Clinical 75 obese women 40.4 (10.8) Clinically relevant elevations in ADHD subscale 
scores were significantly higher in obese 
individuals than expected frequencies: 
DSM-IV inattentive: 41.3%, χ2=113.2, p<.001 
ADHD-index:  30.7%,  χ2=52.4, p<.001  
 
Nazar et al. (2012) [61] Clinical 155 obese women  38.9 (10.7) ADHD rate: 28.3% (CI: 23.78%-32.82%); higher 
than expected prevalence of 4% (CI: 3.8%-5.0%)  
 
BMI:  
Obese ADHD vs. obese non-ADHD groups: 
38.45±4.24 vs. 39.51±5.65, t-test=1.055, 
p=n.s 
     
Studies examining prevalence of overweight/obesity in individuals with ADHD 
Children and adolescents  
Spencer et al. (1996) [62] Clinical, case-control 124 ADHD boys  
109 controls  
6-17 Weight; ADHD vs. control boys:  
62±19 kg vs. 58±17 kg, F=2, p=n.s 
 
Biederman et al. (2003) [63] Clinical, case-control 140 ADHD girls  
122 controls  
6-17 Average age- and height-corrected weight index: 
1.1±0.2; greater than average but not reflective of 
overweight or obesity 
 
Weight index; ADHD vs. control groups:  
112±27.3 vs. 113±28.6, t-test=.42, p=.676 
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Holtkamp et al. (2004) [64] Clinical 97 ADHD boys 5.5-14.7 Mean BMI standard deviation score (SDS):  
0.25±1.2; significantly higher than age-adapted 
reference value (0), p=.038 
 
Obesity: 7.2%; higher than estimated, p=.0008 
Overweight: 19.6%; higher than estimated, 
p=.0075 
 
Curtin et al. (2005) [65] Clinical  98 ADHD  
 
3-18  Overweight in full sample: 17.3%;  
non-significantly different from an age-matched 
reference population 
 
Overweight in untreated vs. treated ADHD 
individuals: 23% vs. 6.3%, p<.05 
 
Faraone and Bierderman (2005) [66] Clinical 568 ADHD  6-12 Mean BMI z-score=0.41 (at baseline, prior to 
stimulant treatment); higher than average BMI 
 
Spencer et al. (2006) [67] Clinical 178 ADHD  6-13 Mean BMI z-score=0.23 (at baseline, prior to 
stimulant treatment); slightly overweight 
compared with age-matched reference 
 
Swanson et al. (2006) [68] Clinical 140 ADHD  3-5.5  Mean BMI: 16.9±1.86; corresponds to 86th 
percentile (according to reference growth charts) 
 
Hubel et al. (2006) [69] Population,  
case-control 
39 ADHD  
30 controls  
8-14 Mean BMI-SDS: 
ADHD individuals: 0.29±1.01 
Controls: 0.05±0.94 
 
ADHD status & overweight:  χ2=0.87, p=n.s 
ADHD status & obesity:  χ2=0.59, p=n.s 
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Lam and Yang (2007) [70] Population 1429  13-17 ADHD score predicted obesity:  
OR=1.07, 95% CI: 1.01-1.14 
 
High ADHD tendency increased risk of obesity by 
1.4 times compared with low ADHD tendency 
 
Ptacek et al. (2009) [71] Clinical 46 ADHD boys 11.03 (2.68) Abdominal circumference mean: 0.6±1.46;  
greater than reference population: t-test=2.78, 
p=.008 
 
Percentage fat mean: 0.51±0.86;  
greater than reference population: t-test=3.98, 
p=.00 
 
Ptacek et al. (2009) [72] Clinical,  
non-medicated vs. 
medicated boys 
52 ADHD non-medicated boys  
52 ADHD medicated boys  
4-16 Greater percentage body fat: t=2.56, p<.012 & 
middle thigh circumference: t=2.18, p<.018 in 
non-medicated ADHD vs. medicated ADHD boys.  
 
No significant differences on other anthropometric 
measures e.g. body weight, arm circumference & 
chest circumference  
 
Dubnov-Raz et al. (2011) [54] Clinical,  
non-medicated vs. 
medicated 
140 ADHD non-medicated  
135 ADHD medicated  
6-16 Mean BMI z-scores ± SD; 
ADHD non-medicated vs. medicated groups: 
0.22±1.02 vs. 0.23±0.90, p=.12 
ADHD vs. control groups:  
0.23±0.97 vs. 0.48±1.04, p=.22  
 
Overweight rates; ADHD vs. control groups:  
19% vs. 35%, p=.02 
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Tashakori et al. (2011) [73] Population,  
case-control 
32 ADHD boys  
32 control boys  
5-6  Overweight rates; ADHD vs. control boys:  
6.25%  vs.  9.375%,  χ2=.21, p=1 
Mean BMI ± SD; ADHD vs. control boys:  
15.44 ± 1.82 vs. 15.54 ± 1.67, p=.82 
 
Ebenegger et al. (2012) [74] Population 450  4-6 Hyperactivity/inattention scores were not 
associated  with  BMI:  β=  -.01, 95% CI: -.08-.06, 
p=.74, nor overweight or obesity (data not shown) 
 
High hyperactivity/inattention scores were 
associated with lower percentage body fat:  
β=  -.2, 95% CI: -.37- -.03, p=.02 
 
Faraone et al. (2012) [75] Population,  
ADHD compared 
with non-ADHD 
25 ADHD  
511 non-ADHD  
6-12 Compared with non-ADHD children, young 
children with ADHD were heavier: t=1.8, p=.03, 
and taller: t=26.3, p<.001, and older children with 
ADHD were lighter and shorter (data not shown) 
 
Yang et al. (2013) [76] Clinical 158 ADHD  6-16.6  Combined ADHD subtype increased risk of 
overweight/obesity compared with inattentive and 
hyperactive/impulsive subtypes:  
OR=2.8, 95% CI: 1.225-6.434, p=.015.  
 
Children in puberty who had ADHD had a greater 
risk of overweight/obesity compared with those in 
the pre-pubertal stage:  
OR=4.098, 95% CI: 1.337-12.191, p=.011 
 
Pauli-Pott et al. (2013) [77] Clinical, case-control 257 with ADHD, ODD/CD or 
comorbid ADHD and 
ODD/CD, & 103 with 
adjustment disorder (controls) 
6-12 ADHD individuals did not significantly differ on 
obesity risk compared with controls: OR=1.49, 
95% CI: 0.59-3.79, nor on BMI-SDS: F=.10, p=n.s 
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Byrd et al. (2013) [78] Population 3050  8-15 Individuals with ADHD (non-medicated) did not 
significantly differ on obesity risk compared with 
controls: 
Males: OR=1.02, 95% CI: 0.43-2.42 
Females: OR=1.54, 95% CI: 0.79-2.98 
 
Gungor et al. (2014) [79] Clinical, case-control 362 ADHD  
390 controls 
5-15 Overweight rates; ADHD vs. control:  
9.4% vs. 1.5% 
Obesity rates: ADHD vs. control:  
7.1% vs. 0.2% 
χ2=30.83, p=.0001  
 
Adults 
Pagoto et al. (2009) [80] Population 6735  18-44 ADHD increased risk of:  
Overweight: OR=1.58, 95% CI: 1.05-2.38, & 
Obesity: OR=1.81, 95% CI: 1.24-2.64,  
after adjusting for socio-demographic factors.  
 
However, after additional adjustment for binge-
eating, associations became non-significant:  
Overweight: OR=1.05, 95% CI: 0.54-2.05 
Obesity: OR=1.41, 95% CI: 0.76-2.52 
     
Longitudinal Studies     
Anderson et al. (2006) [81] Population 665  Aged 9.1-16.6 at 
baseline, and 
followed-up at 
three waves – 
ages 11.1-20.8, 
16.6-26.5 & 
27.8-38.2  
 
ADHD was not associated with BMI z-score 
trajectory: 
Males:  
Mean difference=0.21, 95% CI: -0.03-0.44,  
Females:  
Mean difference=0.23, 95% CI: -0.05-0.52 
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Mustillo et al. (2003) [82] Population 991  Aged 9, 11 & 13 
at baseline, and 
followed-up 
annually over an 
8-year period 
 
Obesity trajectory (no obesity, childhood obesity, 
adolescent obesity, and chronic obesity) was not 
associated with ADHD: F=.38, p=.76 
Biederman et al. (2010) [83] Clinical, case-control 137 ADHD  
124 controls 
Aged 6-17 at 
baseline and 
followed-up 
after 10-11 years 
BMI z-scores at follow-up;  
ADHD vs. controls: 
Males: 
0.55±1.0 vs. 0.60±0.9, t-test= -0.49, p=.628 
Females:  
0.61±0.9 vs. 0.38 ± 1.0, t-test=0.70, p=.486 
 
Other anthropometric measures studied, e.g. height 
and weight: no significant differences between 
ADHD and control groups 
aInclusion criteria: (1) English language, (2) human studies (in children, adolescents or adults), (3) assessment of ADHD or ADHD symptoms based on standardised 
criteria, (4) studies that applied statistical analyses to data (i.e. exclude descriptive studies), and (5) studies that accounted for ADHD treatment. 
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2.1.2 Cross-sectional studies examining the association between ADHD and obesity  
 
Examination of the prevalence of ADHD in obese individuals   
 
Studies on children/adolescents  
 
In children/adolescents, four studies which examined the prevalence of ADHD in obese 
individuals were identified, two of which were conducted in clinical settings (for obesity 
treatment) [49,57] and two studies in the general population [58,59]. All these studies 
reported an association between ADHD or ADHD symptoms and obesity.  
 
Erermis et al. (2004) [57] analysed the frequency of psychopathology in a clinical study 
group of 30 obese adolescents (aged 12-16 years) obtaining treatment in a paediatric 
endocrinology outpatient clinic, in a non-clinical obese group of 30 obese adolescents 
matched for age and sex, and in a control group of 30 normal weight adolescents, also 
matched for age and sex. Obesity was defined according to age and sex-specific standardised 
percentile curves of BMI. The study excluded individuals with mental retardation, chronic 
physical illness, bipolar disorder or any other psychotic disorder. They found that the 
occurrence of ADHD was significantly higher in the sample of clinical obese adolescents 
(13.3%) compared to the non-clinical obese group (3.3%) and the control group (3.3%). It is 
important to note that the mean BMI was significantly lower in the non-clinical obese group 
compared to the clinical obese group, which may represent as a bias when comparing the 
prevalence of psychopathology between the two groups. Additional limitations to this study 
include a small sample size (n=90), which prevented examination of sex differences, and use 
of a non-structured psychiatric interview that was used to diagnose several 
psychopathologies, including ADHD.  
 
Further evidence for the potential comorbidity between ADHD and obesity is provided by 
Agranat-Meged et al. (2005) [49], who studied a clinical sample of 26 morbidly obese (BMI 
> 95th percentile) children/adolescents (aged 8-17 years), hospitalised in an eating disorder 
unit. ADHD diagnoses were made according to DSM-IV criteria, through use of the semi-
structured interview Schedule for Affective Disorders and Schizophrenia for School-Age 
Children-Present and Lifetime Version (K-SADS-PL). The authors observed that 57.7% of 
participants presented with ADHD, which is significantly higher than the 10% prevalence of 
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ADHD found in the general population in the same age group. Interestingly, 60% of 
participants were diagnosed with the combined type of ADHD, whilst 40% had the 
predominantly inattentive type. Although the study attempted to minimise the sample bias by 
utilising a stringent exclusion criteria (IQ < 80, developmental or neurological disorders, 
obesity related to known medical causes), it must be stressed that the clinical sample was 
small and consisted of hospitalised morbidly obese children. Furthermore, lack of a clinical 
control group prevents a firm conclusion being drawn from the results.  
 
In a community-based sample of 2414 children (aged 7-17 years), Erhart et al. (2012) [58] 
found that overweight/obesity (BMI >90th and >97th percentiles respectively) increased the 
risk of ADHD by approximately 2-fold, after controlling for confounders including socio-
demographic factors and psychiatric comorbidities of ADHD (emotional problems, conduct 
problems and peer problems). Body weight and height were measured by trained staff at an 
examination centre, while ADHD was assessed by parental report through use of the German 
ADHD Rating Scale (FBB-HKS/ADHS), which is based on DSM-IV criteria. The study also 
examined the reverse association, and found that children with ADHD had almost a 2-fold 
increased risk of overweight/obesity. Interestingly, the severity of impulsivity symptoms, but 
not inattention or hyperactivity symptoms, was significantly related with higher BMI values. 
Further, the authors speculated that abnormal eating patterns may contribute to the ADHD-
obesity association, as they found that children with ADHD  were  more  likely  to  endorse  “lost 
control  over  eating’’  and  ‘‘food  dominates  life’’ via questionnaire compared with their peers 
without ADHD. However, mediation by eating problems was not formally tested. 
Furthermore, there was a lack of sufficient information on past ADHD medication, which 
may be important to consider in relation to potential effects on growth.  
 
Delgado-Rico et al. (2012) [59] studied the association between BMI and impulsivity 
(assessed dimensionally using the UPPS-P Scale) in a population sample of 63 children (aged 
12-17 years). Exclusion criteria included past/current evidence of medical or psychological 
disorders. The results showed that BMI positively predicted impulsivity in overweight/obese 
children compared with normal weight children (BMI International Obesity Task Force 
(IOTF) cut-off points), independent of socio-demographic factors. A major limitation of the 
study is the very small sample size (n=63).  
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Studies on adults  
 
In adults, three studies examining the prevalence of ADHD in obese individuals were 
identified, all of which were based on clinical samples and all reported a link between ADHD 
and obesity [48,60,61]. Altfas (2002) [48] studied a sample of 215 obese adults (mean age 
43.4 years) treated in a bariatric clinic. Out of these patients, a subset of 24.7% presented 
with ADHD (assessed via semi-structured interviews, according to DSM-IV criteria), and this 
subset had significantly higher BMI than patients without ADHD. Furthermore, the 
prevalence   of   ADHD   was   significantly   higher   in   the   extreme   obese   group   (BMI   ≥   40), 
42.6%, compared with the obese (BMI 30-39.9) and overweight (25-29.9) groups, 22.8% and 
18.9%, respectively. Fleming et al. (2005) [60] examined a sample of 75 obese women (mean 
age  40.4;;  BMI  ≥  35)  consecutively  referred  to  a  medical  obesity  clinic.  Out  of   this  sample,  
26.6% of patients were identified as probable ADHD cases. Although a formal ADHD 
diagnosis was not performed, the authors used a highly sensitive instrument and also 
combined data from several different questionnaires to obtain a valid estimate of ADHD 
diagnosis [50]. The patient sample exhibited higher frequencies of probable inattention and 
combined ADHD compared with the expected frequencies. On the other hand, there were no 
significant differences for probable hyperactivity/impulsivity. Nazar et al. (2012) [61] studied 
a sample of 155 obese women (mean age 38.9 years;;   BMI   ≥   30) seeking treatment at a 
weight-loss clinic. Exclusion criteria were less than 5 years of schooling/inability to read and 
write, current alcohol/drug abuse, history of bipolar or psychotic disorder, age > 60 years, 
and presence of uncontrolled clinical, neurological or endocrine disorders (particularly if they 
affect weight, appetite and attention). ADHD diagnosis was made by the K-SADS interview, 
adapted for adults. The rate of ADHD in the sample was 28.3%, which is higher than the 
expected prevalence for adults in the general population (approximately 4% [5]). While 
ADHD became more frequent with increasing BMI, this was not statistically significant. 
Significant limitations of all these clinical studies include small sample sizes (n=215, n=75 
and n=155), possible selection bias (two studies examined only females [60,61] and the other 
had a sample which was about 90% female [48]), lack of a control group, and either complete 
[48,60] or partial [61] lack of adjustment for comorbid psychiatric disorders of ADHD, such 
as depression and anxiety. 
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Further studies of interest 
 
It is of interest to mention four other studies identified during the literature search, although 
these do not meet the criteria for review; none of the studies controlled for (or mentioned) 
medication status [84-87] and one study did not use formal criteria for assessing ADHD [84]. 
These studies provide further insight into the ADHD-obesity association, through 
examination of ADHD symptoms dimensionally [85,87], use of population samples (which 
are comparatively lacking) [85-87], and examination of ADHD in relation to risk factors for 
obesity [86].  
 
Braet et al. (2007) [87] examined a clinical sample of 56 overweight children (referred to a 
paediatric centre) and 53 normal weight controls (aged 10-18 years), and found a 
significantly higher prevalence of impulsivity in overweight children and adolescents. 
Overweight was defined according to the 2000 Centres for Disease Control and Prevention 
(CDC) growth charts for the US, and ADHD symptoms and diagnosis were assessed via 
interview with the child using The Structured Clinical Interview for DSM-IV, Childhood 
version (KID-SCID). Overweight boys reported more difficulties in focussing their attention, 
while both overweight boys and girls reported more problems in shifting their attention 
compared with normal weight controls. Furthermore, overweight boys in particular showed 
significantly more hyperactivity, impulsivity and inattention symptoms compared with 
control boys. However, no significant difference in the occurrence of ADHD diagnosis was 
detected, although neither the medication status nor potential comorbid psychiatric disorders 
of the patients were reported.   
 
Koshy et al. (2011) [84] studied a population sample of 1,074 schoolchildren (aged 5-11 
years) from 15 different schools, and found that obesity (BMI z-score  ≥  1.64  SD)   increased 
the risk of ADHD by 4.7 fold. While weight and height were measured during the 
anthropometric survey as part of the study, ADHD diagnosis was ascertained via parental 
questionnaire,   with   the   question,   “Does your child have attention deficit hyperactivity 
disorder  (ADHD),  which  has  been  diagnosed  by  a  doctor?”  This  means  of  assessing  ADHD  
excludes potential undiagnosed cases, and so is unlikely to identify all ADHD cases within 
the sample. Indeed, the prevalence of ADHD in the sample was 3.4%, which is lower than 
expected for a population sample in the UK, where the study was based. Furthermore, this 
study did not control for comorbid psychiatric disorders of ADHD, and it is possible that the 
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results may be affected by sampling bias as the questionnaire response rate was extremely 
low (30.3%).  
 
van Egmond-Fröhlich et al. (2012) [85] examined a population sample of 11,378 children 
(aged 6-17 years), whose  height and weight were measured by trained staff during a physical 
examination, while ADHD symptoms were assessed by parents via the Strengths and 
Difficulties Questionnaire (SDQ). The results showed an association between 
overweight/obesity (BMI IOTF cut-off points) and ADHD symptom scores, after controlling 
for age and sex. However, when additionally controlling for other factors, namely parental 
BMI, parental smoking, socioeconomic status and migrant status, the association became 
non-significant except in adolescent girls. The authors proposed a number of hypotheses for 
an association only in adolescent girls, including the idea that binge-eating, which is most 
prevalent in adolescent females, may partly account for this finding; however this was not 
examined.  
 
McWilliams et al. (2013) [86] studied a sample of 424 schoolchildren (aged 9-11 years) at 
risk of obesity, identified via a screening process involving teacher report and child self-
report. Height and weight were measured during the study, while information on ADHD was 
obtained from both parents and teachers via the SDQ. Interestingly, in addition to 
investigating the association between BMI and ADHD, this study examined risk factors for 
obesity, namely physical activity and sedentary activity, in relation to ADHD. High 
inattention/hyperactivity scores were not related with BMI or physical activity in either boys 
or girls, but were associated with sedentary activity in both boys and girls. Analyses were 
adjusted for socio-demographic factors, psychiatric comorbid disorders of ADHD, BMI, 
physical activity and sedentary activity. Limitations of this study include possible selection 
bias - as participants were selected based on their risk of obesity, and lack of a control group 
to   compare   with   the   “at   risk   of   obesity”   group. Furthermore, physical activity/sedentary 
activity data were based on crude self-reports,   either   “none/a   little/a   lot”,   relating   to   the  
previous 24 hours.  
 
Summary 
 
In summary, all 7 studies (5 clinical and 2 population) that met inclusion criteria for review, 
in both children/adolescents and adults, reported a higher than expected prevalence of ADHD 
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in obese individuals. The further studies of interest also produced results that were generally 
consistent with these findings. However, common limitations of the studies include absence 
of a control group in clinical studies, and lack of examination of sex differences in both 
clinical and population studies. Furthermore, very few studies have examined potential 
factors that could account for the association between ADHD and obesity.  
 
Examination of the prevalence of overweight/obesity in individuals with ADHD  
 
Studies on children/adolescents  
 
A total of nineteen studies examining the prevalence of overweight/obesity in ADHD 
children were identified, thirteen of which were conducted in clinical settings [54,62-
68,71,72,76,77,79] and six in the general population [69,70,73-75,78]. Nine of the clinical 
studies [64-68,71,72,76,79], and three population studies reported an association between 
ADHD and obesity or elevated BMI/weight [69,70,75].  
 
Spencer et al. (1996) [62] examined a clinical sample of 124 boys with diagnosed ADHD 
(according to DSM-III-R criteria) and 109 typically developing controls (aged 6-17 years). 
Exclusion criteria were IQ < 80, major sensorimotor handicaps (paralysis, deafness and 
blindness), psychosis, autism, suicidality, mental retardation, adopted and stepchildren, and 
those from the lowest socioeconomic class. The majority of patients, 89%, received 
pharmacological treatment, including stimulants, at some point in their lives. Body mass was 
assessed using age- and height-corrected weight indices derived from standard growth tables 
(an index > 100 indicates greater than normal weight for height and age). The results showed 
that those with ADHD presented with a greater than average body mass (age- and height-
corrected weight index: 109±15), although there was no significant difference between the 
body mass of ADHD patients and controls. It is possible that the non-significant findings in 
this study may be attributable to past pharmacological treatment of most of the patients, as 
some psychotropic drugs have anorexigenic effects. Thus, a limitation of this study is lack of 
examination of the impact of past pharmacotherapy on the association. Further, this study did 
not account for psychiatric comorbid disorders. Using similar methodology, the same authors 
assessed the body mass of 140 girls with ADHD and 122 female controls (aged 6-17 years) 
[63]. As before, they found that patients with ADHD presented with a greater than average 
body mass, although there was no significant difference between the body mass of ADHD 
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patients and controls. In contrast to their previous study, the effect of comorbid depression 
and past pharmacotherapy were controlled for. However, they did not account for the 
duration or dose of past treatment.  
 
Holtkamp et al. (2004) [64] assessed a group of 97 boys (aged 5.5-14.7 years) diagnosed with 
ADHD (according to DSM-IV criteria) in a Child Psychiatry Department, and found that the 
mean BMI of these patients was significantly higher than the age-adapted reference values of 
the general German population. Furthermore, the prevalence of obesity (7.2%;;  BMI  ≥   97th 
percentile) and overweight (19.6%;;  BMI  ≥  90th percentile) were significantly higher in the 
clinical sample compared to the occurrence in the general population of the same age. This 
study excluded individuals with somatic, neurologic or comorbid psychiatric disorders. 
However, the study lacked a control group, did not control for socioeconomic class, and 
consisted of a sample of boys only.  
 
Curtin et al. (2005) [65] examined 98 children/adolescents (aged 3-18 years) diagnosed with 
ADHD (according to DSM-IV criteria) in a Child Psychopathology Unit. The findings 
showed that 17.3% were overweight (BMI z-scores >95th percentile), which was not 
significantly different from the prevalence rate in an age-matched reference population. 
However, when the authors examined the possible anorexigenic effects of stimulant 
medication, they found that the prevalence of overweight was significantly higher in 
untreated patients compared with treated patients (23% versus 6.3%). Although only a small 
number of children received alternative medications, the effects of these on weight status 
were not examined due to the small sample size of the study. Further, the study did not 
control for psychiatric comorbidities. Interestingly, three other clinical studies which assessed 
the effect of stimulants on growth in children with ADHD (collective age range between 3-13 
years) found that the mean BMI of patients with ADHD at baseline was higher than average 
[66-68]. However, these studies only provide limited information on the association between 
ADHD and obesity as they do not report prevalence rates for overweight or obesity, nor do 
they control for comorbid psychiatric disorders.  
 
In two similar clinical studies, Ptacek et al. (2009) [71,72] examined the association between 
ADHD and anthropometric measures, including percentage of body fat and abdominal 
circumference. ADHD was assessed by means of clinical diagnosis according to DSM-IV 
criteria, as well as the Conners’  Rating Scale for parents and/or teachers. The first study was 
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based on a sample of 46 boys with (non-medicated) ADHD (mean age 11.03 years), and 
excluded those with any comorbid psychiatric disorders. The findings showed that ADHD 
cases had significantly higher values of percentage body fat and abdominal circumference 
compared with a reference (Czech) population, although there were no differences on weight 
or BMI. In the second study, the authors compared 52 non-medicated and 52 medicated boys 
with ADHD (aged 4-16 years), and again excluded those with comorbid psychiatric 
disorders. Non-medicated ADHD boys had significantly higher percentage body fat than 
medicated ADHD boys. Important limitations of these studies include examination of boys 
only and use of very small sample sizes.   
 
Dubnov-Raz et al. (2011) [54] examined BMI (age and sex specific) in a clinical sample of 
275 ADHD children (aged 6-16 years) – 135 of which were treated with methylphenidate and 
140 were untreated.  ADHD was diagnosed according to DSM-IV-TR criteria. Exclusion 
criteria were the presence of other mental or somatic health conditions (e.g. epilepsy, mental 
retardation, cerebral palsy, prior significant brain injury, hearing/visual impairments, 
pervasive developmental disorder and mental disorders). The authors compared the BMI z-
scores of the ADHD untreated group versus the ADHD treated group, and compared the BMI 
z-scores of the entire ADHD group (treated and untreated) versus typically developing 
controls; the results showed there were no significant differences in BMI z-scores. The 
prevalence of overweight (BMI z-score   ≥85th percentile) was significantly lower in the 
ADHD group (19%) compared with the control group (35%). These results largely contradict 
findings of previous studies, which may be due to important methodological limitations e.g. 
lack of control for any confounders, largely male sample (73%) and failure to compare the 
untreated ADHD group with the typically developing controls. 
 
Yang et al. (2013) [76] examined a clinical sample of 158 children/adolescents (aged 6-16.6 
years) diagnosed with ADHD (according to DSM-IV criteria, and verified by parent and 
teacher interviews). The study excluded individuals with comorbid psychiatric disorders 
(psychosis, autism, depression, anxiety and mood disorder), sensorimotor handicaps 
(paralysis, deafness and blindness) and somatic disorders (cardiovascular disorders, 
hyperthyroidism, serious gastrointestinal stenosis, dysphagia, exogenous steroid hormones 
and sexual development disorders). Interestingly, the authors examined the ADHD subtypes 
individually to identify which subtype(s) may be associated with overweight/obesity. The 
findings showed that children with the combined subtype of ADHD had approximately a 3-
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fold increased risk of overweight/obesity (defined according to the national growth chart for 
Chinese children and adolescents aged 0-18 years), whilst individually the inattentive and 
hyperactive-impulsive subtypes contributed little to obesity. Interestingly, ADHD cases that 
had started puberty had a four-fold increased risk of overweight/obesity compared with pre-
pubertal ADHD cases, suggesting that puberty may play an important role in the association 
between ADHD and obesity.  Limitations of the study include lack of a control group, lack of 
control for socioeconomic factors and estimation of pubertal stage based on self-reports.  
 
In a clinical sample, Pauli-Pott et al. (2013) [77] studied whether the ADHD-obesity 
association is independent of ODD/CD, which are commonly comorbid with ADHD. The 
authors examined 360 children, of which 257 (6-12 years) were diagnosed with ADHD, 
ODD/CD or comorbid ADHD and ODD/CD, and 103 children with adjustment disorder 
(control group). Diagnoses were made according to ICD-10 criteria. The exclusion criteria 
were IQ < 70, diagnosis of pervasive developmental disorder or epilepsy, and physical 
diseases known to affect body weight (e.g. pituitary diseases). The results showed that 
ADHD was not associated with BMI standard deviation scores (SDS), while ODD/CD was 
linked with BMI-SDS, after adjusting for socio-demographic factors. ADHD was not 
associated with obesity (BMI-SDS ≥   97th percentile according to age and sex German 
reference data), after adjusting for socio-demographic factors and ODD/CD. In contrast, 
ODD/CD was associated with obesity after adjusting for socio-demographic factors and 
ADHD. The authors thus concluded that ADHD is not associated with obesity independent 
from ODD/CD, while ODD/CD is independently linked with obesity. Limitations of the 
study include lack of data on past stimulant medication and a high proportion of missing IQ 
data.  
 
Gungor et al. (2014) [79] studied a clinical sample of 362 children (aged 5-15 years) 
diagnosed with ADHD (according to the K-SADS-PL interview), and compared them with 
390 control children, matched for age and sex. The results showed that the frequency of 
overweight   (BMI   ≥85th percentile)   and   obesity   (BMI   ≥95th percentile) were higher in the 
ADHD group compared with the control group, 9.4% vs. 1.5% and 7.1% vs. 0.2%, 
respectively. Limitations of the study include a predominantly male ADHD sample (86% 
male), and lack of control for any confounders.  
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In a local community study, Hubel et al. (2006) [69] compared the weight status of 39 boys 
with ADHD versus 30 typically developing control boys (aged 8-14 years). Height and 
weight were measured during the study according to a standard protocol, and ADHD was 
diagnosed based on DSM-IV criteria. The study excluded individuals with endocrine, 
metabolic, physical or other psychiatric disorders (except conduct disorders). The mean BMI-
SDS was higher in ADHD boys compared with the control boys (0.29 ± 1.01 and 0.05 ± 0.94, 
respectively). Interestingly, the associations remained significant after controlling for 
anxiety/depression symptoms and general psychological impairments. The authors compared 
children with the combined type of ADHD versus the hyperactive-impulsive type, and found 
no difference in weight status between these two groups.  Further, differences in BMI-SDS 
between ADHD cases and controls were more marked in older children. However, there were 
no significant associations between ADHD and overweight or obesity. Since age effects were 
not accounted for in the analyses, it is not possible to rule out an association between ADHD 
and overweight/obesity, particularly as the differences in weight status between ADHD cases 
and controls were more marked in adolescence.  
 
Lam and Yang (2007) [70] examined the association between ADHD tendency and 
overweight/obesity in a sample of 1429 students (aged 13-17 years) from the general 
population. The group obtained information on “ADHD tendency” rather than diagnosis 
because ADHD symptoms were self-reported by students (via interview, based on DSM-IV 
criteria), and neither parents nor teachers assessed symptoms. Weight and height were 
measured during the study by trained staff. Participants with a high ADHD tendency were 
reported to have a 1.4 increased risk for obesity (defined according to the CDC BMI cut-offs) 
compared to those with a low ADHD tendency, after control for potential confounding 
factors, including socio-demographic factors and snoring. Limitations of this study include 
assessment of ADHD tendency rather than ADHD symptoms and lack of control for 
comorbid psychiatric disorders.  
 
In a population sample of 64 boys (aged 5-6 years), recruited from 9 kindergartens, Tashakori 
et al. (2011) [73] compared anthropometric measures of 32 ADHD boys with 32 typically 
developing boys, matched on age. Exclusion criteria were children with a history of disease 
that can affect growth, or those with growth failure due to a medical condition. ADHD was 
diagnosed through use of the   Conners’   Rating   Scale,   via   either   parent   or   teacher   report.  
Weight and height were measured by study staff according to standard protocols. There were 
51 
 
no significant differences between ADHD and typically developing boys on the frequency of 
overweight (BMI 85th-95th percentile), 6.25% vs. 9.375%, respectively, nor on measures of 
height, weight or BMI. Limitations of this study include the very small sample size (n=64), 
examination of boys only, and lack of control for any confounders.  
 
Ebenegger et al. (2012) [74] studied 450 preschool children (aged 4-6 years) and examined 
hyperactivity/inattention scores in relation to two adiposity measures – BMI and percentage 
body fat, as well as lifestyle characteristics – physical activity, television viewing and eating 
habits. Weight and height were measured during the study according to a standard protocol, 
while ADHD symptoms were assessed by parents via the SDQ. Hyperactivity/inattention 
scores were not associated with BMI, nor   overweight   or   obesity   (BMI   ≥90th or 97th 
percentiles respectively, for age and sex, according to the Swiss national percentiles). On the 
other hand, higher hyperactivity/inattention scores were associated with lower percentage 
body fat, after controlling for socio-demographic factors. The authors attributed this finding 
to the higher levels of physical activity in children with higher scores of 
hyperactivity/inattention.  Physical activity was measured with an activity monitor for at least 
3 days, and defined according to moderate-vigorous, vigorous and sedentary activity. 
However, conversely, higher scores of hyperactivity/inattention were associated with greater 
television viewing time and less healthy eating habits (e.g. lower fruit and vegetable 
consumption and more frequent snacking in front of the television) – which in these young 
children may possibly contribute to weight gain over the long-term, as suggested by the 
authors. The study is limited by child assessment of hyperactivity/inattention by parents only 
(rather than evaluation by teachers, who are important and reliable informants of child 
behaviour [88]) and lack of control for psychiatric comorbidities of ADHD.  
 
Faraone et al. (2012) [75] studied growth (weight and height) in relation to ADHD status in a 
population sample of 1012 children (aged 6-12 years), recruited via telephone survey. Parents 
reported child height, weight and ADHD symptoms. ADHD was assessed using an adapted 
questionnaire of the K-SADS. Results were stratified by age, and showed that younger 
children with ADHD were more likely to be heavier and taller, whereas in contrast, older 
children with ADHD were lighter and shorter, compared with non-ADHD children. These 
findings were independent of a range of socio-demographic factors. However, the study did 
not account for psychiatric comorbidities of ADHD. Furthermore, the study is impeded by 
various other limitations. Only around half of the participants contacted were asked questions 
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about ADHD symptoms (n=536), and this resulted in a very small sample of children who 
met criteria for ADHD (n=25). In line with this, subsamples were very small after stratifying 
by age, and so the reported age-differences in growth according to ADHD status may not be 
an accurate representation of the general population. Additionally, the study only examined 
weight and height separately, and did not consider BMI, which provides an estimation of 
body weight relative to height. Finally, use of a telephone survey may introduce misreporting 
of information.  
 
Byrd et al. (2013) [78] examined a population sample of 3050 children/adolescents (aged 8-
15 years), with the aim to study the impact of both ADHD medication and gender on the 
association between ADHD and   obesity   (≥95th percentile of US body mass index-for-age 
reference). ADHD diagnosis was based on a structured interview, The National Institute of 
Mental Health Diagnostic Interview Schedule for Children IV (DISC-IV), which is in 
accordance with DSM-IV criteria, in combination with parental reports and information on 
medication use. Weight and height were measured at an examination centre using a standard 
protocol. The findings showed that non-medicated males with ADHD were about as likely as 
males without ADHD to be obese, whereas non-medicated females with ADHD had odds of  
obesity of 1.54 times compared with females without ADHD – although this was statistically 
non-significant (95% CI: 0.79-2.98) at p=0.05. The study controlled for confounders 
including socio-demographic factors and psychiatric comorbidities of ADHD (major 
depressive disorder and conduct disorder). Interestingly, males with ADHD who were 
medicated had a significantly reduced risk of obesity (OR=0.42, 95% CI: 0.23-0.78). A 
significant limitation is that the study did not collect data on the age at which children were 
diagnosed with ADHD or began taking ADHD medication; it is possible that some children 
who recently began/stopped taking medication were misclassified.    
 
Comment 
 
There is evidence that children/adolescents with ADHD have a higher than average BMI. 
However, most studies cover a wide age range of children/adolescents, which is an important 
limitation given that growth velocity varies at different ages, and similarly, ADHD symptoms 
may manifest differently during development. Other common limitations include examination 
of only boys and lack of a control group in clinical studies.  
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Adult studies 
 
In adults, one population study in 6735 adults (aged 18-44 years) by Pagoto et al. (2009) [80] 
was identified, which reported a link between ADHD and obesity.  The prevalence rates of 
overweight and obesity in adults with ADHD were 33.9% and 29.4% respectively, compared 
with 28.8% and 21.6% in adults with no history of ADHD. Childhood ADHD was assessed 
using a retrospective version of the Diagnostic Interview Schedule for DSM-IV, and adult 
ADHD was assessed using the Adult ADHD Clinical Diagnostic Scale, the ADHD Rating 
Scale, and an adaptation of the ADHD Rating Scale; weight and height were self-reported. 
Adult ADHD was associated with increased odds of overweight (BMI: 25.0-29.9) by 1.58 
times and obesity (BMI  ≥35.0) by 1.70 times, after controlling for socio-demographic factors 
and depression. However, these associations did not remain significant after controlling for 
binge-eating (defined according to DSM-IV criteria). Interestingly, the authors found that 
binge-eating mediated the association between adult ADHD and obesity, while depression 
did not. However, inferences of causality are limited due to the cross-sectional design of the 
study.  
 
Further studies of interest 
 
Four other studies of interest were identified during the literature search, although these do 
not meet the criteria for review. These did not use formal criteria for diagnosis of ADHD [89-
91] (asking respondents whether or not they had received a clinical diagnosis of ADHD), 
and/or did not control for medication status [92] or psychiatric comorbidities [90]. These 
studies are all based on population samples, three of which examined very large samples of > 
60,000 participants [89-91], and three studies explored potential factors which may underlie 
the link between ADHD and obesity [90-92].   
 
Waring and Lapane (2008) [89] examined 62,887 children (aged 5-17 years) and found that 
children with ADHD had an increased risk of overweight (defined according to CDC BMI 
cut-offs) by odds of about 1.5 times, after controlling for socio-demographic factors, 
depression and anxiety. Weight and height were self-reported.  
 
Kim et al. (2011) [90] examined 66,707 children (aged 6-17 years), whose parents 
participated in a telephone survey. The results showed that both boys and girls with ADHD 
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were at increased risk for obesity (defined according to CDC BMI cut-offs), with odds of 
1.42 and 1.85 times respectively, after controlling for socio-demographic factors. 
Interestingly, ADHD was associated with reduced participation in physical activity and 
organised sports. However, physical activity and organised sports were not associated with 
obesity in children with ADHD; a formal test for mediation was not performed though. Also, 
it is important to note that the physical activity and sport data were based on crude parental 
reports – either yes/no for participating in vigorous activity (20 minutes) for 3 or more days 
per week, and yes/no for participating in organised sports during the past 12 months. As the 
data for this study were obtained from parental reports via telephone survey, it is possible that 
the responses may be misreported or affected by recall bias.  
 
In another parent-based telephone survey, Lingineni et al. (2012) [91] studied 68,634 children 
(aged 5-17  years),   and  did  not   find  an  association  between  ADHD  and  obesity   (BMI  ≥95th 
percentile according to sex and age), after controlling for potential confounders. ADHD was 
associated with reduced participation in sports and greater television viewing time, although 
the latter data were based on crude   parental   reports,   yes/no   and   ≥1   hour/<1   hour   daily,  
respectively. As in the aforementioned study, because data were obtained from parents during 
a telephone survey, it is possible that the responses may be misreported or affected by recall 
bias.  
 
de Zwaan et al. (2011) [92] examined self-report data from 1633 adults (aged 18-64 years), 
and found that ADHD increased the risk of obesity (BMI  ≥30)  by approximately 2-fold, after 
adjustment for socio-demographic factors, depression and anxiety. Further, ADHD was 
associated with binge-eating (defined according to DSM-IV criteria); adjusting for binge-
eating reduced the magnitude of the association between ADHD and obesity, but still 
remained significant, suggesting the association is only partly explained by binge-eating. As 
the study is based on cross-sectional data, it is not possible to infer causality.  
 
Summary 
 
In summary, 13 out of the 20 studies that met inclusion criteria for review reported that the 
BMI in individuals with ADHD was higher than expected. In children/adolescents, 9 out of 
13 clinical studies and 3 out of 6 population studies reported these findings, and the only 
adult study also confirmed these results. These inconsistent findings may be due to several 
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common limitations of the studies, including lack of control for important confounders e.g. 
socio-demographics or ADHD psychiatric comorbidities, examination of single sex samples, 
and lack of control groups (in clinical studies).  Furthermore, few studies attempted to 
evaluate potential factors that could underlie the ADHD-obesity association.  
 
2.1.3 Longitudinal studies examining the association between ADHD and obesity  
 
Three longitudinal studies which examine the link between ADHD and obesity were 
identified as meeting the criteria for review [81-83]; none of these studies identified an 
association. As is evident, there is very limited information on the long-term ADHD-obesity 
association; nine additional studies, which do not meet the criteria for review, were the only 
other longitudinal studies located [93-101], five of which reported an association [93,95,97-
99]. Although these nine studies do not control for medication use, they all except for two 
studies [93,101] use formal criteria for assessing ADHD, and provide important insight into a 
field which is currently critically lacking in research attention. Thus, all twelve longitudinal 
studies will be discussed. Collectively, these studies examine the ADHD-obesity association 
over the life course, spanning childhood/adolescence and adulthood. 
 
There are four studies which focus on the longitudinal association in children/adolescents, 
three of which are based on population samples [81,82,93], and one is based on a clinical 
sample [83]. Graziano et al. (2010) [93] prospectively studied 57 toddlers, aged 2 years at 
baseline, to investigate self-regulation skills in relation to later obesity at 5.5 years. Self-
regulation, a multi-level construct involving control of e.g. attentional, emotional and 
behavioural processes, is often impaired in ADHD [102]. At 2 years, the toddlers underwent 
a series of laboratory examinations designed to assess self-regulation abilities, specifically 
sustained attention, emotion regulation and inhibitory control/reward sensitivity. At 2 years 
and   later   at   5.5   years,   children’s   height   and   weight   were measured by trained staff. Poor 
emotion regulation and inhibitory control skills, but not poor attention, at 2 years, were 
significantly associated with overweight (defined according to CDC BMI cut-offs) at 5.5 
years, after controlling for 2 year-old BMI. Although ADHD is related with poor self-
regulation, the study did not examine ADHD per se, and so these findings cannot be directly 
extrapolated to children with ADHD. In another study in very young children, Griffiths et al. 
(2011) [100] found that obesity (IOTF cut-offs for BMI) at 3 years did not predict 
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hyperactivity/inattention problem scores at 5 years, in either boys or girls, in a population 
sample of 11,202 children. Height and weight were measured by trained staff, while ADHD 
symptoms were assessed by parents via the SDQ. The analysis was adjusted for 
emotional/behavioural problems at 3 years, weight status at 5 years, and socio-demographic 
factors. In contrast, adjusted cross-sectional analyses showed that obese 5-year-old boys, but 
not obese 3-year-olds, were more likely to have elevated hyperactivity problem scores as well 
as screen positive for hyperactivity. An important limitation of this study, as well as the 
aforementioned study by Graziano et al. (2010) [93], is that the follow-up time is very short, 
which may not allow detection of a longitudinal ADHD-obesity association, as it is possible 
that this link may manifest over a longer time period.    
 
Studies which have examined the association between ADHD and obesity in older 
children/adolescents over longer follow-up times have not found significant longitudinal 
associations [81-83]. Anderson et al. (2006) [81] prospectively studied a sample of 655 
youths, aged between 9.1-16.6 years at baseline, and followed-up at three waves – ages 11.1-
20.8 years, 16.6-26.5 years and 27.8-38.2 years. The authors examined three disruptive 
disorders: ADHD, ODD and CD in relation to BMI z-scores from childhood to 
adolescence/adulthood. Psychological disorders were assessed using structured diagnostic 
interviews, consistent with DSM-III-R criteria, with participants (at each wave) or both 
participants and parents (at baseline and wave 1, using the DISC-1R). Height and weight 
were reported by parents (at baseline and wave 1) or self-reported by participants (at waves 2 
and 3). Although overall disruptive disorders were associated with higher mean BMI z-scores 
at all ages, ADHD per se was not, after controlling for socioeconomic status. Limitations of 
the study include assessment of ADHD by parents and participants, and not from third 
sources e.g. teachers or other relevant persons, and lack of control for comorbid psychiatric 
disorders. Mustillo et al. (2003) [82] prospectively examined the weight status and mental 
health, including ADHD, of 991 youths (aged 9, 11 and 13 years at baseline) annually over 
an 8-year period. Mental health outcomes were assessed using a structured interview, the 
Child and Adolescent Psychiatric Assessment (CAPA), and diagnoses were based on DSM-
IV criteria. Height and weight were measured at an examination using standard techniques. 
Children were categorised into four groups based on obesity trajectories: no obesity, chronic 
obesity, childhood obesity and adolescent obesity (obesity was defined according to CDC 
BMI cut-offs). This study did not identify any association between ADHD diagnosis and 
obesity in either children or adolescents, after adjusting for socio-demographic factors and 
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comorbid psychiatric disorders. However, there are limitations which should be considered; 
ADHD diagnosis was based on information from only parents and children, and not third 
relevant sources, and the statistical model used did not allow evaluation of whether the 
potential association between obesity and ADHD was more likely to occur at a particular age 
or if the association existed over time. In a clinical sample, Biederman et al. (2010) [83] 
compared the growth of 137 ADHD cases with that of 124 controls (aged 6-17 years at 
baseline) at a 10-to-11-year follow-up. ADHD was diagnosed using DSM-IV criteria, and 
based on maternal and offspring interviews; the K-SADS-E was used to assess participants 
younger than 18 years, and the SCID for participants 18 years and older. Weight and height 
were measured according to standard protocols. There were no significant differences in BMI 
z-scores or weight z-scores between ADHD cases and controls at follow-up, after adjusting 
for socio-demographic factors; stratification by sex did not alter the results. This study is 
limited by the relatively small sample size, collection of growth data on only a subset of 
participants at follow-up (with possible introduction of sampling bias), and lack of control for 
psychiatric comorbid disorders.  
 
There are seven longitudinal studies which are based in adults, four of which found an 
association [95,97-99] and three did not [94,96,101]. In a population study of 5813 males, 
Duarte et al. (2010) [94] prospectively examined the association between childhood mental 
health, including inattention-hyperactive symptoms (at 8 years) and obesity in adults (at 18-
23 years). Parents and teachers rated mental health using the Rutter questionnaire, whereas 
height and weight were measured according to standard protocols. High levels of child 
inattention-hyperactive symptoms were significantly associated with a two-fold increased 
risk of adult overweight/obesity (BMI  ≥25), after controlling for socio-demographic factors; 
however, this association did not remain significant after additionally controlling for CD 
symptoms. Important limitations of the study include examination of males only, and possible 
selection bias due to attrition, as non-participants at follow-up had significantly higher levels 
of childhood inattention-hyperactivity symptoms compared with participants.  
 
Fuemmeler et al. (2011) [95] studied the association between childhood ADHD symptoms 
and adult obesity, in a population sample of 11,666 participants (mean age 15.65 years at 
baseline), followed-up to mean age 28.9 years. ADHD symptoms experienced between 5-12 
years were retrospectively reported in adulthood, using a Likert scale based on DSM-IV 
criteria. Height and weight in adulthood were measured by study personnel according to 
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standard protocols. This study examined individual ADHD symptoms categorically – to study 
levels of clinical relevance, as well as dimensionally – to assess whether ADHD symptom 
scores contribute to obesity; this was aimed at addressing gaps in research as most studies to 
date have not examined individual ADHD symptoms dimensionally. On the categorical scale, 
screening positive for hyperactive-impulsive symptoms was associated with increased odds 
of obesity (BMI  ≥30)  by 1.63 times, whereas inattentive and combined symptoms were not 
associated with obesity. On the dimensional scale, those with 3 or more hyperactive-
impulsive or inattentive symptoms, compared with those with no symptoms, had the highest 
odds of obesity. All analyses controlled for socio-demographic factors as well as depression, 
physical activity, smoking and alcohol use. Further, there were positive linear associations 
between hyperactive-impulsive and inattentive symptoms and both BMI and waist 
circumference. The main limitation of this study is reliance on retrospective self-reports to 
assess ADHD symptoms, which may impact the results due to potential recall bias. 
 
In a population sample of 12,981 participants, White et al. (2012) [97] prospectively studied 
the association between child behavioural problems - including ADHD (at 5 and 10 years), 
and later obesity (at 10, 26, 30 and 34 years). At 5 years, height was measured by health 
visitors, and at 10 years, both height and weight were measured by school medical staff. At 5 
and 10 years, behaviour was assessed by parents and teachers using questionnaires based on 
the  Rutter  Parent  Scale,  Conners’  Parent  Rating  Scale   and  Conners’  Teacher  Rating  Scale.  
Obesity  was   defined   as   BMI   ≥28.5,   as   data   from   a   related   cohort   found   that   obese   adults  
under-report their BMI by approximately 1.5 kg/m2. Children  with  behaviour  scores  of  ≥1  SD  
above the mean were classed as having high levels of behaviour problems.  At the 10 year 
baseline, high levels of hyperactivity problems predicted obesity at 26 years (odds of 1.4), 
high levels of attention problems predicted obesity at 34 years (odds of 1.3), and high levels 
of collective conduct/impulsivity/hyperactivity problems predicted obesity at 30 (odds of 1.4) 
and 34 years (odds of 1.4). At the 5 year baseline, high levels of hyperactivity problems 
predicted obesity at 30 years (odds of 1.4). These associations were independent of socio-
demographic factors, baseline BMI, parental BMI, childhood cognitive ability and the 
participant’s   height. No associations were detected between inattention/hyperactivity 
problems at 5 years and obesity at 10 years. This study did not control for psychiatric 
comorbid disorders of ADHD.  
 
59 
 
McClure et al. (2012) [96] prospectively examined the association between childhood mental 
health, including ADHD symptoms (at 10 and 14 years), and adolescent/adult BMI (at 14 and 
mean age of 24.3 years) in a population sample of 655 participants. ADHD was assessed by 
parental report using the Overt/Covert Antisocial Questionnaire (OCA) and the Child 
Behaviour Checklist (CBCL). Height and weight were self-reported. The results showed that 
ADHD symptoms at 10 years were not associated with either adolescent or adult BMI, and 
that ADHD symptoms at 14 years were not associated with adult BMI. The authors 
controlled for a number of confounders e.g. socio-economic status, number of biological 
children, parental smoking, family communication, overweight and obesity (at 14 and/or 10 
years), CD and depression (at 10 and 14 years). Important limitations of the study include 
report of child ADHD symptoms by parents only and not by other relevant persons, and 
questionable measurements of some variables included in analysis, e.g. child and adolescent 
overweight were not assessed by quantitative measures (e.g. height and weight), but rather by 
reporting of overweight by parents and teachers, suggesting possible inaccurate assessment.   
 
Recently, Cortese et al. (2013) [98] prospectively studied the association between childhood 
ADHD and obesity in a sample of white men (111 ADHD cases and 111 controls). The 
ADHD cases were diagnosed according to DSM-IV-TR criteria, and were referred to a 
research clinic in childhood (mean age 8.3 years at baseline), and were followed-up 33-years 
after initial ADHD diagnosis (mean age 41.2 years). Height and weight at follow-up were 
self-reported. Exclusion criteria were children with aggressive or antisocial behaviour to rule 
out comorbid CD. The results showed that childhood ADHD predicted significantly higher 
BMI and a two-fold  increase  in  obesity  (BMI  ≥30)  in  adult  men,  compared  with  men  without 
childhood ADHD. This was independent of socio-demographic factors and life-time mood, 
anxiety and substance use disorders. However, the results of this study are based on a small 
sample of white males, and so cannot be extrapolated to women or other racial/ethnic groups. 
The same authors, Cortese et al. (2013) [99], conducted a similar study, but instead 
retrospectively examined the association in a large population sample of 34,653 adults (aged 
≥20  years  at  follow-up). ADHD symptoms experienced in childhood, before 12 years, were 
retrospectively self-reported at follow-up in adulthood, via structured interviews based on 
DSM-IV-TR criteria. Weight and height were self-reported in adulthood. In the entire 
sample, ADHD   was   not   associated   with   obesity   (BMI   ≥30)   over   the   long-term, after 
controlling for socio-demographic factors and mood, anxiety and substance use disorders; 
stratification by sex did not alter the associations. Examination of continuous ADHD 
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symptom scores showed that in the entire sample, impulsive and inattentive symptoms (but 
not hyperactive symptoms) in childhood were associated with obesity in adulthood, after 
control for potential confounders as before. Stratification by sex revealed that these 
associations were only apparent in women (all ADHD symptoms were associated with 
obesity), and the magnitude of these was small e.g. for impulsivity symptoms (which showed 
the largest association), OR=1.09, 95% CI: 1.03-1.14. An important limitation of this study is 
the reliance on retrospective self-reports of ADHD, which may explain the low prevalence of 
ADHD in this sample (<2%) compared with the occurrence in the general population. The 
discrepant findings of the two studies by Cortese et al. may be attributed to differences in 
study design, including possible referral bias in the clinical versus population samples. 
 
Most recently, Korczak et al. (2014) [101] studied the association between psychopathology, 
including ADHD symptoms, in childhood/adolescence, and BMI in adulthood, in a 
community sample of 3294 participants. At baseline, information on ADHD symptoms was 
collected on children (aged 4-11 years) and adolescents (aged 12-16 years), via parental and 
self-report, respectively, using questions derived from the DSM-III. Cut-off points to 
discriminate between screening positive or negative for ADHD were produced from the scale 
scores that best classified clinical diagnoses made by psychiatrists in a random sample of 
children (n=194) in the study. At follow-up in adulthood (aged 21-33 years), weight and 
height were obtained via self-reports. While initial results showed that childhood ADHD was 
positively associated with adult BMI, this association did not remain significant after 
accounting for childhood CD, in either boys or girls. In contrast, in both boys and girls, 
childhood CD predicted increased adult BMI, independent of childhood ADHD. However, 
neither adolescent ADHD nor CD predicted adult BMI. All analyses were adjusted for socio-
demographic factors and depression; alcohol use and cigarette smoking were additionally 
adjusted for in adolescent analyses. A main limitation of this study is the very wide age range 
of participants at baseline and consequently follow-up; for example, younger children may be 
less likely than older children to be classified as having ADHD or another mental health 
problem (as it can be difficult to classify symptoms at a very young age),  and  so  it’s  possible  
that any potential association may have been attenuated.  
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Summary 
 
In summary, none of the 3 longitudinal studies (2 population and 1 clinical) which met 
inclusion criteria for review found an association between ADHD and obesity. All 3 studies 
were conducted in children/adolescents, and an important common limitation is the wide age 
range of participants at baseline within each study. As there may be a developmental effect, 
i.e. the association may manifest over time e.g. from childhood to adolescence, it may be 
difficult to assess the link studying children of different ages at baseline. There were 9 
additional longitudinal studies located (8 population and 1 clinical), which although did not 
meet inclusion criteria, are of interest as they provide insight into the long-term association 
which is currently lacking investigation. Only 5 (4 population and 1 clinical) out of the 9 
additional studies reported a long-term association. Other common limitations of longitudinal 
studies include lack of adjustment for comorbid psychiatric disorders, examination of single 
sex samples and lack of assessment of potential factors underlying the association.  
 
2.1.4 Literature review summary: conclusion and limitations of studies  
 
In summary, the literature suggests an association between ADHD and obesity in both 
clinical and population studies, although the findings are not consistent. Overall, the cross-
sectional results demonstrate that the prevalence of ADHD in obese individuals is higher than 
expected (as reported by 7 out of 7 studies), and that individuals with ADHD present with a 
higher than average BMI (as reported by 13 out of 20 studies). This indicates comorbidity 
between obesity and ADHD. The results from longitudinal studies are less clear, primarily 
due to the paucity of such studies. As only 3 longitudinal studies met criteria for review (none 
of which reported an association), the additional 9 longitudinal studies located were also 
evaluated to gain further understanding. There is evidence to suggest a long-term association 
between ADHD and obesity from childhood to adulthood. However, to date it remains 
unknown whether a longitudinal association exists from childhood to adolescence – an 
important target period for early intervention strategies. If the association does indeed 
manifest over the childhood-adolescent period, this would have important clinical 
implications in the prevention of adverse health trajectories.  
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The results from the described studies should be viewed in light of several limitations, 
discussed within the context of the main headings below.  
 
Predominance of clinical studies  
 
Most investigations to date rely on clinical samples which may be subject to selection biases, 
e.g. gender, referral, comorbid psychopathology and symptom severity biases, and thus may 
not be representative of the population of youth at large.  
 
Several clinical studies only examine either boys or girls, yet there is some epidemiological 
evidence to suggest the ADHD-obesity link may exhibit sex differences, with reports of an 
association only in females [78,85,99]. The small sample size of most of the clinical studies 
also hinders examination of sex differences. Large population studies have the statistical 
power to study sexual dimorphism, yet only a handful have examined this 
[78,83,85,86,90,99-101], which have overall yielded mixed results.  
 
Previous research shows high rates of psychopathology in clinical samples of obese 
individuals [103,104]. Such clinical samples may be biased with a higher prevalence of 
psychopathology because obese individuals who experience psychological problems related 
to their weight status may be more likely to seek clinical help for overweight than those who 
do not; this is in accordance  with  Berkson’s   bias   [105]. Additionally, there is evidence to 
suggest that weight concern mediates the association between weight and psychopathology in 
adolescents [106]. 
 
The lack or incomplete adjustment for comorbid psychiatric disorders is a significant 
limitation particularly in clinical studies, as clinically diagnosed ADHD is typically comorbid 
with other psychopathologies [25]. Epidemiological studies which examine ADHD as 
symptoms on a dimensional scale rather than a clinical diagnosis may minimise such 
confounding [25], based on the assumption that symptoms and personality factors of 
psychological disorders are normally distributed in the general population [107]. In line with 
this, genetic studies have provided evidence that ADHD may be best considered as a 
dimensional rather than discrete condition [108,109]. Further, there are studies which suggest 
that traits typically associated with ADHD, e.g. problems with attention and 
impulse/inhibitory control, are more common among obese children and increase the risk of 
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obesity [93,110-113]. Therefore, taken together, research to date suggests it is important to 
study ADHD on a dimensional scale in the general population, although the minority of 
studies have done so [74,85,95,99,100,114]. Only a few studies have found an association 
between ADHD symptom scores and obesity [85,95,99]; further research is thus necessary to 
expand on these preliminary findings. If confirmed, the public health implications would be 
significant, highlighting that sub-threshold ADHD symptoms (non-clinical cases) which 
present in the general population contribute to the risk for obesity.  
 
Independence of ADHD-obesity association from conduct disorder 
 
In relation to comorbidity, ADHD is a complex and heterogeneous disease. CD is one of the 
primary psychiatric comorbidities of ADHD; approximately 40-70% of children with ADHD 
also present with CD [115]. Given the considerable overlap in symptomatology between the 
two disorders, it is also plausible that CD may be associated with obesity – as some studies 
suggest [77,97,101,116]. Similar to ADHD, CD is linked with high impulsivity [117], 
addictive behaviour [118], psychosocial stress [119], peer problems [120], and abnormal 
eating patterns [121], which may increase the risk of overweight/obesity. Additionally, it is 
possible that factors specifically related with CD, such as aggression, may contribute to 
elevated BMI [122]. Because of the high comorbidity between ADHD and CD, it is important 
to examine whether the potential ADHD-obesity link is independent of CD to assess 
specificity of the association. Only some of the studies that have examined the ADHD-
obesity link have accounted for CD, by either excluding CD cases [64,82,98] or adjusting for 
CD [58,77,94,96,101]. Three studies found that the association between ADHD and 
BMI/obesity was independent of CD [58,64,98], whilst the other five studies negate this 
[77,82,94,96,101]. Further work is therefore required to clarify these mixed findings.    
 
Unknown mechanisms underlying ADHD-obesity association 
 
Little is known about the pathways linking ADHD and obesity. To date, it remains unclear 
which symptom dimension(s) of ADHD (inattention, hyperactivity or impulsivity) 
contributes to the potential ADHD-obesity association, since only a few studies have 
examined this [76,95,99]. Although it has previously been hypothesised that inattention and 
impulsivity, rather than hyperactivity, may be important in conferring risk for obesity [123], 
there is some limited evidence to suggest that hyperactivity symptoms may also contribute to 
64 
 
the association, but only in women [99]. Further research is thus needed to examine whether 
the individual ADHD symptoms contribute differentially to the association with obesity. A 
better understanding of this can provide insight into the psychopathological underpinnings of 
the ADHD-obesity link, and may have important clinical implications - allowing specific 
prevention and treatment strategies targeting one or more symptoms.  
 
Only a few studies which examine the ADHD-obesity link have also investigated potential 
mediating factors (e.g. energy balance related factors) which may underlie the association 
[74,80,86,90-92]. Of these studies, all of which are cross-sectional, some have reported that 
ADHD is linked with physical inactivity [90,91], binge-eating [80,92], increased television 
viewing [74,91] and less healthy eating habits [74], which  may  be  referred  to  as  “obesogenic  
behaviours”.   It   is   important to note that while binge-eating was assessed using validated 
psychopathology screeners based on DSM-IV criteria [80,92], the measurement of physical 
activity across different studies was overall not as robust [86,90,91], apart from one study 
[74]. Physical   activity   levels   were   measured   using   crude   reports   (e.g.   “yes”   or   “no”   to  
participating in physical activity) [86,90,91], which do not provide insight into the volume 
(e.g. hours per week) or intensity (e.g. moderate-to-vigorous/light) of physical activity 
[86,90,91]. The single study which took into account volume and intensity of physical 
activity found that ADHD symptoms were linked with increased physical activity, which 
seems counterintuitive given the potential link between ADHD and obesity. Further research 
using quantitative methods to measure physical activity levels is needed to expand on these 
findings.   
 
Two studies (in adults) formally examined whether binge-eating mediated the ADHD-obesity 
association [80,92], while no studies have tested mediation by physical inactivity. Binge-
eating mediated the association in adults; it is currently unknown whether mediation holds in 
children/adolescents. Importantly, to date there are no existing longitudinal studies that have 
examined mediation of the association by obesogenic factors. Thus it remains unknown 
whether obesogenic factors underlie the long-term ADHD-obesity association.  
 
Lack of longitudinal studies  
 
Studies in the field of ADHD-obesity research are predominantly cross-sectional, and thus 
cannot provide insight into developmental trajectory, thereby hindering theoretical potential 
65 
 
clinical advancements. Although it is impossible to fully decipher causality of the ADHD-
obesity link in humans, longitudinal prospective studies can provide valuable information on 
the direction of the association, as well as pathological pathways linking the two conditions. 
To date, longitudinal studies have not examined potential underlying mechanisms or the 
direction of the ADHD-obesity association. All existing longitudinal studies examine ADHD 
as a risk factor for obesity, although it is plausible that the association may be driven from the 
direction of obesity to ADHD, as factors linked with obesity e.g. leptin (appetite-regulation 
hormone) and sugar-rich diet may contribute to ADHD-like behaviours [124,125]. Moreover, 
the association may be bidirectional due to a third underlying factor associated with both 
obesity and ADHD [126-129]. Thus, research is required to study the directionality and 
mechanisms of the long-term association, which currently remain unevaluated.  
 
Two of the latest longitudinal studies demonstrated a link between childhood ADHD and 
adult obesity, although one study was based on a small clinical sample (n=207) of only men 
[98], whilst the other population study (which used retrospective reports for ADHD and self-
reports for weight/height) found an association in only women [99]. These discrepant 
findings may be attributed to differences in study design, including possible referral bias in 
the clinical versus population samples. There are two other longitudinal studies which found 
a link between childhood ADHD and adult obesity [94,95], and three studies which did not 
[96,97,101]; limitations of these studies include gender bias, retrospective self-reports on 
ADHD and lack of control for comorbid psychiatric disorders. 
 
Little is known about the early developmental trajectory of the ADHD-obesity link from 
childhood to adolescence. This is an important period to study as this is when ADHD and 
obesity frequently manifest [4,5], and when behavioural/lifestyle patterns start to form, and 
thus provides an opportunity for intervention to prevent an adverse trajectory into adulthood. 
The few longitudinal studies in children/adolescents are generally limited by small sample 
sizes and provide inconsistent results [81-83,93,100]. One study in toddlers (2 year-olds) 
reported a link between behavioural difficulties and obesity over a 3.5 year period [93]; 
however these results do not directly relate to ADHD. Another study in toddlers [100] and 
studies in older children have not confirmed the association between ADHD and obesity [81-
83]. A further limitation of these studies is the sole use of  body mass index (BMI) 
[82,93,100], which may not adequately reflect adiposity because BMI does not distinguish 
between fat mass and lean mass [130,131]. Indicators of abdominal obesity, such as waist-hip 
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ratio (WHR), provide additional measures of adiposity, and may more accurately identify 
individuals at risk for health consequences of overweight [130,132].  
 
Despite the limitations of the longitudinal studies, there is evidence to suggest that ADHD 
predicts obesity over the long-term; however it remains unknown whether the association is 
bidirectional i.e. whether obesity also predicts ADHD. Thus, there is a need for longitudinal, 
prospective studies to establish temporal precedence e.g. whether when baseline BMI is taken 
into account, ADHD symptoms predict obesity, and whether when baseline ADHD is taken 
into account, obesity predicts ADHD.  
 
2.1.5 Clinical implications of understanding the nature of ADHD-obesity link  
 
Understanding the directionality of the ADHD-obesity association has important clinical 
implications. A bidirectional association would highlight the importance of screening obese 
patients for ADHD, as well as monitoring weight status in ADHD patients. This would 
enhance the diagnosis and treatment of both conditions. The treatment of ADHD in obese 
patients could lead to an improvement in the management of obesity. The treatment of 
ADHD is highly important because aside from potential weight problems, the great social and 
personal impairments related with this condition would add to the burden of obesity. 
Likewise, monitoring weight status in ADHD patients may prevent or improve the clinical 
and psychological consequences of obesity. 
 
Interestingly, preliminary research suggests that treatment of ADHD leads to weight loss in 
obese patients with ADHD [133]. However, before planning screening and intervention 
programmes aimed at reducing obesity through ADHD treatment, it is necessary to extend the 
current preliminary literature, addressing gaps in knowledge that relate to the ADHD-obesity 
association which may inform such programmes. In addition to understanding the 
directionality of the association, knowledge of underlying mechanisms also has important 
clinical implications in the prevention and treatment of comorbid ADHD and obesity. 
Although underlying mechanisms have not been examined in longitudinal studies, the 
literature proposes potential mechanisms which allude to a bidirectional association [123].  
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2.1.6 Potential mechanisms underlying the association between ADHD and obesity  
 
There are three pathways which could explain the ADHD-obesity association: (1) ADHD 
and/or related behaviours/deficits may precede the development of obesity, (2) Obesity 
and/or related factors may precede the manifestation of ADHD symptoms, or (3) There may 
be a bidirectional association due to common biological factors which result in the 
manifestation of both ADHD and obesity.  
 
2.1.7 ADHD precedes the development of obesity 
 
In the literature on potential mechanisms underlying the ADHD-obesity association, the 
greatest focus appears to be on the role which ADHD may play in the development of 
obesity. Symptoms of ADHD may confer risk for abnormal eating behaviours - most notably 
binge-eating, as well as reduced physical activity [123]. In turn, these obesogenic behaviours 
may lead to a chronic positive energy balance, resulting in fat accumulation, and ultimately 
obesity. Although it is not clear which specific symptoms of ADHD may contribute to 
obesogenic behaviours, there is evidence to suggest that impulsivity and inattention may play 
a significant role, whilst hyperactivity might not be as important [134]. Although the 
potential link between hyperactivity and obesity may seem counterintuitive, the increased 
motor activity in children with ADHD may relate to increased fidgetiness or restlessness, 
rather than regular physical activity which is necessary for weight management.  
 
Binge-eating and physical activity are modifiable behavioural risk factors for obesity, and are 
relatively easy to classify and measure. Thus, examination of these factors is a good place to 
start in elucidating potential mechanisms underlying the ADHD-obesity link, and may pave 
the way for future behavioural intervention studies, if the factors are found to contribute to 
the association. This thesis examines whether binge-eating and physical activity help explain 
the ADHD-obesity link.  
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2.1.8 Binge-eating and other disordered eating behaviours  
 
Association between ADHD and binge-eating/disordered eating behaviours   
 
Binge-eating is described as recurring episodes of eating significantly large quantities of food 
in a short period of time, accompanied by feelings of loss of control [7]. ADHD has been 
linked with binge-eating or overeating [24,135-138], as well as other disordered eating 
behaviours, including emotional eating [24,135] (eating in response to emotional states like 
tension and worry), external eating [24,135] (eating in response to environmental cues such 
as visual and olfactory stimuli) and poor eating habits (e.g. eating foods high in fat and sugar) 
[74,139,140]. Two similar studies have used structural equation modelling to show that, in 
males and females, ADHD symptoms were positively correlated with several forms of 
disordered eating behaviours, all of which were linked with overeating, which in turn was 
associated with higher BMI [24,135]. Further, two cross-sectional studies in adults found that 
binge-eating partially mediated the ADHD-obesity association [80,92]. 
 
Contribution of ADHD symptoms to binge-eating/disordered eating behaviours  
 
The ADHD symptom of inattention is considered important in contributing to the ADHD-
obesity link [123]. Inattention can affect regular eating patterns, resulting in abnormal eating 
behaviours. Indeed, clinical studies have demonstrated that women with ADHD may 
disregard internal signs of hunger and satiety, such that they neglect eating when they are 
engaged in interesting activities and tend to eat when they are less stimulated, at which point 
they may be very hungry and thus over-consume [141]. It is also possible that, in patients 
with ADHD, the greater cognitive effort required to sustain attention and perform standard 
mental tasks may result in increased appetite, and thereby weight gain over the long-term 
[142]. Compared to obese patients without ADHD, obese patients diagnosed with the 
predominantly inattentive type of ADHD have been reported to experience greater difficulties 
in losing weight, despite more frequent clinical visits and longer duration of treatment [48]. It 
has been suggested that the stress related to attention and organisational problems may induce 
a coping mechanism in the form of compulsive eating, which could hinder weight loss 
initiatives [143].  
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It is proposed that impulsivity is another key factor driving the ADHD-overeating-obesity 
pathway [25], and there is some direct evidence to suggest an association between 
behavioural impulsivity and binge-eating [24,134,144]. Impulsivity is a personality trait best 
conceptualised dimensionally that encompasses rashness (behaviour that lacks thought or 
deliberation), as well as lack of foresight or planning [87,145].  The three main characteristics 
of impulsivity - a heightened drive for reward, deficient inhibitory control, and poor decision 
making - without concern for future consequences, may contribute to overeating [146].    
 
At the level of higher-order cognitive brain functioning, attention and impulsivity are 
constructs of executive function (EF) – which refers to the capacity for self-understanding 
and self-regulation [147]. In addition to impulse and attention control, EF represents other 
neurocognitive processes that are important for goal-directed behaviours, including 
prioritising, planning, self-motivation and memory [148]. EF impairment is a core feature of 
ADHD [147,148], and has also been linked with obesity [149,150]. It has been suggested that 
impaired EF is an important factor driving the pathway from ADHD to obesity development, 
such that decreased EF predicts increased symptoms of ADHD, which in turn elevates the 
risk of overeating behaviours, which ultimately leads to increased BMI [102]. However, only 
a few studies have directly examined whether impaired EF provides a link between ADHD 
and obesity, and these have provided conflicting results [151,152]. 
 
Gene x environment interactions  
 
A genetic predisposition for ADHD symptoms, coupled with our modern obesogenic 
environment, may play an important role in the rise of comorbid ADHD and obesity, which 
has been observed over the past decade. Given the well-established comorbidity between 
ADHD and drug abuse [18], along with the understanding that highly palatable foods may be 
as addictive as some drugs [153,154], it is perhaps not surprising that ADHD has been found 
to be associated with overeating, particularly as our current food environment may cultivate 
such excessive consumption [25]. Palatable food is a readily available, fairly inexpensive and 
legal means of enhancing mood, and so in our modern society may have the potential for 
abuse and dependence when used beyond essential energy requirements, as animal models 
suggest [155]. Thus, it has been proposed that ADHD symptoms may confer a risk for 
obesity in our present environment, such that an interaction between genes and environment 
may contribute to the ADHD-obesity connection [25]. In previous decades such an 
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association may not have been detected because the environmental risk for its development 
was largely absent. Highly palatable foods may be addictive as their dopamine-activating 
properties appear to alleviate the symptoms and hypo-dopaminergic state of ADHD, thereby 
providing a form of self-medication [24]. This is in line with evidence of ADHD being linked 
with a high fat and sugar diet [140], and suggestions that ADHD and sugar intake have 
increased in parallel in recent years [125]. Certain cases of obesity may therefore be the 
consequence of a food addiction [25,156] due to low dopamine levels [15]. Thus, food 
addiction, along with the dopamine system, may provide a unifying thread linking ADHD 
and obesity.  
 
Conclusions 
 
Overall, the evidence to date suggests that ADHD is associated with binge-eating and other 
disordered eating behaviours linked with overeating [24,135-138], although not all studies 
demonstrate such a link [157]. Further, there are unclear results from a recent study which 
found that symptoms of ADHD were significantly, but not differentially, greater in obese 
patients with and without binge-eating behaviours [158]. While there is some limited 
evidence in adults showing that binge-eating may mediate the cross-sectional ADHD-obesity 
association [80,92], it is currently unknown whether binge-eating mediates the long-term 
association. Thus, the extent to which binge-eating may contribute to the ADHD-obesity 
association is unclear, and requires further study.   
 
It has been hypothesised that the link between ADHD and increased food intake may be due 
to elevated energy expenditure, given the hyperactive component of ADHD [159]. However, 
there is evidence which shows that ADHD is associated with reduced physical activity, thus 
contesting this theory. Considering the significant role of physical inactivity in obesity 
development, it is important to examine whether physical inactivity may be a factor 
underlying the ADHD-obesity association.  
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2.1.9 Physical inactivity  
 
Association between ADHD and physical inactivity  
 
Concurrent with the escalating incidence of obesity, recent reports highlight a worldwide rise 
in physical inactivity [160,161], with a global prevalence of approximately 17% [162]. In 
terms of child and adolescent physical activity, only one third of young people are estimated 
to be adequately physically active [163]. Physical inactivity has been identified as the fourth 
leading risk factor for non-communicable diseases, and given its high prevalence, is 
considered to be a major public health concern [161]. The physical health consequences of 
physical inactivity, most notably obesity, hypertension, and type 2 diabetes, are well 
established [164]. In recent years, growing evidence has demonstrated that physical inactivity 
is also associated with mental illness, including depression and anxiety [165,166]. The impact 
of physical activity specifically on child and adolescent mental health has received 
comparatively less research attention. Studies suggest that physical inactivity is linked with 
emotional/behavioural problems, cognitive impairment and poor academic achievement in 
children and adolescents [167-175]. Given that physical activity has been found to positively 
impact many of the neurobiological and cognitive factors linked with ADHD [176], it seems 
plausible that ADHD and physical activity could be associated. Moreover, it has been 
postulated that physical inactivity may be an important factor underlying the ADHD-obesity 
association [177,178]. Although mediation of the association by physical inactivity has not 
been examined to date, there are a few studies which examine the link between ADHD and 
physical activity in children and adolescents which provide some preliminary insight. 
 
There is some evidence which suggests that the association between physical activity and 
ADHD may manifest at an early age. In a small study (N=32), it was reported that in a free-
play setting, pre-schoolers with ADHD participated in less play activity than controls, as well 
as less social, and more solitary play [179]. In larger population studies examining older, 
school-age children and adolescents, some studies report an association between physical 
inactivity and ADHD [90,91,174,180], whilst others do not [74,86,139]. The proposed 
association between ADHD and physical inactivity may seem counterintuitive given that 
hyperactivity is a core symptom of ADHD. Although children with ADHD have been 
reported to exhibit increased motor activity, including during the night [181,182] and during 
school activities [181], such elevated activity may relate to an increased number and 
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magnitude of movements [183] e.g. increased fidgetiness or restlessness, rather than regular 
and sustained physical activity which promotes physical fitness and weight management. In 
line with this, children with ADHD have been reported to exhibit poor physical fitness 
[184,185], and are less likely to engage in moderate to vigorous physical activity [90,174] 
and organised or structured sports [90,91,180]. The intensity of physical activity may be 
particularly important for health outcomes, as studies have shown that vigorous physical 
activity has a greater impact on preventing child obesity and psychological problems than 
lower levels of physical activity [186,187]. In light of this, it can be hypothesised that 
reduced levels of moderate or vigorous intensity activity in children with ADHD may 
increase the risk for obesity. Further, ADHD children have been described as being more 
“sluggish”   and   “underactive”   [188], and   it   is   suggested   that   “sluggishness”   is   positively  
associated with hyperactivity [177]. ADHD may therefore be characterised by varying 
periods of overactivity and underactivity, and this poor system of energy regulation may 
hinder sustained effort in physical activities [177].   
 
Although it remains unclear why a link between ADHD and physical inactivity may exist, it 
is possible to speculate that the neurocognitive, psychosocial and physical impairments linked 
with ADHD may contribute to the potential association. Physical activities normally require 
increased concentration, perception, planning, and self-motivation, which may be challenging 
for ADHD children who typically experience a range of EF impairments. The social 
functioning problems linked with ADHD, namely rule breaking [189] and peer 
rejection/neglect [22], may give rise to difficulties in participating in organised or structured 
sports, which require cooperation with authorities, rule adherence and team-work. Children 
with ADHD can suffer from low self-esteem [21] which may also contribute to lack of 
participation in team physical activities. In terms of physical impairments, ADHD is often 
associated with motor coordination problems or delayed motor development [184,190,191], 
which in turn may contribute to reduced participation in physical activity and subsequently 
compromised physical fitness [192,193]. Compared with their peers, children with ADHD 
may experience more negative feelings about physical activity [194], which may stem from a 
range of psychosocial factors - poor self-esteem, peer problems and/or embarrassment 
because of motor clumsiness. Psychosocial problems may increase susceptibility to isolation 
or ostracism (ADHD has previously been linked with bullying and ostracism [195]), which in 
turn may encourage more time spent in solo activities, such as TV viewing and playing video 
games – sedentary activities which have been linked with ADHD [89,90], and may increase 
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risk for weight gain over the long-term. Additionally, psychosocial problems may contribute 
to depression or anxiety – common psychiatric comorbidities of ADHD [196], which have 
been linked with physical inactivity and obesity [197,198]. 
 
Impact of physical activity on ADHD symptoms  
 
Research has consistently demonstrated that physical activity has beneficial effects on mental 
health, alleviating stress, depression and anxiety, in addition to improving cognitive 
functions. It is suggested that the positive effects of physical activity may have the greatest 
impact during childhood, when the brain is still developing, and in individuals with impaired 
brain functioning [176]. This is in line with the cognitive reserve hypothesis, which states that 
the beneficial impact of physical activity is larger for those with cognitive reserve challenges 
[199]. There is some evidence to support this theory; studies suggest that the positive impact 
of physical activity on cognition is greatest in children [200] and in older adults [201], as well 
as in older adults with cognitive impairment [202] and who are at risk for Alzheimer’s  
disease [203]. Children with ADHD could represent a subgroup that may particularly benefit 
from physical activity, given that their cognitive, behavioural as well as potential weight 
problems may all improve with regular physical activity. Physical activity may reduce the 
risk for obesity directly, as well as indirectly via alleviation of ADHD symptoms. 
 
There is evidence which suggest that physical activity may benefit cognitive and behavioural 
factors implicated in ADHD, such as attention [204], hyperactivity [205], EF [201] and 
academic performance [169].  Although there are only a few, small clinical studies which 
directly examine the impact of physical activity on behaviour/cognition in children with 
ADHD, the initial findings are largely encouraging. In a study of 21 ADHD children (aged 7-
12 years), a 10-week moderate to vigorous physical activity programme  improved attention, 
social and thought problems, as well as total behaviour problems, in the physical activity 
group compared with control group [206]. In another study which compared 20 ADHD 
children (aged 8-10 years) with a healthy match control group, a single 20-minute bout of 
moderate-intensity exercise improved inhibitory control, stimulus classification and 
processing speed, as well as reading  and arithmetic performance, in both ADHD and control 
participants [207]. Further, a study of 17 ADHD children (aged 5-8 years) found that an 8-
week programme of daily moderate to vigorous physical activity improved inhibitory control 
and alleviated a range of impairments, including social problems, poor self-esteem and motor 
74 
 
problems [208]. Interestingly, a study of 25 ADHD boys (aged 7-15 years) found that a 30-
minute bout of exercise improved attention independent of methylphenidate treatment [209], 
and another study which recorded the activity levels of 18 ADHD boys (aged 8-12 years) 
over 1 week found that increased physical activity predicted improved EF [210]. In contrast 
to the positive results of these studies, one group which studied the impact of a 5-week 
exercise programme on 19 ADHD children (aged 5-13 years) did not find significant 
behavioural differences between exercise and non-exercise participants [211]. These studies 
are limited by very small sample sizes, reliance on clinical samples that may be subject to 
selection biases, and lack of a control group in some studies. Importantly, only the short-term 
impact of physical activity on ADHD behaviours has been examined, and so it remains 
unknown whether physical activity has a long-lasting effect on ADHD symptoms.  
  
There is evidence from animal and human studies which support the concept that physical 
activity, or physically active play (in young children), may alleviate ADHD behaviours by 
impacting neurobiological factors implicated in ADHD. Specifically, physical activity may 
positively impact neurotransmitter imbalances, brain derived neurotrophic factor (BDNF) 
levels and cerebral brain structure and function.  
 
Studies suggest that physical activity enhances dopaminergic, noradrenergic and adrenergic 
activity in the central nervous system [212-214]. For example, a study in rats showed that an 
acute bout of physical activity (treadmill running) resulted in increased extracellular levels of 
dopamine and noradrenaline in the striatum of both exercise trained and non-trained rats 
[213]. Further, exercise has been shown to increase dopamine receptor binding in rats [214]. 
Other animal studies which report beneficial effects of physical activity on behaviour 
attribute the findings to neurotransmitter alterations [215,216]. Interestingly, one study in 
humans indirectly examined dopamine response to acute exercise in children by studying 
measures linked with dopamine activity - spontaneous eye blink rates, acoustic startle eye 
blink response and motor impersistence [217]. The results suggested that dopamine levels 
increased after a single bout of exercise, and consequently the authors postulated that exercise 
could potentially be used as a dopaminergic adjuvant in the treatment of ADHD symptoms.  
 
Studies in rats consistently show that exercise increases levels of brain BDNF [218-220] - a 
growth factor which stimulates neuronal outgrowth and differentiation, synaptic connectivity 
and neuronal repair [221]. Further, there is evidence showing that BDNF plays a major role 
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in cognitive improvements following exercise in brain-injured rats [222]. Intriguingly, social 
play in juvenile rats can elevate BDNF levels [223], suggesting that play also has an 
important role in BDNF activation and thereby potentially cognition.  Several human studies 
also report increases in BDNF levels following acute physical activity [212,224-226].  
Interestingly, one study examined the impact of acute exercise on BDNF, dopamine, 
noradrenaline and adrenaline blood levels, as well as learning performance, in healthy adult 
males [212]. Exercise was linked with increased levels of BDNF and all measured 
neurotransmitters, with high intensity exercise yielding the greatest increases. In turn, 
elevated BDNF and neurotransmitter levels were associated with improved learning 
performance. Consequently the authors proposed that BDNF and the measured 
neurotransmitters may mediate the association between physical activity and learning.  
 
Animal studies show that physical activity can induce a range of positive effects on cerebral 
structure, including increased angiogenesis [227] and neurogenesis [228], as well as 
increased blood flow [229] and vasculature maintenance [220] – all of which may enhance 
cognitive performance [176]. In humans, studies show that older adults who are aerobically 
fit or aerobically trained exhibit benefits to cerebral structure in the form of increased brain 
volume [230] and reduced tissue loss to the frontal, parietal and temporal cortices [231]. 
Further, these groups of older adults also show signs of cerebral function benefits in terms of 
greater task-related activity in prefrontal and parietal regions that are involved in inhibitory 
functioning, and greater activity in the anterior cingulate cortex, a region associated with 
attentional control processes [232]. 
 
Conclusions 
 
In summary, only a few population studies have investigated the association between ADHD 
and physical inactivity in children/adolescents, and yielded conflicting results 
[74,86,90,91,139,174,180]. There are a few, small, clinical studies reporting improved 
behaviour in children diagnosed with ADHD following a short-term period or acute bout of 
physical activity [206-209,211]. However, it remains unevaluated whether physical activity 
has a long-term impact on ADHD symptoms, and whether physical inactivity mediates the 
ADHD-obesity link.  
 
76 
 
Overall the evidence to date suggests that binge-eating and physical inactivity – factors that 
have been linked with ADHD, may underlie the ADHD-obesity association. It is also 
hypothesised that obesity, or factors linked with obesity, may contribute to ADHD [123].  
 
2.1.10 Obesity precedes the development of ADHD  
 
There are several hypothesised mechanisms which explain how obesity could potentially 
contribute to the manifestation of ADHD symptoms, although there is currently relatively 
little evidence to support these theories. These include behavioural, biological and foetal 
programming mechanisms.  
 
2.1.11 Behaviour problems   
 
Overweight or obese individuals often present with poor impulse control [87,112,233], which 
is closely tied with binge-eating [234-236] – a common feature of obesity [237]. Studies 
show that obese patients in weight-loss programmes score higher on trait impulsivity and 
engage more frequently in impulsive behaviours, such as substance abuse, compared with 
lean individuals, according to self-report questionnaires [238-240].  In line with this, studies 
involving behavioural tasks have demonstrated that obese individuals have problems with 
delay gratification [110,241,242] and inhibitory control [233,243] – core characteristics of 
impulsivity. For example, when presented with the choice between a small, immediate edible 
reward, or a larger, delayed edible reward, obese children more often chose the immediate 
reward, compared with normal weight children [110,241]. In response to inhibition tasks, 
obese children demonstrated highly variable, quite slow and inaccurate reactions – reflecting 
poor inhibitory control due to attention problems [233]. Interestingly, a study in adolescent 
girls which also examined response inhibition showed not only behavioural evidence for a 
link between BMI and impulsivity, but also neural evidence [243]. The neuroimaging results 
demonstrated that palatable food stimuli was linked with reduced activation of brain regions 
involved in inhibitory control in girls with larger BMI [243]. Furthermore, activation of brain 
reward regions correlated positively with BMI, in response to food stimuli [243].  
 
 It has been suggested that the behavioural impulsivity often observed in obese individuals 
could lead to ADHD symptoms of impulsivity, which in turn may give rise to inattention and 
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hyperactivity symptoms [123]. For example, patients with bulimic behaviour or other 
behaviours associated with binge-eating were reported to exhibit repeated and impulsive 
interruptions of their daily activities in order to obtain food, resulting in disorganisation, 
inattention and restlessness, which are related to ADHD [134].   
 
2.1.12 Excessive daytime sleepiness  
 
It has recently been proposed that excessive daytime sleepiness (EDS), which is frequently 
associated with obesity [244], may mediate the link between obesity and ADHD [123,245]. 
In obese individuals, EDS may arise due to upper airway obstruction during sleep - the most 
common respiratory complication of obesity which can impact sleep quality [244]. ADHD 
has also been linked with a range of sleep problems, including EDS, according to a recent 
meta-analysis [246].  In a study of 70 obese children, EDS was significantly associated with 
symptoms of inattention, hyperactivity and impulsivity [247]. Although the link between 
EDS and hyperactivity/impulsivity may seem counterintuitive, the development of ADHD 
symptoms in obese individuals with EDS could be a mechanism to help counteract the feeling 
of   sleepiness.   Interestingly,   according   to   the   “hypoarousal   theory”   of   ADHD,   individuals  
with ADHD may be sleepier than controls, and might rely on motor hyperactivity and 
impulsivity to stay alert, and withstand the propensity to fall asleep [248]. Therefore, EDS 
may contribute to explaining the comorbidity between obesity and ADHD.  
 
2.1.13 Leptin 
 
Obese individuals often present with resistance or deficiency in leptin – an adipocyte-derived 
hormone which acts on the hypothalamus to regulate food intake and energy expenditure, and 
as such plays an important role in body adiposity [249]. Obesity and hyperphagia are the 
main characteristics observed in animal models that are leptin resistant or deficient [250,251], 
confirming the effects of leptin on body composition. Leptin is a pleiotropic hormone that 
acts on many areas of the brain, and other well-documented functions of leptin include 
regulation of reproduction, glucose homeostasis, bone formation and inflammation [249]. 
Research also suggests that leptin impacts cognition via influencing neuronal/synaptic 
function and structure, and neuronal survival and proliferation [249], and there is 
experimental evidence for this in rats [252]. In humans, studies suggest that low levels of 
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leptin are linked with cognitive deficits; for example, reduced leptin levels were associated 
with impaired learning and memory in men infected with human immunodeficiency virus 
(HIV) [253], and high levels of leptin were related with improved cognitive function in the 
elderly [254]. Interestingly, Paz-Filho et al. examined the impact of leptin replacement in a 5-
year old boy with leptin deficiency due to a loss-of-function gene mutation [124]. At 
baseline, the boy was morbidly obese and exhibited neurocognitive developmental delays. 
Following leptin replacement, the authors reported both marked weight loss and an improved 
rate of development in various aspects of neurocognitive functioning [124]. These findings 
suggest that leptin plays an important role in both body composition and cognition, and this 
work is in line with reports that obesity and cognitive impairment are related [255]. 
Considering all available evidence, it is plausible to speculate that leptin may be a factor 
underlying the link between obesity and cognition [249]. This may have important 
implications in the context of the association between obesity and ADHD, since ADHD is 
typically characterised by cognitive deficits.   
 
2.1.14 Sugar-rich diet 
 
The increase in sugar intake in recent years has been epidemiologically and physiologically 
related with the rise in obesity [256], and sugar may have a direct causal role in obesity 
development [257]. While it is suggested that individuals with ADHD consume excess sugar 
due to their susceptibility to addiction [24], it has also been postulated that sugar may be a 
factor contributing to the development of ADHD symptoms [125]. There is some longitudinal 
evidence supporting the latter scenario; for example, pre-schoolers who consumed a “junk  
food”   diet   rich   in   sugar  were at increased risk for hyperactivity at 7 years, compared with 
children who consumed less junk food [258]. A potential pathway from sugar intake to the 
development of ADHD symptoms has been hypothesised [125]. Chronic excessive sugar 
intake, which is related with obesity, can result in increased dopamine release in the striatum 
which is associated with reward. This may lead to increased sugar consumption, which over 
the long-term, results in a reduction of striatal dopamine D2 receptors. To compensate, 
further sugar may be consumed, eventually resulting in desensitisation of the dopamine 
signalling pathway and potentially reduced dopamine levels. The hypo-dopaminergic state 
can ultimately give rise to ADHD symptomatology. Thus, sugar intake may contribute to the 
pathway linking obesity to ADHD.   
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2.1.15 Pre-pregnancy obesity 
 
Studies show that maternal pre-pregnancy obesity is one potential risk factor for poor 
neurodevelopment outcomes in the offspring [259], including ADHD symptoms [260,261], 
providing evidence that obesity may contribute to ADHD development. Davis has proposed 
that excess sugar consumption may underlie the link between pre-pregnancy obesity and 
ADHD [25]. Prenatal exposure to excess sugar, which is more likely to occur in obese than 
normal weight mothers, may adversely affect foetal brain development, given the known 
neurochemical impact, and addictive potential, of sugar on the brain [262]. This theory was 
developed from the understanding that prenatal exposure to alcohol – another addictive 
substance, can give rise to foetal alcohol spectrum disorders, which include symptoms similar 
to those of ADHD. As such, Davis has loosely coined the neurodevelopmental consequences 
that may arise from prenatal exposure to excess sugar as   “foetal sugar   spectrum  disorder”. 
Prenatal exposure to addictive substances may have a sensitising impact on the foetal brain, 
and may partly explain the high prevalence of substance abuse in those with ADHD. On the 
other hand, it could be argued that because ADHD is linked with high sugar intake, a genetic 
predisposition for ADHD may account for the potential link between prenatal exposure to 
excess sugar and child ADHD symptoms. However, some evidence against this comes from a 
study by Rodriguez et al. (2010) who report that the association between pre-pregnancy 
obesity and ADHD remained significant after controlling for parental ADHD symptoms 
[261]. Thus, this suggests that pregnancy-related factors, in addition to genetic influences, 
may account for the association.  
 
2.1.16 Common mechanisms underlying the link between ADHD and obesity 
 
ADHD and obesity share many neurocognitive and behavioural parallels, including EF 
deficits e.g. poor attentional and impulse control, binge-eating and physical inactivity, as 
described above. These similarities are supported at the level of the brain; neuroimaging 
studies in ADHD and obese individuals have revealed common brain structural 
abnormalities, including in the frontal cortex [263-266], a region which is important for self-
regulation and EF. Further, there are reports of overlapping effects of psychotropic and 
metabolic drugs, which imply crossover of drug action pathways; studies suggest that 
methylphenidate, commonly administered for ADHD treatment, may also reduce obesity 
[267], and metformin, used to treat obesity, may improve mood disorders [268]. Taken 
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together, these lines of evidence suggest that there may be common biological processes 
linking ADHD and obesity, and these may include shared genetic, neuroendocrine and foetal 
programming mechanisms – indicative of a potential bidirectional ADHD-obesity 
association.  
 
2.1.17 Genetic factors 
 
The “reward   deficiency   syndrome”   has been observed in both ADHD [19,128] and obese 
[126] patients, implicating a common genetic dysfunction of the dopaminergic reward system 
in underlying the connection between ADHD and obesity [15,269]. There is already 
considerable evidence suggesting that dopamine-related genes are involved in the 
pathophysiology of ADHD [14,19], and some studies suggest that these genes may also 
contribute to obesity [11,270,271]. Indeed, mutations in the genes coding for DRD2 and 
DRD4, which are the main receptors involved in mediating the reward pathway, have been 
found in both ADHD [11,12] and obese patients [11,270]. Interestingly, the 7-repeat (7R) 
allele of DRD4 - a variant associated with decreased affinity for dopamine, was found to be 
significantly related with childhood inattention and maximal lifetime BMI in a sample of 
women with seasonal affective disorder (SAD) [271].  The reward pathway has been 
implicated in SAD, given that cravings for high-carbohydrate/high-fat foods and significant 
weight gain typically accompany the depressive episodes in winter. Considering this, the 
findings of the study suggest that childhood inattention and adult obesity could reflect 
different manifestations of a common dysfunction of the 7R allele of DRD4, which may be 
related to low dopamine activity in the brain reward pathway as well as prefrontal attentional 
areas [271]. Further support for involvement of the dopaminergic system in the pathology of 
both ADHD and obesity comes from imaging studies that have revealed that ADHD patients 
exhibit an increased density of striatal DAT [272], and that obese patients show decreased 
availability of striatal DRD2 and DRD4 - which were inversely related with weight status 
[270,273]. 
 
The fat mass and obesity (FTO) gene - identified as the gene most strongly linked with 
obesity in genome-wide association studies (GWAS) [274,275], appears to exert its effects on 
adipocytes via modulation of brain pathways implicated in food intake and energy 
metabolism [276]. In line with this, expression of FTO is highest in the brain [275], and 
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studies show that this gene may also impact brain structure and function, and has been 
associated with microcephaly, reduced brain volume, psychomotor delay and poor EF, in 
humans [277-279]. Interestingly, one study reported that an adult female with duplication of 
FTO presented with ADHD, mental retardation and obesity [280]. More recently, studies 
have examined whether single nucleotide-polymorphisms (SNPs) in FTO that have 
previously been linked with obesity are also associated with ADHD.  The FTO allele A at 
rs8050136 has been reported to be associated with ADHD behaviours in children, although 
was not found to be linked with BMI in the same study – possible due to insufficient 
statistical power (n=451), as the authors speculated [281]. Another study reported that FTO 
allele A at rs1558902 was not associated with ADHD in children, although the link with 
obesity was not reported in the same study [282]. In a study of young pre-schoolers, FTO 
allele A at rs9939609 was associated with reduced risk for ADHD symptoms, and was not 
related with BMI [283]. It is possible that the very young age of the participants accounted 
for the lack of association with BMI, and may potentially have caused difficulties in 
accurately identifying ADHD behaviours. Interestingly, the study also showed that 
rs9939609 was linked with increased food responsiveness, which is understood to activate 
brain reward pathways, and thereby may account for the reported reduced ADHD symptoms 
[283]. The possible pleiotropic effects of FTO require further study to improve understanding 
of how this gene may contribute to the ADHD-obesity link.  
 
Another possible common biological mechanism may involve BDNF, as evidenced by 
preliminary animal studies. In one study, heterozygous BDNF+/- mice exhibited aggressive 
behaviour and greater appetite/food intake [284]. Another group found that 50% of 
heterozygous BDNF+/- (FBH) mice became obese and consumed approximately 47% more 
food than the wild type and heterozygous BDNF+/- non-obese (NBH) mice [285]. The NBH 
mice displayed greater locomotor activity than the wild type and FBH mice, suggesting that 
obesity may mask increased activity in the FBH mice. In humans, one small population study 
did not find that BDNF was linked to both ADHD and obesity [286], but there have been 
patient case studies reporting otherwise [129].  For example, an 8-year old girl with 
functional loss of one copy of the BDNF gene presented with hyperphagia, severe obesity, 
impaired cognitive function and hyperactivity [129]. Another study in 4 children showed that 
microdeletions at 11p14.1, which encompasses the BDNF gene, was associated with both 
ADHD and obesity [287].  
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Melanocortin-4-receptor (MC4R), which plays an important role in the hypothalamic control 
of food intake, and well-known for its involvement in obesity [288], may also contribute to 
the development of ADHD [289]. In a study of 29 participants (adults and children), 
homozygous and heterozygous MC4R mutations were associated with both ADHD and 
obesity [289]. The authors proposed that altered appetite regulation, which is associated with 
MC4R deficiency, may be a key common mechanism linking the disorders. Patient case 
reports in children have also demonstrated that MC4R mutations are linked with both ADHD 
and obesity [290,291].  
 
It is possible that numerous other genes may be implicated in both ADHD and obesity, as 
suggested by a recent GWAS study which examined 32 common obesity risk alleles in 
relation to ADHD risk [282]. The study found that nudix; nucleoside diphosphate linked 
moiety X-type motif 3 (NUDT3), G protein-coupled receptor, family C, group 5, member B 
(GPRC5B), glucosamine-6-phosphate deaminase 2 (GNPDA2), mitogen-activated protein 
kinase 5 (MAP2K5), and cell adhesion molecule 2 (CADM2) genes were significantly linked 
with ADHD. Further research is required to elucidate the role of potential common genetic 
pathways in underlying the association between ADHD and obesity.  
 
2.1.18 Stress and the role of cortisol  
 
Childhood psychosocial stress or adversity, e.g. unfavourable family conditions, 
socioeconomic disadvantage and parental psychopathology, has been reported to increase the 
risk for ADHD [292-294] and obesity [295,296]. Research suggests that cortisol, which is the 
hormonal end product of the hypothalamic-pituitary-adrenal (HPA) axis – a major 
neuroendocrine component of the stress system, represents an important factor linking stress 
and disease [297]. Cortisol has a number of functions, including involvement in metabolism 
(e.g. gluconeogenesis and lipolysis) [297] and brain functioning (e.g. neurogenesis and 
neuronal survival) [298], which suggests that dysregulation of the hormone may contribute to 
the pathogenesis of psychiatric disorders and obesity. Indeed, there is extensive evidence 
implicating dysregulation of the HPA axis along with altered cortisol levels in 
psychopathology [297,299]. In the context of ADHD, studies have reported lower daytime 
plasma cortisol, a decreased cortisol awakening response (CAR) and a blunted cortisol 
response to psychosocial stressors in children with ADHD [300-303], although there are 
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some inconsistencies between studies [304-307]. It is possible that this hypo-functioning of 
the HPA axis may contribute to ADHD behaviours [300] considering that the HPA axis is 
understood  to play an important role in regulating behaviour, including attention, learning, 
memory, emotion and movement [308,309]. Further, an association between a down-
regulated stress response and ADHD is consistent with the “hypoarousal theory” of ADHD, 
which states that the disorder is a result of under-arousal, and the manifestation of ADHD 
symptoms is a compensatory mechanism to promote arousal [248].  
 
Less is known about the association between cortisol and obesity. In one of the largest studies 
to date in men in this research field, a weak negative association was reported between serum 
cortisol levels and adiposity measures [310].  However, other studies have reported elevated 
cortisol levels [311] and CAR [312,313] in overweight/obese individuals. Further, clinical 
studies show that patients treated with cortisol often become obese, and patients with 
hypercortisolaemic conditions often also present with obesity [314]. Thus, it has been 
hypothesised that elevated cortisol secretion in response to stress can contribute to visceral 
obesity [314]; this is in line with the role which cortisol plays in regulating adipose tissue 
differentiation, function and distribution [315]. Further, in light of evidence from animal 
studies, it has been postulated that increased cortisol levels may disrupt food intake regulation 
by stimulating the neuropeptide Y system (involved in increasing food intake), and inhibiting 
the leptin system (involved in reducing food intake), and thereby result in increased energy 
intake and fat accumulation [314].  
 
Physical inactivity has been linked to both stress [316] and obesity [164], and may impact the 
association between stress and cortisol levels [317]; thus complex interactions may exist 
between stress, cortisol, physical inactivity and obesity.  
 
2.1.19 Shared transmission may occur via foetal programming 
 
Maternal stress during pregnancy has been associated with both ADHD [318] and obesity 
[40] in the offspring; these associations may be attributable to dysregulation of the offspring 
HPA axis, which has been linked with prenatal stress [319]. It has been suggested that 
prenatal stress may also impact offspring dopaminergic functioning, although the evidence 
for this is limited [320]. Other prenatal maternal factors, for example, pre-pregnancy obesity 
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and smoking, have also been linked with both obesity [321,322] and ADHD [261,318]. In a 
review, Odent (2010) suggested that prenatal life is a critical period for gene-environment 
interactions for both ADHD and obesity, and considering the reported association between 
the two disorders, he hypothesised that ADHD and obesity should be considered as two 
facets of the same disease [323]. These lines of evidence support the concept that potential 
common mechanisms linking ADHD and obesity may originate during foetal development. 
This theory shall be explored in depth below.  
 
2.2 Foetal origins of ADHD and obesity    
 
2.2.1 The Developmental Origins of Health and Disease (DOHaD)  
 
The concept that the prenatal environment can influence foetal development and later adult 
health is ancient, as evidenced, for example, by Hippocratic writings (400 B.C.) [324]. This 
phenomenon has been studied scientifically from around the 1940s in humans [325,326]. 
However, the turning point for this research came in the 1980-90s, following Barker and 
colleagues’  seminal observations that low birthweight was associated with cardiovascular and 
metabolic disease (e.g. coronary heart disease, diabetes mellitus and hypertension) [327-330], 
suggesting that poor foetal growth programs later disease - giving rise to the “foetal origins of 
adult   disease” hypothesis [34,35]. This hypothesis has since evolved and now the 
“Developmental   Origins   of   Health and   Disease   (DOHaD)”   model is commonly used to 
describe the phenomenon whereby environmental insults that occur during critical periods of 
pre- or postnatal development can induce adaptations in the offspring, which may optimise 
survival, but may also increase the risk for disease later in adult life [36,331,332].  
 
In epidemiological studies, reduced birthweight is commonly used as a measure of poor 
foetal growth or development, reflecting adverse intrauterine conditions [37]. More 
specifically though, foetal or infant adaptations in response to environmental cues may 
include alterations to metabolism, hormone production and tissue sensitivity to hormones, 
which may affect organ development, resulting in permanent changes to physiologic and 
metabolic homeostatic set points [332]. Such adaptations,   termed   “predictive   adaptive  
responses”,  are  made  in expectation of the future postnatal environment, on the basis of cues 
from the prenatal or early postnatal environment, and are theorised to alter the phenotype of 
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the offspring so as to optimally meet the challenges of the predicted environment [333]. From 
an evolutionary perspective, developmental plasticity can confer a Darwinian advantage by 
increasing the likelihood of survival and reproductive success, when the predictive adaptive 
response is appropriate [333,334]. However, when there is a mismatch between the predicted 
and actual environment, the changes made to the offspring can be maladaptive [333], and 
consequently give rise to later disease, as animal models have demonstrated [335,336]. The 
impact of environmental insults can differ depending not only on the stimulus itself, but also 
on its timing during development. Specifically, insults that arise during early gestation, when 
organogenesis and differentiation occur, can cause structural defects, whist insults during late 
gestation, when foetal maturation occurs, can lead to functional alterations [337]. 
 
Barker   and   colleagues’   initial findings on associations between low birthweight and 
cardiovascular/metabolic disease have been replicated by numerous other studies [338-343], 
and also extended such that low birthweight has now been linked with various other adult 
health outcomes, as documented by a recent review [36], including mental illness [344,345]  
and obesity [346,347]. Although studies which have examined the association between the 
intrauterine environment and later health outcomes have focused on those born at low 
birthweight, it has become increasingly apparent that U-shaped associations may exist 
between birthweight and later disease [348], highlighting that both low and high birthweight 
may reflect suboptimal intrauterine conditions.  
 
2.2.2 Evidence for foetal origins of ADHD and obesity  
 
There is growing evidence that an adverse intrauterine environment, as reflected by altered 
foetal growth, is linked with a range of mental health outcomes, including depression, 
schizophrenia, increased vulnerability to stress and behavioural disorders, in children and 
adults [37]. In the context of behaviour, case-control studies have consistently demonstrated 
that low birthweight children have increased hyperactivity and inattention problems, in 
comparison to normal birthweight controls [349-353]. Emotional problems in children have 
also been linked with low birthweight, as summarised in a review [354], and evidenced by a 
longitudinal study that showed low birthweight was associated with an increased risk for both 
internalising and externalising problems, observed in childhood and early adulthood [355]. 
Further, other studies have shown that the impact of birth size on child behaviour, including 
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hyperactivity/inattention, antisocial behaviour and peer problems, is graded across the entire 
birthweight range [356-359], and there is some evidence the associations may be U-shaped 
[360,361]. Interestingly, when the impact of birthweight was compared with that of head 
circumference at birth, head circumference showed stronger associations with 
hyperactivity/inattention [356,362]. As head circumference is an indicator of brain volume 
[363], these results suggest that altered brain development (implied via head size) may 
contribute to conferring risk for behaviour problems.  
 
The association between birthweight and later risk of obesity has been studied extensively, as 
documented by a recent review [364]. Numerous studies have demonstrated a link between 
high birthweight and later increased BMI [365-368], and there is evidence that this effect 
may be graded above a certain birthweight threshold (3500g) [364]. As BMI is strongly 
associated with both lean mass and fat mass, it has been suggested that the link between high 
birthweight and BMI could represent an association between birthweight and lean mass 
[364]. Indeed, one study found that birthweight was positively associated with muscle mass 
in a sample of men and women [369], and another found no association between birthweight 
and percentage body fat among children [370]. On the other hand, while individuals born 
small are more likely to have a lower BMI later in life than those born large, they are at 
increased risk of abdominal obesity, reduced muscle mass and high fat mass [347,371-374]. 
Other studies have reported J-shaped or U-shaped associations, suggesting that both high and 
low birthweights may be associated with obesity [343,375,376]. However, a recent 
systematic review and meta-analysis concluded that high birthweight, but not low 
birthweight, increases the risk for obesity [364]. The authors proposed that rapid postnatal 
“catch-up”  growth,  which  can  occur  amongst individuals born too small (particularly in the 
high-calorie environment of developed countries), may account for the association between 
low birthweight and obesity [364]. Interestingly, a study in a low birthweight mouse model 
showed that prevention of postnatal catch-up growth reversed the development of obesity and 
glucose-intolerance [377]. On the other hand, it is possible that high birthweight, often related 
with maternal overweight/obesity or diabetes [378,379], may play a more direct role in the 
later risk of obesity. Maternal over-nutrition or diabetes can lead to foetal hyperglycaemia 
and hyperinsulinaemia, which in turn can promote excessive fat deposition during the third 
trimester [38,364]. Excess foetal adiposity can persist throughout life, and may lead to 
obesity [364].   
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As briefly described, there is substantial evidence that the foetal environment may be linked 
with both psychopathology and obesity [37,38]. Given the consistent findings of associations 
between altered foetal growth and both ADHD and obesity, it is possible that these 
correlations may partly explain the later potential link between ADHD and obesity. However, 
it is important to highlight that while altered foetal growth reflects adverse intrauterine 
conditions, it is a proxy marker which is not causally linked with later disease [37]. It is likely 
that altered foetal growth lies on the causal pathway linking prenatal insults with later 
pathology [37]. Prenatal maternal factors that may alter foetal development and initiate 
downstream programming pathways include, for example, pre-pregnancy obesity and 
smoking, each of which have been independently linked with ADHD and obesity 
[261,318,321,322].  
 
2.2.3 Glucocorticoid programming of ADHD and obesity 
 
One potentially important common early life risk factor for ADHD and obesity is prenatal 
exposure to excess glucocorticoids (GC). In the literature, it has been alluded that prenatal 
exposure to excess GC, due to either prenatal maternal stress or exposure to synthetic 
glucocorticoids (sGC), may reduce foetal growth [380,381], as well as impact the developing 
HPA axis [319] and dopaminergic system [320], which in turn have each been implicated in 
brain and metabolic functioning [37,126,270,297,364]. In line with this, prenatal GC has been 
associated with the programming of psychopathology and metabolic disease, although it 
remains unclear whether these associations more specifically encompass ADHD and obesity. 
A better understanding of these links will provide insight into whether the risk for the 
ADHD-obesity association may originate in utero. 
 
2.2.4 HPA axis: major stress system of the body 
 
Cortisol, a glucocorticoid stress hormone, is the end product of the HPA axis – a major 
neuroendocrine component of the stress system. The stress system is vital for life as it is 
involved in regulating the normal daily cycles of rest and activity, as well as situations of 
acute or chronic stress [382]. During life, we are constantly challenged by intrinsic or 
extrinsic adverse forces, known as stressors [383]. Exposure to a stressor, either emotional or 
physical, induces activation of the entire system of stress regulation, including the HPA axis 
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Figure 2.2: The HPA axis.  
ACTH: adrenocorticotropin hormone 
AVP: arginine vasopressin 
CRH: corticotropin-releasing hormone 
Adapted by permission from Macmillan 
Publishers Ltd: Nature Reviews Neuroscience, 
5(12):917-30, Copyright (2004) [385].   
Hypothalamus 
Pituitary 
Adrenal glands 
[297]. Stimulation of the HPA axis ultimately results in the release of cortisol into the blood 
circulation, which acts to control the body’s  response  to  stress [383].  
 
The HPA axis comprises a feedback loop, 
which includes the hypothalamus, pituitary 
and adrenal glands (Figure 2.2) [384,385]. In 
response to stress, the hypothalamus secretes 
two hormones – corticotropin-releasing 
hormone (CRH) and arginine vasopressin 
(AVP), which act on the pituitary to 
stimulate adrenocorticotropin hormone 
(ACTH) production and release. In turn, 
ACTH acts on the adrenal cortex and induces 
the production and secretion of cortisol. 
Most cortisol that circulates in the blood is 
bound to the corticosteroid-binding globulin 
protein. Cortisol exerts its effects by binding, 
in its unbound form, to mineralocorticoid 
receptors (MR) and glucocorticoid receptors 
(GR). Regulation of the HPA axis is 
achieved via the negative feedback of 
cortisol to the pituitary, hypothalamus as 
well as other brain regions, including the hippocampus. Among its various effects, including 
inhibition of the immune system, growth and reproductive functions, cortisol is also involved 
in regulating metabolism (e.g. gluconeogenesis and lipolysis) and brain functioning (e.g. 
neurogenesis and neuronal survival) [297,298,383]. In line with this, dysregulation of the 
HPA axis along with altered cortisol levels have been implicated in various pathologies, 
including obesity and mental illness [297].  
 
2.2.5 HPA axis during pregnancy, glucocorticoids and foetal development 
 
During pregnancy, considerable changes arise in the physiological activity of the HPA axis 
[386,387]. From about 8-10 weeks gestation, CRH is also produced and secreted from the 
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placenta, resulting in a progressive and significant rise in plasma CRH levels during 
pregnancy [387,388]. Placental CRH has the same structure and biological activity as 
hypothalamic CRH, and regulates both maternal and foetal pituitary-adrenal function [389]. 
Whilst hypothalamic CRH production is inhibited by cortisol, placental CRH synthesis is 
stimulated by cortisol in a positive feedback loop [389]. Over the course of pregnancy, there 
is a gradual increase in plasma CRH, and thereby ACTH and cortisol levels, and during the 
last 6 weeks of gestation, these hormone concentrations increase rapidly [388]. Cortisol levels 
at the end of pregnancy are considerably high, which trigger the final maturation of several 
foetal organs, including the lungs and brain [390]. The effect of cortisol on the developing 
lungs is particularly important in preparing the foetus for extra-uterine life; this underpins the 
widespread use of prenatal sGC treatment in threatened preterm delivery to accelerate foetal 
lung maturation, thereby reducing the risk of neonatal respiratory distress syndrome and 
mortality [390].  
 
Although GC are lipophilic and readily cross the placenta, foetal cortisol levels are 
approximately 10-fold lower than maternal levels due to the actions of placental 11β-
hydroxysteroid   dehydrogenase   type   2   (11β-HSD2) – an enzyme which regulates foetal 
exposure to maternal cortisol [391]. However, the efficiency of  placental  11β-HSD2 can be 
reduced by various prenatal maternal factors, including stress [392,393]. Normally, placental 
11β-HSD2 converts approximately 50-90% of endogenous maternal cortisol to inactive 
cortisone [388,394]. In  contrast,  placental  11β-HSD2 does not extensively metabolise sGC, 
inactivating only about 2% of dexamethasone and 7% of betamethasone [395] (two 
commonly administered sGC), allowing the majority of sGC to cross the placenta to exert its 
intended therapeutic effect on foetal tissues. There is strong animal evidence that foetal 
overexposure to GC, either endogenous or synthetic, can for example, reduce foetal 
growth/birthweight and alter HPA axis development, programming an increased risk for 
adverse health outcomes including brain and metabolic sequelae (Figure 2.3 depicts foetal 
overexposure to maternal endogenous GC) [396]. In line with this, in humans, prenatal 
exposure to maternal stress has been associated with mental health and metabolic 
impairments in the offspring, and a proposed mechanism is foetal exposure to elevated 
cortisol levels [40,41,43,318,397]. Examining this potential mechanism in humans is 
complex, but can be explored in a quasi-experimental manner by investigating the impact of 
prenatal sGC treatment on later behaviour and obesity outcomes. This research can 
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additionally provide insight into the long-term side effects of prenatal sGC treatment, which 
is of concern in the field of obstetrics [390].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.6 Glucocorticoid programming of mental health and obesity 
 
Prior to discussing the evidence for a programming effect of GC on behaviour and obesity, a 
brief description of how prenatal exposure to excess GC may impact foetal development in 
relation to these health outcomes is presented. It is important to note that endogenous GC and 
synthetic GC exhibit different receptor binding affinities and so their physiological effects are 
likely to differ; endogenous GC bind to both MR and GR, whilst sGC bind mainly to GR 
[398].   
 
 
Figure 2.3: Interaction between maternal, placental and foetal compartments depicting 
overexposure of the foetus to cortisol, and consequent programming of adverse brain and 
metabolic sequelae. CRH: corticotropin releasing hormone, ACTH: adrenocorticotropin 
hormone, HSD2:   11β-hydroxysteroid dehydrogenase type 2. Reprinted from 
Psychoneuroendocrinology, 38, Reynolds RM, Glucocorticoid excess and the developmental 
origins of disease: Two decades of testing the hypothesis, 1-11, Copyright (2013) [396], with 
permission from Elsevier. 
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2.2.7 Impact of prenatal exposure to excess glucocorticoids on foetal development  
 
Exposure to prenatal maternal stress has been linked with reduced birthweight [380], with 
excess maternal GC as a potential causal mechanism [41]; it is possible that small birth size 
may reflect altered brain development [37]. Moreover, for decades, animal and human studies 
have suggested that prenatal sGC treatment reduces birthweight [381,399]. It is understood 
that the premature maturation of foetal tissues stimulated by prenatal sGC limits subsequent 
tissue development and growth, resulting in growth retardation [398].    
 
Endogenous GC are essential for normal brain development, exerting a wide range of effects 
in most regions of the foetal brain, initiating terminal maturation, remodelling of axons and 
dendrites, and affecting cell survival [400]. However, sustained elevation (or reduction) of 
GC levels can impair these processes, and thereby permanently modify brain structure and 
function [401]. Animal studies have demonstrated that, at the cellular level, prenatal sGC or 
prenatal stress can have a range of effects on the developing brain, including reduced neuron 
proliferation [402,403], and altered neuron structure and synapse formation [404]. Further, in 
both animals and humans, prenatal sGC has been associated with reduced density of 
hippocampal neurons in the offspring [405,406]. At the organ level, animal studies have 
shown that prenatal sGC can reduce cerebral weight/volume and cerebellar weight, whilst 
human studies have demonstrated an association between prenatal sGC and both reduced 
cortical surface area and reduced complexity of cortical folding, in term offspring [407,408]. 
Further, sGC has been consistently linked with reduced head circumference at birth in 
humans [381].  
 
Animal models provide strong evidence that prenatal exposure to sGC affect foetal HPA axis 
development, causing permanent changes in the HPA axis that persist over the long-term 
[409]. For  example,  prenatal  dexamethasone  exposure  or  11β-HSD2 inhibition permanently 
elevates basal GC levels or HPA axis responsiveness in offspring rats [410], sheep [411], 
guinea pigs [412] and primates [413]. These effects are dependent on timing of exposure and 
dose of sGC, and may be sex-specific [411,414,415]. There is animal evidence demonstrating 
that prenatal sGC exposure in the latter half of pregnancy reduces hippocampal MR and GR 
levels, which in turn reduces hippocampal GC-feedback sensitivity, thereby permanently 
altering   the   “set-point” of the HPA axis [410]. In humans, little is understood about the 
impact of overexposure to prenatal GC on offspring HPA axis function. The literature 
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suggests that prenatal sGC exposure reduces HPA axis activity in the human neonate [416], 
but this change may not necessarily associate with decreased cortisol levels later in life. In 
adults, one study found that prenatal sGC exposure was associated with a tendency to exhibit 
elevated morning cortisol levels [417], and another found that prenatal exposure to severe 
stress was linked with elevated cortisol responses during a psychological challenge (Trier 
Social Stress Test) [418]. In contrast, infants whose mothers were exposed to the 9.11 World 
Trade Centre atrocity showed lower cortisol levels, but only if the mother developed post-
traumatic stress disorder (PTSD) and was exposed in the third trimester of pregnancy [419]. 
Thus, it is possible that the long-term impact of prenatal GC on HPA axis function may 
depend on underlying vulnerability or genetic factors, and developmental timing of exposure 
[420]. 
 
The developing dopaminergic system may also be permanently affected by prenatal exposure 
to GC, as evidenced by animal studies [421-423]. For example, in rats, prenatal sGC 
promotes premature maturation of dopamine during foetal development [424], and elevates 
spontaneous locomotor activity in adult offspring [421].  Further, there is evidence that other 
brain neurotransmitter systems including serotonin, adrenaline and noradrenaline may be 
programmed by prenatal GC [390].  
 
As described, prenatal GC exposure may affect foetal physiological systems that have in turn 
been implicated in mental health and metabolic outcomes. The evidence presented provides 
rationale for the concept that prenatal GC exposure can program child behaviour and obesity.   
 
2.2.8 Prenatal maternal stress and mental health in children and adolescents  
 
There is substantial evidence from animal studies showing that prenatal maternal stress has a 
long-term adverse impact on behaviour, as has been reviewed [425]. For example, in 
primates, prenatal stress has consistently been linked with impaired attention, neuromotor 
behaviour, and adaptiveness in novel and stress-inducing situations (e.g. increased anxiety) in 
the offspring [426,427]. In line with the findings from animal studies, there is good evidence 
from numerous prospective studies in humans that prenatal stress is associated with adverse 
child mental health outcomes, including behavioural and emotional problems, as described in 
detail in reviews [39,41,425]. The most consistently observed outcome associated with 
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prenatal stress is an increase in symptoms of ADHD in children [318,428-431]. Several 
studies have found that the magnitude of these effects are considerable, with one study 
showing that prenatal anxiety accounted for 22% of the variance in ADHD symptoms [429], 
and another found that exposure to stressful events doubled the risk for ADHD behaviours 
[431]. Furthermore, two other studies found that women in the top 15% for anxiety symptoms 
at gestational week 32 had a doubled risk, from 5% to 10%, of having children with ADHD 
symptoms, or other behavioural and emotional problems, even after adjustment for a wide 
range of confounders [428,432]. Other adverse mental health outcomes that have been 
associated with prenatal stress include anxiety, depression, and externalising problems, such 
as conduct disorder [428,429,432]. Additionally, prenatal stress has been linked with child 
atypical laterality or mixed-handedness [433,434], which is an index of neurobehavioural 
organisation and has in turn been associated with ADHD and other psychiatric disorders 
[434,435].  
 
An important question which this research has raised is whether the link between prenatal 
stress and child mental health may be explained by other prenatal or postnatal factors, 
including smoking during pregnancy or postnatal anxiety, as well as genetic vulnerability 
[39]. Research suggests that it is likely that interactions between prenatal and genetic factors 
account for child outcomes [436]. Most studies have found that the association in question 
persists after controlling for prenatal and/or postnatal factors, thus supporting the concept that 
prenatal stress programs later child behaviour, as occurs in the animal models [39].   
 
2.2.9 Does prenatal exposure to cortisol program child behaviour? 
 
Studies in animals provide strong evidence that foetal exposure to GC is a mechanism 
underlying the link between prenatal stress and behaviour problems. Indeed, in primates, 
prenatal stress along with its associated increase in maternal HPA axis activity has been 
linked with long-term behaviour problems in the offspring [427,437]. The key role of 
elevated maternal cortisol levels has been highlighted in research which showed that the 
adverse behavioural effects of prenatal stress can be mimicked by administering ACTH to the 
pregnant mother and eliminated by adrenalectomy [438]. Furthermore, animal models have 
consistently shown that prenatal exposure to both elevated endogenous maternal GC and sGC 
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alter foetal brain development and consequently impact upon behaviour [41,409,420], 
including hyperactivity [439] and attention [427].   
 
However, it is unclear whether a comparable GC mechanism exists in the programming of 
behaviour in humans. Interestingly, a recent study showed that elevated maternal cortisol 
levels in early pregnancy was linked with both increased amygdala volume and affective 
problems in 7-year-old girls [440]. In line with these findings, other studies have 
demonstrated that elevated maternal cortisol levels predict adverse infant temperament 
[441,442]. However, it is unknown whether foetal overexposure to cortisol accounts for the 
changes in brain structure and/or behaviour. There is evidence though that maternal plasma 
and foetal plasma cortisol levels strongly correlate [443], which could be attributable to the 
placenta serving as only a partial barrier to maternal cortisol. Around 10-50% of maternal 
cortisol can cross the placenta into the foetal compartment [388,394], and potentially 
adversely affect foetal brain development if maternal levels are clinically high [41]. However, 
the correlation between maternal and foetal plasma cortisol levels does not prove that 
elevated maternal cortisol programs behaviour; for example, simultaneous stimulation of 
cortisol production in both the mother and foetus by placental CRH may be one possible 
alternative explanation for the correlation [41]. There is limited direct evidence though 
showing that in utero exposure to increased cortisol levels, as measured in amniotic fluid via 
amniocentesis, was linked with impaired cognitive development in infants of mean age 17 
months [444]. The authors were, however, unable to distinguish whether the cortisol derived 
from the amniotic fluid reflected foetal exposure to maternal cortisol or foetal production of 
cortisol. There are clearly limitations in this field of human research, largely due to ethical 
considerations.  
 
Thus, due to the paucity of human evidence, it remains unclear whether foetal exposure to 
cortisol is directly linked with adverse child behaviour. Prenatal sGC treatment crosses the 
placenta readily and is known to exert effects on foetal tissues, most notably the lungs for 
intended therapeutic benefit. Therefore, the routine administration of sGC in cases of 
threatened pre-term birth offers an opportunity to study whether prenatal exposure to GC is 
associated with long-term programming of behaviour in humans in a quasi-experimental 
manner.  
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2.2.10 Prenatal exposure to sGC treatment and mental health in children and 
adolescents  
 
While the adverse impact of prenatal sGC on offspring behaviour in animals is well-known 
[409], very little is understood about the effects of prenatal sGC treatment on child behaviour, 
including ADHD symptoms. The few existing studies report inconsistent findings. Some 
studies report an association between repeated prenatal sGC treatment and distractibility, 
hyperactivity and aggressive behaviour [445], as well as attention problems [446] in young 
children, but others do not [447-449].   
 
French et al. (2004) [445] examined a cohort of 541 very preterm infants (all born before 32 
weeks gestation), to study the impact of repeated prenatal sGC treatment (n=260 sGC 
exposed vs. n=281 unexposed) on later child behaviour and disabilities. One course of sGC 
treatment consisted of 2 doses of 11.4mg of betamethasone, which was administered at 
weekly intervals in cases considered to be at ongoing risk of preterm birth. Children exposed 
to three or more courses of treatment, compared with unexposed children, were at increased 
risk for distractible, hyperactive and aggressive behaviour at 3 years and later at 6 years, after 
adjustment for confounders, including gestational age and infant sex. Children exposed to one 
or two courses of treatment did not differ in behaviour from unexposed children. Crowther et 
al. (2007) [446] studied the impact of repeated prenatal sGC treatment on the behaviour and 
general development of 1047 children. Mothers received an initial course of prenatal sGC and 
then were randomly assigned to either the repeat sGC group (n=521), who were administered 
11.4mg of betamethasone per dose, or saline placebo group (n=526); the dose was repeated 
weekly if the mother remained at risk for preterm birth before 32 weeks of gestation. 
Children exposed to repeat doses of antenatal GC, compared with the placebo group, were 
more likely to have attention problems at 2 years, after adjustment for confounders including 
gestational age.  
 
Thorp et al. (2003) [447] studied the effects of prenatal phenobarbital and repeated sGC on 
child behaviour and cognition in 294 cases at risk of preterm delivery.  The study was a 
secondary analysis to a trial that was primarily designed to examine whether prenatal 
phenobarbital (and vitamin K) prevents intracranial haemorrhage in premature newborns. As 
such, the treatment group (n=149) were administered phenobarbital (dosage dependent on 
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imminence of delivery) and sGC, and the control group (n=145) were administered placebo 
and sGC. Prenatal sGC treatment administered to all mothers consisted of 2 doses of 12mg of 
betamethasone, repeated weekly as necessary. The results showed that prenatal phenobarbital 
and repetitive sGC treatment were not associated with behaviour or cognitive impairments in 
7-year-old children, after adjustment for gestational age and other confounders. Trautman et 
al. (1994) [448] examined behaviour, cognition and temperament in 26 children, aged 6 
months to 5.5 years, who were prenatally treated with sGC because they were at risk of 
congenital adrenal hyperplasia (CAH), and compared them with 14 unexposed CAH-risk 
pregnancies. Children in the treatment group were prenatally exposed to dexamethasone 
during all or part of gestation, and the total dosage ranged from 21mg to 322mg. The results 
showed no significant differences in behaviour problems or cognition between the exposed 
and unexposed children, yet prenatally exposed children had more temperament problems. 
The findings were independent of CAH status and sex, as well as other potential confounders; 
however, gestational age was not accounted for. Hirvikoski et al. (2008) [449] also examined 
the impact of dexamethasone treatment (administered daily; maximum dose 1.5mg) in CAH-
risk pregnancies, in a sample of 61 children, aged between 7-17 years. Behaviour did not 
significantly differ between exposed children (n=26) and unexposed control children (n=35), 
after accounting for confounders including gestational age. 
 
Overall, these few studies are limited by several methodological issues. First, prenatal sGC 
treatment-selection bias is a main issue which previous studies have not fully addressed; it is 
essential to disentangle the potential effect of treatment from the conditions precipitating 
treatment. Matching techniques, such as propensity-score-matching, which matches cases and 
controls on baseline treatment-related covariates, thereby mimicking the randomisation 
procedure in randomised controlled trials (RCTs), have not yet been used to examine prenatal 
sGC treatment effects. This matching procedure would allow the impact of prenatal sGC 
exposure on mental health to be isolated from the confounding effects of treatment. Second, 
most previous studies are restricted by small sample sizes and short follow-up times (young 
children only). One study examined the long-term association and reported that adults at age 
31 who received a single course of prenatal sGC did not differ on mental health outcomes 
from those in the placebo condition [450]. However, the placebo group in this study received 
cortisone acetate with 1/70th of sGC potency, and so the impact of sGC from non-exposure 
cannot be completely assessed. Third, the impact of repeated doses of prenatal sGC has 
mainly been examined, and so little is known about the long-term impact of low/infrequent 
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doses of prenatal sGC exposure on later child behaviour. This is particularly important given 
that current guidelines recommend that only a single course of sGC should be administered 
(either 2 doses of 12mg of betamethasone or 4 doses of 6mg of dexamethasone) because of 
concerns regarding potential long-term effects of repeated sGC treatment [451]. Fourth, some 
studies compare the impact of repeated prenatal sGC exposure (treatment group) with a 
single dose of sGC (control group), and so the effects of sGC from non-exposure cannot be 
completely evaluated. 
 
2.2.11 Prenatal exposure to glucocorticoids and obesity in children and adolescents 
 
Animal studies support the hypothesis that prenatal overexposure to GC, either endogenous 
or synthetic, can program long-term metabolic disorders, including obesity, as described in 
several reviews [42,392,452]. For example, in rats, prenatal dexamethasone exposure resulted 
in increased intra-abdominal fat depots, in combination with increased leptin levels, in the 
adult offspring [453]. Furthermore, adult offspring of rats prenatally exposed to 
dexamethasone had increased GR expression and attenuated fatty acid uptake, selectively in 
visceral adipose tissue, which may contribute to both adipose and hepatic insulin resistance 
[454]. In the rat, prenatal dexamethasone exposure also reduces foetal plasma and placental 
leptin [455], and placental expression of the Ob-Rb receptor which mediates leptin action 
[456]. These effects may have important long-term metabolic implications as the 
concentration of leptin in foetal cord blood has been associated with birth size and infancy 
weight gain in humans [457]. Prenatal sGC exposure in animals has consistently been related 
with the programming of other metabolic factors, including blood pressure, and glucose and 
insulin levels [42,392,452].     
 
In humans, it is unclear whether obesity may be programmed by excess prenatal exposure to 
GC. There is limited evidence of an association between prenatal stress and body 
composition in children and adolescents [40,458]. Moreover, there is very little evidence to 
implicate excess prenatal exposure to GC as a potential underlying mechanism in the 
programming of obesity.  Van Dijk et al. (2012) [459] examined a subsample of 1320 
children and found that elevated maternal cortisol levels were linked with higher fat mass 
index in girls, and lower fat mass index in boys, suggestive of sex-specific effects; this study 
however did not find an association between prenatal stress (measured as job strain) and child 
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adiposity measures. An important limitation of this study is that cortisol was not optimally 
assessed because the participants provided samples at different stages of gestation and at 
different times of the day. Furthermore, elevated maternal cortisol levels do not necessarily 
reflect foetal overexposure to cortisol. Dalziel et al. (2005) [417] examined the impact of 
prenatal sGC treatment on a range of cardiovascular risk factors, including body composition, 
in a RCT that followed-up 534 neonates to adulthood. The exposed group were administered 
12mg or 24mg of betamethasone, repeated 24 hours later if delivery had not occurred, whilst 
the placebo group were administered 6 mg of cortisone acetate with 1/70th of sGC potency. 
At 30 years of age, adults prenatally exposed to betamethasone (n=253) did not differ from 
unexposed adults (n=281) on body composition (weight, height, BMI or WHR), or other 
cardiovascular risk factors e.g. blood pressure, diabetes, and plasma fasting concentrations of 
lipids or cortisol. However, there was some evidence that prenatal sGC exposure may be 
associated with increased central insulin resistance, as measured by the 30 minute insulin and 
120 minute glucose response to an oral glucose tolerance test. A significant limitation of this 
study is that the control group was exposed to placebo that contained a small portion of sGC 
potency, and thus comparisons between exposure and non-exposure could not be fully 
assessed. In another RCT, Dessens et al. (2000) [460] also reported no differences in body 
composition (weight or height) between prenatally sGC exposed (n=48) and unexposed 
(n=33) adults aged 20-22 years.  Although, the exposed group had significantly lower systolic 
blood pressure compared with the unexposed group. The exposed group were administered a 
single course of 24mg of betamethasone and orciprenaline (a drug that can be used in 
threatened pre-term birth to stop contractions), whilst the placebo group was administered 
orciprenaline and 2ml of saline. Thus, in this study it is not possible to distinguish between 
the potential long-term effects of betamethasone from those of orciprenaline. Other research 
has demonstrated associations between prenatal sGC treatment and higher blood pressure in 
childhood [461], as well as other adverse metabolic outcomes in the offspring, including 
increased levels of neonatal cord blood leptin [462].  
 
Overall, due to the very limited evidence, it remains unclear whether prenatal exposure to 
sGC is associated with either child behaviour or obesity, and thus further study is warranted. 
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2.2.12 Birthweight and placental weight as potential factors mediating the 
glucocorticoid programming pathway 
 
Little is known about the GC programming pathway. It is possible that birth size lies on the 
pathway, since altered birth size is well-known to be associated with prenatal exposure to 
sGC or maternal stress [380,381], and adverse health outcomes in the offspring, including 
mental illness [37] and obesity [364]. Considering the key role of the placenta in regulating 
foetal exposure to GC, it is also plausible that the placenta may mediate GC programming. 
Indeed, there is evidence to suggest that prenatal exposure to sGC or maternal stress may 
impact placental size as well as function [46,47,393]; altered placental characteristics in turn 
may affect foetal development and consequently adult health [45,463]. This is in line with 
recent evidence suggesting that the placenta may play an important role in foetal 
programming, and may be a useful marker of later disease risk [464]. However, it is unclear 
whether altered placental characteristics are related with later mental health or obesity in 
children and adolescents.     
 
2.2.13 Placental programming of mental health and obesity   
 
2.2.14 Placental development and physiology  
 
The placenta is a highly specialised organ constituting the active interface between maternal 
and foetal blood circulations, which functions to support normal growth and development of 
the foetus, and sustain pregnancy [465,466]. The placenta is discoid shaped, and weighs an 
average of 470g [467]. Placental weight is directly proportional to foetal weight, and at term, 
the birth-to-placental-weight ratio is normally around seven [468]. Pregnancy pathologies and 
lifestyle factors are associated with alterations to this ratio and changes to placental function, 
which in turn can impact foetal development [468-470].  
 
2.2.15 Structure of the placenta 
 
The foetal facing surface of the placenta, where the umbilical cord inserts, is known as the 
chorionic plate, which is the region that contains the foetal chorionic blood vessels that 
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branch from the umbilical vessels [466,468]. The maternal facing surface of the placenta is 
the basal plate. In between these two plates lies the intervillous space, which contains the 
chorionic villi – the main functional units of the placenta. The villi are finger-like projections 
which are extensively branched, and generally contain an outer surface layer of 
muntinucleated syncytiotrophoblast (Figure 2.4A). The villi contain foetal blood vessels, and 
the terminal regions of the villi is where most of the maternal-foetal exchange occurs [471]. 
Circulating maternal blood enters the intervillous space through spiral endometrial arteries 
and bathes the villi, returning back via endometrial veins. Oxygen-depleted blood from the 
foetus passes through two umbilical arteries to the arterio-capillary-venous network within 
the chorionic villi (Figure 2.4A). Following maternal-foetal exchange, the oxygen-enriched 
foetal blood returns to the foetus via the single umbilical vein.  
 
The maternal blood in the intervillous space and the foetal blood in the chorionic villi are 
separated via the placental membrane. Initially, the placental membrane is comprised of four 
layers, the syncytiotrophoblast, the cytotrophoblast, the connective tissue of the villus and the 
endothelium lining the foetal capillaries (Figure 2.4B). By around the 20th gestational week, 
the cytotrophoblast layer of many villi disappear, such that the placental membrane becomes 
very thin (comprising three layers), and consequently the syncytiotrophoblast comes in direct 
contact with the foetal capillary endothelium (Figure 2.4C), thereby facilitating maternal-
foetal exchange [466]. 
 
During pregnancy, the foetus is surrounded by amniotic fluid and enclosed within the foetal 
membranes, which comprise the foetal-facing amnion and maternal-facing chorion [472]. 
These membranes play an important role in the successful maintenance and termination of 
pregnancy, undergoing rupture during the first stage of labour.  
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2.2.16 Development of the placenta 
 
The endometrium undergoes changes in structure in anticipation of implantation, a process 
known as decidualisation [468]. Endometrial stromal cells take on an epithelioid appearance, 
and the endometrial glands secrete nutrients to be utilised by a successful conceptus for 
growth and development in early gestation [468]. The fertilised egg, the zygote, undergoes a 
series of mitotic divisions, generating a ball of cells, a morula, which eventually gives rise to 
the blastocyst [468]. The blastocyst contains an inner cell mass, which develop into the 
foetus, and an outer layer, the trophectoderm, which forms the placenta and extraembryonic 
membranes. Following attachment of the blastocyst to the endometrium, the trophectoderm 
proliferates and differentiates into an inner cytotrophoblastic layer and an outer multi-
nucleated syncytiotrophoblastic mass [468]. The syncytiotrophoblast penetrates the 
endometrium epithelium, thereby invading the endometrium, and resulting in implantation of 
the blastocyst [466,468]. Proliferating cytotrophoblast cells evaginate into the 
syncytiotrophoblast, which initiates development of the chorionic villi of the placenta [473]. 
Figure 2.4: (A) The foetal placental circulation. The dotted line shows the position of (B) 
which is a section through the chorionic villus at approximately 10 weeks. (C) A section 
through the chorionic villus at full term. Reprinted from Thrombosis Research, 114, Gude 
NM, Roberts CT, Kalionis B, King RG, Growth and function of the normal human placenta, 
397-407, Copyright (2004) [466], with permission from Elsevier.  
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The trophectoderm of the blastocyst undergoes extensive proliferation and differentiation, 
giving rise to a range of trophoblastic cell lineages [466]. In essence, differentiation may be 
split into two main pathways: the villous pathway, which ultimately generates the 
syncytiotrophoblast (outer epithelial layer of the chorionic villi) which forms the site of 
maternal-foetal exchange; and the extravillous pathway, which gives rise to extravillous 
trophoblast cells which are involved in invading the endometrium and remodelling maternal 
uterine arteries [466]. 
 
2.2.17 Function of the placenta 
 
The placenta sustains foetal homeostasis by carrying out an array of physiological functions 
which, after birth, are performed by the kidney, gastrointestinal tract, lungs and endocrine 
glands of the neonate [465]. Accordingly, the main functions of the placenta are to mediate 
transfer of nutrients and respiratory gases, synthesise and release a range of hormones, as 
well as provide an immunological barrier between mother and foetus. From the maternal to 
foetal compartments, the placenta transfers glucose, amino acids, lipids, water, ions, minerals 
and vitamins. Oxygen is transferred to the foetus, while carbon dioxide and other waste 
products are transported to the mother, via the placenta. The placenta itself also has a 
metabolic demand, and requires nutrients and oxygen to function [466]. In terms of endocrine 
functioning, the placenta secretes numerous hormones, e.g. oestrogens, progesterone, 
placental lactogen, stress response regulatory hormones and various growth factors, into both 
the maternal and foetal circulations to serve a number of functions, including regulation of 
pregnancy, metabolism, foetal growth and parturition. The immunological role of the 
placenta includes protecting the foetus from xenobiotics (chemical compounds that are 
foreign to the body) via e.g. export pumps or metabolic action of enzymes present within the 
placenta [466]. While the placenta reduces foetal exposure to some xenobiotics, there are 
several that can readily cross the placenta, including alcohol, nicotine, lithium, warfarin and 
many anticonvulsants [466,474]. Further, the placenta forms a barrier to prevent transmission 
of infection from mother to foetus, although some bacteria (e.g. Treponema pallidum, which 
causes syphilis, and Toxoplasma gondii, which causes toxoplasmosis) and several viruses 
(e.g. HIV, rubella, polio and varicella) can be transferred across the placenta [466].   
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2.2.18 Role of the placenta in foetal programming  
 
The placenta, providing an interface between the mother and foetus, appears to be in a key 
position to play a direct role in foetal programming. Indeed, any disturbances in the maternal 
compartment must be transferred across the placenta in order to affect the foetus. Recent 
studies have demonstrated that the placenta responds to perturbations in the maternal 
environment with a range of structural and functional adaptations, including changes in 
placental size, morphology, blood flow, nutrient transporter abundance, and endocrine 
functioning – all of which are closely inter-related during development [463,468]. Such 
placental alterations in turn can affect foetal growth and development, which may lead to 
disease later in adult life [45,463,465]. In light of this, it is surprising that the role of the 
placenta in foetal programming has received only limited research attention to date.  
 
2.2.19 Placental size and programming  
 
Recently, epidemiological studies have begun to examine the role of the placenta in foetal 
programming of disease. It is possible to study this epidemiologically because alterations to 
the maternal environment and placental function can be reflected in placental size at birth, 
which in turn may be related to the later development of disease [475].  
 
2.2.20 Impact of placental size on function  
 
Typical measures of placental size are placental weight and surface area, as well as placental-
to-birth-weight ratio. Placental weight is the most common measure of placental size, and is a 
summary of many dimensions of placental growth, including surface area and thickness 
[476,477]. Placental surface area is estimated by the length and breadth of the placenta, and 
reflects the area for maternal-foetal exchange during gestation [464]. Placental-to-birth-
weight ratio is a measure of placental weight relative to birthweight, and reflects the 
efficiency of the placenta e.g. a low ratio may reflect an efficient placenta, indicating that 
proportionately more resource has been invested in growth of the foetus rather than placental 
growth [475].  
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Variation in the size of the placenta affects aspects of its function, in particular the ability to 
transfer nutrients to the foetus via changes in the exchange surface area [478]; in general, 
small placentas are associated with small foetuses [479]. Furthermore, changes in placental 
size may impact the endocrine functioning of the placenta [463], which in turn can affect the 
development of foetal organs and tissue growth. For example, animal research in sheep 
shows that maternal concentrations of progesterone and placental lactogen are decreased 
under various suboptimal intrauterine conditions, and it is suggested that this may partly be 
due to reduced placental size [463]. Given the metabolic actions of progesterone and 
placental lactogen, lower levels of these hormones can in turn result in reduced glucose 
supply to the foetus [463]. Changes in placental growth may also be related with altered 
expression of nutrient transporters, such as glucose and amino acid transporters, which may 
accordingly impact foetal nutrient supply [463]. In addition, placental size has been 
negatively correlated with placental vascularity, which may have consequences for foetal 
blood supply [463].  
 
Placental size is affected by various maternal influences, such as psychosocial stress, BMI 
and smoking [44,46], indicating that the placenta is receptive to the maternal environment, 
and undergoes changes in size in an effort to maintain foetal development in suboptimal 
conditions [463]. For example, in response to maternal undernutrition, the placenta may 
undergo compensatory enlargement [480]; although this adaptation may improve the overall 
nutrient supply to the foetus, ensuring a normal birthweight is achieved, the relative 
contribution of specific nutrients to foetal organs may be altered, which may affect the 
structure and function of developing organs [463]. As such, placental compensatory 
mechanisms may often ensure a normal birthweight is achieved in adverse circumstances, 
whilst the placenta itself may be markedly affected [465] – reflecting the physiological 
stresses which occurred during development. Therefore, compared to birthweight and other 
common indices used to identify suboptimal intrauterine conditions, placental phenotype may 
provide additional insight into the intrauterine environment and improve our understanding of 
the processes underlying foetal programming. In line with this, epidemiological associations 
between birthweight and later disease are not always consistent [348,360,481], and it has 
become increasingly apparent that placental characteristics also need to be taken into account 
when predicting health outcomes [463,464]. Thus, placental size may enhance the ability to 
predict later disease, as several lines of evidence suggest [464,465,482].   
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Interestingly, a study by Lumey [480] suggests that depending on the timing of exposure, 
prenatal insults may not noticeably affect birthweight, whereas placental weight is affected 
regardless of the timing. This study investigated the effects of undernutrition at different 
stages of pregnancy on placental and foetal growth during the Dutch Famine. Exposure to 
famine in the 1st trimester was associated with an increased placental weight and no apparent 
effect on birthweight, whereas exposure in the 3rd trimester resulted in a decrease in both 
placental weight and birthweight. These results imply that compensatory placental growth 
may occur in response to undernutrition in early pregnancy in order to maintain normal foetal 
weight; in late gestation, such compensatory mechanisms are insufficient, reflected by the 
decrease in placental weight and foetal weight. 
 
2.2.21 Maternal factors that influence placental and foetal development 
 
There is extensive evidence demonstrating that maternal factors can impact placental 
structure, most notably size, while less is known about the maternal influence on placental 
function. Gestational complications in general have been linked with reduced placental size 
[47,476,483]. However, in a recent large study, Tegethoff et al. (2010) found that maternal 
psychosocial stress during pregnancy was associated with increased placental weight as well 
as increased birthweight [46]. Although there is otherwise very little known about the relation 
between maternal prenatal stress and placental size, there are several previous studies that 
have in contrast reported a negative association between maternal prenatal stress and 
birthweight [484-486]. The study by Tegethoff et al. (2010) suggests that the placenta may 
undergo compensatory enlargement in response to maternal stress in order to maintain foetal 
development under adverse intrauterine conditions [46]. The authors suggested that growth 
hormones e.g. insulin-like growth factor hormones and placental growth hormone, as well as 
cytokines e.g. interleukin 10, may contribute to mediating the link between maternal prenatal 
stress and placental growth [46]. Studies in rodents have shown that maternal prenatal stress 
can affect placental gene expression [487], including  reducing  11β-HSD2 expression [488]. 
In  rats,  inhibition  of  11β-HSD2 has been linked with reduced placental and foetal growth, as 
well as adverse cardiovascular and metabolic outcomes in the adult offspring [452]. 
Interestingly, in humans, maternal prenatal anxiety has also been associated with reduced 
placental   11β-HSD2 gene expression [393]. Taken together, the animal and human studies 
support the hypothesised association between maternal prenatal stress and elevated foetal 
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exposure to cortisol, and suggest that altered placental structure and function may mediate 
foetal programming by prenatal stress.  
 
There is also evidence from human studies that glycyrrhizin, a natural constituent of 
liquorice,  inhibits  placental  11β-HSD2 [394], which in turn may increase foetal exposure to 
cortisol and impact development. In line with this, excessive maternal consumption of 
liquorice during pregnancy has been associated with poorer cognition and behaviour in 
children, including greater attention problems, which may reflect altered foetal brain 
development [489].  
 
Prenatal sGC administration has also been linked with altered placental characteristics. In all 
species studied to date, including human, prenatal sGC treatment has been associated with 
reduced placental size [47,475], which in turn may account for the link between prenatal sGC 
and reduced foetal growth [381]. The foetus is growth retarded to a lesser degree than the 
placenta, suggesting placental efficiency is increased in response to sGC, despite the decrease 
in placental weight [475]. One study in humans found that although repeated sGC exposure 
was associated with reduced placental size, there were no evident changes in placental 
histology [47]. Animal studies have demonstrated that prenatal sGC can affect placental 
morphology e.g. increase surface area for nutrient exchange and hypovascularisation of the 
foetal villi, as well as alter placental nutrient transporter expression and endocrine function 
[475]. Furthermore,  prenatal  sGC  treatment  has  been  associated  with  altered  placental  11β-
HSD2 expression across different species, including increased expression in humans [463].   
 
Maternal body composition, which reflects long-term environmental and nutritional 
conditions, is known to affect the placenta [45]. As maternal body composition impacts 
maternal metabolism and nutrient availability, it can thereby affect the environment of the 
feto-placental unit throughout pregnancy [45]. Maternal BMI has been positively associated 
with placental weight and a high placental-to-birth-weight ratio [44,475]. Similarly, increased 
gestational weight gain has been linked with greater placental weight [44]. It is possible that 
maternal body composition impacts placental function. For example, smaller maternal upper-
arm muscle mass before pregnancy has been associated with lower activity of the amino acid 
transporter System A in the term placenta [490]. Altered amino acid transfer may in turn 
affect foetal development.  
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Maternal nutrition can also alter placental development, as evidenced, for example, from 
studies that have investigated restriction of maternal nutrition during pregnancy. One study 
examined pregnant women in Saudi Arabia who fasted during Ramadan [491], which is an 
annual period of Islamic day-time fasting, lasting for one month. Fasting during the second or 
third trimester of gestation was associated with reduced placental weight and placental-to-
birth-weight ratio, while birthweight was unaffected [491]. This suggests that in response to 
fasting, placental growth slows but efficiency is increased to sustain foetal development 
[491]. Another study found that during the Dutch famine of 1944-1945, maternal 
undernutrition during the first trimester of pregnancy was associated with increased placental 
weight and placental-to-birth-weight ratio, while there was no change in birthweight [480]. 
The authors concluded that because undernutrition in early pregnancy can induce 
compensatory placental growth, yet does not affect birthweight, the latter marker of foetal 
growth may not be an appropriate proxy for maternal undernutrition for all pregnancy 
trimesters [480].  
 
Other maternal lifestyle factors, including smoking and alcohol consumption during 
pregnancy have been linked with altered placental and foetal development [492-494]. 
Smoking has been linked with reduced placental weight [44,492], which is in line with 
morphological research which has shown that smoking can affect placental cell proliferation 
and differentiation, increase the rate of placental cell death, and reduce placental 
vascularisation [495-497]. In turn, these changes to the placenta can affect foetal growth and 
development; in line with this, it well established that prenatal smoking is linked with 
reduced birthweight [44,492,498]. Prenatal smoking has also been associated with increased 
placental-to-birth-weight ratio [492], suggesting that poorer placental function may lead to 
increased placental growth relative to the foetus in attempt to maintain foetal development 
[492]. In terms of alcohol consumption during pregnancy, some studies have reported 
negative associations with placental weight and birthweight, whilst others have not found any 
associations [44,492-494,499-501]. There is some evidence that prenatal alcohol use is 
associated with reduced placental-to-birth-weight ratio [492]. Although it is unclear how 
alcohol affects placental and foetal development, it is suggested that alcohol can result in 
vasoconstriction and increased perfusion pressure, as well as endocrine changes to the 
placenta [502].  
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With respect to medical factors during pregnancy, it is well established that gestational 
diabetes impacts placental and foetal growth [44,503]. Both placental weight and birthweight 
are increased in response to maternal and foetal hyperglycaemia [44,503]. At the structural 
level of the placenta, hyperproliferation and hypervascularisation occurs, which results in 
expansion of the placental surface and exchange areas [503]. These adaptations contribute to 
increased oxygen diffusion across the placenta to compensate for the impaired foetal oxygen 
supply in diabetic pregnancy [503]. Gestational hypertension has been linked with reduced 
birthweight  [44,504], as well as reduced placental weight [483,505], yet the findings for the 
latter are somewhat inconsistent because some studies have not found any associations with 
placental weight [44,469]. Morphological research has shown that gestational hypertension is 
associated with various ultra-structural alterations, including decreased number of syncytial 
microvilli, patchy syncytial necrosis and narrowing of foetal capillaries [505,506], which may 
contribute to the  reported reduction in placental size, and altered foetal growth.      
 
2.2.22 Placental size and disease  
 
As described, a range of maternal factors can impact placental growth and consequently 
foetal growth and development; in turn, altered foetal development may affect long-term 
health, in accordance with the foetal programming phenomenon. It is thus possible that 
altered placental size may lie on the programming pathway linking prenatal exposures to later 
disease. In line with this, characteristics related to placental growth (placental weight, surface 
area and placental-to-birth-weight ratio) have been associated with various adult diseases, in 
particular cardiovascular and metabolic outcomes e.g. coronary heart disease, diabetes, stroke 
and hypertension [45,507]. Either a disproportionately large or small placenta may be linked 
with later disease, and there is some evidence for U-shaped associations [45]. Foetuses with a 
disproportionately small placenta may suffer due to an impaired placental supply capacity, 
whereas those with a disproportionately large placenta may experience an increased 
metabolic burden due to having to share nutrients with an enlarged placenta [34,508]. 
 
2.2.23 Sex differences in placental growth and programming  
 
Males and females grow at different rates in utero, with males growing faster from an early 
stage of gestation, even from before implantation [509,510].  It is suggested that sex 
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differences in foetal growth are mediated by sex specific placental function [511]. Research 
shows that at any placenta weight, males are more likely to be taller than females, and males 
have a smaller placental-to-birth-weight ratio [512]. Thus, while males grow more quickly, 
they invest less in placental growth; this indicates that male placentas are more efficient but 
may have a poorer reserve capacity, which may render them more vulnerable to 
undernutrition [464]. Research suggests that in response to maternal undernutrition, male 
placentas more readily undergo compensatory enlargement, most likely to extract more 
nutrients from the mother; however, if the compensation is insufficient, and the foetus 
continues to be undernourished, then the need to share nutrients with an enlarged placenta 
may exert additional metabolic demands on the foetus, and consequently contribute to an 
increased risk of later disease [508]. In line with this, one study  found that in males, 
increased placental size and reduced birthweight were associated with hypertension, and 
these results were related with maternal socioeconomic status, an indicator of diet [508].   
 
In a recent review that examined sex differences in the placenta, it was suggested that males 
and female placentas undergo different adaptations in response to the same adverse 
intrauterine conditions (see Figure 2.5) [511]. The review proposed that males are more likely 
to undertake a minimalist approach under adverse intrauterine conditions, with few gene, 
protein or functional changes in the placenta in order to allow increased or continued 
placental and foetal growth [511]. If adverse conditions are sustained, and foetal demand for 
resources exceeds supply, this male strategy of continued growth may increase the risk of 
adverse outcomes, such as intrauterine growth restriction or preterm birth [511]. In contrast, 
female placentas may be more likely to undergo multiple placental gene and protein 
adaptations under adverse intrauterine conditions to reduce growth minimally without growth 
restriction (greater than the 10th percentile) [511]. This female approach of decreasing growth 
reduces foetal demand for resources, and may ensure survival under continued adverse 
conditions [511]. Considering all lines of evidence, sexual dimorphism in placental 
adaptations could underlie the known sex differences in neonatal morbidity and mortality 
(with males at increased risk [513,514]) [511], and could also contribute later in life to sex 
differences in child or adult health [508].    
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Figure 2.5: Overview of the sex-differences in placental response to the same maternal environment. 
Reprinted from Placenta, 31, Clifton VL, Review: Sex and the Human Placenta: Mediating Differential 
Strategies of Foetal Growth and Survival, S33-S39, Copyright (2010) [511], with permission from Elsevier. 
 
 
 
 
 
 
 
 
 
 
 
2.2.24 Placental size and mental health and obesity 
 
Little is known about the association between placental size and later development of 
psychopathology or obesity. Although to date there are no apparent studies that have 
examined placental size in relation to behaviour or general mental health in children or 
adolescents, there are some related studies which provide preliminary insight. Evidence from 
Finnish population studies (n > 4000) show that low placental weight and low birthweight are 
associated with schizophrenia or schizotypal traits in adults [515-517]. Although these studies 
are limited in that they do not examine sex differences or the placental-to-birth-weight ratio, 
the results suggest that reduced placental and foetal growth, possibly due to suboptimal 
intrauterine conditions (e.g. undernutrition), may adversely impact brain development, 
programming an increased risk of later psychopathology. This is in line with findings from a 
recent study in mice which examined the effect of maternal undernutrition on the 
development of the placenta and foetal brain [518]. Maternal undernutrition during a critical 
stage of hypothalamus development resulted in the breakdown of placental tissue and altered 
placental gene expression to allow a continued supply of nutrients to the developing 
hypothalamus, despite reduced maternal food intake [518]. Thus, the study showed that the 
placenta undergoes adaptations, sacrificing its own development, in order to preserve foetal 
brain development during a critical stage of gestation. However, these placental adaptations 
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can only sustain foetal growth and brain development over the short-term in times of acute 
maternal undernutrition [518]. It is thus likely that chronic undernutrition would affect foetal 
brain development, and consequently later mental health; this may be reflected in reduced 
placental weight and birthweight, as the aforementioned human studies suggest [515-517].  
 
An important correlate of decreased placental size is reduced foetal blood flow, which may 
adversely impact neurodevelopment [84,519]. It has been suggested that compromised 
placental and foetal blood flow e.g. due to maternal smoking, may be associated with altered 
brain cell numbers and structure [84]. Interestingly, a small study (n=6) which examined 
ADHD adolescents born pre-term found a link between low neonatal cerebral blood flow and 
increased dopamine receptor availability in adolescence [519]. This suggests that deficient 
blood flow to the developing nervous system can have a long term adverse impact on 
dopaminergic neurotransmission via increasing receptor availability, which in turn may 
increase the risk of behaviour problems, including ADHD. 
 
To current knowledge, there is only one study that has examined the association between 
placental size and later risk of overweight, which examined overweight and body 
composition (fat mass and lean mass) outcomes in adults (mean age 61.5 years) [520]. This 
study is based on a Finnish population birth cohort (n = 2003), consisting of participants born 
in 1934-1944, around the time of World War 2 (WW2). The results showed that in the whole 
sample, placental size was not associated with any of the examined obesity outcomes [520]. 
The analyses were subsequently stratified by maternal height, a marker of lifetime nutrition, 
and according to peroxisome-proliferator-activated   receptor   γ2   (PPARγ2) genotype [520]. 
PPARγ2  variants   have   related with overweight, insulin resistance and type 2 diabetes, and 
additionally   there   is   evidence   that   PPARγ   plays   a   significant   role   in   regulating   placental  
vascular proliferation, trophoblast differentiation and invasion [521-523]. In a subsample of 
participants who carried the   Pro12Pro   genotype   of   the   PPARγ2 gene and whose mothers 
were tall, an enlarged placental surface area and a long lesser diameter (that bisects the 
maximal diameter at right angles) predicted overweight (BMI  ≥  25  kg/m2) and high body fat 
percent [520]. Increased   birthweight   was   associated   with   BMI   ≥   25   kg/m2 (although this 
increased BMI was found to be due to greater lean body mass rather than fat mass) [520]. The 
authors suggested that the reported associations in offspring whose mothers were tall was 
evidence that compensatory placental enlargement occurs in women who were well 
nourished before pregnancy and undernourished during pregnancy (there were widespread 
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food shortages during WW2, when the cohort was born) [520]. This concept is consistent 
with findings in sheep; standard sheep farming practices involve expanding placental size by 
undernourishing ewes, which results in fatter lambs at birth [524,525]. As the associations 
were   only   found   in   participants   with   the   Pro12Pro   genotype   of   the   PPARγ2   gene,   this  
suggests that interactions between maternal nutrition and genes related with the 
placenta/obesity influence the risk for later obesity. However, the study is limited by lack of 
information on maternal nutrition during pregnancy, so it is only possible to speculate that the 
food shortages common at the time were associated with placental enlargement. Furthermore, 
placental-to-birth-weight ratio was not assessed, and so it is not known how the changes in 
placental size were related with birthweight, and sex differences were not examined.   
 
To date, it is not known whether placental size contributes to intrauterine programming of 
psychopathology or obesity in children or adolescents. While there is some very scant 
evidence of associations in adults, the findings are generally limited by lack of examination 
of the placental-to-birth-weight ratio, which provides insight into placental efficiency. Also, 
importantly, studies have not assessed sexual dimorphism, despite the evidence of sex 
differences related to the placenta and the outcomes under study, mental health and obesity 
[511,526,527].     
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3. Aims and hypotheses of the thesis 
 
Obesity and ADHD frequently manifest in childhood and persist throughout the life course, 
and so from a preventative viewpoint, it is important to examine these conditions as early as 
possible during development. Indeed, understanding the role of the early developmental 
period in contributing to later disease risk is important for future intervention strategies that 
aim to prevent adverse health trajectories. This thesis investigates obesity and ADHD 
symptoms across childhood to adolescence and examines potential risk factors, spanning 
prenatal life through to childhood and adolescence.  
 
Aims  
 
The overall objective of this thesis is to examine the nature of the ADHD symptom-obesity 
association in children and adolescents, investigating the direction of the link and potential 
underlying behavioural and prenatal pathways (see Figure 3.1 for overview of main 
associations under study). This work will address critical gaps in knowledge relating to the 
ADHD-obesity association, and there are two main significant implications of this work. 
First, it will provide theoretical insight into the pathology underlying both ADHD and 
obesity, in terms of both early-life programming and later psychopathological/behavioural 
mechanisms in childhood and adolescence. Second, from a public health perspective, it will 
provide information on potential risk factors for ADHD and obesity, and thus may pave the 
way for future advancements in the prevention, diagnosis and treatment of both conditions. 
 
The first aim of this thesis is to examine the association and directionality between ADHD 
symptoms (combined inattention-hyperactivity, inattention and hyperactivity) and obesity in 
children and adolescents. Behavioural factors – physical activity and binge-eating - will be 
explored as potential mediators underlying the association.  Further, the directionality 
between ADHD symptoms and physical activity, and the impact of ADHD symptoms on 
binge-eating, will be examined from childhood to adolescence. Overall, this work will assess 
whether (1) ADHD symptoms and obesity are reciprocal risk factors for one another i.e. 
whether there is a bidirectional ADHD-obesity association, (2) physical inactivity and/or 
binge-eating mediate the association, (3) physical inactivity is a risk factor for ADHD 
symptoms, and (4)  ADHD symptoms confer risk for physical inactivity and binge-eating.  
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The second aim of this thesis is to examine whether prenatal factors confer common risk for 
both mental health (including ADHD symptoms) and obesity, in childhood and adolescence. 
Specifically, the impact of prenatal sGC treatment on later mental health and obesity will be 
studied. Similarly, the association of placental size on mental health and obesity will be 
examined. In sum, this work will provide further understanding of the foetal origins of mental 
health and obesity, and provide insight into whether the risk for the ADHD-obesity 
association is established in utero.   
 
Hypotheses  
 
This thesis set out to investigate the following hypotheses, which can be divided into two 
themes of study. The first theme explores the focal ADHD symptom-obesity association, 
along with underlying behavioural mediators, while the second theme investigates potential 
underlying prenatal pathways:  
 
Theme I:  
Exploring directionality and underlying behavioural mediators of the association between 
ADHD symptoms and obesity 
 
1. There will be both concurrent and long-term associations between ADHD symptoms and 
obesity over the period of childhood to adolescence.  
 
2. The ADHD symptom-obesity association will be bidirectional over the long-term, from 
childhood to adolescence.  
 
3. The ADHD symptoms of inattention and hyperactivity will each contribute to the 
potential ADHD symptom-obesity association.  
 
4. The behavioural factors, physical inactivity and binge-eating, will associate with ADHD 
symptoms and mediate the potential ADHD symptom-obesity association.  
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Theme II:  
Investigating whether prenatal factors confer common risk for mental health and obesity 
 
Prenatal exposure to synthetic glucocorticoids  
 
5. Prenatal sGC exposure will be associated with child/adolescent mental health (ADHD 
symptoms, general psychiatric disturbance, antisocial disorder and neurotic disorder) and 
obesity.  
 
6. Placental or birth size will mediate the association between prenatal sGC exposure and 
later mental health.  
 
Placental size 
 
7. Placental size will be associated with mental health (ADHD symptoms, general 
psychiatric disturbance, antisocial disorder and neurotic disorder) and obesity in children 
and adolescents.  
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Figure 3.1: Overview of putative associations under study in this thesis. 
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4. Methods 
 
This chapter begins with an introduction to statistical methods used in this thesis to draw 
causal inferences from observational data. Next, the study population is presented, followed 
by a description of the data used throughout the entire thesis. Finally, the method for each 
study theme (I-II) is described individually, including information on theme-specific 
variables and statistical analysis.  
 
4.1 Statistical methods for causal inference in observational studies 
 
In most quantitative empirical analyses, the main aim is to estimate the causal effect of an 
independent (exposure) variable on a dependent (outcome) variable. The design of RCTs is 
considered to be the gold standard in elucidating such cause-and-effect associations, due to 
the randomisation procedure, which ensures that exposed and unexposed status will be not be 
confounded by measured or unmeasured baseline characteristics [528,529]. However, in 
many areas of public health research, it is not feasible to assign study participants randomly 
to exposures or treatments, largely due to cost and ethical considerations, and thus in these 
situations observational study designs are typically employed [528]. The lack of 
randomisation in observational studies can introduce confounding (measured and 
unmeasured), so exposed and unexposed status groups may not be directly comparable, and 
thus causality cannot be affirmed [529].    
 
However, specialised study designs and statistical methods can be employed to allow 
tentative causal inferences to be drawn from observational data. These are particularly useful 
in the field of life course epidemiology, where observational research is the only possibility 
for causal inference. According to Susser (1991), three main criteria must be met to infer 
causality in epidemiology: (1) association (a causal factor, X, must occur together with the 
putative effect, Y); (2) time-order (X must precede Y); and (3) direction (a change in Y is due 
to a change in X) [530]. Prospective, longitudinal study designs, which involve repeated 
observations of risk factors and outcomes over time, are well-suited to allow consideration of 
Susser’s  criteria  for  causality.   
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When considering treatment effects in observational studies, establishing causality is 
particularly difficult because treatment-selection bias is a main issue; indeed, the baseline 
characteristics of treated and untreated groups often differ systematically, so the two groups 
are not exchangeable and thus it is difficult to disentangle the potential effects of treatment 
from baseline characteristics or covariates [529]. Propensity-score-methods, such as 
propensity-score-matching, have proven to be useful in reducing the impact of such 
treatment-selection bias when using observational data, and thus these techniques can be used 
to estimate causal effects of treatment [529,531].  
 
4.1.1 Propensity-score-matching 
 
The propensity score is defined as the probability of treatment assignment based on observed 
baseline covariates [531]. Matching on the propensity score creates balance or similarity 
between treated and untreated subjects on the distribution of measured baseline covariates, 
and thus reduces confounding associated with receipt of treatment [529]. This matching 
technique mimics the randomisation procedure prior to treatment allocation in RCTs, and 
thereby facilitates estimation of treatment effects using observational data [529].    
 
In practice, the propensity score is typically estimated via logistic regression modelling, 
whereby the treatment status is regressed on measured baseline covariates [529]. Propensity 
scores should be log transformed if the distribution of the scores is skewed. While there are 
various matching procedures [529],   a   particularly   precise   method   is   “nearest   neighbour  
matching”  within  a  specified  caliper  distance,  whereby  a  treated  subject  (case)  is  matched  to  
an untreated subject (control) whose propensity score is most similar, and the difference 
between the matched scores is below a pre-specified threshold (the caliper distance) [532]. 
Recent research has suggested a caliper width of 0.2 of the standard deviation (SD) of the 
logit of the propensity score is optimum in minimising the mean square error of estimated 
treatment effects [533]. Matching each case to many controls can be useful when the sample 
size between the two groups differ considerably, and where 1:1 matching would discard 
many controls that could potentially be matched; indeed, ratio matching has been shown to be 
advantageous, and the optimum matching is normally reached with 5 matches to a single case 
[534]. Following the formation of a matched subsample, treatment effects can be estimated 
by directly comparing the outcomes between the matched cases and controls.  
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Propensity-score-matching is used in this thesis to estimate the treatment effects of prenatal 
sGC on mental health in children and adolescents. Previous studies in this field have in 
particular found it challenging to account for the confounding effects of preterm birth, which 
is not only the primary factor linked with prenatal sGC treatment, but is also a well-known 
risk factor for poor mental health [535]. Through use of propensity-score-matching here in 
this thesis, it is possible to disentangle the potential effect of prenatal sGC treatment on 
mental health from the conditions precipitating treatment, thereby addressing an important 
limitation of previous research.  
 
However, a main disadvantage of propensity-score-matching is that, particularly in large 
studies, many controls are excluded from analysis, resulting in loss of data which may reduce 
the precision of the estimated association between the treatment and outcome [536]. To 
assess whether the results are replicable or merely due to certain characteristics in the 
propensity-score-matched subsample, it is useful to also examine all available data – 
matching each case to all possible controls on important confounders prior to analysis. 
Mixed-effects analysis is useful in examining treatment effects, and can be applied to 
complete datasets.  
 
4.1.2 Mixed-effects modelling 
 
Mixed-effects modelling is a flexible technique which allows analysis of correlated data, 
which occur frequently in statistical analyses due to hierarchical levels or grouping of data 
[537]. In the context of analysing treatment effects of prenatal sGC, there may be correlations 
within the data due to certain characteristics related to sGC treatment or mental health.  
 
Mixed models use both fixed and random effects in the same analysis. Fixed effects refer to 
factors of primary interest such as exposures; for example, treatment levels are typically 
considered as fixed effects [537]. Random effects are factors which are not of primary 
interest, and are associated with the sampling procedure; subject effects, e.g. confounders 
related with sGC treatment or mental health, which represent general variability among 
subjects, are considered as random effects [537]. It is these subject or random effects that 
introduce correlations within the data. The mixed-effects model is able to handle the 
variability introduced by random effects [537], and thus does not assume that the association 
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between e.g. a treatment and outcome is the same across different random effects [538]. As 
such, in this thesis, a random intercept model is used to allow the effect of prenatal sGC 
treatment on mental health to vary as a function of random effects (representing important 
confounders) [538], thereby accounting for confounding by subject effects. Another 
important advantage of mixed-effects modelling is that it is robust in examining unbalanced 
data [538], and thus is suited to the analyses in this thesis where there are unequal numbers of 
sGC cases and controls. In essence, mixed models can provide flexibility in estimating 
treatment effects while accounting for correlations within the data which arise from subject 
effects [537].  
 
4.1.3 Bootstrapping 
 
Causal pathways, whereby the effect of an exposure on an outcome occurs through one or 
more potential mediators, can be evaluated via mediation analyses, such as bootstrapping 
[539]. The bootstrap is a widely used non-parametric resampling method which generates 
accurate confidence intervals to assess mediation (indirect) effects [539-541]. The 
bootstrapping method involves randomly sampling with replacement from the original 
dataset, so that a new sample of observations is obtained, from which an indirect effect is 
computed; this process is repeated thousands of times, and an empirical approximation of the 
sampling distribution of the indirect effect is generated and used to compute confidence 
intervals [539-541]. Research suggests that bootstrapping is a more powerful technique than 
traditional (single sample) mediation methods, such as the Baron and Kenny method [542] 
and the Sobel test [543]; in contrast/compared to the latter, the bootstrap does not impose any 
assumption about the shape of the distribution of the indirect effect, maintains better control 
over Type 1 error rates and can handle small sample sizes (e.g. ranging between 20-80 cases) 
[540,541,544-546]. Therefore, the literature advises bootstrapping to be used wherever 
possible when assessing mediation [541], and as such, mediation analyses in this thesis are in 
keeping with this recommendation. 
    
4.2 Study population description  
 
The study population comprised a prospective mother-child birth cohort, The Northern 
Finland Birth Cohort 1986 (NFBC 1986), based in the two northernmost provinces of Finland 
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– Oulu and Lapland. Pregnant women with an expected date of delivery between July 1, 1985 
and June 30, 1986 were eligible for participation in the study. There was a 99% participation 
rate of all pregnancies in the specified time frame and study area. At baseline, the cohort 
consisted of N=9362 women and N=9479 live and stillbirths. There were three main waves of 
data collection: pregnancy/birth, 7-8 years and 15-16 years.  
 
Women were consecutively recruited at their first antenatal health care visit to tax-paid 
maternity health centres, which are used by almost all pregnant women in Finland (99.8%) 
and provide high-quality standardised care [260,547]. Indeed, Finland has very low rates of 
maternal and infant mortality [548], as well as low prevalence of suboptimal care [549], 
compared with international rates.  The national guidelines for antenatal care advise that 
women visit a maternity health centre monthly from the start of pregnancy to the 28th 
gestational week, twice per month from the 28th to 36th gestational week, and weekly after the 
36th gestational week [550].  
 
Data from n=8954 liveborns (n=4596 boys and n=4358 girls) were available for analysis in 
this study, after excluding stillborns (n=47), multiple births (n=226 twins and n=6 triplets) 
and those who had not consented use of their data (n=249) (Figure 4.1). Follow-up of cohort 
members was performed via use of the national population-based registries, which identify all 
residents by unique personal numbers, thereby allowing detection of current addresses. Thus, 
cohort members could be traced even outside the original geographic area. Postal 
questionnaires, which focused on child health and well-being, were sent out to all who were 
alive and traced, at child ages 7-8 years (parent and teacher reports) and 15-16 years (parent 
and adolescent reports). At 7-8 years, n=8106 (91%), and at 15-16 years, n=6934 (77%), 
were available for analysis (Figure 4.1). Additionally, at 15-16 years, adolescents attended 
individual clinical examinations, n=6491 (70%).  
 
4.3 Ethics 
 
The ethics committee of Northern Ostrobotnia Hospital District approved the NFBC 1986 
study. Participation in the study was voluntary, and both parents and adolescents provided 
written informed consent.  
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Liveborn singletons (n = 8954; 94%) 
Boys (n = 4596) 
Girls (n = 4358) 
 
 
 
 
Excluded from analysis: (n = 525; 5%) 
Stillborns (n = 47*) 
Twins (n = 226) 
Triplets (n = 6) 
No consent to use data (n = 249)  
 
 
 
 
 
Follow-up at 7-8 years (n = 8106; 91%) 
Boys (n = 4125) 
Girls (n = 3981) 
 
 
 
 
 
Follow-up at 15-16 years (n = 6934; 77%) 
Boys (n = 3336) 
Girls (n = 3598) 
 
 
 
Parental questionnaire/medical records: 
(n = 8954; 100% of target population) 
Pregnancy and birth data 
 
 
 
Postal questionnaires to parents: 
(n = 7951; 85% of target population) 
Growth, health, living habits and family 
conditions 
Postal questionnaires to teachers: 
(n = 8106; 87% of target population) 
School behaviour and performance 
 
 
 
 
 
Postal questionnaires to adolescents:  
(n = 6934; 75% of target population) 
Growth, health, behaviour, living habits 
and family conditions  
Clinical examinations in adolescents:  
(n = 6491; 70% of target population) 
Includes growth measurements and blood 
samples 
Postal questionnaires to parents: 
(n = 6607; 72% of target population) 
Health, behaviour, living habits and 
family conditions 
 
 
 
Loss to follow-up (n = 848; 9%) 
 
 
 
Loss to follow-up (n = 1172; 14%) 
 
 
 
Total born (n = 9479) 
 
 
 
 
Figure 4.1: NFBC 1986 participants and data collection.  
*1 set of triplets were stillborn. 
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4.4 Data collection 
 
Table 4.1 presents the variables studied in this thesis, and indicates their use as a predictor, 
outcome and/or confounder, according to study theme. A description of the collection and 
classification of these variables, as well as justification for considering variables as potential 
confounders, is provided in this section.  
 
Table 4.1: The predictor, outcome and confounder variables used in this thesis, according to theme (I-II). 
Variable Predictor Outcome Confounder 
    
Pregnancy data    
Prenatal sGC treatment II   
Total prenatal sGC dose    II 
Interval between prenatal sGC 
exposure & birth (days) 
  II 
Parity   II 
Pre-pregnancy BMI   II 
Gestational weight gain   II 
Smoking    II 
Alcohola    II 
Gestational complications   II 
Birth data    
Gestational age   II 
Birthweight   II 
Placental size II  II 
Child and adolescent data    
ADHD symptoms  
(and other behaviour problems) 
I I, II I 
Indices of overweight/obesity I I, II I 
Physical activity  I I I 
Binge-eating  II  
Puberty onset & start agea   I 
Socio-demographic data    
Maternal age   II 
Maternal education   I, II 
Social class   II 
Family environment   I, II 
Infant sex   I, II 
aVariables that were considered as potential confounders, but excluded from final analyses as descriptive 
analyses showed no indication for their inclusion as confounders.  
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4.4.1 Pregnancy and birth data 
 
Women were recruited at the first antenatal visit (around gestational week 12), and provided 
background information (n=8954) by completing structured self-administered questionnaires, 
which were returned by gestational week 24, if still pregnant. Background information used 
in this thesis included data on general health (pre-pregnancy weight, height and smoking 
during pregnancy) and parity. Antenatal clinical data and birth outcome data (n=8954) were 
obtained from hospital medical records (completed by midwives during pregnancy and at 
birth), and abstracted onto study forms. Clinical information included data on gestational 
weight gain and gestational complications (e.g. hypertension, diabetes and pre-eclampsia).  
 
Pregnancy data 
 
Prenatal sGC treatment 
 
The original NFBC 1986 dataset did not include data on prenatal sGC treatment, and so this 
information was obtained via systematic chart review (see Figure 4.2 for screening process to 
identify sGC cases).  
 
In Finland in 1985/86, prenatal sGC treatment was administered at the discretion of the 
medical practitioner in only rare cases, as use of sGC during pregnancy was still controversial 
at the time. This explains the relatively few number of sGC cases studied here (n=55 at 
baseline). Further, there was no standard protocol for sGC treatment in the cohort, although 
caution was taken as only small and infrequent doses were administered (described further in 
“theme-specific  methods”,  section  4.6).   
 
Total prenatal sGC dose 
 
 Information on prenatal sGC dosage (mg), including number of doses and total dose, was 
obtained from hospital medical records. When examining the impact of prenatal sGC on child 
outcomes, it is important to consider the total sGC dose because there is evidence to suggest 
that there is a dose-response association with birth and placental size [47,381], as well as 
behaviour problems [445]. Exposure to an increasing number of prenatal sGC doses has been 
 
 
125 
 
associated with a greater reduction in birthweight and placental weight [47,381], and poorer 
behaviour [445]. 
 
Interval between prenatal sGC exposure and birth (days) 
 
Information on the number of days between prenatal sGC exposure and birth was obtained 
from hospital medical records. The length of time between exposure to prenatal sGC and 
birth (days) is important to consider because a longer interval time could provide opportunity 
for further foetal growth, and thus potentially minimise the impact on birth/placental size and 
mental health outcomes.  
 
Parity 
 
Information on maternal parity (number of previous deliveries) was obtained from the 
pregnancy questionnaire. Parity was included as a continuous measure in all analyses. 
Previous studies have shown that parity is positively associated with birthweight and 
placental size [44], and it is possible that parity may partly reflect social adversity as larger 
family size has been related with a respective increased and decreased risk of ADHD and 
obesity in children [292,551]. 
 
Pre-pregnancy BMI 
 
 Maternal height and weight data were obtained from the pregnancy questionnaire. Pre-
pregnancy BMI was calculated as pre-pregnancy weight (kg) / height2 (m²), and was included 
as a continuous measure in all analyses. There is evidence from previous studies that pre-
pregnancy BMI is positively associated with birthweight and placental weight [44], as well as 
child ADHD [260] and obesity [552].   
 
Gestational weight gain 
 
Gestational weight gain information was derived from maternal pre-pregnancy weight and 
maternal weight at the last antenatal appointment, collected from medical records. 
Gestational weight gain was calculated as weight at last antenatal appointment (kg) – pre-
pregnancy weight (kg), and included as a continuous measure in all analyses.  Studies have 
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shown that gestational weight gain is positively associated with birthweight and placental 
weight [44], and excessive weight gain during pregnancy has been related with increased risk 
of child ADHD and obesity [260,553]. 
 
Smoking during pregnancy 
 
Information on maternal smoking during pregnancy was obtained from questionnaires 
completed during pregnancy. Mothers were asked whether they smoked during pregnancy, 
and answers were dichotomised: (1) yes and (2) no. Further, mothers were asked about the 
number  of  cigarettes  smoked  per  day  during  pregnancy,  which  was  dichotomised  :  <10  or  ≥  
10 cigarettes per day. Studies have shown that maternal smoking during pregnancy is related 
with reduced birthweight and placental weight [44], and may also be linked with child 
ADHD symptoms and overweight [318,554].  
 
Alcohol during pregnancy 
 
Information on maternal alcohol consumption during pregnancy was obtained from 
questionnaires completed during pregnancy. Mothers were asked whether they had consumed 
alcohol during pregnancy, and answers were dichotomised: (1) yes and (2) no. There is some 
evidence to suggest that prenatal alcohol exposure is associated with altered foetal and 
placental growth and an increased risk for ADHD, although overall the findings are 
inconsistent [44,492-494,499-501].  
 
Gestational complications 
 
Information on the following pregnancy related complications were collected from medical 
hospital records (all dichotomised as yes/no): gestational hypertension (assessed by blood 
pressure measurements at antenatal health visit), gestational diabetes (determined by oral 
glucose tolerance test at antenatal health visit), pre-eclampsia (assessed by clinician) and 
placental praevia (assessed by clinician).  
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All mothers N = 9362 
All hospitals N = 36 
 
Selection criteria for chart review to identify potential sGC cases: 
 
Inclusions: 
 
x Duration   of   hospital   stay   ≥2   days   (treatment   administered in hospital 
only and usually administered over 2 days). 
x Delivery within 2 days of admission (thus including those with 
incomplete treatment). 
 
Exclusions: 
 
x Diabetics (diabetics were not prenatally treated with sGC in 1986). 
x Symptoms not indicative of threatened pre-term birth, in accordance 
with the clinical diagnosis in the Finnish Hospital Discharge Register 
(FHDR), e.g. nausea, vomiting and diarrhea.  
x Women discharged before delivery with pre-eclampsia or hypertonia.  
 
Potential sGC cases found: 
 Admissions N = 2164 
Mothers N = 1493 
sGC cases found n = 55 Study exclusion criteria: 
Prednisone n = 2 
Hydrocortisone n = 1 
Exposure  to  sGC  ≤4  days  prior  birth n = 11 
 
sGC cases in study: 
 n = 41 (at birth) 
                 n = 37 (at 8 years) 
       n = 29 (at 16 years) 
 
    
Figure 4.2: Flowchart of systematic screening process to identify sGC cases within the NFBC 1986. 
Reproduction of the figure from Khalife et al. (2013) [629], permitted under the Creative Commons 
Attribution Licence 3.0. 
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Birth data 
 
Gestational age (completed weeks) 
 
Gestational age was obtained from hospital medical records, and examined as a continuous 
measure,   or   dichotomised:   (1)   term   birth   (≥37  weeks)   and   (2)   pre-term birth (<37 weeks). 
Gestational age is related to several variables under study in this thesis; it is positively 
associated with birthweight and placental weight [44], and earlier gestational age, in 
particular pre-term birth, is associated with a range of poor child outcomes, including ADHD 
and obesity [535,555]. The threat of pre-term birth is associated with prenatal sGC treatment, 
and so gestational age needs to be carefully accounted for in analyses which examine the 
long-term impact of prenatal sGC on child mental health.  
 
Birthweight  
 
Medical personnel measured birthweight (g) accurate to ±10g, immediately after birth. 
Birthweight is an important confounder to consider because it is related with a number of 
prenatal factors and child outcomes. Of particular relevance to this thesis, birthweight is 
positively associated with gestational age (and thus pre-term birth is linked with smaller birth 
size) and placental weight [44], and negatively associated with prenatal sGC treatment [381]. 
There is also evidence that birthweight is related with child ADHD and BMI [360,364]. Thus, 
it is possible that birthweight may mediate the link between prenatal sGC and later child 
health outcomes.  
 
Placental size 
 
Medical personnel measured placental size (placental weight and surface area). Prior to 
inspection, placentas were washed and any blood clots were removed. Placentas were 
weighed to the nearest gram within 30 minutes following delivery. Placental weight included 
membranes and the umbilical cord, cut approximately 5cm from the neonate. Whilst spread 
out on a plane, placental breadth and length were used to measure placental surface area 
(maternal side) in centimetres squared. The placental-to-birth-weight ratio was calculated as 
(placental weight [g]/birthweight [g]) x 100 to produce a percentage of placental weight 
relative to birthweight.  
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Placental weight is highly correlated with birthweight because foetal growth is dependent on 
the nutrient transfer capacity of the placenta, which is partly reflected by placental size 
[463,479]. Of relevance to this thesis, placental size has previously been linked with prenatal 
sGC treatment [47] and has been implicated in contributing to later health outcomes [470]. It 
is thus possible that placental size, similar to birth size, could lie on the causal pathway 
linking prenatal sGC with later pathology.  
 
4.4.2 Child and adolescent data 
 
Postal questionnaires, which included a wide range of health and lifestyle related questions, 
were sent to parents, teachers, and adolescents.  At 7-8 years, parents (n=7951; 85%) 
provided information on child growth (height and weight) and child physically active play, 
while teachers (n=8106; 87%) provided information on child behaviour. At 16 years, parents 
(n=6607; 72%) provided information on adolescent behaviour. Further, at 16 years, 
adolescents provided self-reports (n=6934; 75%) including information on growth (height 
and weight), mental health, physical activity and binge-eating behaviours. Additionally, 
adolescents attended individual health examinations, including growth measurements 
(n=6476; 70%).  
 
Mental health in children and adolescents  
 
Mental health was assessed in childhood at 8 years, and later in adolescence at 16 years, 
using validated screeners of psychopathology and via multiple informants (teachers, parents 
and adolescents). It is important to highlight that the NFBC 1986 is a stimulant-naïve 
population sample [556], with the exception of one boy who received methylphenidate 
(Ritalin), for a few months at 12 years, to treat ADHD.   
 
Teachers assessed the behaviour of 8-year-old children using the Rutter B2 scale [557], a 
questionnaire specifically designed for use by teachers in school settings, and intended to 
screen for childhood psychopathology. Teachers are important and reliable informants of 
child behaviour, and are often the first to recognise problematic behaviour and refer children 
for further evaluation [88]. The Rutter B2 has been reported to demonstrate both good test-
retest reliability (r = 0.89) and inter-rater reliability (r = 0.72) [558], as well as good internal 
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consistency  (Cronbach’s  α  =  0.85)  [559]. The validity, i.e. accuracy and predictive power, of 
the Rutter B2 has also been confirmed via Receiver Operating Characteristic (ROC) analysis 
[560]. Further, it was reported that this screener was the most valid, and overall had the 
greatest power to discriminate psychiatric disturbances, compared with the Parent 
Questionnaire (Scale A2) and the Children’s  Depression  Inventory  (CDI)  [560].  
 
The Rutter B2 consists of 26 items, each of which  are   rated   as   either   it   ‘certainly   applies’  
(scored  2),  ‘applies  somewhat’  (scored  1)  or  ‘does  not  apply’  (scored  0);;  yielding  a  total  score  
ranging from 0 to 52. The total score reflects general child behaviour. Furthermore, the 
questionnaire generates three sub-scores: the inattention-hyperactivity sub-score (the sum of 
three items - restless, squirmy and fidgety, and poor concentration), the neurotic sub-score 
(the sum of four items – often worried, miserable, fearful and tears on arrival at school) and 
the antisocial sub-score (the sum of six items – destructive, fights, disobedient, lies, steals and 
bullies). Additionally, the ADHD symptoms of inattention   (item  “poor  concentration”)   and  
hyperactivity   (sum   of   items   “restless”   and   “squirmy   and   fidgety”) can be assessed 
individually. Using specified score cut-off values, it is possible to discriminate between 
children screening positive and negative as probable clinical cases for behavioural disorders 
[557,561]. A total Rutter score  of  ≥  9  indicates  probable  psychiatric  disturbance  in  general.  
Probable combined inattention-hyperactivity (or probable ADHD) is defined as a total score 
of  ≥  9  and  sum  of  all  three  inattention-hyperactivity  items  ≥  3.  Inattention  is  defined  as  item  
“poor   concentration”   ≥   2,   and   hyperactivity   as   sum   of   items   “restless”   and   “squirmy   and  
fidgety”  ≥  3.  Probable  neurotic  disorder   is   identified  with  a   total  score  of  ≥  9  and  a  higher  
score on the neurotic items than antisocial items, whereas antisocial disorder is identified 
with  a  total  score  of  ≥  9  and  a  higher  score  on  antisocial  items  than  neurotic  items.   
 
Parents reported adolescent behaviour of 16-year-olds using the Strengths and Weaknesses of 
ADHD symptoms and Normal behaviour (SWAN) scale [562]. Various studies have 
validated use of the SWAN in home settings [563-565], and recent publications have 
reconfirmed the validity of the scale e.g. Lakes et al. (2012) found that the SWAN 
demonstrates   strong   internal   consistency   (Cronbach’s   α = .95) and that the test-retest 
reliability is good (r = .66) [566,567].  
 
The SWAN consists of 18 items based on the symptoms of ADHD listed in the DSM-IV. 
SWAN measures 9 items in the inattention subscale (attending to detail, sustaining attention, 
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listening, following through, organising, engaging in sustained effort, keeping track of things, 
ignoring extraneous stimuli and remembering), 9 items in the hyperactive-impulsivity 
subscale (sitting still, staying seated, modulating motor activity, playing quietly, settling 
down, modulating verbal activity, reflecting on questions, waiting turn and entering into 
games or conversation); all 18 items are measured in the ADHD combined subscale. As this 
scale measures both weaknesses (scored 3, 2 and 1) and strengths (scored -1, -2 and -3), 
along with average behaviour (scored 0), it is expected to produce a normal distribution of 
behavioural scores, thereby reducing the risk of over/under identifying ADHD behaviour. 
The 95th percentile of the distribution of mean scores on each subscale was used as a cut-off 
point to identify adolescents with ADHD symptoms as probable clinical cases. The cut-off 
values for the inattention, hyperactive-impulsivity and combined subscales were respectively 
0.625, 0.125 and 0.277, previously described in detail [556]. 
 
In this study, all teacher (childhood) and parental (adolescent) assessments of behaviour were 
examined as both continuous and categorical measures. According to the screening criteria 
described above, categorical measures were dichotomised and coded as: (1) screen positive 
for probable clinical diagnosis (coded 1) and (2) screen negative for probable clinical 
diagnosis (coded 0). 
 
Adolescents provided mental health self-reports at 16 years by completing the Youth Self 
Report (YSR) [568] – a widely used questionnaire, derived from the Child Behaviour Check 
List (CBCL), for use by 11-18 year olds. The YSR has been established as a valid and 
reliable screener for adolescent behavioural and emotional problems [569-573]; test-retest 
reliability has been reported to be good (r = 0.65 for 11-14-year-olds; r = 0.83 for 15-18-
year-olds),  in  addition  to  good  internal  consistency  (Cronbach’s  α = 0.86) [568].  
 
 The YSR includes 112 items covering behavioural and emotional problems, which are 
scored on a three-point  scale  (‘certainly  applies’  scored  2,  ‘somewhat  applies’  scored  1  and  
‘does  not  apply’  scored  0).  The  questionnaire  consists  of  eight  syndrome  subscales,  which  are  
broadly categorised into three scales: the internalising scale - which reflects emotional 
problems (syndrome scales 1-3: withdrawn, somatic complaints and anxious/depressed), the 
externalising scale – which reflects behavioural problems (syndrome scales 7-8: delinquent 
behaviour and aggressive behaviour) and other syndromes (syndrome scales 4-6: social, 
thought and attention problems). In this study, the YSR total problem score (continuous) is 
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examined in order to tap into the entire spectrum of adolescent behavioural and emotional 
problems, providing a general overview of mental health.  
 
Indices of overweight/obesity: BMI and WHR in children and adolescents  
 
Body Mass Index (BMI)  
 
BMI was calculated as weight (kg) / height2 (m2). At 7 years, mothers reported child weight 
and height. In Finland, child weight and height are measured regularly at routine health 
examinations, and so maternal reports of these measurements are expected to be reliable. At 
16 years, weight and height were measured during a health examination (by trained staff) and 
were also self-reported. Self-reported height and weight data (n=701; 10% of sample) were 
used for those who did not attend the health examination. The correlations between clinical 
and self-report data showed significant, large positive effect sizes: height; r=.85, p<.001; 
weight, r=.95, p<.001. Obesity was defined using the International Obesity Task Force 
(IOTF) age and sex-specific cut-off points for BMI [574]. According to the IOTF cut-off 
points, BMI was categorised into three groups: (1) normal weight, (2) overweight, and (3) 
obese, at 7 and 16 years.  
 
BMI has been described as vital in classifying and monitoring obesity [575]; it is the most 
widely used and convenient index of adiposity, and has been recommended as the main 
measure of overweight and obesity in children and adolescents in epidemiological studies 
[27]. BMI is associated with relative adiposity, as well as metabolic outcomes e.g. blood 
pressure and blood lipids, in children and adolescents [27,28]. Given appropriate cut-offs, 
BMI can be used to classify child and adolescent obesity with high specificity and sensitivity, 
thereby identifying few false positives [576]. The IOTF have produced reference charts for 
child and adolescent BMI using pooled international data, and have defined age and sex-
specific BMI cut-offs to classify overweight and obesity which correspond to the respective 
adult cut-offs   (≥   25   kg/m2 and   ≥   30   kg/m2) [574]. In this way, it is possible to compare 
obesity across populations and use a consistent definition over the lifespan [27].  
 
 
 
 
 
 
133 
 
Waist-Hip Ratio (WHR) 
 
At 16 years, waist and hip girths were measured at health examinations. WHR was calculated 
as waist girth (cm) / hip girth (cm), and dichotomised into (1) normal and (2) abdominal 
obesity categories, according to the 95th percentile sex-specific cut-off points (.914 for boys 
and .862 for girls). The majority of adolescents in the cohort had begun puberty by 16 years 
(n=91%), and our descriptive analyses showed no significant impact of puberty on the 
associations under study (see Results, section 5.1.1). Thus, puberty was not considered 
further in relation to the WHR further in this study.  
 
Abdominal obesity is a useful marker of health risks associated with overweight, such as 
cardiovascular disease and adverse metabolic outcomes e.g. poor lipid profile and 
hyperinsulinaemia, as has been demonstrated in adults and children/adolescents [132,577-
579]. There is evidence that abdominal obesity may more accurately identify individuals at 
risk of health consequences of obesity, compared with body mass [130,132]. Although there 
are no accepted cut-off values to define abdominal obesity, use of a high, age and sex-
specific percentile cut-off, such as the 95th percentile for WHR (as used in this thesis), is 
recommended [27,580]. 
 
Physical activity in children and adolescents  
 
At  7  years,  children’s  preference  for  physically  active  play  was  assessed  by  asking  parents,  
“Does  your  child  like  to  participate  in  active  play?”  reported  as  either  (1)  often  (2)  sometimes  
or  (3)  hardly  ever.  As  the  number  of  children  falling  into  the  “hardly  ever”  category  was  very  
small (.3%), physically active play was categorised into two groups: high (often) and low 
(sometimes and hardly ever) preference for physically active play.  
 
At 16 years, physical activity outside school hours was evaluated separately for moderate-to-
vigorous  physical  activity  and  light  physical  activity,  by  asking  the  adolescents,  “How  many  
hours per week do you participate in a) brisk and b) light physical activity outside school 
hours?”  In  the  questionnaire,  the  term  “brisk” was defined as physical activity causing at least 
some  sweating  and  shortness  of  breath,  while  the  term  “light  physical  activity”  was  defined  
as causing no sweating or shortness of breath. In addition, the adolescents were asked about 
their daily time spent in physically active commute to and from school. The response 
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alternatives (not at all, less than 20 min, 20–39 min, 40–59 min, and at least 1 hour per day) 
were multiplied by five (5 school days a week) to correspond to 0, 1, 2.5, 3.75, and 5 hours 
per week [581]. The level of physical activity was defined as metabolic equivalent of task 
(MET)-hours per week, based on the intensity and volume of physical activity, and was 
divided into quintiles. For the calculations, a MET intensity value of 3 METs was used for 
light physical activity, 5 METs for brisk physical activity, and 4 METs for commuting 
physical activity [582]. The intra-class correlation coefficient for physical activity levels 
described in terms of quintile categories of MET hours per week was 0.70 (95% CI: 0.58–
0.80), and the proportion of subjects who were classified in exactly the same category or next 
to the same category in two different tests was 86%. Adolescents were categorised into three 
groups according to their weekly level of physical activity: (1) active (two highest quintiles), 
(2) moderately active (third and fourth quintiles), and (3) inactive (lowest quintile). The test-
retest reliability of these physical activity questions among a separate group of Finnish 
adolescents aged 15–16 years has been reported to be good [581].  
 
Binge-eating in adolescents  
 
At 16 years, an index of binge-eating  was  ascertained  by  asking  adolescents,  “How  often  do  
you   devour   large   amounts   of   food?”   Binge-eating was dichotomised: (1) yes (once a 
month/once a week/2 or 3 times a week/daily) and (2) no (never/hardly ever/occasionally). 
This classification was established a priori in the absence of a measure for “loss of control”  
(essential in defining binge-eating), and aims to discriminate more common occasional 
episodes of overeating from actual binge-eating.  
 
Puberty onset & start age  
 
Information on puberty was obtained from adolescent self-report questionnaires. To ascertain 
puberty onset, girls were asked whether they had begun menses, and boys were asked 
whether they had begun ejaculation, and answers were dichotomised: (1) yes and (2) no. To 
ascertain puberty start age, girls and boys were asked at what age (in years and months) they 
had their first menses or ejaculation, respectively. Puberty start age was analysed as a 
continuous variable (months), and was considered as a potential confounder because the 
timing of puberty may impact BMI and WHR, particularly in girls [583,584], as well as 
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mental health [585]. Earlier puberty onset has been related with increased BMI and mental 
health problems in both boys and girls [583-585].  
 
4.4.3 Socio-demographic data 
 
Socio-demographic data were collected from the questionnaires completed by mothers during 
pregnancy (maternal age, maternal education, social class and family conditions), parents at 
child ages 7/8 and 16 years (maternal education and family conditions), and from hospital 
medical records (infant sex).  
 
Maternal age (years) 
 
Information on maternal age at recruitment was obtained from a questionnaire completed by 
mothers during pregnancy. Both very young and advanced maternal ages are linked with: a 
range of gestational obstetric complications e.g. preterm labour, gestational diabetes and 
placenta praevia; poor birth outcomes e.g. low birthweight; and altered placental growth 
[586-588], which in turn could impact child health outcomes, including mental health and 
obesity [350,364,470,535,555,589,590]. Thus, maternal age should be considered when 
examining prenatal factors in relation to ADHD and obesity outcomes.   
 
Maternal education 
 
Information on maternal highest level of education was collected from questionnaires 
completed during pregnancy, and at child ages 7 and 16 years. The educational levels 
reported were: (1) less than nine years of primary education, (2) basic education, (3) 
matriculation examination, (4) vocational course, 5) vocational education, 6) vocational 
college, (7) polytechnic, (8) university, and (9) other or degree not finished. These education 
levels were categorised according to the International Standard Classification of Education 
(ISCED) and the Finnish National Board of Education, forming four educational categories: 
(1) basic education:  ≤9  years  (level  1),  (2) upper secondary education: 10-12 years (levels 3-
6), (3) tertiary  education:  ≥13  years  (levels  7-8), and (4) other or degree not finished (level 9). 
Further, this variable was also examined as a dichotomised variable: (1) <11 years of 
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education and (2) ≥11 years of education, defined according to the number of compulsory 
years of education in Finland.  
 
Maternal education is an indicator of socioeconomic position, and has previously been 
associated with child ADHD and BMI, with lower levels of maternal education related with 
an increased risk for these outcomes [294,591]. Thus, it is important to consider maternal 
education as a confounder throughout this thesis.  
 
Social class 
 
Information on social class was obtained from the pregnancy questionnaire and based on 
paternal occupation (or maternal occupation, if missing data or single mother), which was 
transformed to an indicator of social class according to a national system of classifications 
and standards in Finland [592]. The variable was dichotomised: (1) class 1 (professional, 
upper/lower  white  collar  or  farmer  ≥  8  hectares  of  land)  and (2) class 2 (unskilled worker or 
farmer < 8 hectares of land).   
 
Lower social class has previously been associated with child ADHD and BMI [593,594], and 
thus social class should be considered as a confounder throughout this thesis.  
 
Family environment 
 
Marital status or family structure change were considered, as appropriate: 
(1) Marital Status. Information on maternal marital status was obtained from the 
pregnancy questionnaire, and the variable was dichotomised: (1) married/co-habiting 
and (2) single/widowed/divorced.  
(2) Family structure change. Information on family structure was collected from 
questionnaires completed by parents during pregnancy, and at child ages 7 and 16 
years; this data allows assessment of any changes in family structure over childhood 
and adolescence. Family structure change from pregnancy to child age 7 years, and 
from 7 to 16 years, were classified into four categories: (1) always a two-parent 
family, (2) single-parent family, (3) reconstructed family, and (4) always a one-parent 
family. 
 
 
137 
 
The family environment is an important confounder to consider as single-parent family and 
changes to family structure may reflect adversity/stress, and can impact child psychology and 
development, including increasing the risk for ADHD and obesity [595,596]. Family 
structure change indicates change in family structure over time (from 0 to 7 years or 7 to 16 
years), and is important to consider in Theme I, where longitudinal associations over 
childhood to adolescence are examined.   
 
Infant sex 
 
Information on infant sex was recorded at birth and obtained from hospital medical records, 
and the variable was dichotomised: (1) male (coded 1) and (2) female (coded 2). There is 
evidence in the literature that both psychopathology and BMI exhibit gender differences. In 
terms of psychopathology, ADHD symptoms and other neuropsychiatric disorders of early-
onset in childhood show a marked male preponderance, while emotional disorders of 
adolescent-onset show a female preponderance [526,597]. With respect to obesity rates, 
evidence suggests that there is no consistent male or female excess [598], although patterns 
of fat distribution and fat levels at which health risks become apparent are understood to 
exhibit sex differences [527,599]. Given that abdominal fat is considered a significant, 
clinically relevant measure of obesity and related health risks [130,600], sex differences in fat 
distribution are important. The onset of puberty gives rise to marked sex differences in fat 
distribution patterns [27]; boys develop greater fat in the upper body (waist circumference) 
area, whereas girls develop greater amounts of fat in the hip and thigh areas [527]. 
Additionally, there is evidence to suggest that the health risks related with adiposity become 
evident at a lower level of fat in boys compared with girls [599].   
 
4.5 Missing data 
 
Although participation rates at each follow-up in the NFBC 1986 were high, it is important to 
consider the potential impact of missing data. The percentage of participants who dropped out 
of the study was 9% at 7-8 years, and 23% at 15-16 years. Additionally, at 15-16 years, the 
drop-out rate for the clinical examination was 30%; self-reported height and weight data 
(10% of the sample) were used for those who did not attend the clinical examination, and 
correlation analyses showed significant, large positive effect sizes between self-report and 
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clinical data (see Methods, section 4.4.2). Attrition analyses were performed at each follow-
up to determine whether participants and non-participants significantly differed on socio-
demographics, birth outcomes, mental health, obesity and obesogenic factors (see Results, 
section 5.1.1 and section 5.2.2).   
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4.6 Theme-specific methods 
 
All analyses were performed using SPSS version 17.0 or 20.0, unless stated otherwise.  
 
4.6.1 Theme I: Exploring directionality and underlying behavioural mediators of the 
association between ADHD symptoms and obesity 
 
4.6.2 Variables 
 
Behaviour  
 
For the main analyses (cross-sectional and longitudinal analyses) ADHD symptoms were first 
examined categorically, as screen positive or negative (yes/no for probable clinical diagnosis) 
– to study levels of clinical relevance, and then continuously – to assess whether ADHD 
symptom scores, including sub-threshold levels, are associated with obesity and obesogenic 
factors. ADHD symptoms were assessed using the Rutter B2 (teacher report) at 8 years, and 
the SWAN (parent report) at 16 years. In exploratory analyses studying specificity of the 
associations, CD symptoms were examined as a categorical measure, at 8 years (using Rutter 
B2) only due to lack of CD data at 16 years.  
 
Obesity and obesogenic factors 
 
For the main analyses, BMI, WHR, physical activity/physically active play and binge-eating 
were examined as categorical measures to indicate clinical levels of concern. BMI was 
categorised as obese/overweight/normal weight (at 8 and 16 years), WHR as yes/no for 
abdominal obesity (at 16 years), preference for physically active play as low/high (at 8 years), 
physical activity as inactive/moderately active/active (at 16 years) and binge-eating as yes/no 
(at 16 years).  
 
Confounders 
 
Adjustments were made for potential confounders associated with ADHD and BMI or 
relevant for this analysis, as indicated by previous research and descriptive analyses (see 
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Results, section 5.1.1): sex [526,597,601], family structure change (from 0 to 7 years or 7 to 
16 years) [595,596], maternal education [294,591], and reciprocal adjustments for BMI and 
physical activity/physically active play [602] as appropriate (to study the association between 
ADHD symptoms and these variables independent of one another). For the longitudinal 
analyses, baseline BMI/ADHD symptoms/physically active play were controlled for to allow 
prediction  of  “new”  cases  of  obesity,  ADHD  symptoms or physical inactivity. Puberty start 
age (months) was considered as a potential confounder [583-585], but was not included in the 
final model as descriptive analyses did not indicate that adjustment of this variable was 
necessary (see Results, section 5.1.1).  
 
4.6.3 Statistical Analysis  
 
Descriptive analysis 
 
Frequency distributions were calculated for child and adolescent characteristics (stratified by 
sex), including ADHD (and CD) symptoms, and categories of BMI, WHR, physically active 
play/physical activity and binge-eating. Further, frequency distributions for these 
characteristics were examined separately for children and adolescents screening positive for 
individual ADHD subtype symptoms (combined ADHD, inattention and hyperactivity). Chi-
square and t-test statistics were used to test for differences in the variables of interest between 
children/adolescents screening positive for combined ADHD versus those screening negative 
for combined ADHD. Correlation analyses were used to examine associations between the 
potential confounders and the predictors/outcomes for the main analyses (inattention-
hyperactivity symptoms, obesity outcomes [BMI and WHR] and obesogenic factors [physical 
activity and binge-eating]). Further, correlation analyses were used to study associations 
between the variables of interest over-time, i.e. from childhood to adolescence.  
 
Comorbidity between probable ADHD and probable CD was assessed by calculating the 
frequency of cases screening positive for both disorders, as well as the proportion of overlap 
between the two disorders.  Further, correlation analyses were used to study comorbidity 
between the symptom scores of ADHD and CD. Frequency distributions were also computed 
for   “pure”   ADHD   and   CD   cases   i.e.   cases   screening   positive   for   either   ADHD   or   CD  
symptoms.  
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Attrition analysis was performed using chi-square statistics to examine whether participants 
and non-participants at the 7/8 and 16 year follow-up stages differed by socio-demographic 
factors (sex, family structure change and maternal education) and the main variables of 
interest in this specific study (ADHD symptoms, BMI and physical activity).  
 
Linear and logistic regression  
 
Cross-sectional and longitudinal analyses between ADHD symptoms and obesity, physical 
activity and binge-eating 
 
First, cross-sectional associations between ADHD symptoms and both obesity and 
obesogenic factors were examined, at 8 and 16 years. At 8 years, multinomial/binary logistic 
regression analyses were used to investigate the associations of ADHD symptoms on obesity 
(BMI) and physically active play. These analyses were adjusted for sex, family structure 
change (from 0-7 years), maternal education (at 7 years), and mutual adjustment for 
BMI/physically active play (according to analysis). Similarly, at 16 years, multinomial/binary 
logistic regression analyses were used to investigate the associations of ADHD symptoms on 
obesity (BMI/WHR), physical activity and binge-eating. These analyses were adjusted for 
sex, family structure change (from 7 to 16 years), maternal education (at 16 years), and 
mutual adjustment for BMI/physical activity (according to analysis). 
  
Second, longitudinal associations were examined, from 8 to 16 years. In these analyses, long-
term associations between ADHD symptoms, obesity (BMI and WHR), physical activity and 
binge-eating were assessed. Bidirectional associations were examined where possible to 
assess whether the potential associations are driven from the direction of ADHD symptoms to 
obesity/physical activity, or the reverse, from obesity/physical activity to ADHD symptoms, 
over the 8-year period, from childhood to adolescence. Multinomial logistic regression 
analyses were used to investigate the associations of ADHD symptoms at 8 years (predictor) 
on obesity (BMI and WHR), physical activity and binge-eating at 16 years (outcomes). 
Binary logistic regression was used to examine the reverse association of BMI and physically 
active play at 8 years (predictors) on ADHD symptoms at 16 years (outcome). Longitudinal 
analyses were adjusted for sex, family structure change (from 7 to 16 years), maternal 
education (at 16 years), mutual adjustment for BMI/physical activity (depending on the 
model) and baseline BMI/ADHD symptoms/physically active play (depending on the model). 
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As there is some evidence that ADHD should be considered as a dimensional rather than 
discrete disorder [108,109], the above analyses (cross-sectional and longitudinal) were 
repeated with ADHD symptoms included as continuous measures, using either 
multinomial/binary logistic regression (when ADHD symptoms are predictors) or linear 
regression (when ADHD symptoms are outcomes).  
 
The longitudinal analyses were also stratified by sex to evaluate whether the associations are 
characterised by any sex differences. In the sex stratified analyses, ADHD symptom 
continuous scores were analysed only because use of ADHD categorical measures 
significantly reduced the number of screen positive cases and impacted statistical power, 
particularly in girls amongst which the prevalence of ADHD is lower (e.g. in adjusted 
analyses for associations with BMI; n=252, 108, 210 for boys and n=80, 26, 47 for girls 
screening positive for inattention-hyperactivity, inattention and hyperactivity, respectively).  
 
It is of interest to study whether the ADHD-obesity association is independent from CD – one 
of the primary psychiatric comorbidities of ADHD. Specificity of the association is best 
evaluated   through   examination   of   “pure”   ADHD   and   CD   cases,   which   should   minimise  
overlap between the two disorders as much as possible. It should be noted however, that due 
to the intrinsic link between ADHD and CD, it difficult – particularly in non-clinical settings, 
to finely distinguish between the two disorders. In the NFBC 1986 population sample (boys 
and girls), 75% of children who screen positive for inattention-hyperactivity also experience 
CD, and 79% of children with CD also experience inattention-hyperactivity - there is thus 
substantial overlap (n=570 cases with both inattention-hyperactivity and CD). Therefore, in 
this study it is only possible to explore the issue of association specificity with preliminary 
analyses, including a small number of children screening positive for either inattention-
hyperactivity symptoms or CD symptoms (n=78 and n=81, respectively, in adjusted 
analyses).  
 
To explore whether the associations under investigation are independent of CD, the analyses 
were repeated (1) with CD instead of ADHD symptoms, and (2) only including children who 
screened positive  for  either  ADHD  symptoms  or  CD  symptoms  i.e.  “pure”  cases.  Due  to  lack  
of data on CD in adolescence, it was only possible to examine whether CD symptoms predict 
obesity, physical inactivity and binge-eating (not vice versa).     
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Mediation analysis 
 
The bootstrap method [539,540] was used to evaluate whether physical activity and/or binge-
eating (16 years) mediated the possible longitudinal association between probable ADHD (8 
years) and obesity (16 years). Likewise, mediation of the potential CD-obesity association by 
physical activity/binge-eating was examined. Mediation confidence intervals were estimated 
for adjusted analyses, based on 5000 bootstrap samples.  
 
To examine potential sex differences, the main mediation analysis (involving ADHD) was 
repeated stratified by sex. Inattention-hyperactivity symptom scores were analysed in the 
stratified analyses rather than ADHD categorical measures, to optimise statistical power, as in 
the previous sex-stratified analysis.  
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4.6.4 Theme II: Investigating whether prenatal factors confer common risk for mental 
health and obesity 
 
4.6.5 Prenatal synthetic glucocorticoid treatment and mental health in children and 
adolescents 
 
4.6.6 Variables 
 
Predictor: prenatal sGC treatment 
 
At baseline, n=55 sGC cases were identified by the chart review (Figure 4.2). After applying 
the exclusion criteria, n=41 cases were available at birth, and n=37 cases were available for 
analysis at the first follow-up at 8 years. Dexamethasone (n=33) or betamethasone (n=4) - the 
sGC of choice for threatened pre-term birth, were administered.  
 
The exclusion criteria for cases were as follows: 
 
1. Cases exposed to sGC  ≤4  days  prior  birth  (n=11).  Dexamethasone  and  betamethasone  are  
long-acting substances (with biological half-lives ranging between 36 and 54 hours) [603], so 
it is unlikely that sGC treatment close to the time of birth could significantly impact foetal 
brain development as there would not be sufficient time for the drug to induce maximum 
effect. Descriptive analyses examining the impact of timing of prenatal sGC exposure show 
that an association between sGC and mental health only holds when exposure time is >4 days 
prior birth. Further, previous work has demonstrated that prenatal sGC has a significant 
impact on birth size when exposure is > 4 days prior birth (unpublished, Ali Khan et al.).  
 
2. Cases exposed to prednisone (n=2) or hydrocortisone (n=1). These sGC are typically 
administered to treat maternal medical conditions (e.g. allergic or inflammatory diseases) as 
they have minimal placental transfer across to the foetus. This is in contrast to 
dexamethasone and betamethasone, which are intended for foetal therapy, and have high 
levels of placental transfer [395].  
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At 8 and 16 years, n=37 and n=29 sGC cases respectively were available for analysis. Out of 
the 37 cases (at 8 years), 13 received a single sGC dose, 23 received 2 doses and the dose 
number for 1 case was not recorded. The total dosage ranged from 10mg to 25mg (the 
maximum total dosage equates approximately to a single course of sGC treatment as 
recommended by current guidelines).  
 
In all analyses, prenatal sGC treatment was analysed as a dichotomous variable: (1) sGC case 
(coded 1) and (2) sGC control (coded 0).  
 
Potential mediators: birthweight and placental weight 
 
Birthweight (g) and placental weight (g) were included as continuous measures in the 
analyses.  
 
Outcome: child and adolescent mental health 
 
For the main analyses, child and adolescent mental health outcomes were examined as 
continuous measures, and were assessed using the Rutter B2 (teacher report) at 8 years, the 
SWAN (parent report) at 16 years, and the YSR (self-report) at 16 years. Categorical 
measures of mental health outcomes were not assessed due to the small number of sGC cases, 
which included only a few participants screening positive for mental health problems (e.g. for 
combined ADHD symptoms, there were 5 cases and 1 case at 8 and 16 years, respectively).  
 
Confounders 
 
Adjustments were made for potential confounders associated with prenatal sGC treatment 
and child mental health, or those relevant for this analysis, which were available in the 
cohort. Birthweight and placental weight have previously been linked with both prenatal sGC 
treatment and child health outcomes [34,47,360,364,381]. Socio-demographic factors 
previously associated with ADHD symptoms were: sex, maternal age, maternal education 
and family structure [501,604,605]. Medical factors previously associated with child mental 
health or relevant for this analysis were: gestational age (weeks) [535], total prenatal sGC 
dose (mg) [445], interval between prenatal sGC exposure and birth (days), parity 
(continuous) [606], pre-pregnancy BMI (continuous) [260], and smoking during pregnancy 
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(no/yes) [604]. Further potential confounders considered were the main gestational 
complications related to pre-term birth: gestational hypertension (no/yes), pre-eclampsia 
(no/yes) and placenta previa (no/yes), but these were not included in the final model as 
descriptive analyses did not indicate that adjustment of these variables were necessary (see 
Results, section 5.2.2). 
 
4.6.7 Statistical analysis 
 
Two analytical strategies were used to analyse the data: (1) analysis of the propensity-score-
matched subsample by linear multiple regression, and (2) analysis of the entire sample by 
mixed-effects modelling. Procedure (1) ensures that treatment-associated confounders 
(measured) are precisely accounted for, thereby minimising treatment-selection bias, while 
procedure (2) also carefully accounting for important confounders, examines whether the 
results are robust and replicable when the entire cohort is analysed.     
 
Descriptive analysis 
 
Chi-square statistics were used to examine whether the sGC cases and controls differed on 
mental health screen positive/negative status (within the entire sample of cases and controls 
available for analysis).  
 
Chi-square and t-test statistics were used to analyse all covariates potentially associated with 
sGC treatment (within the entire sample). Analysis of any significant differences between 
matched cases and controls (within the propensity-score-matched subsample) by the 
covariates was examined by chi-square and t-test statistics. Examination of any differences 
on mental health scores between cases and controls (within the entire sample and propensity-
score-matched subsample) was performed using t-test statistics.  
 
Linear regression analyses were used to examine whether the interval between prenatal sGC 
treatment and birth (days) had an impact on the association between sGC and mental health. 
Further, correlation analyses were used to examine the effect of time of sGC treatment prior 
to birth on mental health outcomes, birthweight and placental weight. 
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Attrition analysis was performed at each follow-up (8 and 16 years) to determine any 
differences in socio-demographics, birth outcomes and mental health outcomes between 
participants and non-participants.  
 
Matching procedure 
 
Two matching procedures were performed. First, propensity-score-matching [531] was used 
to match sGC cases and controls. The covariates associated with sGC treatment, gestational 
age and pre-pregnancy BMI (see Results, Table 5.18), were included as predictors in the 
logistic regression model used to calculate the propensity scores. The propensity scores were 
log transformed to normalise the distribution of the scores. sGC cases were matched to 
controls on the logit propensity score,   using   “nearest   neighbour   matching”   with   a   caliper  
width (matching range) of ± 0.171402 (0.2 SD of the mean logit of the propensity score) 
[533]. The large NFBC 1986 dataset made it possible to very precisely match each sGC case 
to 5 controls; ratio matching has been shown to be advantageous, and the optimum matching 
is normally reached with 5 matches to a single case [534]. This yielded a sample of n=222 
children at 8 years (sGC cases, n=37; controls, n=185) and a sample of n=174 adolescents at 
16 years (sGC cases, n=29; controls, n=145).   
 
The second matching procedure took full advantage of the entire cohort by matching each 
sGC case, n=41, to all possible controls, n=6650, on gestational age and sex (Table 4.2) – 
confounders selected based on a priori information. Pre-term birth is a well-known risk factor 
for poor mental health outcomes [535] and is associated with gestational complications [607]. 
Male foetuses may be more vulnerable to adverse intrauterine conditions [508], and are at an 
increased risk of behavioural problems in childhood [605,608]. Thus, by matching on these 
known risks, it was possible to disentangle the impact of prenatal sGC exposure on mental 
health from the confounding effects of pre-term birth and sex.  
 
A  “grouping”  variable,   based  on  gestational   age   and   sex,  was  used   to  match   the cases and 
controls. There were no sGC cases born within gestational weeks 41 to 43, therefore the 2229 
controls born within those gestational ages could not be compared with the cases and 
consequently excluded from all subsequent analyses. At 8 years, n=6116 children were 
available for analysis (sGC cases, n=37; controls, n=6079) and at 16 years of age, n=5108 
adolescents were examined (sGC cases, n=29; controls, n=5079). This analytical strategy, 
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whereby the greatest number of possible controls are matched to each case, maximises use of 
all available data, thereby enhancing the precision of the analysis [609].  
 
 
 
Regression models: linear regression and mixed-effects modelling 
 
Linear multiple regression was used to investigate the association between prenatal sGC 
treatment and child mental health, within the propensity-score-matched subsample. 
Adjustments were made for all potential confounders as indicated by previous research or 
relevant for this study: birthweight, placental weight, socio-demographic factors (sex, 
maternal age, maternal education and family structure), and medical factors (total prenatal 
sGC dose (mg), interval between prenatal sGC exposure and birth (days), parity and smoking 
during pregnancy). Cohen’s  f2 was used as an effect size estimator for the associations.     
 
Mixed-effects modelling was used to re-analyse the association between prenatal sGC and 
mental health, but here the entire cohort was examined. In the model, the fixed effects were 
the  predictor  (prenatal  sGC)  and  confounders.  The  “grouping”  variable,  based  on  gestational  
age and sex, was included as a random effect; this allowed the model representing the impact 
Table 4.2: Matching procedure for mixed-effects analysis; each sGC case (n=41) 
matched to all possible controls (n=6650) on gestational age and sex.  
Group Gestational age and sex Case Control 
1 27 weeks; Female 1 1 
2 30 weeks; Male 1 2 
3 32 weeks; Male 1 9 
4 32 weeks; Female 1 2 
5 35 weeks; Male 2 31 
6 36 weeks; Male 4 87 
7 36 weeks; Female 2 73 
8 37 weeks; Male 3 199 
9 37 weeks; Female 4 167 
10 38  weeks; Male 4 574 
11 38 weeks; Female 6 507 
12 39 weeks; Male 5 1201 
13 39 weeks; Female 5 1033 
14 40 weeks; Male 1 1362 
15 40 weeks; Female 1 1402 
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of   sGC   on   mental   health   to   vary   as   a   function   of   the   “group”,   thereby   reducing   the  
confounding effects of pre-term birth and sex. Adjustments were made for relevant 
confounders (similar to the initial linear regression analysis): birthweight, placental weight, 
socio-demographic factors (maternal age, maternal education and family structure), and 
medical factors (total prenatal sGC dose (mg), interval between prenatal sGC exposure and 
birth (days), parity, smoking during pregnancy and pre-pregnancy BMI).  
 
Mediation analysis 
 
The bootstrap method [539,540] was used to formally evaluate whether birthweight and 
placental size (placental weight, surface area and placental-to-birthweight ratio) mediated the 
possible association between prenatal sGC and mental health, within the propensity-score-
matched subsample. Mediation confidence intervals were estimated for adjusted analyses, 
based on 5000 bootstrap samples. To facilitate interpretation of the results, birthweight, 
placental weight and placental surface area were analysed as continuous measures in 1000g, 
100g and 10cm2 increments, respectively.  
 
Power analysis 
 
A post hoc power analysis was performed to assess whether the analysis was sufficiently 
powered to detect any possible significant impact of sGC treatment on mental health, at 8 
years and 16 years. The power analysis was run using G*Power 3 [610]. 
 
4.6.8 Prenatal synthetic glucocorticoid treatment and obesity in children and 
adolescents  
 
The analysis as described above, with sGC cases and controls matched by gestational age and 
sex, was repeated to examine the association between prenatal sGC treatment and obesity. 
For this analysis, BMI and WHR were included as continuous measures, and adjustments 
were made for the confounders as described above. 
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Descriptive analysis 
 
Chi-square and t-test statistics were used to examine whether the sGC cases and controls 
differed on BMI and WHR. 
 
Mixed-effects model 
 
The association between prenatal sGC treatment and obesity (BMI and/or WHR) at 8 and 16 
years was examined using mixed-effects modelling. Adjustments were made for relevant 
confounders: birthweight, placental weight, socio-demographic factors (maternal age, 
maternal education and family structure), and medical factors (total prenatal sGC dose (mg), 
interval between prenatal sGC exposure and birth (days), parity, smoking during pregnancy 
and pre-pregnancy BMI).  
  
Power analysis 
 
A post hoc power analysis was performed to assess whether the analysis was sufficiently 
powered to detect any possible significant impact of sGC treatment on BMI and/or WHR, at 
8 years and 16 years. The power analysis was run using G*Power 3 [610]. 
 
4.6.9 Investigation of placental size in conferring common risk for mental health and 
obesity 
 
4.6.10 Variables 
 
Placental size 
 
The variables related to placental size were: placental weight (g), placental surface area (cm2) 
and placental-to-birth-weight ratio. For the descriptive and initial analyses, placental weight 
and surface area were analysed continuously in 1g and 1cm² increments, respectively. 
Additionally, to examine frequency distributions for descriptive purposes, placental weight 
was stratified into three categories according to its distribution in the study population: (1) < 
550g (< 25th percentile), (2) 550-719g (25th-75th percentiles), and (3) > 720g (> 75th 
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percentile). For the main analysis, placental weight and surface area were analysed as 
continuous measures in 100g and 10cm² increments, respectively, to facilitate clinical 
interpretation of the results.  
 
Child and adolescent mental health/obesity 
 
Mental health outcomes were examined categorically, as screen positive or negative (yes/no) 
for probable clinical diagnosis, and were assessed using the Rutter B2 (teacher report) at 8 
years and the SWAN (parent report) at 16 years.  
 
For the main analyses, BMI was examined as a dichotomous variable: overweight/obese and 
normal weight, at both 8 and 16 years. The overweight (n=915) and obese (n=288) categories 
were pooled to maximise statistical power, as indicated by preliminary analyses (placental 
size accounts for a small portion of the variance of the outcomes under study). WHR was 
examined categorically as yes/no for abdominal obesity at 16 years.  
 
Confounders 
 
Adjustments were made for potential confounders which may be related to placental size and 
mental health/obesity, as indicated by the descriptive analysis and the literature: gestational 
age (weeks) [44,611], birthweight (grams) [38,611], maternal socio-demographic and 
medical factors [44,260,483,501,552-554,591,596,612]. The socio-demographic factors were 
maternal age (years), maternal education, family structure and social class. The medical 
factors were parity (continuous), pre-pregnancy BMI (continuous), gestational weight gain 
(continuous) and smoking during pregnancy (yes/no). Gestational diabetes (coded yes/no) 
was adjusted in analyses involving obesity (but not mental health) outcomes. Other medical 
factors considered but not included in the final model because adjustments were not indicated 
by descriptive analyses (see Results, section 5.2.12) were alcohol consumption during 
pregnancy (yes/no), and gestational complications - gestational hypertension and pre-
eclampsia (all coded yes/no). Furthermore, factors related to maternal psychological well-
being were also considered in this specific analysis, as prenatal maternal anxiety has been 
linked with altered placental function [393], as well as child ADHD and BMI [40,318]. These 
were   “feelings   during   pregnancy”   (tired/normal/very   good),   “physical/intellectual  
occupational  strain”  (very  strenuous/strenuous/moderately  strenuous/relatively  easy/easy) and 
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“desirability   of   pregnancy”   (not   at   all   desirable/later   would   have   been   more  
desirable/occurred at right time). These variables related to psychological well-being were 
not included in the final model as descriptive analyses did not indicate that adjustments were 
necessary (see Results, section 5.2.12).  
 
4.6.11 Statistical analysis  
 
Descriptive analysis 
 
Frequency distributions for the birth/placental outcomes, mental health outcomes, BMI 
categories and WHR categories were calculated. Correlation and ANOVA analyses were 
performed to identify any associations between placental size and both the potential 
confounders and mental health/obesity outcomes.   
 
Logistic regression 
Logistic regression analyses were used to investigate the association between placental size 
(placental weight, surface area and placental-to-birth-weight ratio) and mental health/obesity 
at 8 and 16 years. Analyses were adjusted for gestational age, birthweight, sex, socio-
demographic factors (maternal age, education, family structure and social class), and medical 
factors (parity, pre-pregnancy BMI, gestational weight gain and smoking during pregnancy; 
gestational diabetes was additionally adjusted for in analyses involving obesity). All analyses 
were also stratified by sex, due to sex differences in the placenta and behaviour/obesity, and 
adjusted as before (except for sex). 
 
To investigate non-linear associations, the analyses were repeated with placental weight 
stratified into 3 groups according to the percentile distribution of placental weight: (1) < 550g 
(< 25th percentile), (2) 550-719g (25th-75th percentiles), and (3) > 720g (> 75th percentile). 
These  3  groups  can  be  broadly  classed  as   (1)  “low”,   (2)  “normal”  and   (3)  “high”  placental  
weight categories, according to the distribution of placental weight in the NFBC 1986. 
Further, analyses were run with placental weight stratified according 100g increments, which 
comprised 8 groups: < 400g, 400-499g, 500-599, 600-699g, 700-799g, 800-899g, 900-999g 
and  ≥  1000g.     
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The literature indicates that maternal pre-pregnancy BMI is a particularly important predictor 
of child obesity [551]. There is a strong heritable component to BMI [613], so maternal pre-
pregnancy BMI is understood to reflect the genetic risk for child obesity. Additionally, it is 
suggested that maternal obesity may impact child BMI via intrauterine programming 
mechanisms, independent of shared genetic susceptibility [614]. Thus, analyses for the 
association between placental weight and obesity were repeated stratified by maternal pre-
pregnancy BMI. 
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5. Theme-specific results 
 
In this chapter, the results from each study theme are presented. The results may also be 
found in the original publications I-III (see Appendix).       
 
5.1 Theme I: Exploring directionality and underlying behavioural mediators of the 
association between ADHD symptoms and obesity 
 
5.1.1 Descriptive analysis  
 
Frequency distributions of the main study variables in children and adolescents in the 
NFBC 1986: 
 
ADHD and CD symptoms 
 
Table 5.1 presents the descriptive statistics of child (8 years) and adolescent (16 years) 
characteristics, stratified by sex, in the NFBC 1986. Overall, ADHD symptoms (at a level 
indicating clinical relevance – positive diagnostic screen) were more common in childhood 
than adolescence, with respective prevalence rates of 9.4% and 5.3% for combined 
inattention-hyperactivity (probable ADHD), 3.9% and 5.1% for inattention symptoms, and 
7.1% and 4.7% for hyperactivity symptoms. CD symptoms (only reported by parents in 
childhood) were experienced by 9.0% of children. Boys had a significantly higher prevalence 
of ADHD and CD symptoms, compared with girls, at both childhood and adolescence.  
 
Comorbidity between ADHD and CD symptoms  
 
In the entire population sample (boys and girls), 75% of children who screened positive for 
inattention-hyperactivity also experienced CD, and 79% of children with CD also 
experienced inattention-hyperactivity - indicating considerable comorbidity between the two 
disorders (n=570 (7.1%) cases screening positive for both disorders). Correlation analyses 
also showed high comorbidity between inattention-hyperactivity and CD symptom scores 
 
 
155 
 
(Pearson  r=.67,  p<.001).  The  prevalence  rates  of  “pure”  probable  ADHD  and  “pure”  probable 
CD were similar, 2.5% and 2.1%, respectively (Table 5.1).  
 
Obesity outcomes, physical activity and binge-eating 
 
Overweight and obesity were more common in childhood than in adolescence, with 
respective prevalence rates of 13.2% and 4.1% (childhood), and 11.8% and 3.6% 
(adolescence). In childhood, overweight/obesity was significantly more common in girls, 
while in adolescence, the opposite trend was observed – boys were significantly more likely 
to be overweight/obese. In adolescence, 5% experienced abdominal obesity, and this rate did 
not differ amongst boys and girls. In childhood, the prevalence of low preference for 
physically active play (sometimes and hardly ever) was 17.9%, and in adolescence, the rate 
of physically inactivity was similar, at 20.0%. Girls were less likely to take part in physically 
active play and physical activity in childhood and adolescence. The rate of binge-eating in 
adolescence was 9.8%, and this did not significantly differ amongst boys and girls.  
 
Frequency distributions of obesity, physical activity and binge-eating by ADHD symptoms 
 
Table 5.2 shows the frequency distributions of BMI, physical activity and binge-eating by 
ADHD symptoms (positive diagnostic screen) at 8 and 16 years. The prevalence of 
overweight and obesity amongst children and adolescents with probable ADHD were 13.3% 
and 4.9% (in childhood), and 10.1% and 6.9% (in adolescence), respectively. In childhood, 
the prevalence of overweight/obesity was highest amongst those with inattention symptoms, 
compared with hyperactivity, while in adolescence, the prevalence of overweight/obesity was 
highest amongst those with hyperactivity symptoms. Children and adolescents with probable 
ADHD respectively had a high prevalence for low preference for physically active play 
(21.3%) and physical inactivity (31.5%). Low preference for physically active play and 
physical inactivity were highest amongst those with inattention compared with hyperactivity 
symptoms. The prevalence of binge-eating was high amongst adolescents with all types of 
ADHD symptoms (16.2% for probable ADHD).  
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Comparison of anthropometric, physical activity and binge-eating data among 
children/adolescents with positive ADHD screen vs. negative ADHD screen  
 
Table 5.3 compares the distributions of anthropometric, physical activity and binge-eating 
data of children/adolescents screening positive for probable ADHD versus their counterparts 
screening negative for ADHD. At 8 years, children with probable ADHD did not 
significantly differ from children who screened negative for ADHD on height, weight or 
BMI, but had significantly higher prevalence of low preference for physically active play. At 
16 years, adolescents with probable ADHD had significantly higher weight and waist girth, 
and had higher rates of overweight/obesity, abdominal obesity, physical inactivity (according 
to MET) and binge-eating, compared with adolescents who screened negative for ADHD.  
 
Confounder analysis 
 
Table 5.4 shows that overall the confounders (sex, family structure change from 0-7 years 
and 7-16 years, and maternal education at 7 and 16 years) significantly correlated with the 
variables of interest. Further, correlation analyses showed that the variables of interest 
(continuous) were significantly associated over time, i.e. from 8 to 16 years, for BMI 
(Pearson r=.62, p<.001), inattention-hyperactivity symptoms (Pearson r=.25, p<.001) and 
physically active play/physical activity (Spearman r=.12, p<.001). These results provide 
rationale for controlling for baseline BMI/ADHD symptoms/physically active play, to ensure 
that   the   ensuing   models   predict   “new”   cases   of   obesity, ADHD symptoms or physical 
inactivity. Cross-sectional analyses at 16 years showed a slight negative association between 
BMI and physical activity (Pearson r=-.04, p<.01). BMI and binge-eating were positively 
associated at 16 years (Spearman r=.06, p<.001).   
 
Puberty start age (in months) was also considered as a potential confounder, as puberty may 
impact BMI and WHR, particularly in girls, as well as mental health. The majority of 16-
year-olds within the NFBC 1986 had already started puberty (n=91%). It is important to note 
that reporting of “puberty  start  age” was low (n=3292). Further, as this data is self-reported it 
may be somewhat unreliable. Partial correlation analyses controlling for sex showed that 
puberty start age was significantly associated with BMI at 16 years (r=-.17, p<.001), but not 
associated with WHR at 16 years (r=-.02, p=.31) nor inattention-hyperactivity symptoms at 8 
years (r=.01, p=.53) or 16 years (r=.01, p=.75). Similarly, Spearman correlation analyses 
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stratified by sex showed that in boys and girls, puberty start age was significantly associated 
with BMI at 16 years (boys, r=-.10, p<.01; girls, r=-.25, p<.001), but not associated with 
WHR at 16 years (boys, r=.02, p=.57; girls, r=-.04, p=.07) nor inattention-hyperactivity 
symptoms at 8 years (boys, r=-.04, p=.16; girls, r=.04, p=.05) or 16 years (boys, r=.01, p=.84; 
girls, r=.01, p=.76). Given that puberty start age was not associated with the independent and 
dependent variables, it cannot be formally considered as a confounder. Considering this, in 
combination with the fact that the vast majority of adolescents had already begun puberty, 
and bearing in mind the large attrition, controlling for this variable was not indicated.    
 
Attrition analysis 
 
Table 5.5 presents the attrition analysis, which examined whether participants and non-
participants at the 7/8 and 16 year follow-up stages differed by socio-demographic factors 
(sex, family structure change and maternal education) and the main variables of interest in 
this study (ADHD symptoms, BMI and physical activity). At 8 and 16 years, participants and 
non-participants differed significantly by family structure and sex – with non-participants 
experiencing more disruptions to family structure, and comprising a higher percentage of 
males. Further, at 16 years, there was a significant difference by BMI and ADHD symptoms 
– with non-participants experiencing higher prevalence of ADHD symptoms and obesity, 
compared with participants. Thus, overall, the subjects dropping out the study at both follow-
up stages were more likely to experience the disorders under study here, as well as lower 
socio-economic standards and comprise a higher percentage of males (who are at increased 
risk for behavioural problems). Therefore, it is possible that  exclusion  of   these  “drop-outs”  
might attenuate any potential association between ADHD symptoms and obesity.
 
 
158 
 
Table 5.1: Characteristics of children at 8 years (n=8106) and adolescents at 16 years (n=6934) in NFBC 1986.  
Characteristics n (%) 
 8 years  16 years 
 All Boys Girls  All Boys Girls 
Body weight defined by BMIa        
Normal 5758 (82.7) 2995 (84.7) 2763 (80.7)  5667 (84.7) 2729 (83.2) 2938 (86.1) 
Overweight 916 (13.2) 419 (11.8) 497 (14.5)  787 (11.8) 416 (12.7) 371 (10.9) 
Obese 288 (4.1) 123 (3.5) 165 (4.8)  238 (3.6) 136 (4.1) 102 (3.0) 
Pb  <.001   <.01 
Abdominal obesity defined by WHRc        
No      6109 (95.0) 3004 (95.0) 3105 (95.0) 
Yes     320 (5.0) 157 (5.0) 163 (5.0) 
Pb      .97 
Physically active play        
Often 5954 (82.1) 3056 (83.0) 2898 (81.1)     
Sometimes 1278 (17.6) 607 (16.5) 671 (15.4)     
Hardly ever 24 (.3) 19 (.5) 5 (.1)     
Pb  <.01     
Physical activity defined by METd        
Active     2534 (40.4) 1406 (46.6) 1128 (34.6) 
Moderately active     2486 (39.6) 1024 (33.9) 1462 (44.8) 
Inactive     1258 (20.0) 588 (19.5) 670 (20.6) 
Pb      <.001 
Binge-eatinge        
No     6139 (90.2) 2915 (89.6) 3224 (90.8) 
Yes     665 (9.8) 338 (10.4) 327 (9.2) 
Pb      .10 
ADHD symptoms (positive diagnostic screenf)        
Inattention-hyperactivity 756 (9.4) 576 (14.0) 180 (4.5)  349 (5.3) 231 (7.0) 118 (3.5) 
Inattention 315 (3.9) 256 (6.2) 59 (1.5)  332 (5.1) 230 (7.1) 102 (3.1) 
Hyperactivity 575 (7.1) 468 (11.4) 107 (2.7)  306 (4.7) 197 (6.1) 109 (3.3) 
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Pb  <.001   <.001 
CD symptoms (positive diagnostic screeng) 725 (9.0) 570 (13.9) 155 (3.9)     
Pb  <.001     
“Pure”  ADHD  symptoms  (positive  diagnostic  screeng), excluding 
CD cases 
       
Inattention-hyperactivity 186 (2.5) 117 (3.3) 69 (1.8)     
Inattention 100 (1.4) 72 (2.0) 28 (0.7)     
Hyperactivity 184 (2.5) 143 (4.0) 41 (1.1)     
Pb  <.001     
“Pure”  CD  symptoms  (positive  diagnostic  screeng), excluding 
inattention-hyperactivity cases 
155 (2.1) 110 (3.1) 44 (1.2)     
Pb  <.001     
Sex  4125 (50.9) 3981 (49.1)   3336 (48.1) 3598 (51.9) 
Pb  .11   <.01 
Family structure change  (from 0-7 years or 7-16 years)        
Always a two-parent family 6761 (85.3) 3447 (85.3) 3314 (85.4)  4506 (75.7) 2249 (76.5) 2257 (75.0) 
Single-parent family 513 (6.5) 271 (6.7) 242 (6.2)  805 (13.5) 419 (14.2) 386 (12.8) 
Reconstructed family 537 (6.8) 277 (6.9) 260 (6.7)  583 (9.8) 254 (8.6) 329 (10.9) 
Always a one-parent family 114 (1.4) 48 (1.2) 66 (1.7)  56 (.9) 19 (.6) 37 (1.2) 
Pb  .22   <.01 
Maternal education         
Basic education (≤  9  years) 1330 (16.9) 668 (16.7) 662 (17.1)  794 (13.0) 401 (13.2) 393 (12.8) 
Upper secondary education (10-12 years) 4318 (54.9) 2248 (56.1) 2070 (53.6)  4045 (66.4) 1999 (65.9) 2046 (66.9) 
Tertiary  education  (≥  13  years) 2224 (28.3) 1092 (27.2) 1132 (29.3)  573 (9.4) 299 (9.9) 274 (9.0) 
Other or degree not finished    682 (11.2) 335 (11.0) 347 (11.3) 
Pb  .07   .61 
aBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
bP value for heterogeneity between males and females.  
cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
dPhysical activity, defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of school hours, including 
commute to and from school.  
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eBinge-eating, defined as no (never/hardly ever/occasionally) vs. yes (once a month/once a week/2 or 3 times a week/daily).  
fScreening positive for symptoms based on fulfilment of criteria according to the Rutter B2 scale (8 years)/Strengths and Weaknesses of ADHD symptoms and Normal 
behaviour (SWAN) scale (16 years).  
gScreening positive for symptoms based on fulfilment of criteria according to the Rutter B2 scale (8 years). 
Table adapted from Khalife et al. (2014) [615], with permission from Elsevier as per the rights retained by authors.   
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Table 5.2: Frequency distributions of BMI, physical activity and binge-eating by ADHD symptoms at 8 and 16 years.  
 n (%) 
 ADHD symptoms (positive diagnostic screen)a 
 8-y-olds (Rutter B2)  16-y-olds (SWAN) 
 Inattention-
hyperactivity 
(n=756) 
Inattention 
(n=315) 
Hyperactivity 
(n=575) 
 Inattention-
hyperactivity 
(n=349) 
Inattention 
(n=332) 
Hyperactivity 
(n=306) 
Sex        
Male 576 (76.2) 256 (81.3) 468 (81.4)  231 (66.2) 230 (69.3) 197 (64.4) 
Female 180 (23.8) 59 (18.7) 107 (18.6)  118 (33.8) 102 (30.7) 109 (35.6) 
        
Body weight defined by BMIb        
Normal 437 (81.8) 185 (82.2) 353 (84.2)  230 (83.0) 219 (83.9) 210 (83.7) 
Overweight 71 (13.3) 27 (12.0) 46 (11.0)  28 (10.1) 23 (8.8) 26 (10.4) 
Obese 26 (4.9) 13 (5.8) 20 (4.8)  19 (6.9) 19 (7.3) 15 (6.0) 
        
Abdominal obesity defined by WHRc        
No     252 (91.6) 239 (92.6) 229 (92.3) 
Yes     23 (8.4) 19 (7.4) 19 (7.7) 
        
Physically active play        
Often 484 (78.7) 200 (78.7) 391 (80.6)     
Sometimes 125 (20.3) 53 (20.7) 88 (18.1)     
Hardly ever 6 (1.0) 3 (1.2) 6 (1.2)     
        
Physical activity defined by METd        
Active     93 (36.6) 89 (36.8) 90 (38.1) 
Moderately active     81 (31.9) 73 (30.2) 78 (33.1) 
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Inactive     80 (31.5) 80 (33.1) 68 (28.8) 
        
Binge-eatinge        
No     243 (83.8) 232 (84.1) 226 (85.0) 
Yes     47 (16.2) 44 (15.9) 40 (15.0) 
aScreening positive for symptoms based on fulfilment of criteria according to the Rutter B2 scale (8 years)/Strengths and Weaknesses of ADHD 
symptoms and Normal behaviour (SWAN) scale (16 years). 
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
dPhysical activity, defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of 
school hours, including commute to and from school.  
eBinge-eating, defined as no (never/hardly ever/occasionally) vs. yes (once a month/once a week/2 or 3 times a week/daily).  
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Table 5.3: Anthropometric, physical activity and binge-eating data among children/adolescents screening positive and negative for inattention-
hyperactivity symptoms. 
 n (%) or mean ± SD 
 Inattention-hyperactivity symptoms (diagnostic screen)a 
 8-y-olds (Rutter B2)  16-y-olds (SWAN) 
 Positive screen 
(n=756) 
Negative screen 
(n=7324) 
P  Positive screen 
(n=349) 
Negative screen 
(n=6258) 
P 
Sex   <.001    <.001 
Male 576 (76.2) 3537 (48.3)   231 (66.2) 3051 (48.8)  
Female 180 (23.8) 3787 (51.7)   118 (33.8) 3207 (51.2)  
        
Height (cm) 123.5 ± 5.6 123.6 ± 5.7 .63  171.2 ± 13.7 170.0 ± 15.4 .15 
        
Weight (kg) 25.0 ± 4.6 24.9 ± 4.6 .68  62.9 ± 14.0 60.7 ± 11.7 <.01 
        
BMI 16.3 ± 2.3 16.2 ± 2.1 .25  21.5 ± 4.2 21.1 ± 3.4 .05 
        
Body weight defined by BMIb   .72    <.01 
Normal 437 (81.8) 4907 (82.7)   230 (83.0) 4798 (84.6)  
Overweight 71 (13.3) 777 (13.1)   28 (10.1) 678 (12.0)  
Obese 26 (4.9) 246 (4.1)   19 (6.9) 193 (3.4)  
        
Waist girth (cm)     75.2 ± 10.1 73.7 ± 8.5 <.01 
        
Hip girth (cm)     92.3 ± 8.7 92.3 ± 7.3 .93 
        
Abdominal obesity defined by WHRc       <.01 
No     252 (91.6) 5086 (95.2)  
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Yes     23 (8.4) 254 (4.8)  
        
Physically active play   <.01     
Often 484 (78.7) 5388 (82.6)      
Sometimes 125 (20.3) 1120 (17.2)      
Hardly ever 6 (1.0) 17 (0.3)      
        
METd     28.4 ± 19.1 31.0 ± 17.0 .02 
        
Physical activity defined by METe       <.001 
Active     93 (36.6) 2239 (41.0)  
Moderately active     81 (31.9) 2164 (39.6)  
Inactive     80 (31.5) 1055 (19.3)  
        
Binge-eatingf       <.001 
No     243 (83.8) 5245 (90.4)  
Yes     47 (16.2) 556 (9.6)  
aScreening positive for symptoms based on fulfilment of criteria according to the Rutter B2 scale (8 years)/Strengths and Weaknesses of ADHD 
symptoms and Normal behaviour (SWAN) scale (16 years). 
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
dMetabolic equivalent of task (MET).  
ePhysical activity, defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of 
school hours, including commute to and from school.  
fBinge-eating, defined as no (never/hardly ever/occasionally) vs. yes (once a month/once a week/2 or 3 times a week/daily). 
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Table 5.4: Correlations of confounders with mental health, obesity (BMI and WHR) and obesogenic factors (physical activity and binge-eating).  
 Confounders 
 Sexa  Family structure change  
(0-7 years) 
 Family structure change 
(7-16 years) 
 Mother’s  education 
(7 years) 
 Mother’s  education 
(16 years) 
 n r p  n r p  n r p  n r p  n r p 
ADHD symptoms                    
8-y-olds  Rutter scores  
(teacher report) 
                   
Inattention-
hyperactivity 
8073 -.27 <.001  7323 .12 <.001  5549 .10 <.001  7289 -.09 <.001  5687 .03 .01 
16-y-olds SWAN scores  
(parent report) 
                   
Combined ADHD 6607 -.14 <.001  6209 .07 <.001  5950 .08 <.001  6187 -.10 <.001  6094 .05 <.001 
                    
Obesity outcomes                    
8-y-olds                    
BMIb 6962 -.03 <.01  6910 .04 <.01  5316 .04 .01  6874 -.04 <.01  5439 -.01 .50 
16-y-olds                    
BMIb 6692 .02 .11  6641 .02 .08  5709 .03 .01  6606 -.06 <.001  5844 .03 .01 
WHRc 6429 -.52 <.001  5968 .03 .04  5115 .02 .28  5939 -.05 <.001  5237 .02 .11 
                    
Physical activity                    
8-y-olds                    
Physically active play  
(low vs. high)d 
7256 .03 .03  7197 .05 <.001  5526 .06 <.001  7158 -.04 <.01  5660 .004 .74 
16-y-olds                    
METe 6278 -.12 <.001  6228 .03 .04  5488 -.03 .01  6194 .09 <.001  5619 -.05 <.01 
                    
Binge-eatingf  
(yes vs. no) at 16y 
6429 -.46 <.001  6318 -.00 .94  5526 -.01 .45  6284 .003 .84  5656 -.01 .55 
aSex coded 0 (male) and 1 (female).  
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
dPreference for physically active play, dichotomised into low (sometimes and hardly ever) and high (often) categories.  
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ePhysical activity defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of school hours, including commute to and 
from school.  
fBinge-eating, defined as no (never/hardly ever/occasionally) vs. yes (once a month/once a week/2 or 3 times a week/daily). 
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Table 5.5: Attrition analysis from 7/8 to 16 years.  
Characteristics  n (%) 
 Dropout (8y) 
(n=848) 
Remain (8y) 
(n=8106) 
P Dropout (16y) 
(n=1679) 
Remain (16y) 
(n=6934a) 
P 
Sex   .01   <.001 
Male 471 (55.5) 4125 (50.9)  1045 (62.2) 3336 (48.1)  
Female 377 (44.5) 3981 (49.1)  634 (37.8) 3598 (51.9)  
       
Family structure at birth   .01    
Married/cohabiting 781 (93.0) 7691 (95.1)     
Single/widowed/divorced  59 (7.0) 396 (4.9)     
       
Family structure change  (from 0-7 years)      <.001 
Always a two-parent family    1070 (79.5) 5576 (86.7)  
Single-parent family    121 (9.0) 382 (5.9)  
Reconstructed family    127 (9.4) 392 (6.1)  
Always a one-parent family    28 (2.1) 82 (1.3)  
       
Maternal education at birth or 7 years   .65   <.001 
Basic education (≤  9  years) 174 (30.7) 2208 (30.2)  290 (21.8) 1009 (15.8)  
Upper secondary education (10-12 years) 332 (58.7) 4400 (60.2)  730 (55.0) 3509 (54.8)  
Tertiary  education  (≥  13  years) 60 (10.6) 698 (9.6)  308 (23.2) 1880 (29.3)  
       
Body weight defined by BMIb  at 7 years      <.01 
Normal    912 (81.5) 4752 (83.0)  
Overweight    141 (12.6) 758 (13.2)  
Obese    66 (5.9) 218 (3.8)  
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Physically active play at 7 years      .80 
Often    1048 (81.6) 4895 (82.2)  
Sometimes    232 (18.1) 1038 (17.4)  
Hardly ever    5 (0.4) 19 (0.3)  
       
ADHD symptoms (positive diagnostic screen)c at 8 years       
Inattention-hyperactivity    225 (13.5) 531 (8.3) <.001 
Inattention    108 (6.5) 207 (3.2) <.001 
Hyperactivity    174 (10.4) 401 (6.3) <.001 
a507 children who dropped out at 8 years participated at 16 years.  
bBMI was defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cScreening positive for symptoms based on fulfilment of criteria according to the Rutter B2 scale.  
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5.1.2 Cross-sectional analysis between ADHD symptoms and obesity/physically active 
play: 8 years  
 
The logistic regression results showed that at 8 years, screening positive for any of the 
ADHD symptoms were not associated with obesity, as shown by the unadjusted analyses 
(e.g. for probable ADHD; OR=1.19, 95% CI: .78-1.80) and the adjusted analyses (Table 5.6). 
The unadjusted results showed an association between probable ADHD and low physically 
active play (OR=1.28, 95% CI: 1.05-1.57), and the adjusted analyses for this association was 
close to statistical significance (p=.05), with increased odds of 1.26 (Table 5.6). The adjusted 
analyses showed no evidence for associations between physically active play and inattention 
or hyperactivity symptoms. Further adjusted analyses showed that ADHD symptoms on a 
dimensional scale (continuous scores) were also not related with obesity or physically active 
play (Table 5.7).  
 
5.1.3 Cross-sectional analysis between ADHD symptoms, obesity and obesogenic factors 
(physical activity and binge-eating): 16 years  
 
At 16 years, both unadjusted and adjusted logistic regression analyses showed that ADHD 
symptoms (diagnostic screen) were associated with obesity (BMI and WHR), physical 
inactivity and binge-eating. For example, unadjusted analyses showed that probable ADHD 
at 16 years was significantly associated with obese BMI (OR=2.05; 95% CI: 1.26-3.35), 
abdominal obesity (OR=1.83, 95% CI: 1.17-2.90), physical inactivity (OR=1.83, 95% CI: 
1.34-2.48) and binge-eating (OR=1.83; 95% CI: 1.32-2.52). Figures 5.1-5.3 show the results 
for the adjusted analyses for associations with probable ADHD (Figure 5.1), inattention 
(Figure 5.2) and hyperactivity (Figure 5.3); these results are also presented in tabulated form 
in Appendix Tables A.1-A.2. The adjusted analyses show that at 16 years, probable ADHD 
significantly increased the risk for obese BMI by approximately 75%, abdominal obesity by 
70%, physical inactivity by 73% and binge-eating by 71%. Further, screening positive for 
inattention was associated with obese BMI, physical inactivity and binge-eating, while 
hyperactivity was related with physical inactivity.  
 
In addition, adjusted analyses showed that at 16 years ADHD symptom scores were also 
linked with the outcomes of interest (Tables 5.8-5.9), although the magnitude of these 
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associations were much smaller in comparison with those yielded from the analyses which 
examined ADHD as a categorical diagnostic screen. This is to be expected though, as these 
analyses examine the impact of one point change in ADHD symptom scores on the outcomes. 
There were significant associations between inattention symptoms and obesity (BMI and 
abdominal obesity) (Table 5.8), while all ADHD symptoms were related with both physical 
inactivity and binge-eating (Table 5.9).    
 
5.1.4 Longitudinal analysis examining the association and directionality between ADHD 
symptoms, obesity and obesogenic factors (physical activity and binge-eating): 8 to 16 
years  
 
The main aim of the longitudinal analysis was to examine the direction of the potential 
ADHD symptom-obesity association, from childhood to adolescence. Furthermore, 
bidirectional associations between ADHD symptoms and physical activity, and the 
association of ADHD symptoms on binge-eating, were studied from childhood to 
adolescence.  
 
The unadjusted and adjusted logistic regression analyses showed significant longitudinal 
associations between ADHD symptoms (diagnostic screen) and both obesity and physical 
inactivity, but not binge-eating. The unadjusted analyses revealed a significant association 
between probable ADHD at 8 years and obesity at 16 years (OR=2.01, 95% CI: 1.37-3.00), 
but non-significance in the opposite direction, i.e. from obesity at 8 years to probable ADHD 
at 16 years (OR=.90, 95% CI: .69-1.18). There were significant associations between 
probable ADHD at 8 years and physical inactivity at 16 years (OR=1.30, 95% CI: 1.01-1.67), 
and low preference for physically active play at 8 years and inattention at 16 years (OR=1.53, 
95% CI: 1.15-2.05). The adjusted analyses yielded similar results, as shown in Figures 5.4-
5.9 and in tabulated form in Appendix Tables A.3-A.5. Probable ADHD at 8 years predicted 
obesity and abdominal obesity at 16 years, increasing the risk of these outcomes by 91% and 
71%, respectively (Figure 5.4/Table A.3). The individual ADHD symptoms of inattention 
and hyperactivity in childhood were also related with obesity in adolescence. Screening 
positive for either inattention or hyperactivity increased the risk for abdominal obesity, by 
approximately 3.5-fold and 2-fold, respectively (Figures 5.5-5.6/Table A.3). Inattention also 
predicted both overweight and obesity, by approximately 2-fold (Figure 5.5/Table A.3). 
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There was no evidence for the reverse association i.e. obesity did not predict ADHD 
symptoms over the long-term (Figures 5.7-5.9/Table A.4). Low preference for physically 
active play at 8 years significantly increased the risk for inattention symptoms at 16 years, by 
approximately 60% (Figure 5.8/Table A.4). There was some evidence for the reverse 
association as inattention-hyperactivity and inattention symptoms were longitudinally 
associated with physical inactivity, increasing the risk by approximately 60% and 90%, 
respectively (Figures 5.4-5.5/Table A.5). There were no significant longitudinal associations 
detected between ADHD symptoms and binge-eating (Figures 5.4-5.6/Table A.5).  
 
Furthermore, adjusted linear regression analyses using continuous measures (for both 
predictors and outcomes) showed significant longitudinal associations from 8 to 16 years e.g. 
inattention-hyperactivity   symptoms   and   BMI   (β=.08,   p<.001),   inattention-hyperactivity 
symptoms   and   physical   activity   (MET)   (β=-.04, p=.02), and physically active play and 
inattention  symptoms  (β=.04,  p=.005). 
 
5.1.5 Longitudinal analysis stratified by sex 
 
Stratification of the longitudinal analysis by sex resulted in significantly reduced numbers of 
cases screening positive for ADHD symptoms, particularly amongst girls (see Methods 
section 4.6.3 for further detail). Thus, to optimise statistical power, ADHD symptoms were 
instead analysed as continuous scores rather than categorical measures (Tables 5.10-5.15).  
 
In both boys and girls, high ADHD symptom scores (inattention-hyperactivity, inattention 
and hyperactivity) at 8 years predicted obesity at 16 years; the associations were of a slightly 
larger magnitude in girls, particularly for inattention symptoms (Tables 5.10-5.11). In boys, 
all childhood ADHD symptom scores were additionally positively associated with adolescent 
overweight and abdominal obesity (Table 5.10). In contrast to the analysis which examined 
the entire sample (boys and girls), the stratified analyses showed that in both sexes, 
overweight at 8 years predicted lower inattention-hyperactivity and hyperactivity scores at 16 
years (Tables 5.12-5.13). There were no associations detected between obesity at 8 years and 
ADHD symptoms at 16 years.  
 
 
 
172 
 
In boys, there was a trend for positive associations between low physically active play at 8 
years and both inattention-hyperactivity and inattention symptoms at 16 years, although these 
associations did not quite reach statistical significance (Table 5.12).  In females, there were 
significant positive associations between low physically active play at 8 years and 
inattention-hyperactivity and hyperactivity symptoms at 16 years (Table 5.13).  There was 
some evidence for the reverse associations – in both boys and girls, high ADHD symptom 
scores at 8 years predicted physical inactivity at 16 years. In boys, from childhood to 
adolescence, inattention-hyperactivity symptoms were positively associated with physical 
inactivity, and inattention symptoms were positively associated with both moderate physical 
activity and physical inactivity (Table 5.14). In girls, inattention-hyperactivity and 
hyperactivity symptoms were positively associated with physical inactivity (Table 5.15). 
Furthermore, in contrast to the analysis which examined the entire sample (boys and girls), 
the stratified analysis revealed that in girls, high inattention scores in childhood predicted 
binge-eating in adolescence (Table 5.15).  
 
5.1.6 Longitudinal analysis exploring independence of the ADHD symptom-obesity 
association from CD symptoms 
 
To explore whether the longitudinal ADHD-obesity association is independent of CD, the 
analyses were repeated (using the entire sample of boys and girls) (1) with CD instead of 
ADHD   symptoms,   and   (2)   including   only   “pure”   probable ADHD or CD cases i.e. cases 
screening positive for either ADHD or CD symptoms (n=78 and n=81, respectively, in 
adjusted  analyses).    Due  to  the  small  number  of  available  “pure”  ADHD  and  CD  cases,  these  
analyses should be viewed as preliminary.  
 
In analysis (1), screening positive for probable CD at 8 years was associated with overweight 
(OR=1.52, 95% CI: 1.07-2.14, p=.02), obesity (OR=2.53, 95% CI: 1.49-4.31, p<.01), 
abdominal obesity (OR=1.67, 95% CI: 1.03-2.71, p=.04) and physical inactivity (OR=1.47, 
95% CI:1.10-1.97, p<.01) at 16 years (Tables A.3 and A.5). Probable CD in childhood was 
not associated with binge-eating in adolescence (OR=1.27, 95% CI: .91-1.78, p=.16) (Table 
A.5).   In   analysis   (2),  where   children  with  CD  symptoms  were  excluded,   “pure”   inattention  
and hyperactivity symptoms at 8 years individually predicted abdominal obesity at 16 years 
(Table 5.16/Table A.3). In analyses excluding children with inattention-hyperactivity 
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symptoms,   “pure”   CD   symptoms   at   8   years   predicted   overweight   at   16   years   (Table  
5.16/Table   A.3).   Neither   “pure”   ADHD   nor   “pure”   CD   symptoms in childhood were 
associated with physical inactivity (or binge-eating) in adolescence (Table A.5).  
 
5.1.7 Mediation analysis of the ADHD symptom-obesity association by physical 
inactivity and binge-eating 
 
Mediation analysis was performed to examine whether physical inactivity or binge-eating 
mediate the ADHD symptom-obesity association. Using the entire sample (boys and girls), 
adjusted bootstrap analyses showed that physical inactivity at 16 years mediated the 
longitudinal association between probable ADHD and obesity (bootstrap estimate=.004, 
percentile 95% CI: .001-.007, n=4524). This mediation model accounted for 24% of the 
variance in obesity at 16 years (adjusted R2=.24, F=235.55, p<.001). In contrast, there was no 
evidence for mediation by binge-eating at 16 years (bootstrap estimate=.001, percentile 95% 
CI: -.001-.003, n=5056). Similarly, physical inactivity mediated the longitudinal association 
between probable CD and obesity (bootstrap estimate=.003, percentile 95% CI: .001-.007, 
n=4514), and this model also accounted for 24% of the variance in obesity (adjusted R2=.24, 
F=239.63, p<.001). As before, binge-eating did not mediate the CD-obesity association 
(bootstrap estimate=.001, percentile 95% CI: -.001-.003, n=5044).  
 
To explore potential sex differences, the main mediation analysis (involving ADHD) was 
stratified by sex, taking into consideration the substantial reduction in statistical power in 
doing so. In this analysis, inattention-hyperactivity was included as a continuous score to 
optimise power, as in the previous sex-stratified analyses. Despite the reduction in power, 
mediation by physical inactivity held for boys (bootstrap estimate=.001, percentile 95% CI: 
.001-.002, n=2169), but did not remain for girls (bootstrap estimate=.001, percentile 95% CI: 
-.0002-.002, n=2353). Similar to the results for the entire sample, mediation by binge-eating 
was not detected in boys (bootstrap estimate=.0001, percentile 95% CI: -.0002-.0006, 
n=2380) or girls (bootstrap estimate=.001, percentile 95% CI: -.0001-.0024, n=2587). 
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Table 5.6: Logistic regression of ADHD symptoms (categorical screen) on BMI and physically active play at 8 years, adjusted for relevant 
confoundersa.  
ADHD symptom screen 
(Rutter B2: teacher report) 
 BMIb  Physically Active Playc 
  Overweight vs. normal  Obese vs. normal  Low vs. high 
  n OR 95% CI P  n OR 95% CI P  n OR 95% CI P 
Inattention-hyperactivity  6221 1.05 .80-1.39 .73  6221 1.11 .71-1.73 .64  6221 1.26 1.00-1.58 .05 
Inattention  6225 .93 .61-1.44 .75  6225 1.32 .71-2.44 .38  6225 1.22 .87-1.72 .26 
Hyperactivity   6229 .86 .62-1.20 .39  6229 1.12 .68-1.84 .67  6229 1.08 .82-1.41 .59 
aAdjusted for gender,  family structure change (from 0 to 7 years), maternal education, physically active play (for model b) and BMI (for model c).  
bBMI defined according to the  International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cPreference for physically active play, dichotomised into low (sometimes and hardly ever) and high (often) categories. 
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Table 5.7: Logistic regression of ADHD symptoms (continuous scores) on BMI and physically active play at 8 years, adjusted for relevant confoundersa.  
ADHD symptom scores 
(Rutter B2: teacher report) 
 BMIb  Physically Active Playc 
  Overweight vs. normal  Obese vs. normal  Low vs. high 
  n OR 95% CI P  n OR 95% CI P  n OR 95% CI P 
Inattention-hyperactivity  6217 .72  .37-1.40 .34  6217 1.47  .66-3.29 .35  6217 1.01 .97-1.06 .62 
Inattention  6225 .93  .61-1.44 .76  6225 1.34 .72-2.50 .35  6225 1.09 .95-1.25 .21 
Hyperactivity   6229 .75  .48-1.19 .22  6229 .88  .43-1.79 .72  6229 1.00 .94-1.07 .98 
aAdjusted for gender,  family structure change (from 0 to 7 years), maternal education, physically active play (for model b) and BMI (for model c).  
bBMI defined according to the  International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cPreference for physically active play, dichotomised into low (sometimes and hardly ever) and high (often) categories. 
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Figures 5.1-5.3: Logistic regression for the associations of ADHD symptoms at 16 years (SWAN:  parent report; categorical screen) on concurrent BMI, WHR, physical activity 
and binge-eating, adjusted for relevant confoundersa. 
 
aAdjusted for gender, family structure change (7-16 years), maternal education, physical activity at 16 years (models b-c) and BMI at 16 years (model d). 
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR. 
dPhysical activity defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of school hours, including commute to and from school.  
eBinge-eating defined as yes (once a month/once a week/2 or 3 times a week/daily) vs. no (never/hardly ever/occasionally). 
*p<.05; **p<.01.  
Figure 5.3: Hyperactivity on BMI (n=5285), WHR (n=4733), physical 
activity (n=5285) and binge-eating (n=5355).  
Figure 5.2: Inattention on BMI (n=5317), WHR (n=4763), physical activity 
(n=5317) and binge-eating (n=5384).  
 
 
 
 
 
  
 
Figure 5.1: Inattention-hyperactivity on BMI (n=5374), WHR (n=4812), 
physical activity (n=5374) and binge-eating (n=5446).  
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Table 5.8: Logistic regression of ADHD symptoms (continuous scores) on BMI and WHR at 16 years, adjusted for relevant confoundersa.  
ADHD symptom scores  
(SWAN: parent report) 
 BMIb  WHRc 
  Overweight vs. normal  Obese vs. normal  Abdominal obesity vs. normal 
  n OR 95% CI P  n OR 95% CI P  n OR 95% CI P 
Inattention-hyperactivity  5374 1.00 1.00-1.01 .72  5374 1.00 .995-1.013 .39  4812 1.01  1.00-1.02 .08 
Inattention  5374 1.00 .99-1.01 .82  5374 1.02 1.00-1.04 .02  4812 1.02  1.01-1.04 <.01 
Hyperactivity   5374 1.00 .99-1.01 .66  5374 1.00  .98-1.01 .51  4812 1.01 1.00-1.02 .55 
aAdjusted for gender,  family structure change (from 7 to 16 years), maternal education and physical activity (16 years).  
bBMI defined according to the  International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
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Table 5.9: Logistic regression of ADHD symptoms (continuous scores) on physical activity and binge-eating at 16 years, adjusted for relevant confoundersa.  
ADHD symptom scores  
(SWAN: parent report) 
 Physical activityb  Binge-eatingc 
  Moderately active vs. active  Inactive vs. active  Yes vs. no 
  n OR 95% CI P  n OR 95% CI P  n OR 95% CI P 
Inattention-hyperactivity  5374 1.00  1.00-1.01 .14  5374 1.01 1.01-1.02 <.001  5446 1.02 1.01-1.02 <.001 
Inattention  5374 1.01 1.00 -1.01 .09  5374 1.03 1.02-1.04 <.001  5446 1.03 1.02-1.04 <.001 
Hyperactivity   5374 1.00 1.00-1.01 .29  5374 1.02 1.01-1.03 <.001  5446 1.03 1.02-1.04 <.001 
aAdjusted for gender,  family structure change (from 7 to 16 years), maternal education and BMI at 16 years (model b) .  
bPhysical activity defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of school 
hours, including commute to and from school.  
cBinge-eating defined as yes (once a month/once a week/2 or 3 times a week/daily) vs. no (never/hardly ever/occasionally). 
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Figures 5.4-5.6: Logistic regression for associations of ADHD symptoms at 8 years (Rutter B2: teacher report; categorical screen) on BMI, WHR, physical activity and binge-eating at 16 years, 
adjusted for relevant confoundersa. 
  
aAdjusted for gender, family structure change (7-16 years), maternal education, BMI at 7 years (models b-c) physical activity at 16 years (models b-c), physically active play at 7 years (model d)  and BMI at 16 years 
(model d). 
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR. 
dPhysical activity defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of school hours, including commute to and from school.  
eBinge-eating defined as yes (once a month/once a week/2 or 3 times a week/daily) vs. no (never/hardly ever/occasionally). 
*p<.05; **p<.01; ***p<.001.  
 
 
 
 
 
 
  
 
 
  
 
  
 
 
 
 
 
  
Figure 5.4: Inattention-hyperactivity on BMI (n=4524), WHR (n=4058), physical activity 
(n=4936) and binge-eating (n=5056).  
Figure 5.5: Inattention on BMI (n=4526), WHR (n=4060), physical activity (n=4937) and 
binge-eating (n=5058).  
Figure 5.6: Hyperactivity on BMI (n=4524), WHR (n=4058), physical activity (n=4936) and 
binge-eating (n=5058).  
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Figures 5.7-5.9: Logistic regression for associations of BMI and physically active play at 7 years on ADHD symptoms at 16 years (SWAN: parent report; categorical screen), adjusted 
for relevant confoundersa. 
 
aAdjusted for gender, family structure change (7-16 years), maternal education, ADHD symptoms at 8 years and mutual adjustment for physically active play (model b)/BMI (model c) at 7 years.  
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cPreference for physically active play, dichotomised into low (sometimes and hardly ever) and high (often) categories.  
*p < .05. 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
  
 
 
Figure 5.7: BMI (n=4810) and physically active play (n=4810) on inattention-hyperactivity. Figure 5.8: BMI (n=4758) and physically active play (n=4758) on inattention. 
Figure 5.9: BMI (n=4741) and physically active play (n=4741) on hyperactivity. 
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Table 5.10: Logistic regression for ADHD symptoms (scores) at 8 years on BMI and WHR at 16 years, in males, adjusted for relevant confoundersa.  
Male ADHD symptom scores 
(Rutter B2: teacher report) 
 Male BMIb  Male WHRc 
  Overweight vs. normal  Obese vs. normal  Abdominal obesity vs. normal 
  n OR 95% CI P  n OR 95% CI P  n OR 95% CI P 
Inattention-hyperactivity  2169 1.11 1.02-1.20 .01  2169 1.24 1.09-1.42 <.01  1938 1.22 1.09-1.37 <.01 
Inattention  2170 1.33 1.06-1.68 .02  2170 2.06 1.43-2.96 <.001  1939 1.89 1.37-2.61 <.001 
Hyperactivity   2171 1.14 1.02-1.27 .03  2171 1.27 1.05-1.54 .01  1940 1.26 1.07-1.49 <.01 
aAdjusted for family structure change (from 7 to 16 years), maternal education, BMI (7 years) and physical activity (16 years).  
bBMI defined according to the  International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
 cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
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Table 5.11: Logistic regression for ADHD symptoms (scores) at 8 years on BMI and WHR at 16 years, in females, adjusted for relevant confoundersa.  
Female ADHD symptom scores 
(Rutter B2: teacher report) 
 Female BMIb  Female WHRc 
  Overweight vs. normal  Obese vs. normal  Abdominal obesity vs. normal 
  n OR 95% CI P  n OR 95% CI P  n OR 95% CI P 
Inattention-hyperactivity  2353 1.10 .95-1.27 .22  2353 1.42 1.15-1.76 <.01  2119 1.07 .88-1.30 .50 
Inattention  2356 1.21 .80-1.84 .36  2356 2.91 1.65-5.12 <.001  2121 1.35 .80-2.27 .27 
Hyperactivity   2358 1.13 .93-1.38 .22  2358 1.51 1.12-2.04 <.01  2123 1.06 .80-1.39 .70 
aAdjusted for family structure change (from 7 to 16 years), maternal education, BMI (7 years) and physical activity (16 years).  
bBMI defined according to the  International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
 cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
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Table 5.12: Linear regression for BMI and physically active play at 7 years on ADHD symptoms (scores) at 16 years, in males, adjusted for relevant confoundersa.     
  Male ADHD symptom scores (SWAN: parent report) 
  Inattention-hyperactivity  Inattention  Hyperactivity 
  n β B 95% CI 
for B 
P  n β B 95% CI 
for B 
P  n β B 95% CI 
for B 
P 
Male BMIb                   
Overweight vs. normal  2359 -.04 -1.79 -3.77-.19 .08  2359 -.02 -.45 -1.51-.60 .40  2361 -.05 -1.24 -2.33--.14 .03 
Obese vs. normal  2359 -.02 -2.21 -5.82-1.41 .23  2359 -.01 -.46 -2.39-1.46 .64  2361 -.04 -1.78 -3.77-.22 .08 
Male physically active playc                   
Low vs. high  2359 .03 1.45 -.28-3.17 .10  2359 .03 .78 -.13-1.71 .09  2361 .03 .66 -.29-1.61 .17 
aAdjusted for  family structure change (from 7 to 16 years), maternal education,  ADHD symptoms (8 years), and mutual adjustment for BMI/physically active play (7 years). 
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cPreference for physically active play, dichotomised into low (sometimes and hardly ever) and high (often) categories. 
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Table 5.13: Linear regression for BMI and physically active play at 7 years on ADHD symptoms (scores) at 16 years, in females, adjusted for relevant confoundersa.     
  Female ADHD symptom scores (SWAN: parent report) 
  Inattention-hyperactivity  Inattention  Hyperactivity 
  n β B 95% CI 
for B 
P  n β B 95% CI 
for B 
P  n β B 95% CI 
for B 
P 
Female BMIb                   
Overweight vs. normal  2450 -.05 -2.25 -4.04--.45 .01  2454 -.05 -1.26 -2.22--.30 .01  2455 -.04 -1.09 -2.07--.12 .03 
Obese vs. normal  2450 -.02 -1.78 -4.91-1.37 .27  2454 -.02 -.78 -2.46-.90 .36  2455 -.03 -1.07 -2.78-.63 .22 
Female physically active playc                   
Low vs. high  2450 .05 2.00 .39-3.61 .02  2454 .06 .83 -.03-1.70 .06  2455 .05 1.10 .22-1.98 .01 
aAdjusted for  family structure change (from 7 to 16 years), maternal education,  ADHD symptoms (8 years), and mutual adjustment for BMI/physically active play (7 years). 
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cPreference for physically active play, dichotomised into low (sometimes and hardly ever) and high (often) categories. 
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Table 5.14: Logistic regression for ADHD symptoms (scores) at 8 years on physical activity and binge-eating at 16 years, in males, adjusted for 
relevant confoundersa.  
Male ADHD symptom scores 
(Rutter B2: teacher report) 
 Male physical activityb  Male binge-eatingc 
  Moderately active vs. active  Inactive vs. active  Yes vs. no 
  n OR 95% CI P  n OR 95% CI P  n OR 95% CI P 
Inattention-hyperactivity  2367 1.04 .98-1.10 .23  2367 1.09 1.02-1.17 .01  2438 .97 .90-1.06 .52 
Inattention  2227 1.21 1.02-1.43 .03  2227 1.44 1.19-1.75 <.001  2441 .95 .75-1.21 .69 
Hyperactivity   2369 1.03 .95-1.10 .53  2369 1.09 1.00-1.20 .06  2440 .96 .86-1.08 .49 
aAdjusted for  family structure change (from 7 to 16 years), maternal education, physically active play at 7 years (model b) and BMI at 16 years 
(model b).  
bPhysical activity defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of 
school hours, including commute to and from school.  
cBinge-eating defined as yes (once a month/once a week/2 or 3 times a week/daily) vs. no (never/hardly ever/occasionally).  
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Table 5.15: Logistic regression for ADHD symptoms (scores) at 8 years on physical activity and binge-eating at 16 years, in females, adjusted for 
relevant confoundersa.  
Female ADHD symptom scores 
(Rutter B2: teacher report) 
 Female physical activityb  Female binge-eatingc 
  Moderately active vs. active  Inactive vs. active  Yes vs. no 
  n OR 95% CI P  n OR 95% CI P  n OR 95% CI P 
Inattention-hyperactivity  2564 .95 .87-1.04 .29  2564 1.13 1.02-1.25 .02  2645 1.11 .99-1.25 .09 
Inattention  2568 .97 .73-1.25 .74  2568 1.30 .97-1.75 .08  2649 1.52 1.10-2.09 .01 
Hyperactivity   2569 .92 .82-1.04 .20  2569 1.17 1.03-1.35 .02  2650 1.10 .93-1.30 .28 
aAdjusted for  family structure change (from 7 to 16 years),  maternal education, physically active play at 7 years (model b) and BMI at 16 years 
(model b). 
bPhysical activity defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of 
school hours, including commute to and from school.  
cBinge-eating defined as yes (once a month/once a week/2 or 3 times a week/daily) vs. no (never/hardly ever/occasionally).  
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Table 5.16: Logistic  regression  for  “pure”  ADHD symptoms or CD symptoms (categorical screen) at 8 years on BMI and WHR at 16 years, adjusted for relevant confoundersa. 
“Pure”  ADHD  or  CD  symptom  screen 
(Rutter B2: teacher report) 
 BMId  WHRe 
  Overweight vs. normal  Obese vs. normal  Abdominal obesity vs. normal 
  n OR 95% CI P  n OR 95% CI P  n OR 95% CI P 
Inattention-hyperactivityb  4178 1.34 .66-2.71 .42  4178 .75 .16-3.56 .71  3766 1.55 .52-4.60 .43 
Inattentionb  4178 2.11 .92-4.81 .08  4178 1.51 .30-7.63 .62  3767 6.91 2.89-16.53 <.001 
Hyperactivityb  4176 1.50 .77-2.91 .23  4176 2.10 .66-6.70 .21  3764 3.83 1.82-8.06 <.001 
Conductc  4181 2.13 1.14-4.00 .02  4181 2.75 .96-7.86 .06  3774 1.38 .47-4.03 .56 
aAdjusted for gender, family structure change (from 7 to 16 years), maternal education, BMI (7 years) and physical activity (16 years).  
bExluding  children  screening  positive   for  CD  symptoms;;  number  of  children  screening  positive  versus  negative   for  “pure”  ADHD symptoms: inattention-hyperactivity, n=78 vs. 
4100 (BMI) and n=61 vs. 3705 (WHR); inattention, n=42 vs. 4136 (BMI) and n=35 vs. 3732 (WHR); hyperactivity, n=86 vs. 4090 (BMI) and n=79 vs. 3685 (WHR).  
cExcluding children screening positive for inattention-hyperactivity   symptoms;;   number   of   children      screening  positive  versus  negative   for   “pure”  CD  symptoms:   n=81  vs.   4100  
(BMI) and n=69 vs. 3705 (WHR).  
 dBMI defined according to the  International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
 eWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
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5.2 Theme II: Investigating whether prenatal factors confer common risk for mental 
health and obesity 
 
5.2.1 Prenatal exposure to synthetic glucocorticoids and mental health in children and 
adolescents  
 
5.2.2 Descriptive analysis  
 
Frequency of mental health problems among sGC cases and controls 
 
Table 5.17 shows the number of sGC cases and controls, within the entire sample, screening 
positive for mental health problems at 8 and 16 years. There were higher percentages of cases 
compared with controls screening positive for each of the mental health outcomes (except 
inattention at 8 years and combined ADHD at 16 years), although these percentage 
differences were only significant for two outcomes – probable psychiatric disturbance and 
antisocial disorder. Due to the small sample size of sGC cases, and consequently small 
number of cases screening positive for mental health problems, mental health scores rather 
than categorical screens were examined throughout the rest of this study, to maximise 
statistical power.  
 
Pregnancy and birth characteristics of sGC cases and controls (unmatched and propensity-
score-matched samples) 
 
Table 5.18 presents the pregnancy and birth characteristics for the cases and controls 
(unmatched), within the entire sample that are available for analysis. Prior to propensity-
score-matching, sGC cases and controls differed significantly on gestational age, birthweight, 
and placental weight. The difference on pre-pregnancy BMI was significant, p=.04 (based on 
all treated cases, n=41). As gestational age and pre-pregnancy BMI precede sGC treatment, 
these covariates were included as predictors in the model used to calculate the propensity 
scores.  
 
Table 5.19 presents the pregnancy and birth characteristics for the propensity-score-matched 
cases and controls. There were no significant differences between the matched sGC cases and 
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controls on any of the socio-demographic or medical factors. Importantly, there were no 
significant differences on gestational age and pre-pregnancy BMI, nor on the mean logit 
propensity score (case mean=-4.35; control mean=-4.36; p=.96) – indicating balance between 
matched cases and controls on treatment-associated confounders.   
 
While all the sGC cases were hospitalised, only one sGC case experienced one of the main 
pregnancy complications related to pre-term birth - gestational hypertension, pre-eclampsia 
or placenta previa (for a full list of recorded pregnancy complications among sGC cases see 
Table A.6). Further analysis showed that this single case did not significantly impact upon the 
mean mental health scores, and consequently was included in all analyses. Out of the 
controls, approximately 15% were hospitalised and 9% experienced the main pregnancy 
complications related to pre-term birth.  
 
Tables 5.18 and 5.19 show that, in both the entire sample and propensity-score-matched 
subsample, sGC cases scored higher on most mental health scores, compared with controls 
(except for inattention at 8 years – both samples, and hyperactivity at 16 years – entire 
sample). However, differences in these raw scores were not statistically significant.  
 
Impact of timing of sGC exposure  
 
Adjusted linear regression analyses show that the interval between prenatal sGC treatment 
and birth (days) had an impact on the association between sGC and mental health, assessed 
using the total Rutter score at 8 years; see Table 5.20. Analyses which included cases 
exposed to sGC ≤ 4 days prior to birth (i.e. on the day of birth, 2, 3 or 4 days prior to birth) 
did not reveal associations between prenatal sGC and the total Rutter score. Associations 
were only detected when analyses included cases exposed >4 days prior to birth. Likewise, 
previous work conducted by our research group and based on data from the entire Finnish 
population shows that prenatal sGC has a significant impact on birth size when exposure is 
>4 days prior to birth (unpublished, Ali Khan et al.). In line with these findings, prenatal sGC 
are long-acting substances (with biological half-lives ranging between 36 and 54 hours) 
[603]; it is thus unlikely that sGC treatment very close to the time of birth could significantly 
impact foetal development as there would not be sufficient time for the drug to induce 
maximum effect. Thus, considering all this information, subsequent analyses only included 
cases exposed >4 days prior to birth.   
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Spearman correlation analyses showed that the interval between prenatal sGC treatment and 
birth (days) had a significant positive association with birthweight (r=.49, p <.01), a non-
significant association with placental weight (r=.10, p=.56) and non-significant negative 
associations with the mental health scores: Rutter total (r=-.20, p=.23), SWAN total (r=-.36, 
p=.06) and YSR total (r=-.14, p=.48).  
 
Attrition analysis  
 
Table 5.21 presents the attrition analyses among sGC cases from birth to 8 years and from 8 
years to 16 years. There were no significant differences by socio-demographic factors and 
birth outcomes between the participants and non-participants at 8 years. Similarly, attrition 
was not characterised by any significant differences from childhood to adolescence by socio-
demographic factors, birth outcomes and mental health (at 8 years).  
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Table 5.17: Mental health positive screening status for sGC casesa (n=37) and controls 
(n=8018), available for analysis.  
Mental health outcomes n (%)  
 Case Control P 
8-y-olds Rutter (teacher report)    
Probable psychiatric disturbance  10 (27.0) 1129 (14.1) .02 
Antisocial disorder  7 (18.9) 718 (9.0) .04 
Neurotic disorder 3 (8.1) 324 (4.0) .21 
Inattention-hyperactivity  5 (13.5) 751 (9.4) .39 
Inattention  1 (2.7) 313 (3.9) .70 
Hyperactivity  3 (8.1) 569 (7.1) .81 
16-y-olds SWAN  (parent report)    
Combined ADHD  1 (3.6) 308 (5.1) .72 
Inattention  2 (7.4) 295 (4.9) .56 
Hyperactivity  2 (7.4) 267 (4.5) .47 
aIncluding cases exposed to prenatal sGC > 4 days prior to birth.  
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Table 5.18: Pregnancy/birth characteristics and mental health scores for the sGC casesa (n=37) and 
controls (n=8018), available for analysis.  
Characteristic Mean ± SD or n (%)  
 Case Control P 
Pregnancy    
Maternal age (years) 29.2 ± 5.0 28.2 ± 5.5 .26 
Family structure   .53 
   Married/co-habiting 36 (97.3) 7606 (95.1)  
   Single/widowed/divorced 1 (2.7) 393 (4.9)  
Education (years)   .90 
   <11  10 (31.3) 2186 (30.2)  
   ≥11 22 (68.8) 5044 (69.8)  
Parity   .63 
   0 11 (29.7) 2713 (34.0)  
   1 16 (43.2) 2658 (33.3)  
   2 6 (16.2) 1439 (18.0)  
   ≥  3 4 (10.8) 1178 (14.7)  
Smoking during pregnancy    .39 
   No 31 (86.1) 6263 (80.4)  
   Yes 5 (13.9) 1531 (19.6)  
Pre-pregnancy BMI 21.1 ± 2.5 22.4 ± 3.5 .07 
Pre-pregnancy BMI categories   .10 
   < 20 14 (37.8) 1916 (24.5)  
   20-24.99 20 (54.1) 4557 (58.3)  
   ≥  25 3 (8.1) 1350 (17.3)  
Main pregnancy complications – risk for pre-term birth    
   Gestational hypertension 0 (.0) 414 (5.2) .15 
   Pre-eclampsia 1 (5.3) 162 (2.0) .78 
   Placenta previa 0 (.0) 13 (.2) .81 
Birth     
Sex   .78 
   Male 19 (51.4) 4083 (50.9)  
   Female 18 (48.6) 3935 (49.1)  
Gestational age at birth (weeks) 37.2 ± 2.0 39.5 ± 1.5 <.001 
Gestational age categories (weeks)   <.001 
   Pre-term birth (< 37) 10 (27.0) 283 (3.5)  
   Term  birth    (≥  37)   27 (73.0) 7733 (96.5)  
Birthweight (g) 3159 ± 688 3591 ± 514 <.001 
Birthweight categories (g)   <.001 
   < 2500 6 (16.2) 184 (2.3)  
   2500-4499 30 (81.1) 7548 (94.1)  
   ≥  4500 1 (2.7) 286 (3.6)  
Placental weight (g) 586 ± 139 648 ± 129 <.001 
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Placental weight categories (g)   .02 
   < 550 14 (37.8) 1564 (19.6)  
   550-719 17 (45.9) 4292 (53.7)  
    ≥  720 6 (16.2) 2143 (26.8)  
Mental health scores    
8-y-olds Rutter (teacher report)    
Total Rutter score 5.2 ± 6.4 3.8 ± 5.0 .10 
Antisocial score 1.1 ± 2.2 .8 ± 1.7 .24 
Neurotic score 1.0 ± 1.3 .7 ± 1.2 .13 
Inattention-hyperactivity score 4.0 ± 1.4 3.9 ± 1.5 .63 
Inattention scoreb .2 ± .5 .3 ± .5 .94 
Hyperactivity scorec 2.8 ± 1.1 2.7 ± 1.1 .48 
16-y-olds SWAN  (parent report)    
Combined ADHD score -19.9 ± 18.2 -19.5 ± 16.7 .91 
Inattention scored -8.5 ± 10.1 -7.5 ± 8.8 .58 
Hyperactivity scoree -11.4 ± 9.5 -12.0 ± 9.0 .73 
16-y-olds YSR (self-report)    
YSR Total Problem score 29.9 ± 16.7 27.0 ± 16.1 .35 
aIncluding cases exposed to prenatal sGC > 4 days prior to birth.  
bScore based on Rutter item number 16 (range 0 to 2). 
cScore based on sum of Rutter items 1 and 3 (range 0 to 4). 
dScore based on sum of 9 SWAN items (range -27 to 27). 
eScore based on sum of 9 SWAN items (range -27 to 27). 
Table adapted from Khalife et al. (2013) [629], permitted under the Creative Commons Attribution 
Licence 3.0. 
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Table 5.19: Pregnancy/birth characteristics and mental health scores for the sGC casesa (n=37) and 
matched controls (n=185); 1:5 matching ratio, matched on logit of propensity score.  
Characteristic Mean ± SD or n (%)  
 Case Control P 
Pregnancy    
Maternal age (years) 29.2 ± 5.0 27.6 ± 5.2 .10 
Family structure   .37 
   Married/co-habiting 36 (97.3) 173 (93.5)  
   Single/widowed/divorced 1 (2.7) 12 (6.5)  
Education (years)   .92 
   <11  10 (31.3) 54 (32.1)  
   ≥11 22 (68.8) 114 (67.9)  
Parity   .98 
   0 11 (29.7) 60 (32.4)  
   1 16 (43.2) 76 (41.1)  
   2 6 (16.2) 32 (17.3)  
   ≥  3 4 (10.8) 17 (9.2)  
Smoking during pregnancy    .17 
   No 31 (86.1) 137 (75.7)  
   Yes 5 (13.9) 44 (24.3)  
Pre-pregnancy BMI 21.1 ± 2.5 20.5 ± 2.6 .22 
Pre-pregnancy BMI categories   .44 
   < 20 14 (37.8) 87 (47.0)  
   20-24.99 20 (54.1) 90 (48.6)  
   ≥  25 3 (8.1) 8 (4.3)  
Main pregnancy complications – risk for pre-term birth    
   Gestational hypertension 0 (.0) 13 (7.1) .23 
   Pre-eclampsia 1 (5.3) 4 (2.2) .41 
   Placenta previa 0 (.0) 1 (.5) .65 
Total sGC dose (mg) 15.4 ± 4.6   
Interval between prenatal sGC exposure and birth (days)    
   6-14 5 (13.5)   
   15-23 0 (.0)   
   24-32 6 (16.2)   
   33-41 8 (21.6)   
   41-49 10 (27.0)   
   50-58 4 (10.8)   
   59-67 2 (5.4)   
   ≥  68 2 (5.4)   
Birth     
Sex   .86 
   Male 19 (51.4) 98 (53.0)  
   Female 18 (48.6) 87 (47.0)  
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Gestational age at birth (weeks) 37.2 ± 2.0 37.5 ± 2.0 .60 
Gestational age categories (weeks)   .90 
   Pre-term birth (< 37) 10 (27.0) 48 (25.9)  
   Term  birth    (≥  37)   27 (73.0) 137 (74.1)  
Birthweight (g) 3159 ± 688 3151  ± 636 .95 
Birthweight categories (g)   .59 
   < 2500 6 (16.2) 23 (12.4)  
   2500-4499 30 (81.1) 160 (86.5)  
   ≥  4500 1 (2.7) 2 (1.1)  
Placental weight (g) 586 ± 139 588 ± 135 .96 
Placental weight categories (g)   .90 
   < 550 14 (37.8) 75 (40.8)  
   550-719 17 (45.9) 84 (45.7)  
    ≥  720 6 (16.2) 25 (13.6)  
Mental health scores    
8-y-olds Rutter (teacher report)    
Total Rutter score 5.2 ± 6.4 4.2 ± 5.4 .30 
Antisocial score 1.1 ± 2.2 .9 ± 1.9 .50 
Neurotic score 1.0 ± 1.3 .8 ± 1.4 .66 
Inattention-hyperactivity score 4.0 ± 1.4 3.9 ± 1.6 .58 
Inattention scoreb .2 ± .5 .3 ± .6 .81 
Hyperactivity scorec 2.8 ± 1.1 2.6 ± 1.1 .35 
16-y-olds SWAN  (parent report)    
Combined ADHD score -19.9 ± 18.2 -19.2 ± 17.8 .76 
Inattention scored -8.5 ± 10.1 -7.9 ± 9.0 .78 
Hyperactivity scoree -11.4 ± 9.5 -11.3 ± 9.7 .76 
16-y-olds YSR (self-report)    
YSR Total Problem score 29.9 ± 16.7 26.7 ± 16.3 .53 
aIncluding cases exposed to prenatal sGC > 4 days prior to birth.  
bScore based on Rutter item number 16 (range 0 to 2). 
cScore based on sum of Rutter items 1 and 3 (range 0 to 4). 
dScore based on sum of 9 SWAN items (range -27 to 27). 
eScore based on sum of 9 SWAN items (range -27 to 27). 
Table adapted from Khalife et al. (2013) [629], permitted under the Creative Commons Attribution 
Licence 3.0. 
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Table 5.20: Linear multiple regression to examine the impact of timing of sGC exposurea  on the association between 
prenatal sGC treatment and the total Rutter score at 8 years, adjusted for relevant confoundersb.   
Interval between prenatal sGC 
exposure and birth (days) 
Prenatal glucocorticoid (GC) treatment (case/control) 
 Unadjusted  Adjustedb 
 B 95% CI for B β P  B 95% CI for B β P 
1 1.06   -.96-3.08      .07   .30    5.87   -1.22-12.96      .39   .10   
2 1.06 -.96-3.08 .07 .30  5.87 -1.22-12.96 .39 .13 
3 1.03 -.99-3.06 .07 .32  5.71 -1.70-13.12 .38 .13 
4 1.03 -.99-3.06 .07 .32  5.71 -1.70-13.12 .38 .13 
5 1.07 -.95-3.10 .08 .30  8.34 .23-16.45 .56 .04 
aInterval between prenatal sGC exposure and birth (days).  
bAdjusted for sex, birthweight, placental weight, socio-demographic factors (maternal age, education and  family structure), 
and medical factors (total prenatal sGC dose, interval between prenatal sGC exposure and birth (days), smoking during 
pregnancy and parity). 
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Table 5.21: Attrition analyses from birth to 8 years and 8 to 16 years, among sGC casesa.  
 Mean ± SD and n (%) 
 All at birth 
(n=41) 
Dropout (8y) 
(n=4) 
Remain (8y) 
(n=37) 
P Dropout (16y) 
(n=9) 
Remain (16y) 
(n=29b) 
P 
Socio-demographic factors (at birth)        
Family structure    .74   .07 
   Married/co-habiting 40 (97.6) 4 (100.0) 36 (97.3)  8 (88.9) 29 (100.0)  
   Single/widowed/divorced 1 (2.4) 0 (.0) 1 (2.7)  1 (11.1) 0 (.0)  
Education    .35   .08 
   <11 years 10 (29.4) 0 (.0) 10 (31.3)  4 (57.1) 6 (23.1)  
   ≥11 years 24 (70.6) 2 (100.0) 22 (68.8)  3 (42.9) 20 (76.9)  
Birth outcomes        
Sex    .96   .25 
   Male 21 (51.2) 2 (50.0) 19 (51.4)  6 (66.7) 13 (44.8)  
   Female 20 (48.8) 2 (50.0) 18 (48.6)  3 (33.3) 16 (55.2)  
Birthweight (g) 3101 ± 738 2565 ± 1075 3159 ± 688 .12 3023 ± 798 3128 ± 761 .72 
Placental weight (g) 597 ± 202 690 ± 551 586 ± 139 .34 567 ± 159 583 ± 142 .78 
Mental health (8-y-olds)        
Total Rutter score    5.2  ±  6.4  6.2 ± 7.8 4.9 ± 6.0 .60 
Antisocial score   1.2 ± 2.2  1.4 ± 2.8 1.0 ± 2.0 .64 
Neurotic score   .9 ± 1.3  1.4 ± 1.3 .8 ± 1.3 .23 
Inattention-hyperactivity score   4.1 ± 1.4  4.2 ± 1.6 4.0 ± 1.4 .65 
Inattention score   .3 ± .5  .2 ± .4 .3 ± .5 .89 
Hyperactivity score   2.8 ± 1.1  3.0 ± 1.4 2.7 ± 1.0 .50 
aIncluding cases exposed to prenatal sGC > 4 days prior to birth. 
bAt 16 years, there was one extra participant who did not take part in the 8 year follow-up.  
Table reproduced from Khalife et al. (2013) [629], permitted under the Creative Commons Attribution Licence 3.0. 
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5.2.3 Association between prenatal sGC treatment and mental health in children and 
adolescents 
 
Linear multiple regression results  
 
Table 5.22 shows the adjusted linear multiple regression results for the association between 
prenatal sGC treatment and mental health outcomes in children and adolescents. The analysis 
was adjusted for sex, birthweight, placental weight, socio-demographic factors (maternal age, 
education and family structure), and medical factors (total prenatal sGC dose, interval 
between prenatal sGC exposure and birth (days), parity and smoking during pregnancy). At 8 
years, there were significant positive associations between prenatal sGC treatment and the 
total Rutter and inattention scores. The other mental health outcomes also showed positive 
associations with sGC treatment, although these did not reach significance (the antisocial 
score was close to significance, with p=.05). The associations for the total Rutter, inattention-
hyperactivity, inattention and antisocial scores showed moderate effect sizes, while those for 
the hyperactivity and neurotic scores showed large and small effect sizes, respectively. 
Similar to the results at 8 years, there were consistent significant positive associations 
between prenatal sGC treatment and each of the mental health scores at 16 years; however, 
these did not reach statistical significance.  
 
Mixed-effects model results  
 
Table 5.23 shows the results of the mixed-effects model, which were very similar to those of 
the first analysis (linear multiple regression). Prenatal sGC treatment showed significant 
positive associations with the total Rutter and inattention scores at 8 years, and was 
consistently associated with higher scores on all other outcomes at 8 and 16 years. 
Additionally, this method revealed neurotic scores were also elevated among sGC cases in 
comparison to controls at 8 years.  
 
Figure 5.10 is a bar chart which summarises the findings, showing the mental health mean z-
scores for the sGC cases and controls. The mean z-scores for the sGC cases were higher than 
controls on the total scores for the Rutter (at 8 years), SWAN (at 16 years) and YSR (at 16 
years) scales.  
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Table 5.22: Linear multiple regression results for the association between prenatal glucocorticoid treatment (casesa, n=37 (at 8y) n=29 
(at 16y), and controls balanced on gestational age and pre-pregnancy BMI, by means of logit of propensity score; 1:5 matching ratio) 
and mental health outcome scores for children and adolescents, adjusted for relevant confoundersb.   
Mental Health Prenatal glucocorticoid (GC) treatment (case/control) 
 Unadjusted  Adjustedb 
 B 95% CI for B β P  B 95% CI for B β P Cohen’s  f2 
8-y-olds Rutter (teacher report)           
Total Rutter score 1.07     -.95-3.10      .08   .30  8.34       .23-16.45      .56   .04    .23 
Antisocial score .28 -.45-1.00 .05 .45  2.93 -.04-5.9 .54 .05 .20 
Neurotic score .11 -.39-.62 .03 .66  1.55 -.55-3.67 .42 .15 .11 
Inattention-hyperactivity score .21 -.40-.72 .04 .58  2.16 -.03-4.35 .52 .05 .33 
Inattention scorec -.02 -.23-.18 -.02 .81  .97 .16-1.80 .64 .02 .23 
Hyperactivity scored .19 -.21-.58 .07 .35  1.19 -.29-2.67 .41 .12 .36 
16-y-olds SWAN  (parent report)           
Combined ADHD score -1.15 -8.48-6.19 -.03 .76  16.20 -14.65-47.04 .34 .30 .11 
Inattention scoree -.53 -4.31-3.24 -.02 .78  9.00 -6.42-24.41 .37 .25 .11 
Hyperactivity scoref -.61 -4.60-3.38 -.02 .76  7.20 -9.85-24.26 .27 .41 .10 
16-y-olds YSR (self-report)           
YSR Total Problem score 2.10 -4.55-8.74 .05 .53  2.30 -26.43-31.00 .05 .88 .12 
aIncluding cases exposed to prenatal sGC > 4 days prior to birth. 
bAdjusted for sex, birthweight, placental weight, socio-demographic factors (maternal age, education and  family structure), and 
medical factors (total prenatal sGC dose, interval between prenatal sGC exposure and birth (days), smoking during pregnancy and 
parity). 
cScore based on Rutter item number 16 (range 0 to 2). 
dScore based on sum of Rutter items 1 and 3 (range 0 to 4). 
eScore based on sum of 9 SWAN items (range -27 to 27). 
fScore based on sum of 9 SWAN items (range -27 to 27). 
Table reproduced from Khalife et al. (2013) [629], permitted under the Creative Commons Attribution Licence 3.0. 
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Table 5.23: Mixed-effects model for the association between prenatal glucocorticoid treatment (casea vs. control, matched for gestational age 
and sex) and mental health outcome scores for children and adolescents, adjusted for relevant confoundersb. 
Mental health Prenatal glucocorticoid (GC) treatment (case/control) 
 Estimates  Pair-wise comparisons 
 n Means SE 95% CI  Mean difference (B) SE 95% CI P 
8-y-olds Rutter (teacher report)          
Total Rutter score      8.04 3.34    1.49-14.60           .02 
GC control 6059 3.59 .32    2.90-4.28                      
GC case 37 11.63 3.33 5.11-18.15      
Antisocial score      2.15 1.12 -.04-4.35 .05 
GC control 6065 .75 .11 .50-1.00      
GC case 37 2.90 1.11 .72-5.01      
Neurotic score      2.48 .84 .84-4.12 .00 
GC control 6076 .65 .02 .61-.70      
GC case 37 3.13 .83 1.50-4.76      
Inattention-hyperactivity score      1.53 1.01 -.43-3.51 .13 
GC control 6069 3.86 .11 3.62-4.09      
GC case 37 5.39 1.00 3.43-7.36      
Inattention scorec      .79 .35 .12-1.47 .02 
GC control 6079 .22 .03 .16-.29      
GC case 37 1.01 .34 .34-1.69      
Hyperactivity scored      .74 .73 -.69-2.17 .31 
GC control 6075 2.63 .08 2.46-2.81      
GC case 37 3.37 .73 1.95-4.80      
16-y-olds SWAN (parent report)          
Combined ADHD score      13.92 12.83 -11.22-39.06 .28 
GC control 4950 -20.23 .86 -22.10- -18.36      
GC case 29 -6.31 12.77 -31.34-18.72      
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Inattention scoree      8.42 6.80 -4.91-21.74 .22 
GC control 4950 -8.00 .49 -9.05- -6.94      
GC case 29 .42 6.77 -12.85-13.69      
Hyperactivity scoref      5.47 6.99 -8.24-19.17 .43 
GC control 4950 -12.22 .38 -13.05- -11.38      
GC case 29 -6.75 6.96 -20.39-6.89      
16-y-olds YSR (self-report)          
YSR Total Problem score      16.39 12.05 -7.24-40.02 .17 
GC control 5079 25.52 1.34 22.67-28.36      
GC case 29 41.91 12.03 18.33-65.49      
aIncluding cases exposed to prenatal sGC > 4 days prior to birth. 
bAdjusted for birthweight, placental weight, socio-demographic factors (maternal age, education and family structure), and medical factors 
(total prenatal sGC dose, interval between prenatal sGC exposure and birth (days), smoking during pregnancy, parity and pre-pregnancy BMI). 
cScore based on Rutter item number 16 (range 0 to 2).  
dScore based on sum of Rutter items 1 and 3 (range 0 to 4). 
eScore based on sum of 9 SWAN items (range -27 to 27). 
fScore based on sum of 9 SWAN items (range -27 to 27). 
Table reproduced from Khalife et al. (2013) [629], permitted under the Creative Commons Attribution Licence 3.0. 
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Figure 5.10: Mental health mean z-scores (SE) for sGC cases and controls 
at 8 years (cases, n=37; controls, n=6059) and 16 years (SWAN: cases, 
n=29; controls, n=4950; YSR: cases, n=29; controls=5079).  
*p<.05 
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5.2.4 Mediation analysis of the sGC-mental health association by birth and placental 
size 
 
The bootstrap method was used to examine mediation of the sGC-mental health association 
by birthweight and placental size (placental weight, surface area and placental-to-birth-
weight  ratio).  Figure  5.11  depicts  each  pathway  (a,  b  and  c’)   in   the  mediation  models,  with  
the examples of birthweight and placental weight as potential mediators. Table 5.24 provides 
the coefficients for each pathway in all the mediation models. As expected, the mediation 
analysis showed that sGC was associated with child mental health (the total Rutter score), 
before and after controlling for the potential mediator (paths   c   and   c’,   respectively).  
Interestingly, there was a significant negative association between sGC and birthweight, with 
sGC treatment related to a decrease of approximately 1120g in birthweight (path a). Further, 
sGC was associated with larger placental-to-birthweight ratio - by approximately 5.4%, and 
larger placental weight - by approximately 137g, although the latter did not quite reach 
statistical significance (p=.05). Neither birthweight nor placental size was associated with 
child mental health (path b).  
 
Bootstrapping showed that there were no significant indirect effects (path ab) of birthweight 
(e.g. for total Rutter score, bootstrap estimate=.69, percentile 95% CI: -1.34-3.04) or 
placental weight (e.g. for total Rutter score, bootstrap estimate=.24, percentile 95% CI: -1.04-
1.98) on the sGC-mental health pathway; see Table 5.24. Indirect effects of placental surface 
area and placental-to-birth-weight ratio were also not detected; see Table 5.24. Thus, there 
was no evidence for mediation by birthweight or placental size.  
 
5.2.5 Power analysis 
 
The post hoc power analysis demonstrated that the analysis was sufficiently powered to 
detect significant differences at 8 years (e.g. for total Rutter score model, 1-β=.80, with an 
effect size f2=.23 and p=.05), but was under-powered at 16 years (e.g. for combined ADHD 
score model, 1-β=.39, with an effect size f2=.11 and p=.05). 
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Figure 5.11: Mediation model for the association between prenatal sGC treatment and child 
mental health.  
Values refer to B coefficient estimates.  
*p<.05, ***p<.001. 
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Table 5.24: Bootstrapping for mediation analysis of birthweight and placental size on the association between sGC (casesa, n=37; controls, n=185), and child mental health (total 
Rutter score), adjusted for relevant confoundersb. 
Mediator  Pathway coefficients  Bootstrapping for indirect effect 
  Path a  Path b  Path c  Path  c’  Path ab  
  B SE P  B SE P  B SE P  B SE P  Data Boot SE of 
Boot 
Percentile 
95% CI 
Birthweight  
(1000g)c 
 -1.12 .31 <.001  -.50 .98 .61  8.90 3.95 .03  8.34 4.11 .04  .56 .69 1.08 -1.34-3.04 
Placental weight  
(100g)d 
 1.37 .71 .05  .10 .44 .82  8.48 4.05 .04  8.34 4.11 .04  .14 .24 .74 -1.04-1.98 
Placental surface 
area (10cm2)e 
 5.11 4.32 .24  -.09 .07 .24  7.95 4.05 .05  8.40 4.07 .04  -.45 -.48 .68 -2.23-.49 
Placental-to-
birth-weight ratio 
 5.40 2.40 .03  -.01 .13 .96  8.94 3.93 .02  8.98 4.00 .03  -.03 .05 .75 -1.41-1.76 
aIncluding cases exposed to prenatal sGC > 4 days prior to birth. 
bAdjusted for  placental weight (in model c), birthweight (in models d and e), socio-demographic factors (maternal age, education and family structure), and medical factors (total 
prenatal sGC dose, interval between prenatal sGC exposure and birth (days), smoking during pregnancy, parity and pre-pregnancy BMI).  
“Data”  is  the  indirect  effect  estimate  calculated  from  the  original  sample.   
“Boot”  is  the  mean  of  the  indirect  effect  estimates  calculated from all bootstrap samples; based on 5000 bootstrap samples.  
“Path  a”  is  the  effect  of  sGC  on  the  respective  mediator. 
“Path  b”  is  the  effect  of  the  respective  mediator  on  child  mental  health. 
“Path  c”  is  the  total  effect  of  sGC  on  child  mental  health.   
“Path  c’”  is  the  direct  effect  of  sGC  on  child  mental  health,  after  controlling  for  the  respective  mediator.   
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5.2.6 Prenatal exposure to synthetic glucocorticoids and obesity in children and 
adolescents  
 
5.2.7 Descriptive analysis  
 
Frequency of obesity among sGC cases and controls 
 
Table 5.25 shows the mean BMI and WHR, as well as frequency distributions of categorised 
BMI and WHR, by sGC cases and controls, at 8 and 16 years. The sGC cases and controls 
did not differ on BMI or WHR.  It is important to note there were a very small number of 
sGC cases with available BMI/WHR data (n=31 at 8 years for BMI, and n=25 for BMI and 
n=27 for WHR at 16 years), and thus these analyses should be viewed as exploratory.  
 
5.2.8 Association between prenatal sGC treatment and obesity in children and 
adolescents  
 
Table 5.26 shows the adjusted mixed-effects model results for the association between 
prenatal sGC treatment and obesity in children and adolescents. The analysis was adjusted for 
birthweight, placental weight, socio-demographic factors (maternal age, education and family 
structure), and medical factors (total prenatal sGC dose, interval between prenatal sGC 
exposure and birth (days), pre-pregnancy BMI, parity and smoking during pregnancy). 
Compared with controls, sGC cases had consistently higher BMI and WHR, at 8 and 16 
years, although these associations did not reach statistical significance. 
 
5.2.9 Power analysis 
 
A post hoc power analysis demonstrated that the analysis was under-powered to detect 
significant differences at 8 years (for BMI model, 1-β=.60,   with   an   effect   size d=.35 and 
p=.05) and 16 years (for BMI model, 1-β=.62,  with  an  effect  size d=.40 and p=.05).  
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Table 5.25: Indices of obesity for sGC casesa and controls, available for analysis.   
Obesity outcomes Mean ± SD or n (%)   
 Case Control P 
8-y-olds:  sGC casesa (n=31) and controls (n=5224)    
BMI 16.3 ± 1.6 16.1 ±2.1 .75 
Body weight defined by BMIb   .44 
Normal 28 (90.3) 4349 (83.3)  
Overweight 3 (9.7) 673 (12.9)  
Obese 0 (0.0) 202 (3.9)  
16-y-olds: BMI; sGC casesa (n=25) and controls (n=4990)  
                WHR; sGC casesa (n=27) and controls (n=4814) 
   
BMI 21.2 ± 3.6 21.2 ± 3.5 .92 
Body weight defined by BMIb   .99 
Normal 21 (84.0) 4231 (84.8)  
Overweight 3 (12.0) 589 (11.8)  
Obese 1 (4.0) 170 (3.4)  
WHR .80 ± .05 .80 ± .06 .94 
Abdominal obesity defined by WHRc   .78 
No 26 (96.3) 4579 (95.1)  
Yes 1 (3.7) 235 (4.9)  
aIncluding cases exposed to prenatal sGC > 4 days prior to birth.  
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
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Table 5.26: Mixed-effects model for the association between prenatal glucocorticoid treatment (casea vs. control, matched for gestational 
age and sex) and obesity outcomes for children and adolescents, adjusted for relevant confoundersb. 
Obesity outcomes Prenatal glucocorticoid (GC) treatment (case/control) 
 Estimates  Pair-wise comparisons 
 n Means SE 95% CI  Mean difference (B) SE 95% CI P 
8-y-olds           
BMI      2.23 1.29 -.30-4.75    .08 
GC control 4942 16.32 .08 16.13-16.51         
GC case 30 18.54 1.28 16.04-21.05      
16-y-olds           
BMI      3.72 2.58 -1.34-8.78 .15 
GC control 4713 21.13 .05 21.04-21.23      
GC case 24 24.85 2.57 19.82      
WHR      .01 .05 -.09-.10 .91 
GC control 4250 .80 .01 .79-.82      
GC case 22 .81 .05 .71-.90      
aIncluding cases exposed to prenatal sGC > 4 days prior to birth. 
bAdjusted for birthweight, placental weight, socio-demographic factors (maternal age, education and family structure), and medical factors 
(total prenatal sGC dose, interval between prenatal sGC exposure and birth (days), smoking during pregnancy, parity and pre-pregnancy 
BMI). 
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5.2.10 Investigation of placental size in conferring common risk for mental health and 
obesity 
 
5.2.11 Descriptive analysis 
 
Frequency distributions for birth, mental health and obesity outcomes 
 
Table 5.27 shows the frequency distributions for birth and mental health/obesity outcomes. 
Of the children included, the mean gestational age at birth was 39.4 weeks and 51.3% were 
male. The mean birthweight was 3575g, whilst mean placental weight, mean placental 
surface area and mean placental-to-birth-weight ratio were 646g, 335cm² and 18.2%, 
respectively. The mean placental weight and surface area for males were respectively 12g and 
3cm² greater than females, whereas the mean placental-to-birthweight ratio was 0.3% greater 
in females. For the three categories of placental weight, <550g, 550-719g   and   ≥720g,   the  
weight ranges from the mean were 422-530g, 578-676g and 726-902g, respectively, for the 
entire sample.  
 
Variables associated with placental size 
 
Table 5.28 shows the correlations of placental size (placental weight, surface area and 
placental-to-birth-weight ratio) with mental health/obesity outcomes and potential 
confounders. Placental surface area was positively associated with the antisocial disorder 
score; there were no other significant correlations between placental size and mental health 
scores. Placental weight and surface area were positively associated with BMI at 8 and 16 
years, and with WHR at 16 years. Placental-to-birth-weight ratio was positively associated 
with BMI at 8 and 16 years. Overall, there were significant associations between placental 
size and sex, gestational age, birthweight, maternal age, family structure, maternal education, 
smoking during pregnancy, parity, pre-pregnancy BMI, gestational weight gain, gestational 
diabetes, pre-eclampsia, feelings during pregnancy and desirability of pregnancy. The 
association between placental size and social class was close to significance. Variables which 
were associated with both the predictor (placental size) and the outcomes (mental health 
and/or obesity) were included as confounders in the main analyses. Although mental health 
scores   were   weakly   correlated   with   “feelings   during   pregnancy”   and   “desirability   of  
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pregnancy”,  we  did  not  consider  these  variables further as these are crude and non-validated 
markers of maternal stress during pregnancy. This resulted in the following variables selected 
as confounders: sex, gestational age, birthweight, socio-demographic factors (maternal age, 
maternal education, family structure and social class) and medical factors (smoking during 
pregnancy, parity, pre-pregnancy BMI and gestational weight gain; gestational diabetes was 
additionally adjusted for in analyses involving obesity). 
 
Table 5.29 shows the ANOVA results for the associations between mean placental weight 
and each of the confounders and mental health/obesity outcomes. There were significant 
associations between mean placental weight and each of the potential confounders, apart 
from maternal education. For the mental health outcomes, mean placental weight was 
significantly greater amongst 8-year-olds screening positive for antisocial disorder (males and 
entire sample), reduced amongst 8-year-olds with neurotic disorder (females) and elevated 
amongst 16-year-olds with inattention symptoms (entire sample). For the obesity outcomes, 
mean placental weight was significantly greater amongst 8 and 16-year-olds with 
overweight/obese BMI (entire sample and both males and females separately). There was a 
trend for increased mean placental weight amongst 16-year-olds with abdominal obesity 
(entire sample and both males and females separately), but this did not reach statistical 
significance.  
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Table 5.27: Birth and child/adolescent characteristics presented as means ± SD or n (%). 
Characteristic Mean ± SD or n (%)  n 
 All Male Female   
Birth outcomes      
Sex  4596 (51.3) 4358 (48.7)  8954 
Birthweight (g) 3575 ± 534 3638 ± 537 3509 ± 523  8954 
   < 2500 2044 ± 449 2025 ± 459 2059 ± 441  248 
   2500-4499 3578 ± 424 3626 ± 420 3528 ± 422  8388 
   ≥  4500 4704 ± 194 4707 ± 197 4697 ± 190  318 
Gestational age at birth (weeks) 39.4 ± 1.6 39.4 ± 1.6 39.5 ± 1.6  8950 
   Preterm birth (< 37 weeks) 34.4 ± 2.3 34.4 ± 2.3 34.3 ± 2.3  366 
   Term  birth    (≥  37  weeks)   39.6 ± 1.2 40.0 ± 1.2 40.0 ± 1.2  8584 
Placental weight (g) 646 ± 132 652 ± 133 640 ± 131  8934 
   < 550 1798 (20.1) 874 (19.1) 924 (21.3)  8934 
   550-719 4774 (53.4) 2425 (52.9) 2349 (54.0)  8934 
    ≥  720 2362 (26.4) 1287 (28.1) 1075 (24.7)  8934 
Placental surface area (cm²) 335 ± 70 337 ± 70 334 ± 69  8821 
Placental-to-birth-weight ratio 18.2 + 3.1 18.0 ± 3.1 18.3 ± 3.0  8934 
Mental health outcomes       
8-y-olds (teacher report)      
Ruttera      
Probable psychiatric disturbance             1140 (14.1) 801  (19.5) 339 (8.6)  8065 
Antisocial disorder 725 (9.0) 570 (13.9) 155 (4.0)  8065 
Neurotic disorder 328 (4.1) 171 (4.2) 157 (4.0)  8065 
Inattention-hyperactivity 756 (9.4) 576 (14.0) 180 (4.5)  8080 
Inattentionb 315 (3.9) 256 (6.2) 59 (1.5)  8088 
Hyperactivityc 575 (7.1) 468 (11.4) 107 (2.7)  8086 
16-y-olds (parent report)      
SWANa       
Combined ADHD  349 (5.3) 231 (7.0) 118 (3.5)  6607 
Inattentiond 332 (5.1) 230 (7.1) 102 (3.1)  6500 
Hyperactivity-impulsivitye 306 (4.7) 197 (6.1) 109 (3.3)  6467 
Obesity outcomes      
8-y-olds      
Body weight defined by BMIf      
Normal 5758 (82.7) 2995 (84.7) 2763 (80.7)  6962 
Overweight 916 (13.2) 419 (11.8) 497 (14.5)  6962 
Obese 288 (4.1) 123 (3.5) 165 (4.8)  6962 
16-y-olds      
Body weight defined by BMIf      
Normal 5667 (84.7) 2729 (83.2) 2938 (86.1)  6692 
Overweight 787 (11.8) 416 (12.7) 371 (10.9)  6692 
Obese 238 (3.6) 136 (4.1) 102 (3.0)  6692 
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Abdominal obesity defined by WHRg      
No 6109 (95.0) 3004 (95.0) 3105 (95.0)  6429 
Yes 320 (5.0) 157 (5.0) 163 (5.0)  6429 
aAssessment of symptoms based on fulfilment of criteria according to the Rutter B2/Strengths and 
Weaknesses of ADHD symptoms and Normal behaviour (SWAN) scale. 
bAssessment based on Rutter item number 16.  
cAssessment based on sum of Rutter items 1 and 3.  
dSWAN subscale consisting of sum of 9 items.  
eSWAN subscale consisting of sum of 9 items.  
fBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-
offs. 
gWaist-hip ratio (WHR), dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
Table adapted from Khalife et al. (2012) [643], permitted under the Creative Commons 
Attribution Licence 3.0. 
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Table 5.28: Correlations of placental size with potential confounders and mental health/obesity outcomes.  
 Placental weight (g)  Placental surface area 
(cm2) 
 Placental-to-birth-
weight ratio 
 n r p  n r p  n r p 
Potential 
confounders: 
           
Sex 8934 -.04 <.001  8821 -.03 .01  8934 .05 <.001 
Birthweight (g) 8934 .65 <.001  8821 .52 <.001  8934 -.19 <.001 
Gestational age 
(weeks) 
8930 .20 <.001  8817 .19 <.001  8930 -.33 <.001 
Maternal age (years) 8934 .07 <.001  8821 .08 <.001  8934 .02 .05 
Maternal education 7855 .02 .09  7766 -.02 .08  7855 .04 <.01 
Family structure 8908 -.05 <.001  8796 -.03 .01  8908 .01 .32 
Family social class 8646 -.02 .08  8536 -.02 .07  8646 .01 .34 
Maternal height 
(cm) 
8848 .09 <.001  8737 .06 <.001  8848 -.05 <.001 
Pre-pregnancy 
weight (kg) 
8744 .22 <.001  8635 .12 <.001  8744 .07 <.001 
Pre-pregnancy BMI 8708 .19 <.001  8600 .10 <.001  8708 .10 <.001 
Gestational weight 
gain (kg) 
8302 .14 <.001  8197 .13 <.001  8302 -.07 <.001 
Parity 8895 .09 <.001  8783 .04 <.001  8895 .03 <.01 
Smoking during 
pregnancy 
8696 -.05 <.001  8588 -.02 .16  8696 .07 <.001 
Alcohol during 
pregnancy  
8499 -.02 .10  8391 .02 .11  8499 .02 .09 
Gestational 
hypertension 
8800 -.02 .13  8689 -.01 .25  8800 .01 .40 
Pre-eclampsia 8800 -.05 <.001  8689 -.04 <.001  8925 .03 <.01 
Gestational diabetes 8925 .05 <.001  8812 .03 <.01  8925 .03 <.01 
Feelings 7218 .05 <.001  7129 .02 .07  7218 .05 <.001 
Occupational stress 
   Physical strain 
   Intellectual strain 
 
6550 
6285 
 
-.01 
-.00 
 
.26 
.91 
  
6470 
6207 
 
.01 
.00 
 
.62 
.79 
  
6550 
6285 
 
-.02 
.02 
 
.17 
.08 
Desirability of 
pregnancy 
7638 -.03 .02  7544 -.03 <.01  7638 .00 .88 
Mental health 
outcomes: 
           
8-y-olds  Rutter 
scores (teacher 
report) 
           
Probable psychiatric 
disturbance 
8046 .01 .30  7948 .02 .10  8046 .01 .51 
Inattention 8069 .01 .25  7971 .00 .73  8069 .02 .04 
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Hyperactivity 8067 .02 .15  7969 .02 .15  8067 .00 .98 
Inattention-
hyperactivity 
8054 .01 .24  7956 .01 .29  8054 .01 .62 
Neurotic disorder 8066 .01 .54  7969 .01 .23  8066 .01 .32 
Antisocial disorder 8059 .02 .07  7961 .03 <.01  8059 -.01 .45 
16-y-olds SWAN 
scores (parent 
report) 
           
Inattention 6594 .01 .39  6512 .01 .65  6594 .01 .32 
Hyperactivity-
impulsivity 
6594 .01 .44  6512 .00 .79  6594 .02 .23 
Combined 6594 .01 .38  6512 .01 .70  6594 .02 .24 
Obesity Outcomes:            
8-y-olds            
BMI 6945 .14 .00  6868 .10 <.001  6945 .03 .01 
16-y-olds            
BMI 6675 .11 .00  6598 .07 <.001  6675 .04 <.001 
WHR 6413 .04 <.01  6338 .03 .02  6413 -.01 .39 
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Table 5.29: Mean placental weight according to potential confounders and child/adolescent mental health and obesity outcomes.  
Potential confounders and 
mental health/obesity outcomes 
Mean placental weight (g) (SD) 
 n (%) All  n (%) Male  n (%) Female 
Potential Confounders         
Birthweight (g) 8934   4586   4348  
   < 2500 247 (2.8) 448 (106)  110 (2.4) 455 (108)  137 (3.2) 443 (105) 
   2500-4499 8370 (93.7) 644 (121)  4259 (92.9) 646 (121)  4111 (94.5) 641 (121) 
   ≥  4500 317 (3.5) 860 (138)  217 (4.7) 837 (139)  100 (2.3) 869 (136) 
   pa  <.001   <.001   <.001 
Gestational age at birth (weeks) 8930   4582   4348  
   < 37 363 (4.1) 524 (163)  189 (4.1) 555 (171)  174 (4.0) 528 (154) 
   37-41 8226 (92.1) 650 (129)  4213 (92) 655 (130)  4013 (92.3) 644 (127) 
   ≥  42 341 (3.8) 600 (127)  180 (3.9) 663 (124)  161 (3.7) 656 (131) 
   pa  <.001   <.001   <.001 
Maternal age (years) 8934   4586   4348  
   < 20 655 (7.3) 636 (125)  336 (7.3) 645 (120)  319 (7.3) 626 (129) 
   20-34 7105 (79.5) 645 (131)  3635 (79.3) 651 (133)  3470 (79.8) 639 (129) 
   ≥  35 1174 (13.1) 654 (142)  615 (13.4) 657 (143)  559 (12.9) 652 (141) 
   pa  .01   .38   .02 
Maternal education (years) 7855   3999   3856  
   < 11 2377 (30.3) 651 (138)  1184 (29.6) 657 (136)  1193 (30.9) 645 (139) 
   ≥  11 5478 (69.7) 645 (127)  2815 (70.4) 651 (129)  2663 (69.1) 640 (125) 
   pa  .09   .17   .27 
Family structure  8908   4570   4338  
   Married/cohabiting  8453 (94.9) 647 (132)  4347 (95.1) 654 (133)  4106 (94.7) 641 (131) 
   Single/widowed/divorced   455 (5.1) 620 (127)  223 (4.9) 614 (123)  232 (5.3) 625 (130) 
    pa  <.001   <.001   .07 
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Family social class (by occupation) 8646   4438   4208  
    I         
    Professional 521 (6.0) 647 (132)  265 (6.0) 647 (142)  256 (6.1) 647 (121) 
    Upper white collar 1723 (20.0) 648 (127)  853 (19.2) 659 (131)  870 (20.7) 638 (122) 
    Lower white collar 3476 (40.2) 644 (131)  1802 (40.6) 651 (130)  1674 (39.8) 638 (131) 
    Farmer  ≥  8  hectares 348 (4.0) 666 (146)  178 (4.0) 676 (154)  170 (4.0) 655 (136) 
    II         
    Unskilled worker 2525 (29.2) 642 (133)  1319 (29.7) 645 (131)  1206 (28.7) 640 (135) 
    Farmer < 8 hectares 53 (.6) 672 (178)  21 (.5) 731 (202)  32 (.7) 633 (151) 
    pa  .03   <.01   .57 
Parity 8895   4565   4330  
   0 3029 (34.1) 623 (128)  1551 (34) 629 (128)  1478 (34.1) 617 (128) 
   1 2969 (33.4) 653 (132)  1485 (32.5) 658 (134)  1484 (34.3) 647 (130) 
   2 1604 (18.0) 660 (134)  863 (18.9) 669 (136)  741 (17.1) 650 (126) 
   ≥  3 1293 (14.5) 666 (132)  666 (14.6) 666 (133)  627 (14.5) 666 (136) 
   pa  <.001   <.001   <.001 
Pre-pregnancy BMI (kg/m2) 8708   4478   4230  
   < 20 2136 (24.5) 612 (121)  1138 (25.4) 618 (120)  998 (23.6) 606 (123) 
   20-24.99 5078 (58.3) 649 (130)  2576 (57.5) 655 (132)  2502 (59.1) 643 (127) 
   ≥  25 1494 (17.2) 683 (142)  764 (17.1) 688 (142)  730 (17.3) 677 (141) 
   pa  <.001   <.001   <.001 
Gestational weight gain (kg) 8262   4244   4018  
   < 11 1911 (23.1) 620 (132)  909 (21.4) 623 (137)  1002 (25.0) 617 (128) 
   11-16.99 4310 (52.2) 645 (126)  2223 (52.4) 650 (125)  2087 (51.9) 640 (126) 
   ≥  17 2041 (24.7) 673 (136)  1112 (26.2) 679 (136)  929 (23.1) 666 (130) 
   pa  <.001   <.001   <.001 
Smoking during pregnancy 8696   4455   4241  
   No 6989 (80.4) 649 (131)  3564 (80.0) 654 (133)  3425 (80.8) 644 (130) 
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   Yes 1707 (19.6) 633 (130)  891 (20.0) 638 (131)  816 (19.2) 627 (129) 
   pa  <.001   <.01   <.01 
Number of cigarettes (per  day) 939   500   439  
   < 10 cigarettes  556 (59.2) 630 (121)  293 (58.6) 634 (116)  263 (59.9) 626 (127) 
   ≥  10  cigarettes   383 (40.8) 631 (138)  207 (41.4) 641 (138)  176 (40.1) 618 (137) 
   pa    .97   .54   .54 
Gestational diabetes 8925   4580   4345  
   No 8760 (98.2) 645 (132)  4489 (98.0) 650 (132)  4271 (98.3) 639 (131) 
   Yes 165 (1.8) 702 (147)  91 (2.0) 718 (158)  74 (1.7) 683 (131) 
   pa  <.001   <.001   <.001 
Mental Health Outcomes         
8-y-olds Rutter (teacher report)b         
Probable psychiatric disturbance 8046   4097   3949  
   Yes 1139  (14.2) 651 (138)  800 (19.5) 660 (141)  339 (8.6) 632 (130) 
   No 6907 (85.8) 646 (129)  3297 (80.5) 651 (127)  3610 (91.4) 642 (129) 
   pa  .25   .09   .15 
Antisocial disorder 8046   4097   3949  
   Yes 724 (9.0) 659 (142)  569 (13.9) 663 (144)  155 (3.9) 646 (135) 
   No  7322 (91.0) 646 (129)  3528 (86.1) 651 (128)  3794 (96.1) 641 (129) 
   pa  .01   .05   .68 
Neurotic disorder 8046   4097   3949  
   Yes 328 (4.1) 641 (133)  171 (4.2) 660 (137)  157 (4.0) 621 (126) 
   No  7718 (95.9) 647 (130)  3926 (95.8) 652 (130)  3792 (96.0) 642 (130) 
   pa  .42   .42   .04 
Inattention-hyperactivity 8061   4103   3958  
   Yes  755 (9.4) 650 (138)  575 (14.0) 656 (136)  180 (4.5) 628 (140) 
   No  7306 (90.6) 647 (129)  3528 (86.0) 652 (129)  3778 (95.5) 642 (129) 
   pa  .57   .44   .16 
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Inattentionc 8069   4108   3961  
   Yes 315 (3.9) 651 (139)  256 (6.2) 657 (139)  59 (1.5) 622 (138) 
   No  7754 (96.1) 647 (130)  3852 (93.8) 652 (129)  3902 (98.5) 642 (130) 
   pa  .61   .54   .25 
Hyperactivityd 8067   4105   3962  
   Yes 573 (7.1) 654 (137)  466 (11.4) 655 (138)  107 (2.7) 653 (132) 
   No  7494 (92.9) 646 (129)  3639 (88.6) 652 (129)  3855 (97.3) 641 (130) 
   pa  .16   .68   .35 
16-y-olds SWAN  (parent report)b         
Combined ADHD  6594   3275   3319  
   Yes 349 (5.3) 659 (138)  231 (7.1) 668 (144)  118 (3.6) 641 (123) 
   No  6245 (94.7) 647 (129)  3044 (92.9) 652 (128)  3201 (96.4) 642 (129) 
   pa  .10   .08   .93 
Inattentione 6488   3227   3261  
   Yes 332 (5.1) 663 (138)  230 (7.1) 666 (140)  102 (3.1) 656 (132) 
   No  6156 (94.9) 646 (128)  2997 (92.9) 652 (127)  3159 (96.9) 641 (129) 
   pa  .02   .11   .26 
Hyperactivity-impulsivityf 6455   3206   3249  
   Yes 306 (4.7) 650 (135)  197 (6.1) 660 (135)  109 (3.4) 632 (133) 
   No  6149 (95.3) 647 (129)  3009 (93.9) 652 (129)  3140 (96.6) 642 (128) 
   pa  .68   .40   .43 
Obesity outcomes         
8-y-olds         
Body weight defined by BMIg 6945   3528   3417  
   Normal 5741 (82.7) 640 (128)  2986 (84.6) 646 (128)  2756 (80.7) 634 (127) 
   Overweight 915 (13.2) 673 (140)  419 (11.9) 680 (142)  496 (14.5) 666 (139) 
   Obese 288 (4.1) 677 (142)  123 (3.5) 691 (152)  165 (4.8) 666 (134) 
   pa  <.001   <.001   <.001 
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16-y-olds         
Body weight defined by BMIg 6675   3272   3403  
   Normal 5650 (84.6) 642 (127)  2720 (83.1) 649 (127)  2930 (86.1) 636 (126) 
   Overweight 787 (11.8) 670 (135)  416 (12.7) 670 (133)  371 (10.9) 670 (138) 
   Obese 238 (3.6) 672 (143)  136 (4.2) 676 (148)  102 (3.0) 667 (136) 
   pa  <.001   <.01   <.001 
Abdominal obesity defined by WHRh 6413   3152   3261  
   No 6093 (95.0) 645 (129)  2995 (95.0) 652 (129)  3098 (95.0) 639 (128) 
   Yes 320 (5.0) 657 (132)  157 (5.0) 659 (121)  163 (5.0) 654 (141) 
   pa  .12   .47   .15 
aFor heterogeneity, analysis of variance. 
bAssessment of symptoms based on fulfilment of criteria according to the Rutter B2/Strengths and Weaknesses of ADHD symptoms 
and Normal behaviour (SWAN) scale.  
cAssessment based on Rutter item number 16. 
dAssessment based on sum of Rutter items 1 and 3.  
eSWAN subscale consisting of sum of 9 items.  
fSWAN subscale consisting of sum of 9 items.  
gBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
hWaist-hip ratio (WHR), dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
Table adapted from Khalife et al. (2012) [643], permitted under the Creative Commons Attribution Licence 3.0. 
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5.2.12 Association between placental size and mental health in children and adolescents 
 
Table 5.30 shows the logistic regression results for the associations between placental size 
(placental weight, surface area and placental-to-birth-weight ratio – as continuous variables) 
and mental health outcomes (categorical) at 8 and 16 years of age, in the entire sample of 
both boys and girls. The results show a trend for positive associations between placental size 
and each of the mental health outcomes at 8 and 16 years of age, in both unadjusted and 
adjusted analyses. The adjusted analyses mostly show stronger and more significant 
associations between placental size and mental health outcomes. At 8 years, there were 
significant associations between placental weight/surface area and antisocial disorder, and 
placental surface area and hyperactivity symptoms. At 16 years, there were significant 
associations between all measures of placental size and inattention symptoms.   
 
Table 5.31 and Table 5.32 show the results for the associations in boys and girls, 
respectively. In girls, no significant associations were identified between placental size and 
mental health outcomes at either 8 or 16 years of age. In contrast, there were significant 
associations between placental size and mental health in boys, indicating that the associations 
observed in the entire sample are accounted for by the male sex. Both unadjusted and 
adjusted logistic regression analyses showed positive associations between placental size and 
mental health outcomes in boys at 8 and 16 years of age. The adjusted analyses show that 
overall, male placental size was significantly associated with symptoms of inattention-
hyperactivity, inattention and hyperactivity at 8 and 16 years, as well as general probable 
psychiatric disturbance and antisocial disorder at 8 years. For example, for every 100g 
increase in placental weight, the risk for probable psychiatric disturbance at 8 years and 
combined inattention-hyperactivity at 16 years increased by 14% and 19%, respectively. 
Furthermore, the adjusted results indicate that compared to placental surface area (10cm2) and 
placental-to-birth-weight ratio, increased placental weight (100g) was the strongest predictor 
of mental health problems in boys at both 8 and 16 years of age.  Additional analyses showed 
that a respective increase of 1g and 1cm² in placental weight and surface area were 
significantly associated with mental health problems in boys. A 1g increase in placental 
weight was associated with probable psychiatric disturbance at 8 years (OR=1.001, 95% CI: 
1.000-1.002) and combined inattention-hyperactivity at 16 years (OR=1.002, 95% CI: 1.000-
1.003), and a 1cm² increase in placental surface area was associated with inattention-
hyperactivity symptoms at 8 years (OR=1.002, 95% CI: 1.001-1.004) and inattention 
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symptoms at 16 years (OR=1.003, 95% CI: 1.000-1.005). A 10g increase in placental weight 
i.e. within 1 SD from the mean, was positively associated with mental health problems in 
boys (for probable psychiatric disturbance at 8 years, OR=1.013, 95% CI: 1.004-1.023).  
 
To test for a potential U-shaped association, we repeated the analyses using stratified 
placental   data,   which   comprised   3   groups:   <550g   (“low”   placental   weight),   550-719 
(“normal”   placental   weight)   and   ≥720g   (“high”   placental   weight).   Table   5.33   shows   that  
compared with normal placental weight, only high placental weight and not low placental 
weight, was significantly associated with mental health problems in boys at 8 and 16 years. 
The analysis was also repeated with placental weight stratified according to 100g increments 
(8 groups:<400g, 400-499g, 500-599, 600-699g, 700-799g, 800-899g, 900-999g and 
≥1000g),  and  similarly  no  association  was  detected  between  low  placental  weight  and  mental  
health. The results therefore do not provide evidence for a U-shaped association, as only large 
placental size was associated with the mental health outcomes.  
 
5.2.13 Association between placental size and obesity in children and adolescents 
 
Table 5.30 shows that in the entire sample, there was a general trend for a positive association 
between placental size (placental weight, surface area and placental-to-birth-weight ratio) and 
obesity outcomes at 8 and 16 years, in both unadjusted and adjusted analyses. In the 
unadjusted analyses, there were significant associations between placental size and 
overweight/obese BMI at 8 and 16 years, but these did not reach significance in the adjusted 
analyses. Similarly, in separate analyses of boys and girls, shown in Tables 5.31 and 5.32, 
there were significant unadjusted associations as observed before, and the adjusted 
associations did not reach significance. Likewise, linear analyses showed there were no 
associations between placental size and obesity outcomes (continuous scale) after adjustment, 
e.g. for the associations between placental weight (100g) and BMI at 8 years, B=.01 (95% CI: 
-.04-.07), and at 16 years, B=.03 (95% CI: -.06-.11).   
 
Table 5.33 shows that after repeating the analysis with stratified placental data (3 groups: 
<550g   [“low”   placental  weight],   550-719g   [“normal”   placental  weight]   and   ≥720g   [“high”  
placental weight]), low placental weight was not associated with obesity outcomes, in both 
the unadjusted and adjusted analyses. In contrast, high placental weight was overall 
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associated with overweight/obese BMI at 8 and 16 years in boys and girls, but only in 
unadjusted analyses. Similar findings were obtained when repeating the analysis with 
placental weight stratified according to 100g increments (8 groups: <400g to  ≥1000g).  Thus,  
there was no evidence for an association with either small or large placental size, in adjusted 
analyses. Further, stratification of the analyses by maternal pre-pregnancy BMI did not reveal 
any associations, as shown in Tables 5.34-5.36.  
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Table 5.30: Logistic regression results for the association between placental size (weight, surface area and placental-to-birth-weight ratio) and mental health/obesity outcomes.  
 Placental Weight (100g)  Placental Surface Area (10cm2)  Placental-to-Birth-Weight Ratio 
 Unadjusted Adjusteda  Unadjusted Adjusteda  Unadjusted Adjustedb 
 OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI 
Mental health outcomes                  
8-y-olds Rutter  
(teacher report) 
                 
Probable psychiatric 
disturbance 
1.03 .98-1.08 6452 1.06 .98-1.14  1.01 1.00-1.01 6376 1.01 1.00-1.02  1.01 .99-1.03 6452 1.02 .99-1.04 
Antisocial disorder 1.08* 1.02-1.14 6452 1.10* 1.00-1.20  1.01 1.00-1.02 6376 1.02* 1.00-1.03  1.02 .99-1.05 6452 1.03 1.00-1.06 
Neurotic disorder .97 .89-1.05 6452 1.02 .90-1.17  1.00 .98-1.01 6376 1.02 .97-1.02  1.00 .96-1.04 6452 1.01 .96-1.05 
Inattention-hyperactivity 1.02 .96-1.08 6467 1.05 .96-1.15  1.01 1.00-1.02 6391 1.01 1.00-1.03  1.00 .98-1.03 6467 1.01 .99-1.04 
Inattention 1.02 .94-1.12 6473 1.03 .90-1.18  1.01 .99-1.02 6397 1.01 .99-1.03  1.00 .96-1.04 6473 1.00 .95-1.05 
Hyperactivity 1.05 .98-1.12 6472 1.09 .98-1.20  1.01 1.00-1.02 6396 1.02* 1.02-1.04  1.00 .97-1.03 6472 1.02 .99-1.06 
16-y-olds SWAN   
(parent report) 
                 
Combined ADHD 1.07 .99-1.16 5533 1.10 .97-1.24  1.01 1.00-1.03 5469 1.02 1.00-1.04  1.03 .99-1.06 5533 1.03 .98-1.07 
Inattention 1.10* 1.01-1.20 5457 1.17* 1.03-1.33  1.01 1.00-1.03 5393 1.03* 1.01-1.05  1.05* 1.01-1.08 5457 1.06* 1.01-1.10 
Hyperactivity-impulsivity 1.02 .93-1.11 5426 1.04 .91-1.19  1.01 .99-1.02 5362 1.02 .99-1.04  1.01 .99-1.02 5426 1.00 .96-1.05 
Obesity outcomesc                  
8-y-olds                  
Overweight/obesityd 1.21*** 1.15-1.27 6100 1.03 .96-1.10  1.03*** 1.02-1.03 6034 1.00 .99-1.02  1.03** 1.01-1.05 6100 1.01 .98-1.04 
16-y-olds                  
Overweight/obesityd 1.18*** 1.12-1.24 5873 1.01 .94-1.09  1.02*** 1.01-1.03 5805 1.01 .99-1.02  1.03** 1.01-1.06 5873 1.00 .97-1.03 
Abdominal obesitye 1.07 .98-1.17 5278 .99 .87-1.13  1.01 .99-1.02 5217 1.00 1.00-1.02  1.02 .99-1.06 5278 1.00 .95-1.05 
aAdjusted for gestational age, birthweight, gender, socio-demographic factors (maternal age, family structure, education and social class) and medical factors (smoking during pregnancy, parity, pre-
pregnancy BMI and gestational weight gain).  
bAdjusted as above, except for birthweight. 
cAdjusted as in a and b, plus adjustment for gestational diabetes.  
dOverweight/obesity defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
eAbdominal obesity defined according to the sex-specific cut-offs at the 95th percentile of WHR. 
*p<.05, **p<.01, ***p<.001.   
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Table 5.31: Logistic regression results for the association between male placental size (weight, surface area and placental-to-birth-weight ratio) and mental health/obesity outcomes.  
 Male Placental Weight (100g)  Male Placental Surface Area (10cm2)  Male Placental-to-Birth-Weight Ratio 
 Unadjusted Adjusteda  Unadjusted Adjusteda  Unadjusted Adjustedb 
 OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI 
Mental health outcomes                  
8-y-olds Rutter  
(teacher report) 
                 
Probable psychiatric 
disturbance 
1.05 .99-1.12 3276 1.14** 1.04-1.25  1.01 1.00-1.02 3236 1.01 1.00-1.03  1.04** 1.01-1.07 3276 1.04* 1.01-1.08 
Antisocial disorder 1.07* 1.00-1.15 3276 1.14* 1.03-1.27  1.01 1.00-1.02 3236 1.02* 1.00-1.04  1.05** 1.02-1.08 3276 1.04* 1.01-1.08 
Neurotic disorder 1.05 .93-1.18 3276 1.19 .99-1.42  1.00 .98-1.02 3236 1.00 .97-1.03  1.04 .98-1.09 3276 1.06 .99-1.13 
Inattention-hyperactivity 1.03 .96-1.10 3282 1.11* 1.00-1.24  1.01 1.00-1.02 3242 1.02** 1.01-1.04  1.03 1.00-1.07 3282 1.03 .99-1.07 
Inattention 1.03 .94-1.14 3286 1.07 .92-1.25  1.01 .99-1.02 3246 1.02 1.00-1.05  1.03 .98-1.08 3286 1.01 .96-1.07 
Hyperactivity 1.02 .94-1.09 3283 1.12* 1.00-1.26  1.01 1.00-1.02 3243 1.03** 1.01-1.05  1.03 .99-1.06 3283 1.04 .99-1.08 
16-y-olds SWAN   
(parent report) 
                 
Combined ADHD 1.10 .99-1.21 2754 1.19* 1.02-1.38  1.01 .99-1.03 2724 1.02 1.00-1.05  1.06* 1.01-1.11 2754 1.06* 1.00-1.11 
Inattention 1.09 .98-1.20 2720 1.17* 1.00-1.37  1.01 .99-1.03 2691 1.03* 1.01-1.06  1.06* 1.01-1.11 2720 1.05 1.00-1.11 
Hyperactivity-impulsivity 1.05 .94-1.17 2701 1.11 .94-1.31  1.01 .99-1.03 2672 1.02 1.00-1.05  1.03 1.00-1.08 2701 1.03 .97-1.09 
Obesity outcomesc                  
8-y-olds                  
Overweight/obesityd 1.23*** 1.15-1.31 3098 1.04 .94-1.15  1.03*** 1.02-1.04 3065 1.01 1.00-1.03  1.03 1.00-1.06 3098 1.01 .98-1.05 
16-y-olds                  
Overweight/obesityd 1.14*** 1.06-1.22 2874 .99 .90-1.10  1.02* 1.00-1.03 2841 1.01 .99-1.03  1.03 1.00-1.06 2874 1.00 .96-1.03 
Abdominal obesitye 1.05 .93-1.18 2591 .96 .80-1.15  1.01 .99-1.04 2563 1.02 .99-1.05  1.02 .96-1.07 2591 1.00 .93-1.06 
aAdjusted for gestational age, birthweight, socio-demographic factors (maternal age, family structure, education and social class) and medical factors (smoking during pregnancy, parity, pre-pregnancy 
BMI and gestational weight gain). 
bAdjusted as above, except for birthweight. 
cAdjusted as in a and b, plus adjustment for gestational diabetes.  
dOverweight/obesity defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
eAbdominal obesity defined according to the sex-specific cut-offs at the 95th percentile of WHR. 
*p < .05; **p < .01; ***p<.001.  
Table adapted from Khalife et al. (2012) [643], permitted under the Creative Commons Attribution Licence 3.0. 
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Table 5.32: Logistic regression results for the association between female placental size (weight, surface area and placental-to-birth-weight ratio) and mental health/obesity outcomes.  
 Female Placental Weight (100g)  Female Placental Surface Area (10cm2)  Female Placental-to-Birth-Weight Ratio 
 Unadjusted Adjusteda  Unadjusted Adjusteda  Unadjusted Adjustedb 
 OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI 
Mental health outcomes                  
8-y-olds Rutter  
(teacher report) 
                 
Probable psychiatric disturbance .94 .86-1.02 3176 .91 .79-1.04  1.00 .98-1.01 3140 1.00 .97-1.02  .99 .95-1.03 3176 .97 .92-1.01 
Antisocial disorder 1.03 .91-1.16 3176 .97 .80-1.20  1.01 .99-1.03 3140 1.01 .99-1.04  1.00 .95-1.06 3176 .98 .92-1.05 
Neurotic disorder .88 .77-.99 3176 .88 .72-1.10  .99 .97-1.02 3140 1.00 .96-1.02  .97 .92-1.03 3176 .96 .89-1.02 
Inattention-hyperactivity .92 .82-1.04 3185 .90 .75-1.10  .99 .97-1.01 3149 .99 .96-1.02  .98 .93-1.03 3185 .95 .90-1.02 
Inattention .98 .91-1.10 3187 1.01 .90-1.13  1.00 .99-1.01 3151 1.01 .99-1.03  1.02 .99-1.10 3187 1.00 .96-1.04 
Hyperactivity 1.07 .93-1.24 3189 .95 .76-1.19  1.00 .97-1.03 3153 .99 .95-1.03  .99 .93-1.06 3189 .98 .90-1.06 
16-y-olds SWAN   
(parent report) 
                 
Combined ADHD  .99 .86-1.15 2779 .92 .74-1.15  1.01 .98-1.04 2745 1.01 .98-1.05  .99 .93-1.05 2779 .97 .90-1.05 
Inattention 1.09 .94-1.27 2737 1.20 .95-1.50  1.01 .98-1.04 2702 1.02 .98-1.06  1.05 .98-1.11 2737 1.06 .98-1.14 
Hyperactivity-impulsivity .94 .81-1.10 2725 .91 .73-1.15  1.00 .97-1.03 2690 1.01 .98-1.05  .98 .92-1.05 2725 .96 .89-1.04 
Obesity outcomesc                  
8-y-olds                  
Overweight/obesityd 1.21*** 1.13-1.29 3002 1.01 .92-1.12  1.02*** 1.01-1.04 2969 1.00 .98-1.01  1.02 .99-1.05 3002 1.00 .97-1.04 
16-y-olds                  
Overweight/obesityd 1.22*** 1.13-1.31 2999 1.02 .91-1.14  1.03*** 1.01-1.07 2964 1.00 .98-1.02  1.04 1.01-1.07 2999 1.01 .97-1.05 
Abdominal obesitye 1.09 .97-1.23 2687 1.03 .86-1.24  1.00 .98-1.03 2654 .98 .95-1.01  1.03 .98-1.08 2687 1.00 .94-1.07 
aAdjusted for gestational age, birthweight, socio-demographic factors (maternal age, family structure, education and social class) and medical factors (smoking during pregnancy, parity, pre-pregnancy 
BMI and gestational weight gain).  
bAdjusted as above, except for birthweight. 
cAdjusted as in a and b, plus adjustment for gestational diabetes.  
dOverweight/obesity defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
eAbdominal obesity defined according to the sex-specific cut-offs at the 95th percentile of WHR. 
***p<.001.  
Table adapted from Khalife et al. (2012) [643], permitted under the Creative Commons Attribution Licence 3.0. 
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Table 5.33: Logistic regression results for the association between stratified placental weighta and mental health/obesity outcomes.    
 Stratified placental weighta 
 All  Males  Females 
 Unadjusted Adjustedb  Unadjusted Adjustedb  Unadjusted Adjustedb 
 OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI 
Mental health outcomes                  
8-y-olds Rutter  
(teacher report) 
                 
Inattention-hyperactivity                   
Low vs. normal placental 
weight 
1.13 .93-1.38 6467 1.01 .78-1.30  1.12 .88-1.42 3282 .96 .71-1.30  1.28 .89-1.83 3185 1.18 .73-1.91 
High vs. normal placental 
weight 
1.22* 1.03-1.46 6467 1.32* 1.06-1.65  1.29 1.06-1.58 3282 1.55** 1.20-2.01  .88 .60-1.29 3185 .98 .53-1.33 
16-y-olds SWAN  
(parent report) 
                 
Inattention-hyperactivity                  
Low vs. normal placental 
weight 
1.06 .79-1.42 5533 1.21 .85-1.73  1.35 .94-1.94 2754 1.44 .92-2.23  .72 .43-1.20 2779 .98 .54-1.79 
High vs. normal placental 
weight 
1.31* 1.02-1.67 5533 1.40* 1.03-1.91  1.54** 1.14-2.09 2754 1.85** 1.26-2.70  .87 .56-1.35 2779 .83 .47-1.45 
Obesity outcomesc                  
8-y-olds 
Overweight/obesityd 
                 
Low vs. normal placental 
weight 
.90 .75-1.07 6100 1.10 .89-1.35  .93 .71-1.21 3098 1.07 .78-1.48  .86 .68-1.06 3002 1.12 .85-1.48 
High vs. normal placental 
weight 
1.64*** 1.43-1.89 6100 1.18 .99-1.40  1.69*** 1.38-2.07 3098 1.17 .91-1.51  1.63*** 1.34-1.98 3002 1.17 .92-1.50 
16-y-olds 
Overweight/obesityd 
                 
Low vs. normal placental 
weight 
.86 .71-1.03 5873 1.09 .87-1.36  1.04 .81-1.35 2874 1.20 .88-1.64  .70* .53-.93 2999 .99 .71-1.38 
High vs. normal placental 
weight 
1.36*** 1.17-1.59 5873 .97 .80-1.17  1.46*** 1.19-1.79 2874 1.11 .86-1.43  1.25 1.00-1.56 2999 .81 .61-1.08 
aPlacental weight stratified according to percentile distribution: (1) low < 550g (< 25th percentile), (2) normal 550-719g (25th-75th percentiles), and (3) high > 720g (>75th percentile).  
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bAdjusted for gestational age, birthweight, socio-demographic factors (maternal age, family structure, education and social class) and medical factors (smoking during pregnancy, parity, pre-pregnancy 
BMI and gestational weight gain).  
cAdjusted as in b, plus adjustment for gestational diabetes.  
dOverweight/obesity defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
*p < .05; **p < .01; ***p<.001. 
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Table 5.34: Logistic regression results for the association between placental weight and obesity outcomes, stratified by maternal pre-pregnancy BMI.  
 Placental weight (100g) 
 Underweight pre-pregnancy BMI (< 20)  Normal pre-pregnancy BMI (20-24.99)  Overweight/obese pre-pregnancy  BMI  (≥25) 
 Unadjusted Adjusteda  Unadjusted Adjusteda  Unadjusted Adjusteda 
 OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI 
Obesity outcomes                  
8-y-olds                  
Overweight/obesityb 1.14 1.00-1.31 1493 .96 .78-1.19  1.15*** 1.08-1.23 3605 1.05 .96-1.14  1.16** 1.05-1.27 989 1.06 .92-1.21 
16-y-olds                  
Overweight/obesityb 1.01 .86-1.19 1415 .89 .70-1.13  1.20** 1.05-1.20 3504 1.07 .97-1.17  1.13* 1.03-1.24 940 .98 .85-1.12 
Abdominal obesityc .99 .75-1.31 1261 .97 .64-1.48  1.06 .95-1.20 3162 1.00 .85-1.18  .99 .85-1.15 841 1.04 .82-1.32 
aAdjusted for gestational age, birthweight, gender, socio-demographic factors (maternal age, family structure, education and social class) and medical factors (smoking during pregnancy, parity, 
gestational weight gain and gestational diabetes).  
bOverweight/obesity defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cAbdominal obesity defined according to the sex-specific cut-offs at the 95th percentile of WHR. 
*p<.05, **p<.01, ***p<.001.   
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Table 5.35: Logistic regression results for the association between male placental weight and obesity outcomes, stratified by maternal pre-pregnancy BMI.  
 Male placental weight (100g) 
 Underweight pre-pregnancy BMI (< 20)  Normal pre-pregnancy BMI (20-24.99)  Overweight/obese pre-pregnancy  BMI  (≥25) 
 Unadjusted Adjusteda  Unadjusted Adjusteda  Unadjusted Adjusteda 
 OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI 
Obesity outcomes                  
8-y-olds                  
Overweight/obesityb 1.08 .88-1.33 777 .90 .65-1.25  1.14** 1.04-1.24 1816 1.05 .92-1.19  1.28** 1.11-1.46 501 1.19 .97-1.44 
16-y-olds                  
Overweight/obesityb .93 .75-1.16 711 .84 .61-1.14  1.09 .99-1.19 1699 1.06 .93-1.21  1.13 .99-1.30 459 1.03 .85-1.26 
Abdominal obesityc .90 .59-1.38 641 .87 .47-1.59  1.04 .88-1.22 1543 .94 .73-1.20  1.01 .81-1.26 402 1.12 .81-1.55 
aAdjusted for gestational age, birthweight, socio-demographic factors (maternal age, family structure, education and social class) and medical factors (smoking during pregnancy, parity, gestational 
weight gain and gestational diabetes).  
bOverweight/obesity defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cAbdominal obesity defined according to the sex-specific cut-offs at the 95th percentile of WHR. 
*p<.05, **p<.01, ***p<.001.   
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Table 5.36: Logistic regression results for the association between female placental weight and obesity outcomes, stratified by maternal pre-pregnancy BMI.  
 Female placental weight (100g) 
 Underweight pre-pregnancy BMI (< 20)  Normal pre-pregnancy BMI (20-24.99)  Overweight/obese pre-pregnancy  BMI  (≥25) 
 Unadjusted Adjusteda  Unadjusted Adjusteda  Unadjusted Adjusteda 
 OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI  OR 95% CI n OR 95% CI 
Obesity outcomes                  
8-y-olds                  
Overweight/obesityb 1.20* 1.00-1.44 716 1.01 .77-1.32  1.18*** 1.08-1.29 1789 1.04 .92-1.17  1.07 .94-1.22 488 .97 .79-1.19 
16-y-olds                  
Overweight/obesityb 1.11 .86-1.43 704 .92 .63-1.34  1.15** 1.04-1.27 1805 1.07 .93-1.23  1.13 .99-1.29 481 .97 .79-1.19 
Abdominal obesityc 1.07 .74-1.56 620 1.11 .62-2.01  1.09 .93-1.29 1619 1.05 .84-1.32  .96 .78-1.19 439 .99 .69-1.43 
aAdjusted for gestational age, birthweight, socio-demographic factors (maternal age, family structure, education and social class) and medical factors (smoking during pregnancy, parity, 
gestational weight gain and gestational diabetes).  
bOverweight/obesity defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cAbdominal obesity defined according to the sex-specific cut-offs at the 95th percentile of WHR. 
*p<.05, **p<.01, ***p<.001.   
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6. Discussion  
 
This thesis addresses important unexplored aspects of the ADHD symptom-obesity 
association. First (Theme I), the association and directionality between ADHD symptoms and 
obesity was examined over an 8-year period, from childhood to adolescence; behavioural 
factors - physical activity and binge-eating - were examined as potential mediators underlying 
the association. Second (Theme II), prenatal factors - prenatal exposure to sGC and placental 
size - were explored as conferring common risk for ADHD symptoms and obesity. This 
chapter begins with a recap of the original hypotheses along with a summary of the findings. 
Next, the results of each study theme are discussed in light of the current literature, followed 
by an overall description of the strengths and limitations of the research. Finally, the potential 
clinical and public health implications of this thesis are discussed, followed by a concluding 
remark on possible future work.  
 
6.1 Original hypotheses and summary of findings  
 
Table 6.1 lists the original hypotheses and summarises the findings. The associations that 
were identified are summarised in an illustrative format in Figure 6.1.  
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Table 6.1: Original hypotheses and summary of findings.  
Hypothesis Support: yes or no 
Theme I: Exploring directionality and underlying behavioural mediators of the association between ADHD symptoms and obesity 
1. There will be both concurrent and long-term associations between ADHD symptoms and obesity over 
the period of childhood to adolescence.  
 
Concurrent associations:  
Childhood   
Adolescence  
Long-term association:  
  
2. The ADHD symptom-obesity association will be bidirectional over the long-term, from childhood to 
adolescence.  
ADHD symptoms predicted obesity:  
Obesity predicted ADHD symptoms:  
  
3. The ADHD symptoms of inattention and hyperactivity will each contribute to the potential ADHD 
symptom-obesity association.   
 
  
4. The behavioural factors, physical inactivity and binge-eating, will associate with ADHD symptoms and 
mediate the potential ADHD symptom-obesity association.  
Probable ADHD predicted physical inactivity:  
Inattention predicted physical inactivity:   
Reduced physically active play predicted inattention: 
ADHD symptoms predicted binge-eating:  
Binge-eating predicted ADHD symptoms: unstudied – 
lack of data 
Physical inactivity was a mediator:  
Binge-eating was a mediator: 
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Theme II: Investigating whether prenatal factors confer common risk for mental health and obesity 
5. Prenatal sGC exposure will be associated with child/adolescent mental health (ADHD symptoms, 
general psychiatric disturbance, antisocial disorder and neurotic disorder) and obesity.  
Child mental health (inattention and general psychiatric 
disturbance):  
Adolescent mental health:   
Child obesity:  
Adolescent obesity:  
  
6. Placental or birth size will mediate the association between prenatal synthetic glucocorticoid exposure 
and later mental health.  
 
  
7. Placental size will be associated with mental health (ADHD symptoms, general psychiatric disturbance, 
antisocial disorder and neurotic disorder) and obesity in children and adolescents.  
Child/adolescent mental health; negative association:  
 
Child/adolescent mental health; positive association 
(ADHD symptoms, general psychiatric disturbance and 
antisocial disorder):  
 
Child/adolescent obesity:   
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Figure 6.1: Overview of associations studied. Black text and arrows indicate associations were identified, while grey text and arrows indicate 
associations were not identified.  
     
Childhood/adolescence Prenatal environment 
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Obesity 
ADHD symptoms 
Physical inactivity 
Binge-eating Prenatal synthetic 
glucocorticoid exposure 
Placental size 
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6.2 Theme-specific discussions 
 
6.2.1 Theme I: Exploring directionality and underlying behavioural mediators of the 
association between ADHD symptoms and obesity   
 
Childhood ADHD symptoms predicted adolescent obesity, yet there was no evidence for the 
reverse (and thus a bidirectional) association, as reported for the first time [615]. Childhood 
ADHD symptoms were also predictive of adolescent physical inactivity (MET), and likewise, 
reduced physically active play in childhood predicted ADHD symptoms in adolescence; both 
associations were of a similar magnitude. Thus, this provides evidence for a bidirectional 
association between ADHD symptoms and physical inactivity. Physical inactivity mediated 
the long-term association between child ADHD symptoms and adolescent obesity, whereas 
there was no evidence for binge-eating as a mediator. The reported longitudinal associations 
over childhood to adolescence were also observed in cross-sectional analyses in adolescents, 
but not in children, suggesting that these associations develop over the long-term.  
 
6.2.2 Directionality between ADHD symptoms and obesity from childhood to 
adolescence  
 
There is substantial evidence to suggest that a comorbid association exists between obesity 
and ADHD [123]. However, because most previous studies are cross-sectional, and the few 
existing longitudinal studies have not examined directionality [81-83,93-99], it has remained 
unclear to date whether ADHD symptoms present prior to the development of obesity or vice 
versa. In terms of child/adolescent research, only one study in toddlers found a longitudinal 
link between poor self-regulation skills (at 2 years) and later obesity (at 5.5 years) [93]. This 
study provides only limited information as it was conducted in very young children with a 
fairly short follow-up time. Using a large, longitudinal, population cohort, this present thesis 
not only confirms the ADHD symptom-obesity link, but also addresses the issue of 
directionality. The results showed that the association was driven from the direction of 
ADHD symptoms to obesity (and not vice versa) over an 8-year period, from childhood to 
adolescence.  
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Due to the observational design of the NFBC 1986 dataset, it is however not possible to 
affirm a causal association between ADHD symptoms and obesity; indeed, reverse causation 
and unmeasured confounding are possibilities. Although longitudinal studies such as the 
NFBC tend to minimise the problem of reverse causation due to the temporal ordering of 
variables, the nature of the early development of ADHD and obesity may introduce some bias 
when studying directionality in child/adolescent samples. ADHD tends to manifest earlier in 
life than obesity (e.g. in NFBC 1986 at 8 year baseline; ADHD rate: 9.4%; obesity rate: 
4.1%), and so this may attenuate any potential association driven in the direction from obesity 
to ADHD symptoms across childhood to adolescence. To overcome this issue, repeated 
measurements of ADHD symptoms and obesity should be analysed over longer follow-up 
periods. In the literature, it is plausibly hypothesised that obesity may give rise to the 
manifestation of ADHD symptoms via obesity-related factors [50] e.g. behaviour problems 
(e.g. impulsivity associated with compulsive eating), leptin deficiency and a sugar-rich diet, 
which may contribute to ADHD-like behaviours [50,124,125]. In support of this hypothesis, 
there is evidence that obesity temporally precedes other psychopathologies e.g. depression 
[616,617], and a recent study identified a bidirectional association between obesity and 
depression [617]. Thus, given previous research and the limitations of the NFBC data, it is 
not possible to rule out that a bidirectional ADHD symptom-obesity association may exist. It 
is also plausible that rather than there being any causal association, ADHD and obesity may 
correlate due to common biological or environmental factors which result in the 
manifestation of both disorders. For example, genetic pleiotropic effects may be one possible 
explanation; several genes have been linked with both ADHD and obesity e.g. DRD2 [11,12], 
DRD4 [11,270], FTO [280], BDNF [129,287], MC4R [289-291] and a range of others 
according to a recent GWAS study [282]. Other common factors include those related to the 
prenatal environment e.g. maternal psychosocial stress [40,318], smoking [318,322] and pre-
pregnancy obesity [261,321], and the postnatal environment e.g. childhood adversity (such as 
unfavourable family conditions or socioeconomic disadvantage) or psychosocial stress  [292-
296].  
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6.2.3 Psychopathological and behavioural underpinnings of the ADHD symptom-obesity 
association  
 
Only a few previous studies have attempted to identify which symptom dimension(s) of 
ADHD may contribute to the ADHD-obesity association [76,95,99]. Although one study 
found that only combined ADHD (and not the individual inattentive or hyperactive-impulsive 
subtypes) associated with obesity [76], the results from other studies overall suggest that 
inattention and impulsivity symptoms may individually be important in conferring risk for 
obesity [95,99]. There is some limited evidence to suggest that hyperactivity symptoms may 
also contribute to the association, but only in women [99]. Similarly, few studies have 
examined potential behavioural mediators which may underlie the association [74,80,86,90-
92]. Cross-sectional studies have reported that ADHD is linked with physical inactivity 
[90,91], binge-eating [80,92], increased television viewing [74,91] and less healthy eating 
habits [74]. However it has remained unknown to date whether behavioural factors mediate 
the long-term association between ADHD and obesity, since there are no existing 
longitudinal studies that have examined this. The longitudinal data presented here provide 
insight into the psychopathological and behavioural underpinnings of the ADHD symptom-
obesity association, thereby addressing another critical limitation of previous research. 
 
Examination of ADHD symptoms separately showed that both inattention and hyperactivity 
were each important in predicting later overweight/obesity, while inattention was important 
in predicting later physical inactivity. As obesity and physical inactivity were controlled for 
reciprocally, the results suggest that ADHD symptoms are independently linked with obesity 
and physical inactivity. Mediation analysis provided evidence for a mediatory effect of 
physical inactivity on the ADHD symptom-obesity association. It is possible that social 
impairments (e.g. peer problems and rule-breaking) related to ADHD symptoms [22,189] 
may hinder child participation in structured physical activities, which typically require 
cooperation, rule adherence and team-work. Children with ADHD are at increased risk of 
experiencing motor coordination problems [184], low self-esteem [21] and negative feelings 
about physical activity [194], which may also contribute to reduced participation in physical 
activity. Further, it has been suggested that excessive daytime sleepiness commonly linked 
with ADHD could contribute to difficulties in initiating physical activity due to a state of low 
arousal [271]. Instead of exercising, children with ADHD may spend more time watching TV 
and playing video games [89,90].  This lack of physical activity could lead to weight gain 
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over time. The results show that inattention symptoms are driving the ADHD symptom-
physical inactivity-obesity pathway. Physical activities require increased concentration, 
perception and self-directedness, which may be challenging for children with inattention. 
There are common biological systems e.g. dopamine and BDNF, associated with ADHD 
[126,127], obesity [128,129] and physical inactivity [217,618], which further supports the 
concept of a link between all these conditions. Interestingly, a recent study suggests that FTO 
may contribute to the pathway linking ADHD symptoms, physical inactivity and obesity, 
although further work is needed to establish this [283].  
 
It has been proposed that inattention may induce abnormal eating behaviours, such as binge-
eating [25,158], which in turn may contribute to the development of obesity over the long-
term. There was no evidence for a long-term association as ADHD symptoms in childhood 
were not associated with later binge-eating in adolescence. Impulsivity has previously been 
linked with binge-eating [24,134,144]; however it was not possible to study this association 
here due to lack of data on impulsivity symptoms, and this is an important limitation. It is 
hypothesised that impulsivity may be a key factor driving the ADHD-obesity pathway via 
overeating [25], and there is considerable evidence in the literature which supports this 
hypothesis and thus warrants further investigation. The three main characteristics of 
impulsivity – a heightened drive for reward, deficient inhibitory control, and poor decision 
making, appear to shed some light on the mechanisms by which this trait may contribute to 
overeating [146].    
 
A heightened drive for reward is characterised by a propensity to engage in highly fun and 
risky behaviours, with a reduced ability to delay gratification [146]. This behaviour is 
understood   to   be   due   to   a   dysfunction   in   the   “brain   reward   cascade”   – known   as   “reward  
deficiency  syndrome”,  which  largely  stems  from  hypo-dopaminergic brain activity [18], and 
is linked with use of unnatural immediate rewards, including excessive consumption. The 
tendency to opt for immediate rather than delayed rewards – even when the latter brings 
greater  reward,  may  for  example,  result  in  the  consumption  of  high  caloric  “fast  food”  instead 
of low caloric home-cooked meals, which take longer to prepare. It is suggested that children 
with   ADHD   may   have   difficulties   waiting   for   healthy   food   when   “fast   food”   is   readily  
available [24,619]. Moreover, ADHD has been linked with a “Western-style  diet”  – high in 
sugar and fat, and low in fruit and vegetables [74,140]. Fatty and sweet foods can have a 
rewarding value [620], which may particularly appeal to individuals with ADHD given their 
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increased sensitivity to reward [621]. Indeed, the consumption of palatable foods can induce 
the release of small amounts of endogenous opiates in the brain [622], which in turn can 
increase dopamine transmission in the brain reward pathways [620]. Thus, it is possible to 
speculate that individuals with ADHD overeat such foods to relieve their hypo-dopaminergic 
state.   Over   the   long   term,   a   “Western-style   diet”   may   lead   to   a   chronic,   positive   energy  
balance and thereby overweight/obesity.  
 
Deficient inhibitory control is the diminished ability to restrain oneself when it is the most 
advantageous and appropriate action [146]. This may manifest as poor planning and problems 
with self-regulation of behaviour, resulting in e.g. lack of concern for daily caloric intake 
and/or eating when not hungry, leading to excessive food intake [24]. In our modern 
obesogenic society, where high-calorie foods are available in excess, self-control of caloric 
intake is vital in maintaining a healthy body weight.   “Fast   food”   or   ready-made meals are 
easier options compared with healthy food choices which normally require planning, 
extended preparation and the ability to exhibit self-control when presented with quicker and 
more tempting alternatives. The large variety of foods widely available today in terms of e.g. 
colour, form, taste and texture, can make self-control difficult for those whose eating is 
typically stimulated by environmental cues. Indeed, there is some evidence that impulsive 
children overeat when presented with a variety of different foods compared with monotonous 
food [623]. 
 
Poor decision making is associated with a failure to assess the advantages and disadvantages 
of action choices, as well as the inability to refrain from immediate gratification when such a 
choice is related to adverse future consequences [146]. The ability to consider options is 
dependent   on   an   accumulated   “emotional   memory”   of   the   consequences   of   past   decisions  
[624]. In impulsive individuals, the negative or positive consequences in the present moment, 
without thought to past events or the future, can tend to influence decision making.  
 
It may also be possible that ADHD symptoms are associated with other disordered eating 
patterns not assessed in this thesis. For example, hyperactivity may be linked with obesity via 
emotional eating - a possible mechanism to cope with the frustration related with the 
restlessness which accompanies hyperactivity. As the results of this thesis showed that 
neither binge-eating nor physical inactivity contributed to the long-term association between 
hyperactivity symptoms and obesity, further studies are required to examine whether other 
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factors, in particular other disordered eating behaviours, may explain the link between 
hyperactivity and weight gain.  
 
6.2.4 Developmental trajectory of the ADHD symptom-obesity association over 
childhood and adolescence  
 
It is of interest to consider the results of the longitudinal ADHD symptom-obesity analysis in 
light of those obtained from the cross-sectional analyses at 8 and 16 years. It is important to 
note that the vast majority of previous cross-sectional studies examine a mix of both children 
and adolescents, and so this thesis provides novel insight into the developmental trajectory of 
the ADHD symptom-obesity association, through both longitudinal and cross-sectional 
analyses across childhood to adolescence. At 16 years, cross-sectional analyses showed that 
ADHD symptoms were associated with obesity, corroborating findings from most previous 
studies in children/adolescents, as reported in a recent review [123]. Further, ADHD 
symptoms were linked with physical inactivity and binge-eating at 16 years, in line with other 
studies in young to older adults [80,90-92]. In contrast, no associations were detected in 8-
year-olds; the few previous studies in children report conflicting results [74,84,86]. 
Importantly, because baseline BMI was adjusted for in longitudinal analyses, the findings of 
this thesis show that ADHD symptoms predict new onset obesity from 8 to 16 years. Overall, 
the findings show longitudinal associations from 8 to 16 years, cross-sectional associations at 
16 years, and no evidence for associations at 8 years, suggesting that the associations develop 
over time, from childhood to adolescence. It is possible that it may take time for the 
behaviours linked with ADHD e.g. physical inactivity, to arise and contribute to weight gain. 
The concept that the ADHD-obesity association develops over the long-term has important 
clinical implications, indicating that childhood may be a key period for intervention strategies 
to prevent the development of adolescent obesity secondary to childhood ADHD.   
 
6.2.5 Sub-threshold ADHD symptoms and later risk for obesity and physical inactivity  
 
As previous research suggests that ADHD may be best considered a dimensional rather than 
discrete condition [108,109], the longitudinal and cross-sectional analyses were repeated with 
ADHD symptoms included as continuous scores instead of categorical diagnoses; similar 
associations as those described before were identified. Thus, this study shows that in the same 
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population sample, both sub-threshold ADHD symptoms and screening positive for ADHD 
confer risk for obesity and physical inactivity. Although only some of the previous studies 
that analysed the ADHD-obesity link have examined ADHD on a dimensional scale, there is 
some evidence to support the findings reported here [85,95,99]. Given the scale of the current 
obesity epidemic, these findings have important public health implications, suggesting that 
personality factors or symptoms of ADHD, which are normally distributed in the general 
population, can increase the risk for obesity and physical inactivity.  
 
6.2.6 Sex-stratified findings of the ADHD symptom-obesity association 
 
Sex-stratified longitudinal analyses showed that in both boys and girls, ADHD symptom 
scores (inattention-hyperactivity, inattention and hyperactivity) increased the risk for obesity; 
the magnitude of the associations was slightly larger in girls. Interestingly, the results showed 
sex differences in the prediction of certain obesity outcomes; in boys, ADHD symptoms 
increased the risk for overweight/obesity and abdominal obesity, whilst in girls, ADHD 
symptoms conferred risk for obesity. These sex differences are important given there is 
evidence that abdominal obesity may more accurately identify individuals at risk of health 
consequences of obesity (e.g. cardiovascular disease and adverse metabolic outcomes) 
compared with body mass [130,132]. Considering this, along with previous research 
suggesting that the health risks related with adiposity become evident at a lower level of fat in 
boys compared with girls [599], the findings presented here suggest that boys with ADHD 
symptoms may be at greater risk of the health consequences of obesity than girls. Previous 
studies that examined sex differences related to the ADHD-obesity link reveal mixed 
findings, with studies reporting no associations [83,86], associations in both boys and girls 
[90], and an association in females only [78,85,99]. The largest of these studies, a cross-
sectional study including >66,000 participants, support the present findings reported here of 
associations in both boys and girls [90]. Further, the findings here showed that ADHD 
symptoms were associated with physical inactivity in both sexes; the results suggest that 
inattention may be particularly important in predicting physical inactivity in boys, while 
hyperactivity may be particularly important in predicting physical inactivity in girls. In 
contrast to boys, inattention symptoms in girls increased the risk for binge-eating. Physical 
inactivity mediated the ADHD symptom-obesity association in only boys, and there were no 
mediatory effects of binge-eating in either sex. It is important to highlight the reduction of 
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statistical power in these sex-stratified analyses, which may account for the results e.g. non-
mediatory effect of physical inactivity in girls, despite the findings of an ADHD symptom-
physical inactivity association in girls. Further, given the link between ADHD symptoms and 
binge-eating in girls, and according to previous hypotheses [85], mediation of the ADHD-
obesity association by binge-eating may be possible in girls, despite the non-findings 
presented here. Thus, these analyses should be viewed as exploratory and further, larger 
studies are required to comprehensively examine sex differences.  
 
6.2.7 Independence of ADHD symptom-obesity association from CD symptoms  
 
Due to the high comorbidity previously reported [196] and observed in the NFBC 1986 
dataset between ADHD and CD, it is important to consider whether CD accounts for the 
associations between ADHD and obesity/physical inactivity. Childhood CD symptoms were 
also associated with adolescent overweight/obesity (BMI and WHR) and physical inactivity, 
and physical inactivity (but not binge-eating) mediated the CD symptom-obesity association. 
The  exploratory  analyses  using  only  “pure”  cases  showed  that   inattention and hyperactivity 
symptoms each remained significantly associated with abdominal obesity, and CD symptoms 
remained   associated  with  overweight.  This   suggests   that   “pure”  ADHD  and  CD  symptoms  
predict differential obesity outcomes.  These results involving  “pure”  cases  are   inconsistent  
with   the   results   involving   “non-pure”   cases   that   showed   significant   associations   across   a  
wider range of obesity/physical activity outcomes. This inconsistency may be due to reduced 
statistical power or may reflect true aetiological differences; thus further study is needed.  
The OR confidence intervals between ADHD and CD symptoms overlap, suggesting that 
there is no significant difference in the prediction of overweight/obesity by ADHD and CD. It 
may thus be the case that comorbid ADHD is most important in conferring risk. Individuals 
with ADHD and comorbid CD experience problems with impulse-control and/or reward 
processing, which may reflect a common genetic basis for behavioural disorders and obesity 
[77].  However, it is difficult to draw conclusions from the results due to the small sample 
sizes  of  “pure”  cases.  Larger  studies  are  required  to  expand  on these preliminary findings, as 
well as understand the pathways by which each type of behavioural disorder may contribute 
to obesity, and whether comorbidity confers the greatest risk.   
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6.2.8 Potential beneficial effects of physical activity on behaviour 
 
While previous studies have found that physical exercise - either a short-term training period 
or acute bout - improves behaviour in children with ADHD [206-209], this thesis extends 
these findings by identifying a long-term link between reduced physically active play and 
inattention symptoms, from childhood to adolescence. These results partly support previous 
hypotheses that physically active play may be one of the most important factors influencing 
human development [625], and that social play may alleviate ADHD symptoms in children 
[626]. In rat models of ADHD, chronic play therapy reduced hyperactivity and impulse 
control problems later in life [627]. It is possible that the beneficial effects of play on 
behaviour may be mediated by maturation of frontal lobe executive functions that are 
important for well-focused, goal-directed behaviours [626]. Moreover, in humans, there is 
extensive evidence linking physical inactivity with emotional/behavioural problems, 
cognitive impairment and scholastic difficulties in children and adolescents [167-175,628]. 
Human and animal studies suggest that physical activity positively impacts neurotransmitter 
levels [212-214], BDNF levels [218-220] and cerebral brain structure and function 
[201,220,229,230,232],  which are implicated in ADHD. Considering the available evidence, 
it is possible to speculate that regular physical activity may alleviate ADHD symptoms over 
the long-term.  
 
6.2.9 Theme I: strengths and limitations 
 
There are important strengths to this work. First, the longitudinal design made it possible to 
identify the directionality of the ADHD symptom-obesity association, as well as study the 
long-term link between ADHD symptoms and both physical inactivity and binge-eating. 
Second, a population-based sample was examined, which reduces the confounding effects 
often observed in clinical studies e.g. comorbid psychiatric disorders, symptom severity, 
referral and medication biases. Importantly, the NFBC 1986 is a stimulant-naïve population 
sample, which allows estimation of the temporal precedence of obesity, as use of stimulants 
can impact body weight. Third, symptoms of ADHD were analysed individually, showing 
that both inattention and hyperactivity contribute to the associations. Fourth, sex differences 
were studied, addressing a common limitation of previous work, and results showed 
associations for both boys and girls. However, sex-stratification reduced the power of the 
analyses, and thus further work is needed to confirm the preliminary findings reported here. 
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Sixth, examination of “pure”  ADHD  and  CD  cases  made it possible to explore whether each 
type of disorder was specifically linked with obesity.  
 
It is important to consider the results in light of the following limitations. First, despite the 
longitudinal design and attempt to control for important confounders, it is not possible to 
affirm a causal link between ADHD symptoms and obesity due to the observational nature of 
the data. Second, it was not possible to examine impulsivity symptoms because the Rutter B2 
scale does not measure impulsivity symptoms per se, and the SWAN combines hyperactivity 
and impulsivity symptoms (reflecting DSM-IV which classifies inattentive and hyperactive-
impulsive ADHD subtypes). Third, it was not possible to account for ADHD psychiatric 
comorbidities in the analyses beyond CD, due to limitations in data availability. However, 
such confounding is likely to be minimal in population studies, particularly where symptoms 
rather than clinical cases are examined [25]. Fourth, binge-eating and physical activity were 
self-reported at 16 years, which may introduce measurement errors and social desirability 
bias. Additionally, binge-eating was assessed based on a question regarding frequency of 
overeating,   yet   “loss   of   control”  was   not   specifically   evaluated,  which   is   also   important   in  
defining binge-eating according to DSM-V criteria.  Finally, MET data was unavailable at 8 
years so instead  data  on  “preference  for  physically  active  play”  was used to indicate physical 
activity levels in childhood. Although physically active play has not been validated yet as a 
measure of physical activity, it is likely to be a good marker because at 8 years the data 
correlated well with physical activity at 16 years, and previous research corroborates this and 
has   shown   that   “low   preference   for   physically   active   play”   at   8   years   associates  with   low  
cardiorespiratory fitness in adolescence [192].  
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6.2.10 Theme II: Investigating whether prenatal factors confer common risk for mental 
health and obesity 
 
6.2.11 Prenatal exposure to synthetic glucocorticoids and later mental health and 
obesity 
 
Prenatal exposure to maternal stress has been linked with psychopathology and metabolic 
impairments in the offspring, and these well-established associations have prompted further 
investigation into potential underlying pathways; foetal exposure to elevated cortisol levels is 
one such mechanism that has been consistently proposed in the literature [40,41,43,318,397]. 
Here, this hypothesised pathway was explored in a quasi-experimental manner through 
investigating the impact of prenatal sGC treatment on later behaviour and obesity outcomes. 
  
6.2.12 Prenatal exposure to synthetic glucocorticoids and mental health in children and 
adolescents 
 
6.2.13 Association between prenatal sGC and mental health in children and adolescents  
 
Consistent with the hypothesis, the results showed that both children and adolescents 
prenatally exposed to sGC scored consistently higher on psychopathology screeners, 
compared with controls, yet the findings for adolescents did not reach statistical significance.  
Specifically, the propensity-score-matched subsample showed that prenatal exposure to sGC 
treatment was significantly associated with the total Rutter and inattention scores in 
childhood, independent of relevant confounders – sex, birthweight, placental weight, socio-
demographic factors and medical factors [629].  
 
Past studies have in particular found it challenging to disentangle the effect of prenatal sGC 
on mental health from pre-term birth, which is associated with both sGC treatment and child 
mental health. Through propensity-score-matching, cases and controls were precisely 
matched on gestational age and pre-pregnancy BMI, and so it was possible to isolate the 
impact of prenatal sGC on mental health from these treatment-associated confounders. 
Therefore, these findings suggest that prenatal sGC is a potential programming agent of child 
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mental health, rather than a mere epiphenomenon that is dependent on pre-term birth. The 
robustness of the findings was tested by examining the association using the entire cohort by 
means of mixed-effects modelling. Very similar results were obtained using the entire sample 
compared with the subsample, providing further evidence that the results are unlikely to be 
affected by confounding.  
 
The findings presented here corroborate and extend previous results of observational studies 
of high-risk pregnancies in humans [445,446]. Most previous studies have examined high-
risk samples rather than normal pregnancies [445-449], making it difficult to differentiate 
between medical complications that prompted treatment and the potential effect of the 
treatment itself on the outcome. The NFBC 1986 is a community rather than high-risk sample 
and so unlikely to be biased by a host of complications that could explain the reported 
association to child mental health. Indeed, both controls and cases experienced pregnancy 
complications and were hospitalised. Out of the controls, approximately 9% experienced the 
most common causes of pre-term birth (gestational hypertension, pre-eclampsia and placenta 
previa) and 15% were hospitalised. Only one case experienced one of the most common 
causes of pre-term birth. In this sense, the results presented are more generalizable at the 
population level, rather than specific to high-risk sub-groups and so are unlikely to be 
affected by confounding of pregnancy complications. 
 
Another significant limitation of previous research is that follow-up times have mainly been 
over the short-term, restricting the assessment of behaviour to young children only (generally 
aged 7 years or less) [445-448]. The potential long-term association between prenatal sGC 
exposure and mental health was studied here by examining adolescents by way of parental-
report specific for ADHD symptoms and self-report for general mental health.  At the age of 
16 years, adolescents prenatally exposed to sGC had higher scores on indices of 
psychopathology than their counterparts, though the associations did not reach significance. 
Despite the fact that a very large population-based cohort was examined, the exposed group 
was small. Given attrition by the 16-year follow-up, only 29 cases remained for examination 
which left the analysis under-powered to detect significant differences at this point - as 
confirmed by the power analysis. The attrition analyses revealed no significant differences 
between participants and non-participants, although cases that dropped out at 16 years were 
slightly more likely to be boys and generally had slightly higher scores on the Rutter at 8 
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years. Nonetheless, the associations at 16 years were consistent with the findings reported at 
8 years.   
 
Given the concerns raised by use of repeat sGC in pregnancy [381,390] and the call for 
longitudinal research [396], it is of public health interest to study long-term risks associated 
with exposure at a low dosage. However, previous studies have mainly evaluated the impact 
of repeat doses of prenatal sGC on child mental health [445-448], despite the current 
guidelines that recommend only a single course of sGC should be administered (either 2 
doses of 12mg of betamethasone or 4 doses of 6mg of dexamethasone). Here, the impact of 
fairly low and infrequent doses of prenatal sGC was studied; the average total dose was 
15.4mg, and the maximum dosage of 25mg is approximately equal to a single course of sGC 
according to current guidelines. Thus, the findings presented here suggest that even at low 
dosages the foetal brain may be sensitive to sGC. Interestingly, the results showed that 
prenatal sGC had a non-specific effect on child mental health, as indicated by an association 
with the total Rutter, which reflects a range of emotional and behavioural problems, including 
ADHD symptoms. A total Rutter  score  of  ≥9  indicates  probable  psychiatric  disturbance,  and  
so the mean Rutter score difference of approximately 8 points between cases and controls 
reflects clinical significance.   
 
6.2.14 Potential mechanisms underlying the association between prenatal sGC and child 
mental health 
 
Cortisol may directly impact brain development because GR and MR, both of which have a 
high affinity for GC, are highly expressed in the foetal brain [630], particularly the 
hippocampus [405]. Interestingly, because sGC binds mainly to the GR as the MR has low 
affinity for sGC [409], it is possible to speculate that the effect reported here in this thesis 
may be isolated to GR activity. The results suggest that the association with mental health 
could be mediated via the GR pathway, which is expressed in a variety of forms and leads to 
altered gene expression; further work is needed to investigate this potential pathway.   
 
Animal studies have shown that prenatal sGC exert widespread effects on the developing 
brain, reducing neuron proliferation [402], as well as affecting neuron structure and synapse 
formation [404]. A recent study in humans showed that repeat prenatal exposure to sGC was 
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associated with a significantly lower density of neurons in the hippocampus of pre-term 
neonates [405]. Similarly, a study in rhesus monkeys demonstrated a link between repeat 
prenatal sGC exposure and reduced number of hippocampal neurons and hippocampal 
volume in offspring aged 10 months [406]. Human and animal studies have shown that 
altered hippocampal structure is associated with psychopathology, including ADHD [631-
633]. In human neonates born at or close to term, a small study (n=16) using magnetic 
resonance imaging (MRI) showed that exposure to repeat doses of prenatal sGC was 
associated with impaired cortical folding [408]. Longer-term structural changes have also 
been detected by MRI in the brains of children (aged 6-10 years) who were born at term and 
exposed to a single course of prenatal sGC [634]. There were significant reductions in the 
thickness of the rostral anterior cingulate cortex (a brain region associated with affective 
problems) in children exposed to prenatal sGC. Furthermore, thinning of the anterior 
cingulate cortex was in turn associated with affective problems (e.g. depression and anxiety); 
however, there was no direct association detected between prenatal sGC and affective 
problems. Together, these findings suggest that prenatal sGC can affect the structure and 
function of the developing brain, and thereby potentially impact long-term mental health.   
 
GR and MR are also highly expressed in the limbic system, hypothalamus and cortex, which 
are regions of the brain that are vital for regulating the HPA axis [635]. It is suggested that 
prenatal GC can influence the development and long-term function of the HPA axis [636]; 
this may bear significant implications for mental health problems, including ADHD, which 
have been related with a dysregulated HPA axis [297,300-303].  There is extensive evidence 
from animal studies demonstrating that prenatal sGC affects foetal HPA axis development, 
consequently causing permanent changes in HPA axis function and thereby behaviour [409]. 
Although very little is known about the long-term impact of prenatal sGC on HPA axis 
function in humans, recent research in children (collectively aged 6-11 years) born at term 
showed that prenatal sGC exposure was associated with increased HPA axis reactivity in 
response to acute psychosocial stress [637,638]. In two adult studies (one sample of preterm 
births followed up at 19 years and the other a largely preterm sample followed up at 30 
years), prenatal sGC exposure was not associated with any significant difference in basal 
plasma cortisol levels; however, stress response was not examined in these studies [417,639].  
 
Prenatal GC may also affect the HPA axis indirectly through its effects on the developing 
thyroid and liver, both of which influence systems that are involved in HPA axis 
 
 
249 
 
development [640]. Thyroid hormone is essential for normal brain development, including 
maturation of neurotransmitter systems [641]. The liver plays an important role in the 
production of corticosteroid-binding globulin as well as 11β-HSD1, both of which directly 
influence cortisol levels in the foetus [642]. GC may also impact epigenetic processes, as 
demonstrated by human and animal research showing that prenatal sGC and maternal stress 
can result in epigenetic modifications to the DNA of offspring, which in turn have been 
associated with long-term changes in gene expression [640]. Several HPA axis regulatory 
genes, e.g. GR, MR, CRH, proopiomelanocortin (POMC) and 11β-HSD2, are regulated by 
DNA methylation and histone acetylation, and there is some evidence that epigenetic 
modification of these genes may be influenced by prenatal GC [640].  
 
6.2.15 Birthweight and placental weight as potential mediators underlying the 
association between prenatal sGC and child mental health  
 
The hypothesis that deviation in birthweight or placental weight mediates the association 
between prenatal exposure to sGC and child mental health was tested. It is possible that 
altered birth size and/or placental size, both of which have been linked to prenatal sGC 
exposure [47,381] and child mental health [37,643], may lie on the GC programming 
pathway. The mediation analyses showed that prenatal sGC was significantly associated with 
reduced birthweight, confirming previous findings [381], but birthweight was not associated 
with mental health, and consequently did not mediate the link between sGC and 
psychopathology. There was also no evidence for mediation by placental weight; placental 
weight was not significantly associated with either prenatal sGC or mental health. 
Interestingly, the association between prenatal sGC and placental weight was positive and 
close to significance (p=.05), and there was a significant link between prenatal sGC and 
increased placental-to-birth-weight ratio. This suggests that in response to prenatal sGC, the 
placenta may undergo compensatory enlargement as a mechanism to minimise the impact of 
sGC on foetal growth and development; although the results show that birthweight remains 
significantly affected. One previous study has reported a link between prenatal maternal 
stress and increased placental weight [46], providing some limited indirect evidence to 
support this finding. However, most previous research has directly demonstrated the contrary 
- that placental size is reduced in response to prenatal sGC [47]. This discrepancy may be 
because, in contrast to this thesis which studied the impact of low sGC dosage, previous 
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research has focussed on examining the effect of repeat sGC doses. It is possible to speculate 
that the placenta may only undergo compensatory enlargement in response to small sGC 
doses; above a certain dosage threshold the placenta may undergo alternative adaptations, 
including a reduction in size. There is evidence to suggest that increasing doses of sGC are 
associated with greater reductions in both placental size and birth size [47,381]. Thus, it is 
possible that low/infrequent doses of sGC, which were assessed, may not exert a large effect 
on birth or placental size [47,644], which could explain the lack of mediation by these 
factors. Further, recent evidence in humans shows that elevated maternal cortisol, though 
within the normal range, is associated with reduced foetal brain growth but not body growth 
[645]. Taken together, these findings suggest that the foetal brain may be more sensitive to 
GC exposure than it is to reductions in foetal size.   
 
Experimental evidence shows that in addition to impacting placental size, prenatal sGC and 
endogenous GC can affect a range of placental functions via e.g. inhibiting the production of 
placental lactogen, and altering placental vascularisation and structure as well as placental 
nutrient transfer [646]. These changes can affect foetal development, and may represent other 
mechanisms via which GC program the HPA axis [640], and thereby psychopathology. 
Interestingly, a recent study in humans demonstrated that prenatal exposure to sGC was 
associated with reduced system A amino acid transporter activity in term placentas [647]. 
This suggests that reduced amounts of system A neutral amino acid substrates are transferred 
to the foetus following sGC exposure, which may impact foetal growth and development 
[647], potentially including brain development (given the importance of amino acids for 
normal brain development [648]). Evidently, further research into the role of placental 
structure and function in GC programming is necessary to improve understanding of 
mechanisms underlying the link between prenatal GC and later psychopathology.  
 
6.2.16 Potential impact of timing of prenatal sGC exposure on child mental health 
 
Interestingly, the results showed that an increased interval between the time of prenatal sGC 
exposure and birth was associated with increased birthweight and a trend for lower problem 
behaviour scores. This suggests that increased interval time provides an opportunity for 
‘catch-up’   growth   whereby   the   foetus may undergo adaptations in response to sGC, 
minimising the final effect of sGC on birth size and possibly brain development. This may 
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have significant clinical ramifications, indicating a need to monitor children who experienced 
a short interval between prenatal sGC exposure and delivery.  
 
Of particular relevance to the work presented here, there is evidence of ontogenetic changes 
in the expression levels of the P-glycoprotein transporter (highly expressed in the placenta 
and foetal blood-brain barrier [649,650]), which is an efflux transporter of both endogenous 
GC and sGC [651], and thought to play a protective role in reducing the transfer of GC from 
maternal to foetal circulations [640]. In late gestation, P-glycoprotein levels decrease in the 
placenta and simultaneously increase in the endothelial cells of the foetal blood-brain barrier 
[649,650]. Thus, P-glycoprotein may provide the foetal brain with some degree of protection 
from the high levels of endogenous GC that arise during late gestation, as well as protection 
from sGC treatment administered late in gestation. Further studies are required to determine 
the threshold level of sGC at which P-glycoprotein remains effective in protecting the brain; 
this research may potentially have implications for dosage levels of sGC administered in 
clinical practice.   
 
The effect of timing of prenatal GC exposure on foetal development may also depend on the 
expression of GR and MR receptors as well as placental 11β-HSD2, which change over the 
course of pregnancy [640]. The expression of the corticosteroid receptors throughout 
gestation is highly region-specific, resulting in differing local sensitivity to both sGC and 
endogenous GC [640]. During late gestation, placental 11β-HSD2 levels are reduced, 
facilitating increased transfer of GC from the mother to the foetus [640], which is necessary 
to trigger final maturation of foetal organs [390]. This change in placental 11β-HSD2 levels 
is mainly of significance to the transfer of endogenous GC (and thus has implications in 
prenatal maternal stress), since the placental enzyme extensively metabolises endogenous GC 
but not sGC [388,394,395]. Collectively, changes in the expression levels of P-glycoprotein, 
corticosteroid receptors and 11β-HSD2 over the course of gestation can impact the amount of 
endogenous GC and sGC that the foetus is exposed or sensitive to, and may partly account 
for the variable effects of prenatal maternal stress and sGC on foetal programming at 
different stages of gestation [640].  
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6.2.17 Prenatal exposure to synthetic glucocorticoids and obesity in children and 
adolescents  
 
Contrary to the hypothesis, there was no significant association detected between prenatal 
exposure to sGC and obesity in children or adolescents. However, there was a trend for 
positive associations between prenatal sGC and measures of obesity at 8 years (BMI) and at 
16 years (BMI and WHR). Furthermore, the positive association between prenatal sGC and 
BMI at 8 years was close to significance (p=.08; mean BMI difference between cases and 
controls=2.23). It is important to highlight that the power-analysis showed that the analysis 
was underpowered to detect significant differences at either 8 years or 16 years. This is 
unsurprising since there were few sGC cases with available BMI (n=31 at 8 years and n=25 
at 16 years) and WHR (n=27 at 16 years) data. While only a small number of cases 
experienced overweight/obesity (n=3; 9.7% at 8 years and n=4; 16% at 16 years), and or 
abdominal obesity (n=1; 3.7%), the proportion of these compared with the controls was high 
(but not statistically significant). Despite the small sample size of cases and lack of power, 
the consistent positive trends that were observed suggest that associations may potentially 
exist, and further investigation with larger sample sizes is warranted to clarify the findings.  
 
Currently, there are very few human studies to refer to in this field, and overall the findings 
do not report an association between prenatal GC and obesity, yet there is some limited 
evidence. One study (n=1320) found that elevated maternal cortisol levels were related with 
higher fat mass index in girls, and lower fat mass index in boys, suggestive of sex-specific 
effects [459]. In contrast, a case-control study (n=534) showed that prenatal sGC exposed and 
unexposed adults did not differ on body composition (weight, height, BMI and WHR), or 
other cardiovascular risk factors [417]. Similarly, another case-control study (n=81) reported 
no differences in body composition (weight and height) in prenatal sGC exposed and 
unexposed adults [460]. However, important limitations of both these case-control studies are 
small sample sizes and comparisons between exposure and non-exposure could not be fully 
assessed because of methodological restrictions (i.e. unexposed group were exposed to a 
small portion of sGC potency [417] or exposed group were administered sGC plus 
orciprenaline [460]). Other related work has demonstrated associations between prenatal sGC 
treatment and higher blood pressure in childhood [461], early signs of insulin resistance in 
adulthood [417], as well as other adverse metabolic outcomes in the offspring, including 
increased levels of neonatal cord blood leptin [462]. There is also some indirect evidence 
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from studies that show a link between prenatal maternal stress and overweight/obesity in 
children and adolescents [40,458], and in young adult men [652]. 
 
Animal studies have consistently shown that prenatal exposure to GC, either endogenous or 
synthetic, can program obesity, as well as other metabolic factors e.g. blood pressure, glucose 
and insulin levels, as described in reviews [42,392,452]. Given the consistent animal 
evidence, and a trend for positive associations between prenatal sGC and obesity measures in 
the NFBC 1986 despite lack of power, large population studies are needed to clarify the 
association in humans.  
 
6.2.18 Theme II: strengths and limitations 
 
There are several strengths to this work, which address common limitations of previous 
research. First, for the mental health analyses, propensity-score-matching was used to account 
for treatment-selection bias (thereby partly mimicking an RCT), in particular gestational age 
and pre-pregnancy BMI, and so it was possible to isolate the effect of the drug from these two 
significant confounders associated with receipt of treatment. The NFBC 1986 is a large 
dataset which allowed very precise matching of cases to controls on the logit propensity 
scores. Thus the results presented are not due to pre-maturity, which its threat would prompt 
treatment, and is known to be a risk for poor neurodevelopmental outcomes, including 
ADHD [611,653], nor pre-pregnancy BMI which was also associated with treatment in this 
sample as well as ADHD [260,261]. The matched cases and controls were also balanced on 
other important confounders, and these confounders were additionally adjusted for in the 
main analysis. Thus, confounding related to sGC treatment and mental health was minimised 
as much as possible. Additionally, the results produced from the propensity-score-matched 
subsample were replicated using the entire cohort by means of mixed-effects modeling, 
demonstrating the robustness of the findings.  Second, precise case classification (exposed >4 
days prior to delivery) was applied to ensure that the drug had sufficient time to act on foetal 
organs including the brain. Studies which do not take exposure time into consideration e.g. 
Dalziel et al. (2005) [450] may be more likely to report null findings as the drug may not 
have had time to act on the foetal brain. Third, the impact of fairly low/infrequent doses of 
sGC was examined, which correspond to current guidelines in clinical practice. Fourth, by 
capitalising on the natural experiment in which pregnant women are treated with sGC, it was 
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possible to explore the hypothesised pathway between foetal overexposure to GC and child 
psychopathology and obesity. 
 
There are also limitations of this research which are important to consider. First, the number 
of sGC cases with available mental health (n=37) and in particular obesity (n=31) data at 
baseline was small. As a result, the obesity analyses were underpowered, although there were 
consistent trends identified at both 8 and 16 years. For the mental health analyses, attrition 
was a limitation, and with a loss of 9 cases by the 16-year follow-up, the analyses were 
under-powered at this point, which is a likely explanation for non-significant findings at this 
age. Second, although the NFBC 1986 is a prospective cohort, it was not originally designed 
to examine sGC treatment outcomes. As a recent chart review was performed to identify sGC 
cases, unmeasured confounding cannot be ruled out. Third, it is not possible to completely 
rule out that the observed differences in mental health scores may be due to the complications 
of pregnancy which prompted sGC treatment. However, this seems unlikely here as both 
cases and controls experienced pregnancy complications, and the matching procedures 
ensured that cases and controls were balanced on important confounders. Due to the very 
small number of sGC cases experiencing pregnancy complications known to be a risk for pre-
term birth (n=1), it was not possible to study these as sub-groups. Further work is required to 
determine the impact of pregnancy complications on later mental health with larger samples. 
Finally, sGC cannot be directly equated to endogenous maternal GC. sGC and endogenous 
GC largely bind to different types of steroid receptors and so may have different biological 
effects. Despite this, sGC provides a useful quasi-experimental model in the absence of direct 
experimental manipulation in humans and provides a tentative proof of concept, warranting 
further research into the role of endogenous GC in the programming of psychopathology.  
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6.2.19 Investigation of placental size in conferring common risk for mental health and 
obesity 
 
6.2.20 Placental size and mental health 
 
6.2.21 Association between placental size and mental health in children and adolescents  
 
The results showed a positive association between placental size (placental weight, surface 
area and placental-to-birth-weight ratio) and mental health problems in boys. Increased 
placental size was linked with overall probable psychiatric disturbance, ADHD symptoms 
and antisocial disorder at 8 years of age, and ADHD symptoms at 16 years [643]. Relevant 
confounders were controlled for and thus the results suggest independent associations by 
placental size. It is important to note that the magnitude of the associations were small; 
however since psychiatric disorders are highly complex – in terms of both aetiology and 
diagnosis, one might expect to identify only small effects when considering just one aspect of 
psychopathological development. The findings suggest that variation in placental size may 
contribute to the causal pathway linking prenatal exposures to later mental health problems.  
 
6.2.22 Potential impact of increased placental size on foetal development  
 
Placental size is affected by a range of maternal factors, such as BMI, gestational weight gain 
and smoking [44], as well as various other medical and socio-demographic factors, as 
demonstrated by the results in this thesis, indicating that the placenta is receptive to the 
maternal environment. There are several lines of evidence suggesting that placental 
overgrowth may occur as a compensatory mechanism in response to various maternal 
prenatal insults e.g. undernutrition, psychosocial stress and low iron levels [46,480,654,655], 
most likely to allow increased extraction of nutrients and other resources from the mother, in 
an effort to maintain foetal development under suboptimal conditions.   
 
There are two possible theories which may explain how increased placental size could 
potentially adversely affect foetal development. First, if compensatory placental expansion is 
insufficient, and the foetus continues to be undernourished, then the need to share nutrients 
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with an enlarged placenta may exert additional metabolic demands on the foetus [508]. In 
such circumstances, it is possible that foetal wasting may occur to provide amino acids for 
placental consumption [656,657]. Second, although placental enlargement may increase 
overall nutrient provision to the foetus, the supply may be unbalanced. It is possible that 
glucose supply to the foetus is increased, but the transfer of other nutrients, such as proteins, 
may not be matched, probably because of differing energy requirements needed to transport 
nutrients across the placenta; glucose is transferred by diffusion – which does not require 
energy, while protein is transferred by active transport – which requires energy [520]. In 
essence, both theories imply that an enlarged placenta may alter nutrient supply to the foetus 
(in particular amino acid/protein supply which is important for foetal brain development 
[648]); consequent foetal adaptations may lead to permanent structural and physiological 
changes to developing organs, programming an increased risk of disease. The results 
presented in this thesis are in line with this, such that it is possible to speculate that increased 
placental size – a possible consequence of an adverse maternal environment, may alter foetal 
nutrient supply, which in turn may affect normal brain development [648,658], increasing the 
risk of psychiatric problems later in life. In support of this potential mechanism, prenatal 
psychosocial stress, a common environmental insult, has been associated with increased 
placental weight [46], and has been directly and independently linked with atypical cerebral 
laterality [433,434], and an increased risk of psychiatric problems in children [41,318]. 
Furthermore, atypical cerebral lateralisation, which has been linked to child and adolescent 
mental health problems (including ADHD [435,659]), was detected in 8-9 year old children 
who had a moderately low birthweight and disproportionately large placenta [660]. On the 
surface, it may seem that the suggested mechanism implies that an increased placental-to-
birthweight ratio would be the strongest predictor of psychiatric outcomes. However, 
compensatory mechanisms in the expanding placenta may ensure that overall nutrient supply 
in increased so that a normal birthweight is still achieved despite suboptimal conditions 
[463]; although, at the same time, the relative contribution of specific nutrients to foetal 
organs may be altered, resulting in the programming of developing organs. This concept 
could explain why placental weight was found to be the strongest predictor of 
psychopathology, compared to the other placental characteristics which were studied. Thus, 
an enlarged placenta may represent an important link between disturbances in the maternal 
environment and perturbed foetal brain development, with ensuing mental health problems in 
children and adolescents.  
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Since placental compensatory mechanisms may often ensure a normal birthweight is 
achieved in adverse circumstances whilst the placenta itself may be markedly affected [465], 
this suggests that the placenta can provide insight into the physiological stresses which 
occurred during development.  Therefore, compared to birthweight and other common 
indices used to identify suboptimal intrauterine conditions, placental phenotype can provide 
additional information about the intrauterine environment and improve our understanding of 
the processes underlying foetal programming. Furthermore, placental size may improve the 
ability to predict later disease, as several lines of evidence suggest [464,465,482]. 
 
Interestingly, placental size was related to a range of mental health problems (including 
general probable psychiatric disturbance) in the NFBC 1986. This may correspond to the 
understanding that placental size is sensitive to various maternal influences, and thus possibly 
represents an archive of gestational insults, which could affect the developing brain non-
specifically.  
 
Whilst increased placental size has been linked with various adult diseases, there have been 
studies which suggest that decreased placental size may also be associated with these same 
disorders. Indeed, there is evidence which indicates that several metabolic outcomes exhibit a 
U-shaped relationship with placental size [470]. In this thesis, a positive linear association 
was identified, which may be explained by factors related to the direction of placental-foetal 
growth disproportion, including maternal nutritional status and the timing of prenatal insults. 
Previous research has shown that in the offspring of mothers who were short and of low 
socio-economic status, hypertension was associated with small placental size, whilst in the 
offspring of tall, middle class mothers, who were likely to have a better lifetime nutrition, 
hypertension was related to large placental size [507]. As Finland is a high income country, it 
is likely that the general nutritional standard of the nation is good. Furthermore, Finland has 
an exemplary antenatal care system, along with very low infant and maternal mortality rates 
[547]. Thus, it is likely that women in the NFBC 1986 experienced compensatory placental 
growth in response to adverse prenatal conditions. Extreme maternal undernutrition at early 
and late stages of gestation have respectively been associated with increased and reduced 
placental size [480]. This correlates with the understanding that in early gestation, placental 
growth potential is greatest, so prenatal insults at this stage most likely induce placental 
growth [660].  In contrast, placental adaptations to insults in late gestation normally result in 
changes to placental structure and function, because placental expansion at this stage is 
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limited [660]. It is possible to speculate that prenatal insults related to socio-demographic 
factors, which tend to be chronic, may induce a trajectory for increased placental size from 
the start of pregnancy. Acute, late gestational insults may alone reduce placental size; 
however such insults are less common than perhaps chronic stressors and so the effect of late 
gestational insults on placental size may be diminished, thereby masking a potential 
association between small placental size and mental health problems. 
 
In support of the concept that early gestational insults may be related to the observed positive 
association between placental size and mental health problems, previous work has 
demonstrated that foetal exposure to maternal stress and smoking in the beginning of 
pregnancy are associated with ADHD symptoms in childhood [318]. It has been suggested 
that exposure to adverse conditions in early gestation may be more detrimental to some 
aspects of offspring health than later exposure [318,661]. It is possible that an enlarged 
placenta may provide a link between chronic, early gestational insults and psychiatric 
outcomes.    
 
6.2.23 Sex-specific effect of placental size on mental health in children and adolescents  
 
The results showed that large placental size was associated with psychopathology only in 
boys. Research suggests that male placentas may more readily undergo compensatory growth 
in response to maternal prenatal insults because of sex differences in foetal and placental 
growth [508,511]. Compared to girls, boys grow faster throughout gestation [662], are 
usually longer at any placental weight and have a smaller placental-to-birth-weight ratio 
[512]; thus male placentas may be more efficient but have less reserve capacity, causing them 
to be more vulnerable to undernutrition [508]; and presumably to other forms of 
physiological stress. A recent review suggested that male and female placentas exhibit 
marked differences in their adaptations to the same adverse intrauterine conditions [511]. 
Male placentas may undergo minimal adaptations with few gene, protein or functional 
changes in the placenta in order to allow increased or continued placental and foetal growth 
[511]. In contrast, female placentas may undergo multiple placental gene and protein 
adaptations under adverse intrauterine conditions to reduce growth [511]. Consistent with 
this, one study found that in response to maternal asthma during pregnancy, there was no 
change in the activity of the male placental 11β-HSD2 enzyme (the feto-placental barrier to 
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maternal cortisol), and the foetus continued to grow [663]. Conversely, females showed 
reduced placental 11β-HSD2 activity and decreased foetal growth [663]. The authors 
suggested that this lack of functional response by the male placenta may contribute to the 
well-known increased risk of morbidity and mortality of the male foetus [663], and it is 
possible that this may also contribute to long term sex differences in child and adult health, as 
the results of this thesis suggest [508]. 
 
6.2.24 Placental size and obesity 
 
The results showed there was no association between placental size and obesity in children or 
adolescents, after adjusting for relevant confounders. This may be because there are other 
important factors, e.g. genes, to consider when examining the association with obesity; 
indeed, there is a strong heritable component to obesity [613]. In line with this, there is only 
one study that has reported a link between increased placental size and obesity in adults, 
which  was  in  a  subsample  of  individuals  who  carried  the  Pro12Pro  genotype  of  the  PPARγ2  
gene and who had tall mothers (suggesting good  maternal   lifetime  nutrition).  The  PPAR  γ2  
gene has been linked with overweight and is also known to play a role in placental 
development. Thus, the findings suggest that interactions between maternal nutrition and 
genes related with the placenta/obesity influence the risk for later obesity. However, further 
work is needed to clarify and expand on these preliminary findings, and sexual dimorphism 
should be examined due to important sex differences in the placenta and the risk for obesity.  
 
There is some indirect evidence for a link between increased placental size and later obesity. 
Increased placental weight and placental-to-birth-weight ratio have been linked with 
gestational diabetes [664], which has been directly related with obesity in 
children/adolescents [665] as well as indirectly via macrosomia (large birthweight) [666]. 
Despite the strict clinical control of blood glucose levels in pregnancies complicated by 
gestational diabetes, the prevalence of foetal and placental overgrowth in such patients 
remains particularly high. Whilst this may be due to the concept that normal glucose levels 
cannot be achieved in diabetic pregnant women, it has been proposed that placental 
adaptations may play a significant role, given the enlarged placental size in these pregnancies 
[664]. Increases in the placental surface area or transporter densities may enhance placental 
nutrient exchange, leading to foetal overgrowth in diabetic pregnancies. For example, the up-
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regulation of placental glucose, lipoprotein lipase and System A amino acid transporters have 
been reported in diabetic pregnancies [667]. Interestingly, a study in rats indicated that 
temporary hyperglycaemia in early gestation was associated with decreased placental System 
A activity and unaltered glucose transport, in combination with increased placental and foetal 
weights at term [668]. These results indicate that even transient periods of metabolic 
disturbances in early gestation can affect placental transport systems, as well as placental and 
foetal growth for the remainder of the pregnancy. From these findings, it is possible to 
propose that maternal metabolic perturbations may induce enhanced placental nutrient 
transport via increases in placental size, which may contribute to foetal overgrowth, in turn 
leading to macrosomia and later obesity.   
 
6.2.25 Placental size in relation to placental function and limitations 
 
Most notably, variation in placental size affects its ability to transfer nutrients via changes in 
the exchange surface area [463], and placental size is directly proportional to foetal size 
[468]. Furthermore, human and animal studies have demonstrated that variation in placental 
size may also be associated with alterations in placental morphology, gene expression e.g. 
placental nutrient transporter and growth factor genes, hormone production, and foetal blood 
supply, each of which may influence nutrient transport capacity as well as other placental 
functions [463,478,669].  For example, pregnant ewes exposed to heat stress or overnutrition 
exhibit compromised placental growth, along with altered placental morphology in the form 
of reduced vascularity, in association with decreased expression of vascular endothelial 
growth factor (VEGF) and its receptor in the placenta [670]. Certain complicated pregnancies 
e.g. diabetes and intrauterine growth restriction (IUGR) are related with abnormal placental 
growth and changes in placental nutrient transporter expression. In human diabetic 
pregnancies, which are associated with enlarged placental size, the expression of placental 
glucose, lipoprotein lipase and System A amino acid transporters are increased [465]. In 
human IUGR pregnancies, which are associated with reduced placental size, the expression 
of placental lipoprotein lipase and System A amino acid transporters are decreased, whilst 
glucose transporter expression is unaffected [465]. These findings are in line with the 
numerous observations in animals which indicate that deviation in placental growth is related 
to alterations in the quantity and specific type of nutrients delivered to the foetus [463]. 
Furthermore, altered expression of placental insulin-like growth factor 2 (Igf2) gene, which 
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controls placental growth, has been reported to affect placental phenotype and efficiency in 
mice [478]. Although, as described, placental size may reflect several aspects of placental 
function, ultimately function is determined by the histomorphology and gene expression of 
the placenta.  Recent work has found that the expression of placental 11β-HSD2 mRNA is 
decreased in anxious pregnant women [393]; since increased foetal exposure to cortisol has 
been associated with neurodevelopmental disorders later in life [41], it is possible that 
reduced placental 11β-HSD2 activity provides a link between altered placental function and 
foetal programming [43]. In animals, reduced 11β-HSD2 levels have been associated with 
decreased placental weight [671]; future studies should investigate whether this is also the 
case in humans, which should provide further insight into how placental size relates to 
function. Also, the protocol used to measure placental weight is of importance in this field of 
research. In the NFBC 1986, placental weight included membranes and the umbilical cord, 
which are not involved in nutrient exchange. Thus, this measurement may in particular affect 
estimation of the placental-to-birth-weight ratio, and is a limitation to consider.  
 
6.3 Overall summary of findings 
 
Overall, the findings showed that the focal association under study was driven from the 
direction of ADHD symptoms to obesity from childhood to adolescence, and that physical 
inactivity was a behavioural mediator underlying the association. Although there was no 
evidence to suggest that ADHD symptoms and obesity share common prenatal risk, prenatal 
sGC and placental size were positively associated with later mental health problems, 
including ADHD symptoms.  
 
6.4 Overall strengths and limitations of research 
 
The major strength of this research is the use of a large, prospective, longitudinal population-
based birth cohort (NFBC 1986), which is well-designed to examine life course disorders, 
such as ADHD and obesity. There were high participation rates (99% at baseline, 91% at 7-8 
years and 77% at 15-16 years) from this unselected population sample. Further, the NFBC 
1986 is a rich dataset, with a wide array of information collected on health and socio-
demographics at several time-points, allowing scope to control for a range of potential 
confounders. With this in mind, along with the prospective and longitudinal design of the 
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study, it is possible to tentatively draw causal inferences from the analyses. Further, wherever 
possible in this thesis, specialised methods to estimate causality or causal pathways were 
applied to the data. However, despite these strengths, due to the observational nature of the 
data, unmeasured confounding is possible and thus causal associations cannot be confirmed. 
Furthermore, similar to other longitudinal studies, attrition is a limitation of this research, and 
may bias the results. However, attrition analyses performed throughout this thesis showed 
that the findings are not likely to be significantly affected by participant drop-outs.  
 
As data was collected from participants prospectively, recall bias is expected to be minimal in 
the NFBC 1986. Further, wherever possible, clinical data was examined to reduce bias. For 
example, medical information on pregnant women was obtained from hospital records.  
Measurements of birth outcomes, including birthweight and placental weight, which were 
performed by medical personnel at the time of birth according to standard protocols, were 
also obtained from hospital records.  
 
The study of ADHD symptoms and obesity in the general population minimises the 
confounding effects often observed in clinical research. Further, use of a population sample 
allowed analysis of ADHD symptoms on a dimensional scale, which is important as there is 
evidence to suggest that ADHD is best considered dimensionally as symptoms or personality 
traits within a population [107-109]. Individuals clinically diagnosed with ADHD are 
typically at the extreme end of the spectrum of ADHD symptoms, and so clinical studies do 
not provide insight into the dimensional aspects of ADHD. The mental health of children and 
adolescents was examined via multiple informants (teachers, parents and self-report) using 
validated screeners of psychopathology, strengthening the reliability of these measures. 
Teachers in particular are important and reliable informants of child behaviour [88], and are 
normally the first to detect behavioural deviations as children with ADHD often disrupt the 
classroom. However, there will inevitably be some imprecision in teacher and parental ratings 
of ADHD behaviour compared with the gold standard of assessing ADHD via clinical 
diagnosis. Specifically, the Rutter B2 (teacher report) assesses probable ADHD based on only 
3 items, in contrast to the DSM V, which assesses 18 items to diagnose ADHD [7]. Also, the 
Rutter B2 does not assess impulsivity, which is a core symptom of ADHD. Furthermore, the 
Rutter B2 does not measure behavioural strengths (in contrast to the SWAN), and so may 
generate skewed behavioural scores. Thus, the Rutter B2 could possibly increase the risk of 
over/under identifying children with ADHD behaviour.  
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Two indices of obesity (BMI and WHR) in adolescents were studied, to provide a more 
complete measure of adiposity, and these were obtained through clinical assessments. 
However, measurements of height and weight at 7 years were reported by mothers rather than 
clinically measured; although it is likely that mothers provide reliable information on these 
measures because child height and weight are regularly measured at routine health check-ups 
in Finland. BMI and WHR are both relative indices of adiposity; these measures do not 
provide information on body composition i.e. fat versus lean body mass, and thus are indirect 
measures of body fat. However, direct methods of measuring adiposity, e.g. MRI and 
computerized axial tomography (CT or CAT), also have limitations and may not be 
appropriate for large scale studies. These methods are expensive, time consuming 
(procedures can take around 20 minutes requiring the subject to remain still and thus may be 
unsuitable for children), and can involve significant radiation exposure (e.g. CT scans) [27]. 
In the absence of suitable direct measures of adiposity, anthropometric measures, which are 
most commonly used in research, provide an appropriate alternative as they offer good 
reliability and validity, provided measurements are performed by trained professionals 
according to standard protocols [27].  
 
6.5 Conclusion and health implications 
 
This thesis provides evidence for a long-term association between ADHD symptoms and 
obesity from childhood to adolescence, and shows that the association was driven from the 
direction of ADHD symptoms to obesity. Exploration of potential underlying pathways 
showed that physical inactivity mediated the association, yet there was no evidence to suggest 
that prenatal factors confer common risk for both ADHD symptoms and obesity. The results 
did however reveal that prenatal exposure to sGC and enlarged placental size increased the 
risk for later mental health problems, including ADHD symptoms. Considering the escalating 
prevalence of both ADHD and obesity, these novel findings are of public health significance, 
providing insight into the pathology, early-life programming and risk factors for both 
disorders. This research paves the way for new prevention/treatment strategies for these 
chronic disorders, in both clinical and population settings, and in particular lays the 
groundwork for future studies that aim to examine whether obesity rates can be reduced with 
ADHD treatment, where appropriate.  
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Before discussing the potential clinical and public health implications of the findings, it is 
important to consider the generalizability of the results. As the NFBC was launched in 1986 
in Finland, time and geographical/cultural differences must be considered. 
Childhood/adolescent obesity has increased dramatically over the past 30 years, and 
awareness and understanding of ADHD has grown in recent decades; there is also evidence 
for geographical differences in prevalence rates of these disorders [27,597]. As such, the 
prevalence rates of obesity and ADHD symptoms reported in the NFBC 1986 are likely to 
differ from those of today, in both Finland and internationally. For example, the prevalence 
of overweight/obesity in 8-year-olds in the NFBC was 17.3%, which is lower than the recent 
estimated rates of 20% reported in Finland (10-year-olds, according to a study in 2006) [672], 
and 33% reported in England (10-11-year-olds, according to Public Health England, 
2012/2013) [673]. The geographical difference in obesity rates could be partly due to 
cultural/lifestyle differences e.g. physical activity levels are generally higher in Finland and 
other Nordic countries compared with the UK [160]. Reports of ADHD rates vary 
substantially across different countries, ranging between 2.2-17.8% [674]. A recent study 
suggests the worldwide prevalence of ADHD in youth is around 5% [6], which is lower than 
the 9.4% rate of child probable ADHD in the NFBC. This discrepancy may partly be due to 
the lack of a definitive test or biomarker for ADHD, which means that assessment of ADHD 
symptoms relies on behavioural descriptions which can be somewhat subjective, and 
influenced by a range of factors e.g. diagnostic criteria, methodological differences in 
psychopathology screeners, culture and ethnicity [674].  
 
6.5.1 Clinical implications 
 
As ADHD typically manifests in childhood [5], and because, as this thesis shows, the ADHD 
symptom-obesity association develops over the long-term, from childhood to adolescence, 
childhood may be the optimal target period for intervention strategies. Children with ADHD 
could be monitored and treated for overweight at an early stage, thereby preventing a 
developmental trajectory of obesity into adolescence. It may also be beneficial to monitor the 
weight of children with other disruptive disorders that are linked with ADHD, including CD. 
Over the long-term, children with ADHD or other disruptive disorders may also be at 
increased risk for metabolic disturbances (e.g. insulin resistance, hypertension and high 
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cholesterol levels) and diseases (e.g. diabetes, cardiovascular disease and cancer) related with 
obesity; studies with longer follow-up into adulthood are required to examine this.  
 
Childhood/adolescence is also a period where adulthood health and lifestyle patterns begin to 
form [675-678], which provides further justification for potential intervention at this early 
stage. For example, childhood ADHD symptoms can persist into adulthood in up to 70% of 
cases [676], and so tackling both behaviour and potential weight related problems early on 
may be important for long-term adult health outcomes. Physical inactivity is a lifestyle factor 
that was found to play an important role in mediating the ADHD symptom-obesity 
association, and was found to be more prevalent among children and adolescents screening 
positive for ADHD compared with their typically developing counterparts. These findings, in 
addition to the well-known association between physical inactivity and obesity [164], suggest 
that physical activity should be particularly encouraged among children with ADHD to 
reduce the risk of obesity. A recent review stated there is a need for non-pharmacological 
interventions to reduce comorbid ADHD-obesity [123], and this thesis paves the way for 
future studies to examine whether physical activity programmes may be one such potential 
strategy.  
 
Pharmacological studies suggest that stimulants used to treat ADHD could also reduce the 
risk of obesity or improve weight status [78,267,679,680]. This is in line with consistent 
reports  of   “loss  of   appetite”   as   a   common   side-effect of stimulant medication [52,53]. It is 
possible that through activation of common brain pathways, e.g. dopaminergic pathways, 
implicated in both ADHD and obesity, stimulants may act to treat both disorders [123]. 
Preliminary studies provide evidence that stimulants can improve both conditions in patients 
with comorbid ADHD and obesity [133,290]. For example, Levy et al. (2009) demonstrated 
that in patients with comorbid ADHD and obesity, stimulant treatment resulted in 
improvements to ADHD behaviours and related EF e.g. impulsivity, working memory and 
distractibility, which in turn were important for compliance with weight loss plans and 
consequent weight reduction [133]. The authors noted that appetite suppression only occurred 
for a short period at the start of treatment [133], and so it is unlikely that appetite suppression 
explained the weight loss in the patients. Interestingly, treated patients reported feeling more 
alert and energised, and also reported greater physical movement, which may have 
contributed to the weight loss [133]. Other studies suggest that stimulant treatment may also 
alleviate abnormal eating behaviours [143,681]. Interestingly, selective serotonin reuptake 
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inhibitors (SSRIs) have also been reported to benefit both ADHD [682] and obesity [683]. 
Further clinical research, in particular longitudinal studies, are required to assess the efficacy 
of ADHD pharmacological therapy in the treatment of comorbid ADHD and obesity.  
 
It is possible that (1) monitoring the weight status of children with ADHD, and (2) screening 
obese children for ADHD, may identify groups of children who may benefit from 
behavioural interventions e.g. physical activity programmes, or stimulant treatment. It may be 
particularly beneficial to monitor the weight of ADHD children during periods of 
developmental weight gain or when ADHD medication is halted, when they may be at most 
risk for overweight/obesity [95].  
 
Prenatal sGC treatment increased the risk of later mental health problems in children; further 
work is necessary to confirm the long-term association in adolescents. Given that use of this 
drug is routine in threatened pre-term birth - the prevalence of which is fairly high (about 5-
9% in developed countries) and is continuously rising [684], these findings have important 
public health ramifications. Current guidelines recommend a single course of sGC (24mg), 
yet the findings in this thesis suggest that even small doses (an average of 15mg) may 
adversely impact child mental health. While the benefits of sGC treatment on the immediate 
health and survival of the neonate are undisputed, the results presented here suggest that it is 
also important to consider long-term health implications of this drug, including those relating 
to mental health. The clinical implications of this work suggest that children prenatally 
exposed to sGC should be monitored closely in order to provide support if mental health 
problems arise. The results also suggest that prenatal exposure to the endogenous form of GC 
(cortisol) may potentially program psychopathology. Foetal exposure to elevated levels of 
maternal cortisol has been proposed as a mechanism underlying the well-established link 
between prenatal maternal stress and adverse neurodevelopmental problems in the child, and 
this work provides tentative support for this hypothesis. Thus, the clinical implications of this 
work may potentially extend to antenatal healthcare in the provision of mental health services 
to ensure the psychological well-being of pregnant women.  
 
Increased placental size was associated with mental health problems in boys during childhood 
and adolescence, and this substantiates the concept that placental size may be a possible 
marker of later disease risk [464].  In male foetuses, placental enlargement may occur in 
response to adverse intrauterine conditions, and could lead to altered foetal brain 
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development, with long-term effects on mental health. Thus, optimising placental growth and 
function via enhancements in maternal care may improve the health outcomes of offspring. It 
is likely that the impact of maternal diet and body composition on placental function will 
form the foundation for potential health interventions in this field, yet more research is 
needed to clarify this.  Furthermore, future work is required to determine whether deviation in 
placental size is causal or lies on the causal pathway linking prenatal exposures to child 
psychopathology.   
 
6.5.2 Public health implications  
 
The findings presented here are based on a population study, and so may be tentatively 
extrapolated to the general public (whilst bearing in mind the differences in population 
samples). Given the rise in overweight and obesity in the general population, the findings 
have important public health implications, suggesting that personality traits or symptoms of 
ADHD, which are normally distributed in the population, can confer risk for obesity and 
physical inactivity. The findings also provide support for the long-term benefits of regular 
physical activity on child behaviour, emphasising the importance of promoting physical 
education in schools, despite pressure to cut back to allow more time for academic classes.  
Physical inactivity and ADHD symptoms have both been linked with poor academic 
performance [20,628], so the promotion of physical education and associated behavioural 
benefits may actually help improve academic outcomes, as well as other mental and physical 
health outcomes in the long-term. A recent report has highlighted the growing levels of 
physical inactivity worldwide, with four-fifths of adolescents not meeting the public health 
guidelines for the recommended levels of physical activity [160]. Children and adolescents 
with ADHD symptoms are in particular less likely to participate in physical activities, as this 
thesis and previous other studies have demonstrated [90,91,174,180]. According to the 
cognitive reserve hypothesis, individuals with cognitive reserve challenges, such as 
individuals with behaviour problems, may in particular benefit from the positive effects of 
physical activity [199]. This theory, in combination with the findings presented here, suggest 
that physical activity should be particularly encouraged among children with ADHD 
symptoms, as this may alleviate the primary symptoms of ADHD, as well as reduce the 
secondary risk of obesity. Further studies are needed to evaluate this, and in particular RCTs 
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are required to examine whether physical activity can be used as main or adjuvant therapy for 
ADHD symptoms.   
 
Raising general awareness about the impact of ADHD-like behaviours on weight, as well as 
promoting physical activity as a means of both alleviating behaviour problems and 
maintaining a healthy weight, may help to reduce the prevalence of obesity and mental health 
problems in the population. For example, the proportion of obesity cases that could be 
“saved”   in   the   population   if   ADHD   were   eliminated,   i.e.   the   population   attributable   risk  
(PAR), would be approximately 4% (given the Relative Risk of acquiring obesity with 
ADHD exposure=1.87 (based on NFBC 1986 data), and the prevalence of ADHD in the 
general population=5% [6]). Considering the immense scale of the current obesity epidemic, 
this PAR may represent a considerable number of people who could potentially be prevented 
from developing obesity.        
 
6.6 Future work 
 
In order to affirm a causal association between ADHD symptoms and obesity, future 
population studies should examine gene data as instrumental variables (variables associated 
with the exposure under study) and apply Mendelian randomisation. This technique can be 
used to estimate the putative casual effect of exposures on outcomes through analysis of gene 
variants related to the exposure [685]. For example, in the context of the ADHD-obesity 
association, if ADHD is causally associated with obesity, then a genetic variant linked with 
ADHD should be associated with obesity. Genetic associations, unlike directly observed 
associations, are understood to be less susceptible to confounding and free from reverse 
causation, because genotypes are randomly assigned at conception [685]. As such, Mendelian 
randomisation may be viewed as analogous to RCTs in establishing causality, but instead 
makes use of observational genetic data [685].   Through   capitalising   on   the   method’s  
powerful control for confounding and reverse causation, recent research has established the 
directionality of potential bidirectional associations e.g. between obesity and vitamin D 
deficiency [686], which could be applied to the ADHD-obesity association.  
 
If a causal association is confirmed, further longitudinal studies and RCTs should assess the 
value of screening and treatment strategies aimed at preventing obesity via addressing the 
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symptoms of ADHD, in both clinical and population samples, irrespective of categorical 
ADHD diagnosis. These should include assessment of the impact of behavioural 
interventions, including physical activity programs, which may complement ADHD 
pharmacotherapy or provide standalone treatment; specifically, evaluation is required to 
determine whether physical activity has the potential to benefit both behaviour and weight 
status in children with ADHD over the long-term. Research is also needed to improve 
understanding of why children and adolescents with ADHD are less likely to take part in 
physical activity, which could include a range of factors e.g. motor coordination problems, 
peer problems, low self-esteem etc., and study whether potential interventions that treat these 
problems can improve participation in physical activity. Future studies should consider the 
symptoms of ADHD (i.e. inattention, hyperactivity and impulsivity) separately in order to 
improve understanding of the biological and neurobehavioural pathways underlying the 
ADHD-obesity link; this in turn could facilitate development of more targeted preventative 
and treatment strategies, aimed at addressing one or more symptoms.  
 
Future larger studies that combine data from several cohorts, thereby increasing the sample 
size of sGC cases, are needed to confirm the findings presented herein of an association 
between prenatal sGC (low/infrequent doses) and child mental health. If confirmed, 
subsequent research should consider the total dose and prerequisites for sGC treatment, in 
order to balance the benefits of the drug on immediate neonate health versus the possible 
long-term health risks. Preterm birth is difficult to predict – there is currently no single test or 
series of tests which allow accurate prediction of impending labour [687]; thus continued 
research into methods of improving the prediction of preterm labour should be encouraged to 
reduce the likelihood of unnecessary administration of sGC i.e. in pregnancies which do not 
result in preterm birth, thereby reducing the incidence of potential long-term side-effects of 
sGC.  
 
While this thesis adds to the growing evidence that placental growth may play a role in foetal 
programming and can predict later disease, the size of the associations detected herein were 
small and thus future studies should evaluate placental size along with other placental 
phenotypes e.g. histomorphology, biochemistry and gene expression, which in combination 
could provide better insight into placental function as well as the conditions experienced in 
utero. Thus, pooling together information on placental size and other placental phenotypes 
could enhance the predictive value of the placenta. With respect to placental programming of 
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psychopathology,   future   studies   could   examine   the   placenta’s   role   in   the   synthesis and 
regulation of neuroactive substances, e.g. serotonin and vasoactive intestinal peptide, which 
are important in foetal brain development; very little is currently understood about the 
placenta’s   involvement   with   these   substances   in   relation   to   the biology of developmental 
brain disorders [688]. While it is currently not feasible to examine various phenotypes of all 
placentas in large birth cohorts, future cohort studies may undertake a more practical 
approach by banking placental tissue, and later, once outcomes are manifest, compare 
placental characteristics of cases versus non-cases in a subsample.  
 
Although this thesis did not find evidence for common prenatal pathways underlying both 
ADHD symptoms and obesity, only two prenatal factors were considered (prenatal sGC and 
placental size), and thus future studies should examine other potential prenatal factors e.g. 
pre-pregnancy BMI or smoking, which have previously been independently linked with both 
conditions [84,261,318,322]. Despite the small number of sGC cases, this thesis identified a 
link between prenatal sGC and mental health problems, and a trend for an association with 
obesity; however, the analysis for the latter outcome was underpowered. Considering this, 
and the substantial animal evidence that prenatal overexposure to GC, either endogenous or 
synthetic, can program behaviour and metabolic disorders [41,42,392,409,420,452], larger 
epidemiological studies are warranted to clarify these associations in humans. If common 
prenatal factors are linked with ADHD and obesity, this would suggest that the association 
may be established in utero, and potential future intervention strategies should consider the 
intrauterine environment in managing the co-occurrence of the disorders.   
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8. Appendix  
 
8.1 Appendix tables 
 
 
  
 
 
Table A.1: Logistic regression of ADHD symptoms (categorical screen) on BMI and WHR at 16 years, after adjustment for relevant confoundersa. 
Rutter B2 (teacher report)  BMIb  WHRc 
    Overweight vs. normal  Obese vs. normal    Abdominal obesity vs. normal 
  n 
Case 
n 
Control 
OR 95% CI P  OR 95% CI P  n 
Case 
n 
Control 
OR 95% CI P 
Inattention-hyperactivity  231 5143 .75 .47-1.19 .22  1.75 1.03-2.97 .04  205 4607 1.70 1.01-2.86 .05 
Inattention  217 5100 .68 .41-1.11 .12  1.80 1.06-3.07 .03  190 4573 1.45 .82-2.55 .21 
Hyperactivity   217 5068 .84 .53-1.32 .45  1.30  .70-2.39 .41  193 4540 1.36 .76-2.44 .30 
aAdjusted for gender, family structure change (from 7 to 16 years), maternal education and physical activity (16  years). 
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs.  
cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
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Table A.2: Logistic regression of ADHD symptoms (categorical screen) on physical activity and binge-eating at 16 years, adjusted for relevant confoundersa. 
Rutter B2 (teacher report)  Physical activityb  Binge-eatingc 
    Moderately active vs. active  Inactive vs. active    Yes vs. no 
  n 
Case  
n 
Control 
OR 95% CI P  OR 95% CI P  n 
Case 
n 
Control 
OR 95% CI P 
Inattention-hyperactivity  231 5143 .95 .69-1.31 .74  1.73 1.25-2.41 <.01  240 5206 1.71 1.18-2.48 <.01 
Inattention  217 5100 .99  .71-1.39 .95  2.02 1.44-2.83 <.001  223 5161 1.55 1.05-2.30 .03 
Hyperactivity   217 5068 .95 .69-1.31 .74  1.46 1.04-2.07 .03  224 5131 1.42 .95-2.13 .09 
aAdjusted for gender, family structure change (from 7 to 16 years), maternal education and BMI at 16 years (model b). 
bPhysical activity, defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of school hours, including 
commute to and from school.  
cBinge-eating, defined as yes (once a month/once a week/2 or 3 times a week/daily) vs. no (never/hardly ever/occasionally). 
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Table A.3: Logistic regression of ADHD and CD symptoms (categorical screen) at 8 years on BMI and WHR at 16 years, adjusted for relevant confoundersa. 
Rutter B2 (teacher report)  BMIb  WHRc 
    Overweight vs. normal  Obese vs. normal    Abdominal obesity vs. normal 
  n 
Case 
n 
Control 
OR 95% CI P  OR 95% CI P  n 
Case 
n 
Control 
OR 95% CI P 
Screen positive cases                 
Inattention-hyperactivity  332 4192 1.32 .93-1.88 .13  1.91 1.10-3.33 .02  274 3784 1.71 1.05-2.78 .03 
Inattention  134 4392 1.71 1.04-2.83 .04  2.35 1.09-5.07 .03  110 3950 3.46 1.91-6.26 <.001 
Hyperactivity   257 4272 1.44 .97-2.13 .07  1.77 .94-3.34 .08  220 3843 2.14 1.28-3.59 <.01 
Conduct  335 4179 1.52 1.07-2.14 .02  2.53 1.49-4.31 <.01  282 3767 1.67 1.03-2.71 .04 
“Pure”  cases                 
Inattention-hyperactivityd  78 4100 1.34 .66-2.71 .42  .75 .16-3.56 .71  61 3705 1.55 .52-4.60 .43 
Inattentiond  42 4136 2.11 .92-4.81 .08  1.51 .30-7.63 .62  35 3732 6.91 2.89-16.53 <.001 
Hyperactivityd  86 4090 1.50 .77-2.91 .23  2.10 .66-6.70 .21  79 3685 3.83 1.82-8.06 <.001 
Conducte  81 4100 2.13 1.14-4.00 .02  2.75 .96-7.86 .06  69 3705 1.38 .47-4.03 .56 
aAdjusted for gender, family structure change (from 7 to 16 years), maternal education, BMI (7 years) and physical activity (16 years).  
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
 cWHR dichotomised using sex-specific cut-offs at the 95th percentile of WHR.  
dExluding children screening positive for CD symptoms.  
eExcluding children screening positive for inattention-hyperactivity symptoms.  
Table adapted from Khalife et al. (2014) [615], with permission from Elsevier as per the rights retained by authors.   
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Table A.4: Logistic regression of BMI and physically active play at 7 years on ADHD symptoms (categorical screen) at 16 years, adjusted for relevant confoundersa.  
 SWAN (parent report) 
 Inattention-hyperactivity  Inattention  Hyperactivity 
 n 
Case 
n 
Control 
OR 95% CI P  n 
Case 
n 
Control 
OR 95% CI P  n 
Case 
n 
Control 
OR 95% CI P 
BMIb 217 4593     207 4551     193 4548    
Overweight vs. normal   .83 .53-1.28 .40    .78 .49-1.23 .29    1.09 .72-1.67 .68 
Obese vs. normal   1.08 .55-2.12 .81    1.19 .62-2.27 .60    .72 .31-1.67 .45 
Physically active playc 217 4593     207 4551     193 4548     
Low vs. high   1.24 .88-1.74 .22    1.61 1.16-2.24 <.01    1.40 .99-1.99 .06 
aAdjusted for gender, family structure change (from 7 to 16 years), maternal education, ADHD symptoms (8 years) and mutual adjustment for  BMI/physically active play (7 years).  
bBMI defined according to the International Obesity Task Force (IOTF) age and sex-specific cut-offs. 
cPreference for physically active play, dichotomised into low (sometimes and hardly ever) and high (often) categories. 
Table adapted from Khalife et al. (2014) [615], with permission from Elsevier as per the rights retained by authors.   
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Table A.5: Logistic regression of ADHD and CD symptoms (categorical screen) at 8 years on physical activity and binge-eating at 16 years, adjusted for relevant 
confoundersa.  
Rutter B2 (teacher report)  Physical activityb  Binge-eatingc 
    Moderately active vs. active  Inactive vs. active    Yes vs. no 
  n 
Case  
n 
Control 
OR 95% CI P  OR 95%CI P  n 
Case 
n 
Control 
OR 95% CI P 
Screen positive cases                 
Inattention-hyperactivity  368 4568 1.27 .99-1.64 .06  1.60 1.20-2.13 <.01  378 4678 1.20 .85-1.68 .29 
Inattention  145 4792 1.27 .85-1.90 .24  1.89 1.24-2.89 <.01  152 4906 .99 .57-1.71 .98 
Hyperactivity   284 4654 1.15 .86-1.52 .35  1.37 .99-1.88 .06  292 4766 .98 .65-1.47 .91 
Conduct  359 4564 1.21 .94-1.56 .14  1.47 1.10-1.97 <.01  369 4675 1.27 .91-1.78 .16 
“Pure”  cases                 
Inattention-hyperactivityd  90 4474 1.19 .73-1.94 .49  1.50 .87-2.60 .15  95 4579 .85 .41-1.78 .67 
Inattentiond  48 4515 .81 .41-1.61 .55  1.44 .71-2.92 .32  52 4622 .76 .27-2.14 .61 
Hyperactivityd  101 4458 1.09 .69-1.74 .70  1.38 .82-2.32 .23  104 4565 .97 .50-1.90 .94 
Conducte  81 4474 .98 .60-1.63 .95  1.08 .59-1.98 .80  86 4579 1.09 .54-2.20 .82 
aAdjusted for gender, family structure change (from 7 to 16 years), maternal education,  physically active play at 7 years (model a) and BMI at 16 years (model a). 
bPhysical activity, defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of school hours, including 
commute to and from school.  
cBinge-eating, defined as yes (once a month/once a week/2 or 3 times a week/daily) vs. no (never/hardly ever/occasionally).  
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dExluding children screening positive for CD symptoms.  
eExcluding children screening positive for inattention-hyperactivity symptoms.  
Table adapted from Khalife et al. (2014) [615], with permission from Elsevier as per the rights retained by authors.   
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 Table A.6: Frequencies of pregnancy complications 
among sGC-treated women in study (n=37). 
Pregnancy complication Frequency 
Premature contractions  3 
Cervical insufficiency  2 
SGA foetus 2 
Albuminuria 1 
Bleeding 1 
Clunium primiparae 1 
Amniotic fluid leakage 2 
Chorionamniotis 1 
Ablatio placentae 1 
Appendicitis  1 
Breech 1 
Urinary tract infection 1 
Uterine myomatosus 1 
Teratoma 1 
Uterine inertia 1 
Pre-eclampsia 1 
Oedema 1 
Uterus arcuatus 1 
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NEW RESEARCH
Childhood Attention-Deﬁcit/Hyperactivity
Disorder Symptoms Are Risk Factors for
Obesity and Physical Inactivity in Adolescence
Natasha Khalife, MSc, Marko Kantomaa, PhD, Vivette Glover, PhD,
Tuija Tammelin, PhD, Jaana Laitinen, PhD, Hanna Ebeling, MD,
Tuula Hurtig, PhD, Marjo-Riitta Jarvelin, MD, PhD, Alina Rodriguez, PhD
Objective: To prospectively investigate the association and directionality between attention-
deﬁcit/hyperactivity disorder (ADHD) symptoms and obesity from childhood to adolescence
in the general population. We examined whether obesogenic behaviors, namely, physical
inactivity and binge eating, underlie the potential ADHD symptom–obesity association. We
explored whether childhood conduct disorder (CD) symptoms are related to adolescent
obesity/physical inactivity. Method: At 7 to 8 years (n ¼ 8,106), teachers reported ADHD
and CD symptoms, and parents reported body mass index (BMI) and physically active play.
At 16 years (n ¼ 6,934), parents reported ADHD symptoms; adolescents reported physical
activity (transformed to metabolic equivalent of task [MET] hours per week) and binge eating;
BMI and waist–hip ratio (WHR) were measured via clinical examination. Obesity was deﬁned
using the International Obesity Task Force (IOTF) cut-offs for BMI and the 95th percentile
cut-off for WHR. Results: Childhood ADHD symptoms signiﬁcantly predicted adolescent
obesity, rather than the opposite. Inattention-hyperactivity symptoms at 8 years were asso-
ciated with indices of obesity at 16 years (obese BMI: odds ratio [OR] ¼ 1.91, 95% conﬁdence
interval [CI] ¼ 1.10–3.33; 95th percentile WHR: OR ¼ 1.71, 95% CI ¼ 1.05–2.78), adjusted for
gender, baseline BMI, physical activity, family structure change, and maternal education.
Child CD symptoms associated with indices of adolescent obesity. Reduced physically active
play in childhood predicted adolescent inattention (OR ¼ 1.61, 95% CI ¼ 1.16–2.24). Childhood
ADHD and CD symptoms were linked with physical inactivity in adolescence (inattention-
hyperactivity; OR ¼ 1.60, 95% CI ¼ 1.20–2.13), but not binge eating. Physical inactivity
mediated the associations. Conclusions: Children with ADHD or CD symptoms are at
increased risk for becoming obese and physically inactive adolescents. Physical activity may
be beneﬁcial for both behavior problems and obesity. J. Am. Acad. Child Adolesc. Psychiatry,
2014;53(4):425–436. Key Words: attention-deﬁcit/hyperactivity disorder symptoms, conduct
disorder symptoms, disruptive behavior, obesity, physical inactivity
A growing number of studies report an as-sociation between obesity and attention-deﬁcit/hyperactivity disorder (ADHD).1-4
According to a recent review, most studies are
limited by use of clinical and/or cross-sectional
data.1 Furthermore, it is unclear whether the as-
sociation is speciﬁc to ADHD, that is, indepen-
dent of other behavioral disorders—in particular,
conduct disorder (CD),5-8 one of the primary
psychiatric comorbidities of ADHD.9 Importantly,
studies have not examined potential underly-
ing mechanisms or the direction of the ADHD–
obesity association.1 Research has mainly examined
ADHD as a risk factor for obesity.10,11 However,
it is plausible that the association may be driven
from the direction of obesity to ADHD, as fac-
tors linked with obesity, for example, leptin (an
appetite-regulation hormone) and a sugar-rich
diet may contribute to ADHD-like behaviors.12,13
Moreover, the association may be bi-directional
because of a third underlying factor associated
with both obesity and ADHD.14-17 Although it
Clinical guidance is available at the end of this article.
This article can be used to obtain continuing medical education
(CME) at www.jaacap.org.
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is impossible to fully decipher the direction of
the association in human beings, prospective
longitudinal and epidemiological studies can
provide valuable information concerning the
general population. Because of the lack of such
studies, the direction of the potential link re-
mains unevaluated.
Recently, Cortese et al. reported a long-term
link between childhood ADHD and adult
obesity, albeit in a small clinical sample (n ¼ 207)
of men only.7 The same authors, using data from
the National Epidemiological Study on Alcohol
and Related Conditions, found a signiﬁcant as-
sociation, but only for women (retrospective re-
ports for ADHD and self-reports for weight/
height).18 These discrepant ﬁndings may be at-
tributed to differences in study design, including
possible referral bias in the clinical versus popu-
lation samples. It is necessary to prospectively
examine the early developmental trajectory of
the potential ADHD–obesity link from childhood
to adolescence, because these disorders mani-
fest early in life.19,20 The few longitudinal studies
of children/adolescents provide inconsistent re-
sults, are limited by small sample size, and do
not examine directionality.21-23 One study in tod-
dlers (i.e., 2-year-olds) reported a link between
behavioral difﬁculties and obesity over a 3.5-year
period21; however, other studies in older children
have not conﬁrmed the association.22,23 Another
limitation is the sole use of body mass index
(BMI),21,22 which may not adequately reﬂect
adiposity.24 Indicators of abdominal obesity, such
as waist–hip ratio (WHR), provide additional
measures of adiposity, and may more accurately
identify individuals at risk for health conse-
quences of overweight.24
Inattention and/or impulsivity symptoms may
confer a risk for certain obesogenic behaviors,
including physical inactivity and binge eating.1
The impact of hyperactivity symptoms remains
unclear.1 To date, only a few population studies
have examined the association between ADHD
and physical inactivity in children and/or ado-
lescents, and have yielded conﬂicting results.25-27
There are a few small clinical studies reporting
improved behavior in children diagnosed with
ADHD after a short-term period or acute bout
of physical activity.28-30 However, the long-term
impact of physical activity on behavior is still
unevaluated. Some evidence suggests an asso-
ciation between binge eating and behavioral
impulsivity.31,32 A recent study found that
symptoms of ADHD were signiﬁcantly, but not
differentially, greater in obese patients with and
without binge eating behaviors.33 Therefore, the
extent to which obesogenic behaviors underlie
the ADHD–obesity association is unclear.
In this study, we investigated the association
and directionality between core ADHD symp-
toms and obesity (BMI and WHR), from child-
hood to adolescence, in a large population cohort.
We also examined the bi-directional associations
between ADHD symptoms and physical activity,
and the impact of ADHD symptoms on binge
eating, from childhood to adolescence. We hy-
pothesized that there would be a signiﬁcant
association between ADHD symptoms (at a
clinically relevant level) and obesity from child-
hood to adolescence, and that physical inactivity
and/or binge eating would mediate this link.
Finally, we explored whether CD symptoms,
commonly associated with ADHD, are related
to obesity, and whether the ADHD symptom–
obesity link is independent of CD.
METHOD
Participants
Participants came from the Northern Finland Birth
Cohort (NFBC) 1986. Children with an expected date of
birth between July 1, 1985 and June 30, 1986 were
eligible; 99% (N ¼ 8,954 live-born singletons) partici-
pated. The ethics committee of Northern Ostrobotnia
Hospital District approved the study, and both parents
and adolescents gave written informed consent.
Postal questionnaires, which included a wide range
of health- and lifestyle-related questions, were sent to
parents, teachers, and adolescents. At 7 to 8 years (n ¼
8,106; 91%), data were gathered via parental and
teacher reports. At 16 years (n ¼ 6,934; 77%), data were
gathered via parental reports and adolescent self-
reports. In addition, adolescents (n ¼ 6,156) attended
health examinations, which included growth mea-
surements. The NFBC 1986 is a stimulant-naive popu-
lation sample,34 with the exception of 1 boy who
received methylphenidate (Ritalin) for a few months at
age 12 years to treat ADHD.
Measures
Behavior. Teachers assessed child behavior of 8-year-
olds using the Rutter B2 scale,35 a well-validated
screener for childhood mental health. Each of the 26
items is rated as it “certainly applies” (scored 2), “ap-
plies somewhat” (scored 1), or “does not apply” (scored
0), yielding a total score between 0 and 52. Screening as
“probable combined inattention-hyperactivity disor-
der” is deﬁned as a total score of "9 and sum of all 3
inattention-hyperactivity items " 3.36 We also exam-
ined the core ADHD symptoms individually, that is,
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inattention (item “poor concentration” ! 2) and hy-
peractivity (sum of items “restless” and “squirmy and
ﬁdgety” ! 3). CD is deﬁned by a total score of ! 9 and
a higher score on the conduct sub-score (sum of 6 items:
“destructive,” “ﬁghts,” “is disobedient,” “lies,” “steals,”
and “bullies”) versus neurotic subscore (sum of 4 items:
“often worried,” “miserable,” “fearful,” and “tears on
arrival at school”).
Parents reported adolescent behavior of 16-year-
olds using the Strengths and Weaknesses of ADHD
symptoms and Normal behavior (SWAN) scale.37 The
SWAN is an 18-item scale based on ADHD symptoms
listed in the DSM-IV (9 items in the inattention subscale
and 9 items in the hyperactive-impulsivity subscale,
and together the 18 items indicate ADHD combined
subtype). As this scale measures both weaknesses
(scored 3, 2, and 1) and strengths (scored "1, "2,
and "3), along with average behavior (scored 0), it is
expected to produce a normal distribution of behav-
ioral scores, thereby reducing the risk of over-
identifying youths as screening positive for ADHD.
The 95th percentile of the distribution of mean scores
on each subscale was used as a cut-off point to iden-
tify adolescents with ADHD symptoms as probable
clinical cases. The cut-off values for the inattention,
hyperactive-impulsivity, and combined subscales
were, respectively, 0.625, 0.125, and 0.277.34
Body Mass Index. Body mass index (BMI) was cal-
culated as weight divided by squared height (kg/m2).
At 7 years, parents reported child weight and height.
At 16 years, weight and height were measured during
a health examination (by trained staff) and were also
self-reported. Self-reported height and weight data
(n ¼ 701; 10%) were used for those who did not attend
the health examination (correlations between clinical
and self-report data: height, r ¼ 0.85, p < .001; weight,
r ¼ 0.95, p < .001). Obesity was deﬁned using the In-
ternational Obesity Task Force (IOTF) age- and sex-
speciﬁc cut-off points for BMI.38 According to the IOTF
cut-off points, BMI was categorized into 3 groups: nor-
mal weight, overweight, and obese, at 7 and 16 years.
Waist–Hip Ratio. At 16 years, waist and hip girths
were measured at health examinations. Waist–hip ratio
(WHR) was calculated as waist girth (in centimeters)
divided by hip girth (in centimeters), and dichotomized
into normal and abdominal obesity categories, ac-
cording to the 95th percentile sex-speciﬁc cut-off points
(0.914 for boys and 0.862 for girls). The majority of
adolescents in the cohort had reached puberty by 16
years (n ¼ 91%), and our descriptive analyses showed
no signiﬁcant impact of puberty on the associations
under study. Thus, we did not consider puberty further.
Physical Activity. At 7 years, children’s preference
for physically active play was assessed by asking par-
ents, “Does your child like to participate in active
play?” reported as often, sometimes, or hardly ever.
The number of children falling into the “hardly ever”
category was very small (0.3%). Thus, we categorized
physically active play into 2 groups: high (“often”) and
low (“sometimes” and “hardly ever”) preference for
physically active play.
At 16 years, physical activity outside school hours
was evaluated separately for moderate-to-vigorous
physical activity and light physical activity by asking
the adolescents, “How many hours per week do you
participate in brisk activity and light physical activity
outside school hours?” In the questionnaire, the term
“brisk”was deﬁned as physical activity causing at least
some sweating and shortness of breath, while the term
“light physical activity” was deﬁned as causing no
sweating or shortness of breath. Adolescents also re-
ported their daily time spent in a physically active
commute to and from school. The response alternatives
(not at all, less than 20 minutes, 20–39 minutes, 40–59
minutes, and at least 1 hour per day) were multiplied
by 5 (for 5 school days a week) to correspond to 0, 1,
2.5, 3.75, and 5 hours per week.39 The level of physical
activity was deﬁned as metabolic equivalent of task
(MET)–hours per week, based on the intensity and
volume of physical activity, and was divided into
quintiles. A MET intensity value of 3 METs was used
for light physical activity, 5 METs for brisk physical
activity, and 4 METs for commuting physical activity.40
The intraclass correlation coefﬁcient for physical ac-
tivity levels described in terms of quintile categories of
MET hours per week was 0.70 (95% CI ¼ 0.58–0.80),
and the proportion of subjects who were classiﬁed in
exactly the same category or next to the same category
in 2 different tests was 86%. Adolescents were catego-
rized into 3 groups according to their weekly level of
physical activity: active (2 highest quintiles), moder-
ately active (third and fourth quintiles), and inactive
(lowest quintile). The test–retest reliability of these
physical activity questions among a separate group
of Finnish adolescents aged 15 to 16 years has been
reported to be good.39
Binge Eating. At 16 years, an index of binge eating
was ascertained by asking adolescents, “How often do
you devour large amounts of food?” Binge eating was
dichotomized into yes (once a month/once a week/2
or 3 times a week/daily) vs. no (never/hardly ever/
occasionally). This classiﬁcation was established a pri-
ori in the absence of a measure for “loss of control”
(essential in deﬁning binge eating), and aims to dis-
criminate more common, occasional episodes of over-
eating from real binges.
Confounders
We controlled for potential confounders as indicated
by previous research and our descriptive analyses.
Gender is associated with both BMI41 and ADHD.42
Family structure change indicates change in family
structure over time (from 0 to 8 years or from 8 to
16 years), and is important in this study, in which
we examined longitudinal associations. The family
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environment has previously been associated with both
offspring BMI43 and ADHD.44 Family structure change
was classiﬁed into 4 categories: always a 2-parent
family, single-parent family, reconstructed family,
and always a 1-parent family. Maternal education,
which is a marker of socioeconomic position, has
previously been associated with both offspring BMI45
and ADHD.46 Educational level categories were
deﬁned by the International Standard Classiﬁcation of
Education and the Finnish Board of Education, forming
4 educational categories: basic education (!9 years),
upper secondary education (10–12 years), tertiary edu-
cation ("13 years), and other or degree not ﬁnished. BMI
and physical activity are closely related,47 so we con-
trolled reciprocally for BMI and physical activity as
appropriate, to study the association between ADHD
symptoms and these 2 variables, independent of one
another. Baseline BMI/ADHD symptoms/physically
active play were controlled for to allow prediction of
“new” cases of obesity, ADHD symptoms, or physical
inactivity.
Data Analysis
Descriptive analyses included frequency distribu-
tions for the child/adolescent characteristics and
linear regression analyses to examine the associations
using continuous measures. At 8 years, baseline as-
sociations were examined between ADHD symptoms
(combined inattention-hyperactivity, inattention, and
hyperactivity)/CD symptoms, BMI, and physically
active play. Furthermore, correlation analyses were
used to examine comorbidity between inattention-
hyperactivity and CD symptoms, as well as associa-
tions over the 8-year period.
The main analyses included all variables as cate-
gorical measures to indicate clinical levels of concern.
ADHD symptoms were examined as screen positive
or screen negative (yes/no for probable clinical diag-
nosis). BMI was categorized as obese/overweight/
normal weight; WHR as abdominal obesity/normal;
preference for physically active play as low/high;
physical activity as inactive/moderately active/active;
and binge eating as yes/no.
We used logistic regression analyses to investigate
the longitudinal associations. We assessed ADHD symp-
toms at 8 years (predictor: teacher Rutter B2) on obesity
(BMI and WHR), and physical activity and binge
eating at 16 years (outcomes). Likewise, we examined
the reverse association by assessing BMI and physi-
cally active play at 8 years (predictors) on ADHD
symptoms at 16 years (outcome: parent SWAN).
To explore whether the associations under investi-
gation were independent of CD, we re-ran the analyses,
ﬁrst, with CD instead of ADHD symptoms and second,
with the inclusion only of children who screened pos-
itive for either ADHD symptoms or CD symptoms (i.e.,
“pure” cases). Because of the lack of data on CD in
adolescence, we were able to examine only whether CD
symptoms predicted obesity, physical inactivity, and
binge eating (not vice versa).
We used the bootstrap method48,49 to evaluate
whether physical activity and/or binge eating (16 years)
mediated the possible association between ADHD
symptoms (8 years) and obesity (16 years). Likewise, we
examined mediation of the potential CD symptom–
obesity association by physical activity/binge eating.
Mediation conﬁdence intervals were estimated for
adjusted analyses, based on 5,000 bootstrap samples.
For all analyses, we controlled for gender, family
structure change, current maternal education, BMI/
physical activity (depending on the model), and base-
line BMI/ADHD symptoms/physically active play
(depending on the model). Analyses were performed
using SPSS software, version 20.0. The signiﬁcance
level was deﬁned as p < .05.
RESULTS
Table 1 shows the descriptive statistics of the
child/adolescent characteristics. The prevalence
of ADHD symptoms at a level indicating clini-
cal relevance in children and adolescents, re-
spectively, were 9.4% and 5.3% for combined
inattention-hyperactivity; 3.9% and 5.1% for
inattention symptoms; and 7.1% and 4.7% for
hyperactivity symptoms. The prevalence of CD
symptoms in children was 9.0%. The baseline
analyses at 8 years did not show any signiﬁcant
associations between ADHD or CD symptoms
and obesity/physically active play.
As expected, descriptive analyses showed high
comorbidity between inattention-hyperactivity and
CD symptoms (Pearson r ¼ 0.67, p < .001; n ¼
570 (7.1%) screening positive for both disorders).
Furthermore, correlation analyses demonstrated
that the variables of interest (continuous) were
signiﬁcantly associated over time, that is, from 8
to 16 years, for BMI (Pearson r ¼ 0.62, p < .001),
inattention-hyperactivity symptoms (Pearson r ¼
0.25, p< .001), and physically active play/physical
activity (Spearman r ¼ 0.12, p < .001). At 16 years,
there was a slight negative association between
BMI and physical activity (Pearson r ¼ $0.04, p <
.01). BMI and binge eating were related at 16 years
(Spearman r ¼ 0.06, p < .001).
The main aim of the study was to examine
the association and directionality between ADHD
symptoms and obesity, from childhood to adoles-
cence, as well as mediation by physical activity and
binge eating. Adjusted linear regression analyses
using continuous measures showed signiﬁcant
longitudinal associations from 8 to 16 years: for
example, inattention-hyperactivity symptoms and
BMI (b ¼ 0.08, p < .001), inattention-hyperactivity
JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
428 www.jaacap.org VOLUME 53 NUMBER 4 APRIL 2014
KHALIFE et al.
TABLE 1 Characteristics of Children at 8 Years (n ¼ 8,106) and Adolescents at 16 Years (n ¼ 6,934) in the Northern
Finland Birth Cohort, 1986
Characteristic
8 Years 16 Years
n % n %
Body weight deﬁned by BMIa
Normal 5,758 82.7 5,667 84.7
Overweight 916 13.2 787 11.8
Obese 288 4.1 238 3.6
Abdominal obesity deﬁned by WHRb
No 6,109 95.0
Yes 320 5.0
Physically active play
Often 5,954 82.1
Sometimes 1,278 17.6
Hardly ever 24 0.3
Physical activity—METc
Active 2,534 40.4
Moderately active 2,486 39.6
Inactive 1,258 20.0
Binge eatingd
No 6,139 90.2
Yes 665 9.8
ADHD symptoms (positive diagnostic screene)
Inattention-hyperactivity 756 9.4 349 5.3
Inattention 315 3.9 332 5.1
Hyperactivity 575 7.1 306 4.7
CD symptoms (positive diagnostic screenf) 725 9.0
“Pure” ADHD symptoms (positive diagnostic screene), excluding CD cases
Inattention-hyperactivity 186 2.5
Inattention 100 1.4
Hyperactivity 184 2.5
“Pure” CD symptoms (positive diagnostic screenf), excluding
inattention-hyperactivity cases
155 2.1
Gender
Male 4,125 50.9 3,336 48.1
Female 3,981 49.1 3,598 51.9
Family structure change (from 0e8 y or 8e16 y)
Always a 2-parent family 6,761 85.3 4,506 75.7
Single-parent family 513 6.5 805 13.5
Reconstructed family 537 6.8 583 9.8
Always a single-parent family 114 1.4 56 0.9
Maternal education
Basic education ("9 y) 1,330 16.9 794 13.0
Upper secondary education (10e12 y) 4,318 54.9 4,045 66.4
Tertiary education (#13 y) 2,224 28.3 573 9.4
Other or degree not ﬁnished 682 11.2
Note: ADHD ¼ attention-deficit/hyperactivity disorder; CD ¼ conduct disorder.
aBody mass index (BMI) categorization, defined according to the International Obesity Task Force (IOTF) age- and sex-specific cut-offs.
bWaistehip ratio (WHR), dichotomized using sex-specific cut-offs at the 95th percentile of WHR.
cPhysical activity, defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of school
hours, including commute to and from school.
dBinge eating, defined as no (never/hardly ever/occasionally) vs. yes (once a month/once a week/2 or 3 times a week/daily).
eScreening positive for symptoms based on fulfilment of criteria according to the Rutter B2 scale (8 years)/Strengths and Weaknesses of ADHD
symptoms and Normal behavior (SWAN) scale (16 years).
fScreening positive for symptoms based on fulfilment of criteria according to the Rutter B2 scale (8 years).
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symptoms and physical activity (MET) (b ¼ "0.04,
p ¼ .02), and physically active play and inatten-
tion symptoms (b ¼ 0.04, p ¼ .005).
The main analyses tested the longitudinal as-
sociations using categorical variables, which
indicate clinical relevance. The unadjusted logis-
tic regression analyses showed a signiﬁcant as-
sociation between probable ADHD at 8 years and
obesity at 16 years (OR ¼ 2.01, 95% CI ¼ 1.37–
3.00), but nonsigniﬁcance in the opposite direc-
tion, that is, from obesity at 8 years to probable
ADHD at 16 years (OR ¼ 0.90, 95% CI ¼ 0.69–
1.18). There were signiﬁcant associations between
probable ADHD at 8 years and physical inactivity
at 16 years (OR ¼ 1.30, 95% CI ¼ 1.01–1.67), and
reduced physically active play at 8 years and
inattention at 16 years (OR ¼ 1.53, 95% CI ¼
1.15–2.05).
The adjusted analyses revealed similar results.
Probable ADHD at 8 years predicted obesity and
abdominal obesity at 16 years (Table 2). Screening
positive for either inattention or hyperactivity
predicted abdominal obesity by more than 2-fold;
inattention also predicted overweight and obesity
(Table 2). There was no evidence for the reverse
association; that is, obesity did not predict ADHD
symptoms over the long term (Table 3). Low
preference for physically active play at 8 years
was associated with inattention symptoms at 16
years (Table 3). There was evidence for the
reverse association, as inattention-hyperactivity
and inattention symptoms were longitudinally
associated with physical inactivity (Table 4). We
did not ﬁnd any signiﬁcant longitudinal asso-
ciations between ADHD symptoms and binge
eating (Table 4).
We explored whether the associations un-
der study were independent of CD symptoms.
Screening positive for probable CD was associ-
ated with overweight, obesity, abdominal obesity
(Table 2), and physical inactivity, but not binge
eating (Table 4). In analyses excluding children
with CD symptoms, “pure” inattention and “pure”
hyperactivity symptoms at 8 years individually
predicted abdominal obesity at 16 years (Table 2).
In analyses excluding children with inattention-
hyperactivity symptoms, “pure” CD symptoms
at 8 years predicted overweight at 16 years
(Table 2). Neither “pure” ADHD nor “pure” CD
symptoms was associated with physical inac-
tivity or binge eating.
Bootstrapping showed that physical inactivity
at 16 years mediated the longitudinal association
between inattention-hyperactivity symptoms and
obesity (bootstrap estimate ¼ 0.004, percentile
95% CI ¼ 0.001–0.007, n ¼ 4,524), and CD
symptoms and obesity (bootstrap estimate ¼
0.003, percentile 95% CI ¼ 0.001–0.007, n ¼ 4,514).
In contrast, there was no evidence for mediation
by binge eating at 16 years (for inattention-
hyperactivity: bootstrap estimate ¼ 0.001, per-
centile 95% CI ¼ "0.001 to 0.003, n ¼ 5,056; for
CD: bootstrap estimate ¼ 0.001, percentile 95%
CI ¼ "0.001 to 0.003, n ¼ 5,044).
DISCUSSION
To our knowledge, we are the ﬁrst to report that
childhood ADHD symptoms prospectively pre-
dict adolescent obesity (clinically measured as
BMI, deﬁned according to IOTF guidelines), and
abdominal obesity (deﬁned according to the
95th percentile for WHR). Childhood ADHD
symptoms predicted later physical inactivity
(MET) in adolescence. Reduced physically active
play in childhood also predicted inattention in
adolescence. Thus, we report evidence for a bi-
directional association between ADHD symp-
toms and physical inactivity. Furthermore, we also
report an association between child CD symp-
toms, adolescent obesity (BMI and WHR),
and physical inactivity. However, it was unclear
whether ADHD and CD symptoms indepen-
dently predicted these associations.
We focused on the ADHD–obesity link because
of the substantial cross-sectional evidence that a
comorbid association exists between obesity and
ADHD in children and adolescents.1 Using a
large, longitudinal, medically untreated popula-
tion cohort, we were able not only to conﬁrm the
ADHD symptom–obesity link, but also to address
the issue of directionality. Our results showed
that the association was driven in the direction
of ADHD symptoms to obesity (and not vice
versa) over an 8-year period, from childhood to
adolescence.
Our longitudinal data provide insight into the
pathogenesis underlying the ADHD symptom–
obesity association. Inattention and hyperactivity
were each important in predicting later over-
weight or obesity, whereas inattention was
important in predicting later physical inactivity.
Mediation analysis provided evidence for a
mediatory effect of physical inactivity on both the
ADHD symptom–obesity and the CD symptom–
obesity associations. It is possible that social im-
pairments (e.g., peer problems and rule breaking)
related to ADHD or CD may hinder child
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TABLE 2 Odds Ratios (OR) and 95% CI for the Associations Between Attention-Deficit/Hyperactivity Disorder and Conduct Disorder (CD) Probable Cases at 8 Years
and Obesity at 16 Yearsa
Rutter B2 (Teacher Report)
BMIb WHRc
n Cases n Controls
Overweight vs. Normal Obese vs. Normal
n Cases n Controls
Abdominal Obesity vs. Normal
OR 95% CI p OR 95% CI p OR 95% CI p
Screen-positive cases
Inattention-hyperactivity 332 4,192 1.32 0.93e1.88 .13 1.91 1.10e3.33 .02 274 3,784 1.71 1.05e2.78 .03
Inattention 134 4,392 1.71 1.04e2.83 .04 2.35 1.09e5.07 .03 110 3,950 3.46 1.91e6.26 <.001
Hyperactivity 257 4,272 1.44 0.97e2.13 .07 1.77 0.94e3.34 .08 220 3,843 2.14 1.28e3.59 <.01
Conduct 335 4,179 1.52 1.07e2.14 .02 2.53 1.49e4.31 <.01 282 3,767 1.67 1.03e2.71 .04
“Pure” cases
Inattention-hyperactivityd 78 4,100 1.34 0.66e2.71 .42 0.75 0.16e3.56 .71 61 3,705 1.55 0.52e4.60 .43
Inattentiond 42 4,136 2.11 0.92e4.81 .08 1.51 0.30e7.63 .62 35 3,732 6.91 2.89e16.53 <.001
Hyperactivityd 86 4,090 1.50 0.77e2.91 .23 2.10 0.66e6.70 .21 79 3,685 3.83 1.82e8.06 <.001
Conducte 81 4,100 2.13 1.14e4.00 .02 2.75 0.96e7.86 .06 69 3,705 1.38 0.47e4.03 .56
Note: aCategorized by body mass index (BMI) and waistehip ratio (WHR), and adjusted for gender, body mass index (8 years), physical activity (16 years), family structure change (from 8 to 16 years), and maternal
education.
bBMI defined according to the International Obesity Task Force (IOTF) age- and sex-specific cut-offs.
cWHR dichotomized using sex-specific cut-offs at the 95th percentile of WHR.
dExcluding children screening positive for CD symptoms.
eExcluding children screening positive for inattention-hyperactivity symptoms.
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participation in structured physical activities,
particularly in organized settings and team
activities. Instead of exercising, children with
ADHD or CD behaviors may spend more time
watching TV and playing video games.50-53 This
lack of physical activity could contribute to
weight gain over time. Our results show that
inattention symptoms are driving the ADHD
symptom–physical inactivity–obesity pathway.
Physical activities require increased concentra-
tion, perception, and self-directedness, which
may be challenging for children with inatten-
tion. There are common biological systems, for
example, dopamine and brain-derived neuro-
trophic factor (BDNF), that are associated with
ADHD,14,15 obesity,16,17 and physical inac-
tivity,54,55 which further support the concept of a
link among all of these conditions. Less is known
about potential mechanisms linking CD and
obesity, and thus this needs further study.
It has been proposed that inattention may
induce abnormal eating behaviors, such as binge
eating,4,33 which in turn may contribute to the de-
velopment of obesity. However, we did not ﬁnd
support for this idea, as core ADHD symptoms in
childhood were not associated with later binge
eating in adolescence. Impulsivity has previously
been linked with binge eating31,32; however, we
could not study this association because of a lack
of data on impulsivity. Furthermore, it may be
possible that ADHD symptoms are associated
with other disordered eating patterns that are not
measured here. For example, hyperactivity may
be linked with obesity via emotionally driven
eating, a possible mechanism to cope with the
frustration related to the restlessness that ac-
companies hyperactivity.
Because of the high comorbidity previously
reported9 and observed in our dataset between
ADHD and CD, it is important to consider
whether CD accounts for the associations bet-
ween ADHD and obesity/physical inactivity. Our
exploratory analyses using only “pure” cases
showed that inattention and hyperactivity symp-
toms each remained signiﬁcantly associated with
abdominal obesity, and CD symptoms remained
associated with overweight. This suggests that
“pure” ADHD and CD symptoms predict differ-
ential obesity outcomes. These results involving
“pure” cases are inconsistent with the original
results that showed signiﬁcant associations across
a wider range of obesity/physical activity out-
comes. This inconsistency may be due to reduced
statistical power or may reﬂect true etiologicalTA
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TABLE 4 Odds Ratios (OR) and 95% CI for the Associations Between Attention-Deficit/Hyperactivity Disorder (ADHD) and Conduct Disorder (CD) Probable Cases (8 Years)
and Physical Activity and Binge Eating (16 Years)a
Rutter B2 (Teacher Report)
Physical Activityb Binge Eatingc
n Cases n Controls
Moderately Active vs. Active Inactive vs. Active
n Cases n Controls
Yes vs. No
OR 95% CI p OR 95% CI p OR 95% CI p
Screen-positive cases
Inattention-hyperactivity 368 4,568 1.27 0.99e1.64 .06 1.60 1.20e2.13 <.01 378 4,678 1.20 0.85e1.68 .29
Inattention 145 4,792 1.27 0.85e1.90 .24 1.89 1.24e2.89 <.01 152 4,906 0.99 0.57e1.71 .98
Hyperactivity 284 4,654 1.15 0.86e1.52 .35 1.37 0.99e1.88 .06 292 4,766 0.98 0.65e1.47 .91
Conduct 359 4,564 1.21 0.94e1.56 .14 1.47 1.10e1.97 <.01 369 4,675 1.27 0.91e1.78 .16
“Pure” cases
Inattention-hyperactivityd 90 4,474 1.19 0.73e1.94 .49 1.50 0.87e2.60 .15 95 4,579 0.85 0.41e1.78 .67
Inattentiond 48 4,515 0.81 0.41e1.61 .55 1.44 0.71e2.92 .32 52 4,622 0.76 0.27e2.14 .61
Hyperactivityd 101 4,458 1.09 0.69e1.74 .70 1.38 0.82e2.32 .23 104 4,565 0.97 0.50e1.90 .94
Conducte 81 4,474 0.98 0.60e1.63 .95 1.08 0.59e1.98 .80 86 4,579 1.09 0.54e2.20 .82
Note: aAdjusted for gender, physically active play at 8 years (for model b), body mass index (BMI) at 16 years (for model b), family structure change (from 8 to 16 years), and maternal education.
bPhysical activity, defined as metabolic equivalent of task (MET) hours per week based on the intensity and volume of physical activity outside of school hours, including commute to and from school.
cBinge eating, defined as yes (once a month/once a week/2 or 3 times a week/daily) vs. no (never/hardly ever/occasionally).
dExcluding children screening positive for CD symptoms.
eExcluding children screening positive for inattention-hyperactivity symptoms.
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differences; thus, further study is needed. The OR
conﬁdence intervals between ADHD and CD
symptoms overlap, suggesting that there is no
signiﬁcant difference in the prediction of over-
weight/obesity by ADHD and CD. It may thus be
the case that comorbid ADHD is most important
in conferring risk. Individuals with ADHD and
comorbid CD experience problems with impulse
control and/or reward processing, which may
reﬂect a common genetic basis for behavioral
disorders and obesity.8 However, it is difﬁcult to
draw conclusions from our results because of the
small sample sizes of “pure” cases. Larger studies
are required to expand on our preliminary ﬁnd-
ings, as well as to understand the pathways by
which each type of behavioral disorder may
contribute to obesity, and whether comorbidity
confers the greatest risk.
Although previous studies have found that
physical exercise—either a short-term training
period or an acute bout—improves behavior in
children with ADHD,28-30 we extend these ﬁnd-
ings by identifying a long-term link between
reduced physically active play and inattention
symptoms. These results partly support previous
hypotheses that physically active play may be
one of the most important factors inﬂuencing
human development,56 and that social play may
alleviate ADHD symptoms in children.57 Physical
inactivity has also been linked with both general
mental health and scholastic difﬁculties in ado-
lescents.58,59 Considering the available evidence,
it is possible to speculate that regular physical
activity may alleviate ADHD symptoms over the
long term.
This study has several strengths. First, the
longitudinal design allowed us to identify the
directionality of the ADHD symptom–obesity
association, as well as to study the long-term link
between ADHD symptoms and both physical
inactivity and binge eating prospectively. Second,
we used a population-based sample, which re-
duces the confounding effects that are often
observed in clinical studies, for example, symp-
tom severity, referral, and medication biases.
Third, we used 2 indices of obesity measured
clinically, namely, BMI and WHR, to provide a
more complete measure of adiposity. Fourth, we
examined the core ADHD symptoms, which
enabled us to determine that both inattention and
hyperactivity contribute to the associations. Fifth,
by examining “pure” ADHD and CD cases, we
explored whether each type of disorder was
speciﬁcally related to obesity.
There are also several limitations to this study.
First, despite the longitudinal design and the
attempt to control for important confounders, we
cannot afﬁrm a causal link between ADHD or CD
symptoms and obesity because of the observa-
tional nature of the study. This is an inherent
problem in human studies. Second, we could not
examine impulsivity symptoms because the Rut-
ter B2 scale, used by teachers to report child
behavior, does not measure impulsivity symp-
toms per se, and the SWAN, used by parents to
report adolescent behavior, combines hyperac-
tivity and impulsivity symptoms (reﬂecting
DSM-IV criteria for a hyperactive-impulsive
ADHD subtype). Third, we could not examine
bi-directionality between CD–obesity/physical
activity because of the lack of parental report on
adolescent CD. Fourth, we did not account for
ADHD psychiatric comorbidities in the analyses
beyond CD, because of limitations in data avail-
ability. Fifth, the participating children’s height
and weight at 7 years were reported by parents
rather than clinically measured. Sixth, MET data
were unavailable at 8 years, so instead we used
data on preference for “physically active play” to
indicate physical activity levels in childhood.
Finally, we were unable to assess gender differ-
ences, because stratiﬁcation by sex signiﬁcantly
reduced our statistical power.
Despite these limitations, our ﬁndings have
signiﬁcant public health implications, with the
potential for novel prevention/treatment strate-
gies for both obesity and ADHD symptoms.
Children with ADHD and/or CD behaviors can
be monitored for overweight/obesity at an early
stage, thus potentially averting a developmental
trajectory of obesity. This work provides support
for the long-term beneﬁts of regular physical
activity on ADHD behaviors, emphasizing the
importance of promoting physical education in
schools, despite pressure to cut back to allow more
time for academic classes. Physical inactivity,
ADHD, and CD symptoms have all been linked
with poor academic performance,59-61 so the pro-
motion of physical education and associated
behavioral beneﬁts may actually help to improve
academic outcomes, as well as improving other
mental and physical health outcomes in the long-
term. Randomized controlled trials are desper-
ately needed to examine whether physical activity
could be used as a behavioral intervention in the
treatment of ADHD and CD.
To summarize, here we have shown that
children with ADHD or CD symptoms are at
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increased risk for becoming obese and physically
inactive adolescents. We found novel evidence
that physical inactivity mediates both the ADHD
symptom–obesity and CD symptom–obesity as-
sociations. We show that reduced physically
active play in childhood constitutes an early risk
factor for inattention symptoms later in adoles-
cence. Considering the escalating prevalence of
both obesity and ADHD/CD, our novel ﬁndings
are of public health signiﬁcance, providing in-
sight into additional risk factors and paving the
way for new prevention/treatment strategies for
these chronic disorders. &
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Abstract
Background: Animal studies demonstrate a clear link between prenatal exposure to glucocorticoids (GC) and
altered offspring brain development. We aim to examine whether prenatal GC exposure programs long-term mental
health in humans.
Methods: Using propensity-score-matching, children prenatally exposed to synthetic glucocorticoids (sGC), n=37,
and controls, n=185, were balanced on important confounders related to sGC treatment - gestational age and pre-
pregnancy BMI. We also used mixed-effects modeling to analyse the entire cohort – matching each sGC case, n=37,
to all possible controls, n=6079, on gestational age and sex. We obtained data from the Northern Finland Birth
Cohort 1986 at four waves – pregnancy, birth, 8 and 16 years. Data on pregnancy and birth outcomes came from
medical records. Mental health was assessed at 8 years by teachers with the Rutter B2 scale, and at 16 years by
parents with the Strengths and Weaknesses of ADHD symptoms and Normal behavior (SWAN) scale and
adolescents by the Youth Self-Report (YSR) scale.
Results: Prenatal sGC treatment was consistently associated with adverse mental health in childhood and
adolescence, as shown by both the propensity-score method and mixed-effects model. Using the propensity-score-
matched subsample, linear multiple regression showed prenatal sGC was significantly linked with general psychiatric
disturbance (B=8.34 [95% CI: .23-16.45]) and inattention (B= .97 [95% CI: .16-1.80]) at 8 years after control for
relevant confounders. Similar findings were obtained at 16 years, but did not reach statistical significance. Mediation
by birthweight/placental weight was not detected.
Conclusions: This study is the first to prospectively investigate the long-term associations between prenatal
exposure to sGC treatment and mental health in children and adolescents. We report an association between
prenatal exposure to sGC and child mental health, supportive of the idea that sGC has a programming effect on the
fetal brain.
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Introduction
Cortisol, a naturally occurring glucocorticoid (GC), plays a
vital role in fetal development [1]. This hormone exerts a wide
range of effects in most regions of the developing brain,
initiating terminal maturation, remodeling of axons and
dendrites, and affecting cell survival [2]. However, sustained
elevation or reduction of GC levels can impair these processes,
and thereby permanently modify brain structure and function
[3], suggesting a role for GC in fetal programming of mental
health. Fetal exposure to elevated levels of maternal cortisol
has been proposed as one mechanism underlying the reported
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connection between prenatal exposure to maternal stress and
symptoms of attention-deficit/hyperactivity disorder (ADHD) in
the offspring [4-6]. ADHD is the most common behavioral
disorder in young people, characterized by inappropriate
inattention, hyperactivity and impulsivity [7,8], and is related to
impairments in all areas of life e.g. social and scholastic
domains [9].
Animal models provide strong evidence that prenatal
exposure to both elevated endogenous maternal GC and
synthetic glucocorticoids (sGC) alter fetal brain development
and consequently impact upon behavior [6,10,11], including
hyperactivity [12] and attention [13]. However, without
experimental evidence in humans the effect cannot be
confirmed. The routine administration of sGC in cases of
threatened pre-term birth offers an opportunity to study whether
prenatal exposure to GC is associated with long-term
programming of behavior in humans in a quasi-experimental
manner.
sGC is commonly administered to pregnant women when
pre-term birth is impending to accelerate fetal lung maturation
and thereby reduce the risk of respiratory distress syndrome,
and neonatal mortality [14]. Yet, very little is known about the
long-term effects of prenatal sGC treatment on child behavior,
including ADHD symptoms. The few existing studies report
inconsistent findings. Some studies report an association
between repeated prenatal sGC treatment and distractibility,
hyperactivity and aggressive behavior [15], as well as attention
problems [16] in young children, but others do not [17-19].
Generally, studies are limited by short follow-up times (young
children only) and mostly examine the impact of repeated
doses of prenatal sGC, and so little is known about the long-
term impact of low/infrequent doses of prenatal sGC exposure
on later child behavior. This is particularly important given that
current guidelines recommend that only a single course of sGC
should be administered (either 2 doses of 12mg of
betamethasone or 4 doses of 6mg of dexamethasone) because
of concerns regarding potential long-term effects of repeated
sGC treatment [20]. One study examined the long-term
association and reported that adults at age 31 who received a
single course of prenatal sGC did not differ on mental health
outcomes from those in the placebo condition [21]. However,
the placebo group in this study received cortisone acetate with
a 70th of sGC potency, and so the impact of sGC from non-
exposure cannot be completely assessed. Further studies are
thus needed to examine this association.
Besides the potential impact on the fetal brain, prenatal
exposure to sGC treatment in humans has been linked with
reduced birth size [22]. Small size at birth, in turn, has been
implicated as a risk factor for child mental health [23]. It is
possible that small birth size, which is a marker of suboptimal
intrauterine conditions, may reflect altered brain development
[23]. Prenatal exposure to maternal stress has also been linked
to reduced birth size [24], with excess maternal GC as a
potential causal mechanism [6]. The placenta, which normally
acts as a barrier to regulate fetal exposure to endogenous
maternal GC (inactivating excess cortisol to cortisone) [25],
may play a key role in GC programming [26]. Prenatal
exposure to sGC and maternal stress have also been
associated with altered placental size [27,28], which in turn has
been linked with child and adolescent mental health [29].
Changes in placental size can affect fetal nutrient and hormone
supply [30], resulting in altered fetal growth and organ
development, including the brain. Thus, it is possible that the
GC-mental health link is mediated by deviation in either birth
size and/or placental size.
To clarify previous inconsistent findings, we examined data
from a large, longitudinal cohort following children and
adolescents. In studies examining prenatal sGC effects on
child mental health, treatment-selection bias is a main issue,
which we address here. It is essential to disentangle the
potential effect of treatment from the conditions precipitating
treatment. Our large dataset enabled us to very accurately
match prenatally sGC exposed (cases) and unexposed
(controls) children on baseline characteristics related to sGC
treatment, by means of propensity-score-matching. However,
an important limitation of propensity-score-matching is that,
particularly in large studies, many unmatched controls are
excluded from analysis, resulting in loss of data which may
reduce the precision of the estimated association between the
treatment and outcome [31]. Thus, we also used the entire
cohort to analyse the data – matching each case to all possible
controls on important confounders. The two matching
procedures allowed us firstly to isolate the impact of prenatal
sGC exposure on mental health from the confounding effects of
treatment, and secondly, to examine the robustness of the
results, thereby addressing important limitations of previous
research. Further, we investigated whether birthweight and
placental weight mediate the association between prenatal
sGC treatment and offspring mental health to gain insight into
the potential causal pathway. This is the first study to
investigate the long-term impact of prenatal sGC treatment
(low/infrequent doses) versus no treatment on mental health,
particularly ADHD symptoms, in childhood (8 years) and again
in adolescence (16 years). We hypothesise that prenatal sGC
treatment will be related to poor mental health outcomes.
Materials and Methods
Participants
The Northern Finland Birth Cohort (NFBC) 1986 recruited
women in early pregnancy with an expected date of delivery
between July 1, 1985 to June 30, 1986; 99% participated.
Prospective data was gathered from pregnancy to child age 16
years. The cohort consists of 9479 births in Oulu and Lapland
provinces. Here, we include N=8954 liveborn singletons with
consent to use their data (exclusions: 226 twins, 6 triplets and
249 without consent).
All pregnant women, literate in Finnish, were consecutively
recruited at their first prenatal health care visit to tax-paid
prenatal health services, which offer high-quality standardized
care used by essentially all women in the country [32]. Women
provided information via structured self-report questionnaires.
Antenatal clinical and birth outcome data were obtained from
maternity health centres and hospital medical records
(completed by midwives during pregnancy and at birth), and
abstracted onto study forms. As the original NFBC 1986
Prenatal Glucocorticoids and Later Mental Health
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dataset did not include data on prenatal sGC treatment, we
screened for potential sGC cases by performing a systematic
chart review (see Figure S1).
The cohort was followed-up at child ages 8 years (n=8106;
91% of original sample) and 16 years (n=6934; 77% of original
sample), and focused on child health and well-being. Follow-
ups were carried out using the national population-based
registries, which identify all residents by unique personal
numbers, to obtain current addresses. Thus, participants could
be traced even outside the original geographic area.
The ethics committee of Northern Ostrobotnia Hospital
District approved the study, and both parents and adolescents
gave written informed consent.
Predictor: Prenatal sGC Treatment
In Finland in 1985/86, prenatal sGC treatment was
administered in rare cases (at the discretion of the medical
practitioner) as use of sGC during pregnancy was still
controversial at the time, which explains the relatively few
number of sGC cases in our study. There was no standard
protocol for sGC treatment in the NFBC 1986 cohort, although
caution was taken as only small and infrequent doses were
administered. Dexamethasone (n=33) or betamethasone (n=4)
- the drugs of choice for threatened pre-term birth, were
administered. At 8 and 16 years, n=37 and n=29 cases
respectively were available for analysis. Out of the 37 cases (at
8 years), 13 received a single sGC dose, 23 received 2 doses
and the dose number for 1 case was not recorded. The total
dosage ranged from 10mg to 25mg (the maximum total dosage
equates approximately to a single course of sGC treatment as
recommended by current guidelines). We obtained data on
sGC treatment, number of sGC doses, total sGC dose and the
interval between prenatal sGC exposure and birth (days), from
medical records.
Fetal exposure to GC is regulated by placental 11β-
hydroxysteroid dehydrogenase type 2 (11β-HSD2) – an
enzyme which normally inactivates 50-90% of endogenous
maternal GC [25,33], but does not extensively metabolize sGC.
Placental 11β-HSD2 inactivates only about 2% of
dexamethasone and 7% of betamethasone [34], allowing the
majority of sGC to cross the placenta to exert its intended
therapeutic effect on fetal tissues. In contrast, prednisone (n=2)
and hydrocortisone (n=1) have minimal placental transfer and
so are typically administered to treat maternal medical
conditions (e.g. allergic or inflammatory diseases) and were
excluded from the analyses.
Betamethasone and dexamethasone are long-acting
substances (with biological half-lives ranging between 36 and
54 hours) [35], so it is unlikely that sGC treatment close to the
time of birth could significantly impact fetal brain development
as there would not be sufficient time for the drug to induce
maximum effect. Thus, we excluded cases who had been
exposed to sGC ≤4 days prior birth (n=11).
Potential Mediators: Birthweight and Placental Weight
Birthweight (grams) was measured accurate to ±10g,
immediately after birth by medical personnel. Placentas were
washed with water and then weighed (including membranes
and umbilical cord, cut approximately 5cm from the neonate) to
the nearest gram within 30 minutes after birth, according to
standard protocols [29].
Outcome: Child and Adolescent Mental health
Teachers assessed child behavior at the age of 8 years
using the Rutter B2 scale [36], a well-validated screener for
childhood mental health. Each of the 26 items is rated as either
it ‘certainly applies’ (scored 2), ‘applies somewhat’ (scored 1)
or ‘does not apply’ (scored 0); yielding a total score between 0
to 52. The questionnaire generates three sub-scores: neurotic,
antisocial and inattention-hyperactivity. Additionally, we
examined the core ADHD symptoms individually i.e. inattention
and hyperactivity.
Parents reported adolescent behavior at 16 years using the
Strengths and Weaknesses of ADHD symptoms and Normal
behavior (SWAN) scale [37]. The SWAN consists of 18 items
based on the symptoms of ADHD listed in the DSM-IV (9 items
in the inattention subscale, 9 items in the hyperactive-
impulsivity subscale, and together the 18 items indicate ADHD
combined subtype). As this scale measures both weaknesses
(scored 3, 2, 1) and strengths (scored -1, -2, -3), along with
average behavior (scored 0), it is expected to produce a normal
distribution of behavioral scores, thereby reducing the risk of
over/under identifying ADHD behavior.
Adolescents provided mental health self-reports at 16 years
by completing the Youth Self-Report (YSR) [38] – a widely
used questionnaire, derived from the Child Behavior Check List
(CBCL), for use by 11-18-year-olds. The YSR includes 112
items covering behavioral and emotional problems, which are
scored on a three-point scale (‘certainly applies’, ‘somewhat
applies’ and ‘does not apply’, scored 2, 1 and 0, respectively).
The YSR total problem score taps withdrawal, somatic
complaints, anxiety/depression, thought problems, social
problems, attention problems, delinquent behavior and
aggressive behavior.
Confounders
We considered potential confounders related to sGC
treatment and child mental health which were available in the
cohort. Socio-demographic factors previously associated with
ADHD symptoms were: sex, maternal age (years), maternal
education (either ≥11 years of education or <11 years of
education, coded 0 or 1, respectively) and family structure
(either married/co-habiting or single/widowed/divorced, coded 0
or 1, respectively) [39-41]; the latter three factors were
measured at recruitment. Medical factors previously associated
with child mental health or relevant for this study were:
gestational age [42], total prenatal sGC dose (mg), interval
between prenatal sGC exposure and birth (days), parity
(continuous) [43], pre-pregnancy body mass index (BMI) (pre-
pregnancy weight [kg] / height2 [m2]) (continuous) [32], and
smoking during pregnancy (no/yes, coded 0/1, respectively)
[40]. We obtained data on the main pregnancy complications
related to pre-term birth from hospital records: gestational
hypertension (no/yes), pre-eclampsia (no/yes) and placenta
previa (no/yes).
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Statistical Analysis
We used two analytical strategies to analyse the data: (1)
analysis of the propensity-score-matched subsample by linear
multiple regression, and (2) analysis of the entire sample by
mixed-effects modeling. All main analyses were performed
using SPSS 20.0, while the power analysis was run using
G*Power 3 [44].
Descriptive Analysis
We carried out descriptive analyses of all covariates
potentially associated with sGC treatment, by means of t-test or
chi-square statistics. Further, we examined whether there were
any significant differences between matched cases and
controls (within the propensity-score-matched subsample) by
the covariates by means of t-test or chi-square statistics.
We performed attrition analyses at each follow-up to
determine any differences in socio-demographics, birth
outcomes and mental health outcomes between participants
and non-participants.
Matching Procedure
We used two matching procedures. First, we used
propensity-score-matching [45] to match sGC cases and
controls. The propensity score is the probability of treatment
assignment based on observed baseline covariates. Matching
on the propensity score creates balance, i.e. similarity,
between cases and controls on the distribution of baseline
covariates and thus reduces confounding associated with
receipt of treatment. This matching technique mimics the
randomization procedure prior to treatment allocation in a
Randomized Controlled Trial (RCT). Thus, propensity-score-
matching facilitates estimation of treatment effects using
observational data.
The covariates associated with sGC treatment were included
as predictors in the logistic regression model used to calculate
the propensity scores. The propensity scores were log
transformed to normalize the distribution of the scores. sGC
cases were matched to controls on the logit propensity score,
using “nearest neighbour matching” with a caliper width
(matching range) of ± 0.171402 (0.2 SD of the mean logit of the
propensity score) [46]. We capitalized on our large dataset by
matching each sGC case to 5 controls; ratio matching has
been shown to be advantageous, and the optimum matching is
normally reached with 5 matches to a single case [47]. This
resulted in a sample of 222 children at 8 years (sGC cases,
n=37; controls, n=185) and a sample of 174 adolescents at 16
years (sGC cases, n=29; controls, n=145).
The second matching procedure took full advantage of the
entire cohort by matching each sGC case, n=37, to all possible
controls, n=6079, on gestational age and sex – confounders
selected based on a priori information. Pre-term birth is a well-
known risk factor for poor mental health outcomes [42] and is
associated with gestational complications [48]. There is
evidence that male fetuses are more vulnerable to prenatal
insults [49], and are at an increased risk of psychiatric
disturbance in childhood [41,50]. Thus, by matching on these
known risks, we were able to isolate the impact of prenatal
sGC exposure on mental health from the confounding effects of
pre-term birth and sex.
A “grouping” variable, based on gestational age and sex,
was used to match the cases and controls. There were no sGC
cases born within gestational weeks 41 to 43, therefore the
2229 controls born within those gestational ages could not be
compared with the cases and consequently excluded from all
subsequent analyses. At 8 years, 6116 children were available
for analysis (sGC cases, n=37; controls, n=6079) and by 16
years of age, 5108 adolescents participated (sGC cases, n=29;
controls, n=5079). This analytical strategy allowed us to use
the greatest number of possible controls per case, thereby
enhancing the precision of the analysis by maximizing use of
all the available data [51].
Regression Models
We used linear multiple regression to investigate the
association between prenatal sGC treatment and child mental
health, within the propensity-score-matched subsample.
Prenatal sGC treatment was dichotomized: sGC case (coded
1) and sGC control (coded 0). The mental health scores were
continuous. We adjusted for all potential confounders as shown
by our descriptive analysis or by previous research. We used
Cohen’s f2 as an effect size estimator for the associations.
We used mixed-effects modeling to re-analyse the
association between prenatal sGC and mental health, but here
we used the entire cohort. In this way, we can determine if the
results are replicable or merely due to certain characteristics in
the subsample. This statistical technique is robust in the
analysis of unbalanced data, and thus is suitable here where
there are unequal numbers of cases and controls. In the model,
the predictor (prenatal sGC) and confounders were included as
fixed effects. The “grouping” variable, based on gestational age
and sex, was included as a random effect, thus allowing the
model representing the impact of sGC on mental health to vary
as a function of the group, thereby reducing the confounding
effects of pre-term birth and sex.
Mediation Analysis
We used the bootstrap method [52,53] to evaluate whether
birthweight and placental weight mediated the possible
association between prenatal sGC and mental health, within
the propensity-score-matched subsample. This is a resampling
method which generates accurate confidence intervals to
assess mediation effects. Bootstrapping does not impose any
assumption about the shape of the distribution of the mediation
effect, and thus it has been suggested that it is a more powerful
technique than single sample methods [52,54].
Power Analysis
We performed a post hoc power analysis to determine
whether our study was sufficiently powered to detect any
possible significant impact of sGC treatment, at 8 years and 16
years.
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Results
Descriptive Analysis
Table S1 shows pregnancy and birth characteristics for the
unmatched cases and controls, available for analysis. Prior to
propensity-score-matching, sGC cases and controls differed
significantly on gestational age, birthweight, and placental
weight. The difference on pre-pregnancy BMI was significant,
p=.04 (based on all treated cases, n=41). As gestational age
and pre-pregnancy BMI precede sGC treatment, these
covariates were included in the propensity-score model.
Table 1 shows pregnancy and birth characteristics for the
propensity-score-matched cases and controls. There were no
significant differences between the matched sGC cases and
controls on any of the socio-demographic or medical factors.
Importantly, there were no significant differences on gestational
age and pre-pregnancy BMI, nor on the mean logit propensity
score (case mean=-4.35; control mean=-4.36; p=.96) –
indicating balance between cases and controls on treatment-
associated confounders.
Table S2 shows the attrition analyses among sGC cases
from birth to 8 years, and from 8 years to 16 years. There were
no significant differences by socio-demographics and birth
outcomes between the participants and non-participants at 8
years. Similarly, attrition was not characterised by any
significant differences from childhood to adolescence by socio-
demographics, birth outcomes and mental health (at 8 years).
While all the sGC cases were hospitalized, only one sGC
case experienced one of the main pregnancy complications
related to pre-term birth (gestational hypertension, pre-
eclampsia or placenta previa). This single case did not
significantly impact upon the mean mental health scores, and
therefore was included in all analyses. Out of the controls,
approximately 15% were hospitalized and 9% experienced the
main pregnancy complications related to pre-term birth.
Regression Models
Table 2 shows the linear multiple regression results for the
association between prenatal sGC treatment and mental health
outcomes in children and adolescents, controlled for sex,
birthweight, placental weight, socio-demographic factors
(maternal age, education and family structure), and medical
factors (total prenatal sGC dose, interval between prenatal
sGC exposure and birth (days), parity and smoking during
pregnancy). There were significant associations between
prenatal sGC treatment and the total Rutter and inattention
scores, at 8 years. The effect sizes for the total Rutter,
inattention-hyperactivity, inattention and antisocial scores were
moderate, while the association for the hyperactivity score
showed a large effect size. Similar to the results at 8 years, we
found consistent significant associations between prenatal sGC
treatment and each of the outcome scores at 16 years;
however, these did not reach statistical significance.
Table 3 shows that the mixed-effects model produced very
similar results to the first analysis. Prenatal sGC treatment was
significantly associated with the total Rutter and inattention
scores at 8 years, and was consistently associated with higher
scores on all other outcomes at 8 and 16 years. Additionally,
this method revealed neurotic scores were also elevated
among sGC cases in comparison to controls at 8 years.
Mediation Analysis
The bootstrap method showed that there were no significant
indirect effects of birthweight (e.g. for total Rutter score,
bootstrap estimate=.67, percentile 95% CI=-1.33-3.00) or
placental weight (e.g. for total Rutter score, bootstrap
estimate=.24, percentile 95% CI=-1.07-2.00) on the sGC-
mental health pathway. Thus, we did not find evidence for
mediation by birthweight or placental weight.
Power Analysis
The post hoc power analysis showed that the study had
sufficient power to detect significant differences at 8 years (e.g.
for total Rutter score model, 1-β=.80, with an effect size f2=.23
and p=.05), but was under-powered at 16 years (e.g. for
combined ADHD score model, 1-β=.39, with an effect size f2=.
11 and p=.05).
Discussion
This study is the first to explore the long-term associations
between prenatal exposure to sGC treatment and mental
health in childhood and adolescence. We found that both
children and adolescents prenatally exposed to sGC scored
consistently higher on internationally validated screening
instruments of mental health, by teacher, parental and self-
reports, than controls. The propensity-score-matched
subsample showed that prenatal exposure to sGC treatment
was significantly associated with the total Rutter and inattention
scores in childhood, independent of relevant confounders –
sex, birthweight, placental weight, socio-demographic factors
and medical factors. Past studies have in particular found it
challenging to disentangle the effect of prenatal sGC on mental
health from pre-term birth, which is associated with both sGC
treatment and child mental health. Through propensity-score-
matching, cases and controls were balanced, i.e. matched, on
gestational age and pre-pregnancy BMI, and so we were able
to isolate the impact of prenatal sGC on mental health from
these treatment-associated confounders. Therefore, our
findings suggest that prenatal sGC is a potential programming
agent of child mental health, rather than a mere
epiphenomenon. We examined the robustness of our findings
by testing the association using the entire cohort by means of
mixed-effects modeling. We found very similar results using the
entire sample compared with the subsample, providing further
evidence that our results are unlikely to be affected by
confounding.
We set out to examine the potential long-term association
between prenatal sGC exposure and mental health, and
therefore studied adolescents by way of parental-report specific
for ADHD symptoms and self-report for general mental health.
Given attrition by the 16-year follow-up, only 29 cases
remained for analysis which left our study under-powered at
this point - as confirmed by our power analysis. Nonetheless,
the pattern of associations at 16 years was consistent with the
findings reported at 8 years.
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Table 1. Pregnancy and birth characteristics for the sGC casesa (n=37) and matched controls (n=185); 1:5 matching ratio,
matched on logit of propensity score.
Characteristic Mean ± SD or n (%)  
 Case Control P
Pregnancy    
Maternal age (years) 29.2 ± 5.0 27.6 ± 5.2 .10
Family structure   .37
Married/co-habiting 36 (97.3) 173 (93.5)  
Single/widowed/divorced 1 (2.7) 12 (6.5)  
Education (years)   .92
<11 10 (31.3) 54 (32.1)  
≥11 22 (68.8) 114 (67.9)  
Parity   .98
0 11 (29.7) 60 (32.4)  
1 16 (43.2) 76 (41.1)  
2 6 (16.2) 32 (17.3)  
≥ 3 4 (10.8) 17 (9.2)  
Smoking during pregnancy   .17
No 31 (86.1) 137 (75.7)  
Yes 5 (13.9) 44 (24.3)  
Pre-pregnancy BMI 21.1 ± 2.5 20.5 ± 2.6 .22
Pre-pregnancy BMI categories   .44
< 20 14 (37.8) 87 (47.0)  
20-24.99 20 (54.1) 90 (48.6)  
≥ 25 3 (8.1) 8 (4.3)  
Main pregnancy complications – risk for pre-term birth    
Gestational hypertension 0 (.0) 13 (7.1) .23
Pre-eclampsia 1 (5.3) 4 (2.2) .41
Placenta previa 0 (.0) 1 (.5) .65
Total sGC dose (mg) 15.4 ± 4.6   
Interval between prenatal sGC exposure and birth (days)    
6-14 5 (13.5)   
15-23 0 (.0)   
24-32 6 (16.2)   
33-41 8 (21.6)   
41-49 10 (27.0)   
50-58 4 (10.8)   
59-67 2 (5.4)   
≥ 68 2 (5.4)   
Birth    
Sex   .86
Male 19 (51.4) 98 (53.0)  
Female 18 (48.6) 87 (47.0)  
Gestational age at birth (weeks) 37.2 ± 2.0 37.5 ± 2.0 .60
Gestational age categories (weeks)   .90
Pre-term birth (< 37) 10 (27.0) 48 (25.9)  
Term birth (≥ 37) 27 (73.0) 137 (74.1)  
Birthweight (g) 3159 ± 688 3151 ± 636 .95
Birthweight categories (g)   .59
< 2500 6 (16.2) 23 (12.4)  
2500-4499 30 (81.1) 160 (86.5)  
≥ 4500 1 (2.7) 2 (1.1)  
Placental weight (g) 586 ± 139 588 ± 135 .96
Placental weight categories (g)   .90
< 550 14 (37.8) 75 (40.8)  
550-719 17 (45.9) 84 (45.7)  
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Our findings corroborate and extend previous results of
observational studies of high-risk pregnancies in humans,
which have examined the effect of repeat prenatal sGC doses
on child mental health [15,16]. Most previous studies have
used high-risk samples in comparison to normal pregnancies,
making it difficult to differentiate between medical
complications that prompted treatment and the potential effect
of the treatment itself on the outcome. Ours is a community
cohort in which both controls and cases experienced
pregnancy complications and were hospitalized. Out of the
controls, approximately 9% experienced the most common
causes of pre-term birth (gestational hypertension, pre-
eclampsia and placenta previa) and 15% were hospitalized.
Only one case experienced one of the most common causes of
pre-term birth. In this sense, our results are more
generalizable, rather than specific to high-risk sub-groups and
so are unlikely to be affected by confounding of pregnancy
complications.
We were able to examine the impact of fairly low and
infrequent doses of prenatal sGC (the average total dose was
15.4mg and the maximum dosage was approximately equal to
a single course of sGC, according to current guidelines). Given
the concerns raised by use of repeat sGC in pregnancy [14,22]
and the call for longitudinal research [55], it is of public health
interest to study long-term risks associated with exposure at
this low dosage. Our findings suggest that even at low dosages
the fetal brain may be sensitive to sGC. Interestingly, we found
that prenatal sGC had a non-specific effect on child mental
health, as indicated by an association with the total Rutter,
which reflects a range of emotional and behavioral problems,
including ADHD symptoms. A total Rutter score of ≥9 indicates
probable psychiatric disturbance, and so the mean Rutter score
difference of approximately 8 points between cases and
controls reflects clinical significance.
Cortisol may directly impact brain development because
glucocorticoid receptors (GR) and mineralocorticoid receptors
Table 1 (continued).
Characteristic Mean ± SD or n (%)  
 Case Control P
≥ 720 6 (16.2) 25 (13.6)  
a. Including cases exposed to prenatal sGC > 4 days prior to birth.
doi: 10.1371/journal.pone.0081394.t001
Table 2. Linear multiple regression results for the association between prenatal glucocorticoid treatment (casesa, n=37 (at
8y) n=29 (at 16y), and controls balanced on gestational age and pre-pregnancy BMI, by means of logit of propensity score;
1:5 matching ratio) and mental health outcome scores for children and adolescents, adjusted for relevant confoundersb.
Mental Health Prenatal glucocorticoid (GC) treatment (case/control)
 Unadjusted Adjusted
b
 B 95% CI for B β P B 95% CI for B β P Cohen’s f2
8-y-olds Rutter (teacher report)          
Total Rutter score 1.07 -.95-3.10 .08 .30 8.34 .23-16.45 .56 .04 .23
Antisocial score .28 -.45-1.00 .05 .45 2.93 -.04-5.9 .54 .05 .20
Neurotic score .11 -.39-.62 .03 .66 1.55 -.55-3.67 .42 .15 .11
Inattention-hyperactivity score .21 -.40-.72 .04 .58 2.16 -.03-4.35 .52 .05 .33
Inattention scorec -.02 -.23-.18 -.02 .81 .97 .16-1.80 .64 .02 .23
Hyperactivity scored .19 -.21-.58 .07 .35 1.19 -.29-2.67 .41 .12 .36
16-y-olds SWAN (parent report)          
Combined ADHD score -1.15 -8.48-6.19 -.03 .76 16.20 -14.65-47.04 .34 .30 .11
Inattention scoree -.53 -4.31-3.24 -.02 .78 9.00 -6.42-24.41 .37 .25 .11
Hyperactivity scoref -.61 -4.60-3.38 -.02 .76 7.20 -9.85-24.26 .27 .41 .10
16-y-olds YSR (self-report)          
YSR Total Problem score 2.10 -4.55-8.74 .05 .53 2.30 -26.43-31.00 .05 .88 .12
a. Including cases exposed to prenatal sGC > 4 days prior to birth.
b. adjusted for sex, birthweight, placental weight, socio-demographic factors (maternal age, education and family structure), and medical factors (total prenatal sGC dose,
interval between prenatal sGC exposure and birth (days), smoking during pregnancy and parity).
c. score based on Rutter item number 16 (range 0 to 2).
d. score based on sum of Rutter items 1 and 3 (range 0 to 4).
e. score based on sum of 9 SWAN items (range -27 to 27).
f. score based on sum of 9 SWAN items (range -27 to 27).
doi: 10.1371/journal.pone.0081394.t002
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(MR), both of which have a high affinity for GC, are highly
expressed in the fetal brain [56], particularly the hippocampus
[57]. Animal studies have shown that prenatal sGC exert
widespread effects on the developing brain, reducing neuron
proliferation [58], as well as affecting neuron structure and
synapse formation [59]. Prenatal sGC has been linked with
reduced density of hippocampal neurons in the offspring, in
both humans and animals [57,60]. Altered hippocampal
structure in turn has been associated with mental health,
including ADHD [61,62]. A recent study demonstrated that
prenatal sGC was associated with thinner brain cortex in
children, which in turn was linked with affective problems [63].
There is also evidence that prenatal sGC has a long-term
impact on hypothalamic-pituitary-adrenal (HPA) axis reactivity
in term-born children, which may bear significant implications
for stress-related psychiatric disorders [64].
Table 3. Mixed-effects model for the association between prenatal glucocorticoid treatment (casea vs. control, matched for
gestational age and sex) and mental health outcome scores for children and adolescents, adjusted for relevant confoundersb.
Mental health Prenatal glucocorticoid (GC) treatment (case/control)
 Estimates Pair-wise comparisons
 n Means SE 95% CI Mean difference (B) SE 95% CI P
8-y-olds Rutter (teacher report)         
Total Rutter score     8.04 3.34 1.49-14.60 .02
GC control 6059 3.59 .32 2.90-4.28     
GC case 37 11.63 3.33 5.11-18.15     
Antisocial score     2.15 1.12 -.04-4.35 .05
GC control 6065 .75 .11 .50-1.00     
GC case 37 2.90 1.11 .72-5.01     
Neurotic score     2.48 .84 .84-4.12 .00
GC control 6076 .65 .02 .61-.70     
GC case 37 3.13 .83 1.50-4.76     
Inattention-hyperactivity score     1.53 1.01 -.43-3.51 .13
GC control 6069 3.86 .11 3.62-4.09     
GC case 37 5.39 1.00 3.43-7.36     
Inattention scorec     .79 .35 .12-1.47 .02
GC control 6079 .22 .03 .16-.29     
GC case 37 1.01 .34 .34-1.69     
Hyperactivity scored     .74 .73 -.69-2.17 .31
GC control 6075 2.63 .08 2.46-2.81     
GC case 37 3.37 .73 1.95-4.80     
16-y-olds SWAN (parent report)         
Combined ADHD score     13.92 12.83 -11.22-39.06 .28
GC control 4950 -20.23 .86 -22.10- -18.36     
GC case 29 -6.31 12.77 -31.34-18.72     
Inattention scoree     8.42 6.80 -4.91-21.74 .22
GC control 4950 -8.00 .49 -9.05- -6.94     
GC case 29 .42 6.77 -12.85-13.69     
Hyperactivity scoref     5.47 6.99 -8.24-19.17 .43
GC control 4950 -12.22 .38 -13.05- -11.38     
GC case 29 -6.75 6.96 -20.39-6.89     
16-y-olds YSR (self-report)         
YSR Total Problem score     16.39 12.05 -7.24-40.02 .17
GC control 5079 25.52 1.34 22.67-28.36     
GC case 29 41.91 12.03 18.33-65.49     
a. Including cases exposed to prenatal sGC > 4 days prior to birth.
b. adjusted for birthweight, placental weight, socio-demographic factors (maternal age, education and family structure), and medical factors (total prenatal sGC dose, interval
between prenatal sGC exposure and birth (days), smoking during pregnancy, parity and pre-pregnancy BMI).
c. score based on Rutter item number 16 (range 0 to 2).
d. score based on sum of Rutter items 1 and 3 (range 0 to 4).
e. score based on sum of 9 SWAN items (range -27 to 27).
f. score based on sum of 9 SWAN items (range -27 to 27).
doi: 10.1371/journal.pone.0081394.t003
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We tested the hypothesis that deviation in birthweight or
placental weight would mediate the association between
prenatal exposure to sGC and child mental health. It is possible
that altered birth size and/or placental size, both of which have
been linked to prenatal sGC exposure [22,27] and child mental
health [23,29], would lie on the GC programming pathway.
However, we did not find support for this idea.
As in all longitudinal studies, attrition occurs at every follow-
up and is the main limitation. With a loss of 9 cases by the 16-
year follow-up, our study was under-powered at this point,
which is a likely explanation for non-significant findings at this
age. The NFBC 1986 is a prospective cohort but was not
designed to examine sGC treatment outcomes - we performed
a chart review to identify sGC cases, thus we cannot rule out
the impact of unmeasured confounders. It is not possible to
completely rule out that the observed differences in mental
health scores may be due to the complications of pregnancy
which prompted sGC treatment. However, this seems unlikely
here as both cases and controls experienced pregnancy
complications, and our matching procedures ensured that
cases and controls were balanced on important confounders.
Due to the very small number of sGC cases experiencing
pregnancy complications known to be a risk for pre-term birth
(n=1), we could not study these as sub-groups. Further work is
required to determine the impact of pregnancy complications
on later mental health with larger samples. Finally, sGC cannot
be directly equated to endogenous maternal GC. sGC and
endogenous GC largely bind to different types of steroid
receptors and so may have different biological effects. Despite
these limitations, sGC provides a useful quasi-experimental
model in the absence of direct experimental manipulation in
humans and provides a tentative proof of concept, warranting
further research to better understand the associations and their
underlying mechanisms.
Our study has important strengths. First, we used propensity-
score-matching to account for treatment-selection bias (thereby
partly mimicking an RCT), in particular gestational age and pre-
pregnancy BMI, and so we were able to isolate the effect of the
drug from these two significant confounders associated with
receipt of treatment. Our large dataset enabled us to very
precisely match cases to controls on the logit propensity
scores. Thus the results presented here are not due to pre-
maturity, which its threat would prompt treatment, and is known
to be a risk for poor neurodevelopmental outcomes, including
ADHD [65,66] nor pre-pregnancy BMI which was also
associated with treatment in this sample as well as ADHD
[32,67]. The matched cases and controls were also balanced
on other important confounders, and these confounders were
additionally adjusted for in the main analysis. Thus, we
minimized confounding related to sGC treatment and mental
health as much as possible. Second, we were able to replicate
the results produced from the propensity-score-matched
subsample using the entire cohort by means of mixed-effects
modeling, demonstrating the robustness of our findings. Third,
we used precise case classification (exposed >4 days prior to
delivery) to ensure that the drug had sufficient time to act on
the fetal brain. Studies which do not take exposure time into
consideration e.g. Dalziel et al. (2005) may be more likely to
report null findings as the drug may not have had time to act on
the fetal brain. Fourth, we assessed child and adolescent
mental health via multiple informants and multiple validated
instruments, which strengthen the credibility of the results and
extend previous findings that have relied almost completely on
parental report. Fifth, we address the growing public health
concern regarding side-effects of sGC treatment by studying
the impact of fairly low/infrequent doses of sGC.
In conclusion, the data we present here, originating from a
population-based cohort, is the largest to date and show an
association between prenatal sGC exposure and child mental
health. Further work is necessary to confirm the long-term
associations. By capitalizing on the natural experiment in which
women are treated with sGC, we were able to explore the
hypothesized pathway between fetal glucocorticoid exposure
and later child mental health. The results show that this
pathway merits further scientific research, though it is a
challenge using human studies. While the benefits of prenatal
sGC treatment on the immediate health and survival of the pre-
term neonate are clear, it is also important to consider the long-
term health implications of this drug, including those relating to
mental health. The clinical ramifications of this study call for
close monitoring of children prenatally exposed to sGC in order
to provide support early if mental health problems arise.
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Abstract
Background: The role of the placenta in fetal programming has been recognized as a highly significant, yet often neglected
area of study. We investigated placental size in relation to psychopathology, in particular attention deficit hyperactivity
disorder (ADHD) symptoms, in children at 8 years of age, and later as adolescents at 16 years.
Methodology/Principal Findings: Prospective data were obtained from The Northern Finland Birth Cohort (NFBC) 1986.
Placental weight, surface area and birth weight were measured according to standard procedures, within 30 minutes after
birth. ADHD symptoms, probable psychiatric disturbance, antisocial disorder and neurotic disorder were assessed at 8 years
(n = 8101), and ADHD symptoms were assessed again at 16 years (n = 6607), by teachers and parents respectively. We used
logistic regression analyses to investigate the association between placental size and mental health outcomes, and
controlled for gestational age, birth weight, socio-demographic factors and medical factors, during gestation. There were
significant positive associations between placental size (weight, surface area and placental-to-birth-weight ratio) and mental
health problems in boys at 8 and 16 years of age. Increased placental weight was linked with overall probable psychiatric
disturbance (at 8y, OR = 1.14 [95% CI = 1.04–1.25]), antisocial behavior (at 8 y, OR = 1.14 [95% CI = 1.03–1.27]) and ADHD
symptoms (inattention-hyperactivity at 16y, OR = 1.19 [95% CI = 1.02–1.38]). No significant associations were detected
among girls.
Conclusions/Significance: Compensatory placental growth may occur in response to prenatal insults. Such overgrowth may
affect fetal development, including brain development, and ultimately contribute to psychopathology.
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Introduction
Mental health problems, in particular attention deficit hyper-
activity disorder (ADHD) symptoms, are a significant cause of
functional disability in children and adolescents [1,2]. While
genetic and childhood environmental factors have been studied
extensively in relation to the development of psychiatric disorders,
accumulating evidence has revealed that prenatal factors are
potentially another powerful source of influence [3], in accordance
with fetal programming [4,5]. Indeed, an adverse intrauterine
environment has been associated with a range of mental health
problems in children, including ADHD symptoms, anxiety and
antisocial disorder [6]. However, our understanding of the
mechanisms linking prenatal exposures to later health outcomes
is very limited. It has recently been suggested that the placenta
may be a significant component in translating maternal influences
during pregnancy, consequently affecting fetal development and
thereby adult health [7,8]. The placenta, providing an interface
between the mother and fetus, appears to be in a key position to
mediate fetal programming. Evidence from recent studies indicates
that the placenta responds to disturbances in the maternal
environment with a range of structural and functional adaptations,
including changes in placental growth [8,9]. Abnormal placental
growth is associated with altered fetal nutrient and hormone
supply [5], which in turn may induce adaptations in the fetus,
thereby programming an increased risk of developing disease in
adult life [8]. In light of this, it is surprising that the role of the
placenta in the programming of psychopathology has received
limited research attention. To our knowledge, only one previous
study has examined the relation between placental size and mental
health, which found that small placental weight was associated
with schizotypal traits in women at 31 years of age [10]. To date,
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it is not known whether placental size is related to mental health in
children and adolescents.
Here we analysed prospective data from a large, longitudinal
cohort to investigate whether characteristics related to placental
size – placental weight, surface area and placental-to-birth-weight
ratio, are associated with mental health, in particular ADHD
symptoms, in childhood and adolescence. We investigated sexual
dimorphism, due to well-established sex differences in behavior
and the placenta. Besides the higher prevalence of behavioral
problems among boys compared to girls [11], male placentas are
more vulnerable to maternal undernutrition, and more readily
undergo compensatory placental growth in response to such insults
[12]. We hypothesise that placental size will be related to
psychopathology, in particular ADHD symptoms, during child-
hood (8 years) and later in adolescence (16 years), after controlling
for relevant confounders.
Methods
Ethics Statement
The ethics committee of Northern Ostrobotnia Hospital District
approved the study, and both parents and adolescents gave written
informed consent.
Cohort
Data were obtained from The Northern Finland Birth Cohort
(NFBC) 1986, which consists of 9479 children born in Oulu and
Lapland provinces, who were studied prospectively from early
pregnancy until 16 years of age (Figure 1). Children with an
expected date of birth between July 1, 1985 and June 30, 1986
were eligible; 99% of eligible births in the study area were
included.
Pregnant women were recruited at maternity health centres, at
their first antenatal visit (approximately gestational week 12), and
provided background information using structured self-report
questionnaires, which were returned by gestational week 24, if still
pregnant. Antenatal clinical and birth outcome data were obtained
from maternity health centres and hospital medical records
(completed by midwives during pregnancy and at birth), and
abstracted onto study forms.
After excluding multiple birth children (226 twins and 6 triplets)
and those who had not consented use of their data (n = 249), data
from 8954 liveborns (4596 boys) were available for analysis
(Figure 1). When children were 8 years of age, teachers were asked
to complete questionnaires regarding child behavior. Of children
still residing in Finland, 90% (n= 8101) of the teachers completed
the questionnaire. At 16 years of age, 74% (n= 6607) of families
still residing in Finland provided information on adolescent
behavior.
Variables
Placental Characteristics. Within 30 minutes following
delivery, placentas were washed with water, cleaned from blood
clots, and then weighed to the nearest gram. Placental weight
included membranes and the umbilical cord, cut approximately
5 cm from the neonate. Whilst spread out on a plane, placental
breadth and length were used to measure placental surface area
(maternal side) in centimetres squared. The placental-to-birth-
weight ratio was calculated by dividing placental weight by birth
weight, and then multiplying by 100 to produce a percentage of
placental weight relative to birth weight.
Child and Adolescent Behavior. Teachers assessed child
behavior at the age of 8 years using the Rutter B2 scale [13], a
well-validated screener for childhood psychopathology. Each of
the 26 items is rated as either it ‘certainly applies’ (scored = 2),
Figure 1. Flowchart of study participants.
doi:10.1371/journal.pone.0040534.g001
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‘applies somewhat’ (scored = 1) or ‘does not apply’ (scored = 0);
yielding a total score between 0 to 52. According to the screening
criteria, a total score of $9 indicates probable psychiatric
disturbance in general. The questionnaire generates three sub-
scores: the neurotic sub-score (the sum of four items – often
worried, miserable, fearful and tears on arrival at school), the
antisocial sub-score (the sum of six items – destructive, fights,
disobedient, lies, steals and bullies) and the inattention-hyperac-
tivity sub-score (the sum of three items – restless, squirmy and
fidgety, and poor concentration ). Probable positive screen for
neurotic disorder is identified by a total score of $9 and a higher
score on neurotic items versus antisocial items, whereas antisocial
disorder is identified by a total score of $9 and a higher score on
antisocial items versus neurotic items. Probable combined
inattention-hyperactivity disorder is defined as a total score of
$9 and sum of all three inattention-hyperactivity items $3.
Additionally, we examined the core ADHD symptoms individually
i.e. inattention (item ‘poor concentration’ $1) and hyperactivity
(sum of items ‘restless’ and ‘squirmy and fidgety’ $3).
At 16 years of age, parents reported adolescents’ behavior using
the Strengths and Weaknesses of ADHD symptoms and Normal
behavior (SWAN) scale [14]. The SWAN is an 18-item scale,
based on the symptoms of ADHD listed in the DSM-IV. As this
scale measures both weaknesses (scored as 3, 2 and 1) and
strengths (scored as 21, 22 and 23), along with average behavior
(scored as 0), it is expected to produce a normal distribution of
behavioral scores, thereby reducing the risk of over-identifying
youths as screening positive for ADHD. The inattentive subscale
and hyperactive-impulsivity subscale each comprise 9 items, and
the combined subscale contains all items. The 95th percentile of
the distribution of mean scores on each subscale was used as a cut-
off point to identify adolescents with ADHD symptoms as
probable clinical cases. The cut-off values for the inattention,
hyperactive-impulsivity and combined subscales were respectively
0.625, 0.125 and 0.277, previously described in detail [15].
Confounders. We considered potential confounders which
may be related to placental size and mental health outcomes, as
indicated by our descriptive analysis as well as the literature. These
were gestational age (weeks) [16], birth weight (grams) [17] as well
as maternal socio-demographic and medical factors [16,18,19,20],
all of which were collected prospectively. The socio-demographic
factors were maternal age (years), education (either ,11 years of
education or $11 years of education, coded as 0 or 1,
respectively), family structure (either married/co-habiting or
single/widowed/divorced, coded as 0 or 1, respectively) and
social class (by occupation; either class 1 (professional, upper/
lower white collar or farmer $8 hectares of land) or class 2
(unskilled worker or farmer ,8 hectares of land), coded as 0 or 1,
respectively). This dichotomized social class variable was based on
paternal occupation (or maternal occupation, if missing data or
single mother), which was transformed to an indicator of social
class according to a national system of classifications and standards
in Finland [21]. The medical factors controlled for were parity
(included as a continuous variable), pre-pregnancy body mass
index (BMI) (pre-pregnancy weight [kg]/height2 [m2]) (included as
a continuous variable), gestational weight gain (weight at last
antenatal appointment [kg] – pre-pregnancy weight [kg]), and
smoking during pregnancy (either no or yes, coded as 0 and 1,
respectively).
Statistical Analyses
We initially performed correlation and ANOVA analyses to
identify any relations between placental size and potential
confounders. Logistic regression analyses were used to investigate
the association between placental size (placental weight, surface
area and placental-to-birth-weight ratio) and mental health
outcomes in children and adolescents. The predictors – the
placental characteristics, were included as continuous variables.
Placental weight and surface area were initially analysed
continuously in 1 g and 1 cm2 increments, respectively. To
facilitate clinical interpretation of the results, the main analysis
included placental weight and surface area as continuous variables
in 100 g and 10 cm2 increments, respectively. All the mental
health outcomes were dichotomized, coded as 1 to indicate the
presence of mental health problems (and 0 if absent), according to
the criteria of each screening instrument. We controlled for
gestational age, birth weight, socio-demographic factors (maternal
age, education, family structure and social class), and medical
factors (parity, pre-pregnancy BMI, gestational weight gain and
smoking during pregnancy).
To investigate non-linear associations, we repeated the analysis
with stratified placental data (8 groups: ,400 g, 400–499 g, 500–
599, 600–699 g, 700–799 g, 800–899 g, 900–999 g and
$1000 g). Furthermore, to assess frequency distributions for
descriptive purposes, placental weight was stratified according to
its distribution in the study population, such that three categories
were formed: ,550 g (represents ,25th percentile), 550–719 g
(represents 25th–75th percentiles) and .720 g (represents .75th
percentile).
Using SPSS 17.0, all analyses were conducted separately for
males and females, due to sex differences in placentas and
behavioral traits.
Results
Table 1 shows birth and child/adolescent behavioural out-
comes. For the three categories of placental weight, ,550 g, 550–
719 g and .720 g, the weight ranges from the mean were 422–
530 g, 578–676 g and 726–902 g, respectively, for the entire study
sample.
Correlation analyses showed that placental size was significantly
associated with the potential confounders. Placental weight
significantly correlated with gestational age (r = .23, p,.01), birth
weight (r = .65, p,.01), maternal socio-demographic factors
(except for education): age (r = .08, p,.01), family structure at
birth (r =2.05, p,.01), social class by occupation (r = .02, p,.05),
and medical factors: parity (r = .11, p,.01), pre-pregnancy BMI
(r = .18, p,.01), gestational weight gain (r = .14, p,.01) and
smoking during pregnancy (r =2.05, p,.01). Table 2 shows
significant associations between mean placental weight and each of
the potential confounders (except for maternal education). Mean
placental weight differed significantly between the dichotomized
mental health outcomes specifying antisocial disorder (males and
entire sample) and neurotic disorder (females) at 8 years, and
inattention symptoms (entire sample) at 16 years.
Both unadjusted and adjusted logistic regression analyses
revealed positive associations between placental size (placental
weight, surface area and placental-to-birth-weight ratio – as
continuous variables) and mental health outcomes in boys at 8 and
16 years of age, as shown in Table 3. The adjusted analyses largely
show stronger and more significant associations between male
placental size and mental health outcomes, including overall
probable psychiatric disturbance, ADHD symptoms and antisocial
disorder in 8-year olds, and ADHD symptoms in 16-year olds. For
example, for every 100 g increase in placental weight, the risk for
probable psychiatric disturbance at 8 years and combined
inattention-hyperactivity at 16 years increased by 14% and 19%,
respectively. Furthermore, the adjusted results indicate that
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compared to placental surface area (10 cm2) and placental-to-
birth-weight ratio, increased placental weight (100 g) was the
strongest predictor of mental health problems in boys at both 8
and 16 years of age. Linear analyses indicated that a respective
increase of 1 g and 1 cm2 in placental weight and surface area
were significantly associated with mental health problems in boys.
A 1 g increase in placental weight was associated with probable
psychiatric disturbance at 8 years (OR =1.001 [95% CI = 1.000–
1.002]) and combined inattention-hyperactivity at 16 years (OR
=1.002 [95% CI = 1.000–1.003]), and a 1 cm2 increase in
placental surface area was associated with inattention-hyperactiv-
ity symptoms at 8 years (OR=1.002 [95% CI=1.001–1.004]) and
inattention symptoms at 16 years (OR=1.003 [95% CI= 1.000–
1.005]). A 10 g increase in placental weight i.e. within 1 SD from
the mean, was positively associated with mental health problems in
boys (for probable psychiatric disturbance at 8 years, OR =1.013
[95% CI = 1.004–1.023]). In girls, no significant associations were
detected between placental size and mental health outcomes at
either 8 years or 16 years of age, as shown in Table 4.
After repeating the analysis using stratified placental data, we
did not find evidence for a U-shaped association, as small placental
size was unrelated to the mental health outcomes.
Discussion
This is the first study to investigate the relation between
placental size and mental health outcomes in children and
adolescents. We identified a positive association between placental
size (placental weight, surface area and placental-to-birth-weight
ratio) and mental health problems in boys; increased placental size
was linked with overall probable psychiatric disturbance, ADHD
symptoms and antisocial disorder at 8 years of age, and ADHD
symptoms at 16 years, after adjusting for known confounders. It is
important to note that the magnitude of the associations were
small; however, because psychiatric disorders are highly complex –
in terms of both etiology and diagnosis, it is expected that any
single variable will contribute a small portion of the variance. Our
results suggest that variation in placental size may play a role in the
causal pathway leading from prenatal exposures to later mental
health problems, but further work is required to determine
causality.
Placental overgrowth may occur as a compensatory mechanism
in response to various maternal prenatal insults [9,22,23,24]. It has
been theorized that an enlarged placenta may reduce its supply of
nutrients to the fetus [5]; consequent fetal adaptations may lead to
permanent structural and physiological changes to developing
organs, programming an increased risk of disease. Our results are
in line with this, such that we may speculate that increased
placental size – a possible consequence of an adverse maternal
environment, may alter fetal nutrient supply, which in turn may
affect normal brain development [25,26], increasing the risk of
psychiatric problems later in life. In support of this potential
mechanism, prenatal psychosocial stress, a common environmen-
tal insult, has been associated with increased placental weight [9],
and has been directly and independently linked with atypical
cerebral laterality [27,28], and an increased risk of psychiatric
problems in children [29,30]. Furthermore, atypical cerebral
lateralization, which has been linked to child and adolescent
mental health problems (including ADHD [31,32]), was detected
in 8–9 year old children who had a moderately low birth weight
and disproportionately large placenta [33]. On the surface, it may
seem that the suggested mechanism implies that an increased
placental-to-birth weight ratio would be the strongest predictor of
psychiatric outcomes. However, whilst possibly reducing nutrient
supply to the fetus, compensatory mechanisms in the expanding
placenta may counteract any intrauterine deficiencies, so that a
normal birth weight is still achieved despite suboptimal conditions
[7]. This concept could explain why we found increased placental
weight was the strongest predictor of psychopathology, compared
to the other placental characteristics which we studied. Thus, an
enlarged placenta may represent an important link between
disturbances in the maternal environment and perturbed fetal
brain development, with ensuing mental health problems in
children and adolescents.
Table 1. Birth and child/adolescent characteristics presented
as means 6 SD or n (%).
Characteristic Mean ± SD or n (%) n
All Male Female
Birth outcomes
Sex 4596 (51.3) 4358 (48.7) 8954
Birth weight (g) 35756534 36386537 35096523 8954
,2500 20446449 20256459 20596441 248
2500–4499 35786424 36266420 35286422 8388
$4500 47046194 47076197 46976190 318
Gestational age
at birth (weeks)
39.461.6 39.461.6 39.561.6 8950
Preterm birth
(,37 weeks)
34.462.3 34.462.3 34.362.3 366
Term birth
($37 weeks)
39.661.2 40.061.2 40.061.2 8584
Placental weight (g) 6466132 6526133 6406131 8934
,550 874 (48.6) 924 (51.4) 1798
550–719 2425 (50.8) 2349 (49.2) 4774
$720 1287 (54.5) 1075 (45.5) 2362
Placental surface area (cm2) 335670 337670 334669 8821
Placental-to-birth-weight ratio 18.2+3.1 18.063.1 18.363.0 8934
Behavioral outcomes
8-y-olds (teacher report)
Rutter a
Probable psychiatric
disturbance
1140 (14.1) 801 (19.5) 339 (8.6) 8065
Antisocial disorder 725 (9.0) 570 (13.9) 155 (4.0) 8065
Neurotic disorder 328 (4.1) 171 (4.2) 157 (4.0) 8065
Inattention-hyperactivity 756 (9.4) 576 (14.0) 180 (4.5) 8080
Inattentionb 1705 (21.1) 1220 (30.0) 485 (12.2) 8088
Hyperactivityc 575 (7.1) 468 (11.4) 107 (2.7) 8086
16-y-olds (parent report)
SWAN a
Combined ADHD 349 (5.3) 231 (7.0) 118 (3.5) 6607
Inattentiond 332 (5.1) 230 (7.1) 102 (3.1) 6500
Hyperactivity-impulsivitye 306 (4.7) 197 (6.1) 109 (3.3) 6467
aassessment of symptoms based on fulfilment of criteria according to the Rutter
B2/Strengths and Weaknesses of ADHD symptoms and Normal behavior
(SWAN) scale.
bassessment based on Rutter item number 16.
cassessment based on sum of Rutter items 1 and 3.
dSWAN subscale consisting of sum of 9 items.
eSWAN subscale consisting of sum of 9 items.
doi:10.1371/journal.pone.0040534.t001
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Table 2. Mean placental weight according to potential confounders and child/adolescent mental health outcomes.
Potential Confounders and
Mental Health Outcomes Mean Placental Weight (g) (SD)
n (%) All n (%) Male n (%) Female
Potential Confounders
Birth weight (g) 8934 4586 4348
,2500 247 (2.8) 448 (106) 110 (2.4) 455 (108) 137 (3.2) 443 (105)
2500–4499 8370 (93.7) 644 (121) 4259 (92.9) 646 (121) 4111 (94.5) 641 (121)
$4500 317 (3.5) 860 (138) 217 (4.7) 837 (139) 100 (2.3) 869 (136)
pa .000 .000 .000
Gestational age at birth (weeks) 8930 4582 4348
,37 363 (4.1) 524 (163) 189 (4.1) 555 (171) 174 (4.0) 528 (154)
37–41 8226 (92.1) 650 (129) 4213 (92) 655 (130) 4013 (92.3) 644 (127)
$42 341 (3.8) 600 (127) 180 (3.9) 663 (124) 161 (3.7) 656 (131)
pa .000 .000 .000
Maternal age (years) 8934 4586 4348
,20 655 (7.3) 636 (125) 336 (7.3) 645 (120) 319 (7.3) 626 (129)
20–34 7105 (79.5) 645 (131) 3635 (79.3) 651 (133) 3470 (79.8) 639 (129)
$35 1174 (13.1) 654 (142) 615 (13.4) 657 (143) 559 (12.9) 652 (141)
pa .012 .381 .019
Maternal education (years) 7855 3999 3856
,11 2377 (30.3) 651 (138) 1184 (29.6) 657 (136) 1193 (30.9) 645 (139)
$11 5478 (69.7) 645 (127) 2815 (70.4) 651 (129) 2663 (69.1) 640 (125)
pa .089 .172 .265
Family structure 8908 4570 4338
Married/cohabiting 8453 (94.9) 647 (132) 4347 (95.1) 654 (133) 4106 (94.7) 641 (131)
Single/widowed/divorced 455 (5.1) 620 (127) 223 (4.9) 614 (123) 232 (5.3) 625 (130)
pa .000 .000 .069
Family social class (by occupation) 8646 4438 4208
I
Professional 521 (6.0) 647 (132) 265 (6.0) 647 (142) 256 (6.1) 647 (121)
Upper white collar 1723 (20.0) 648 (127) 853 (19.2) 659 (131) 870 (20.7) 638 (122)
Lower white collar 3476 (40.2) 644 (131) 1802 (40.6) 651 (130) 1674 (39.8) 638 (131)
Farmer $8 hectares 348 (4.0) 666 (146) 178 (4.0) 676 (154) 170 (4.0) 655 (136)
II
Unskilled worker 2525 (29.2) 642 (133) 1319 (29.7) 645 (131) 1206 (28.7) 640 (135)
Farmer ,8 hectares 53 (.6) 672 (178) 21 (.5) 731 (202) 32 (.7) 633 (151)
pa .025 .001 .565
Parity 8895 4565 4330
0 3029 (34.1) 623 (128) 1551 (34) 629 (128) 1478 (34.1) 617 (128)
1 2969 (33.4) 653 (132) 1485 (32.5) 658 (134) 1484 (34.3) 647 (130)
2 1604 (18.0) 660 (134) 863 (18.9) 669 (136) 741 (17.1) 650 (126)
$3 1293 (14.5) 666 (132) 666 (14.6) 666 (133) 627 (14.5) 666 (136)
pa .000 .000 .000
Pre-pregnancy BMI (kg/m2) 8708 4478 4230
,20 2136 (24.5) 612 (121) 1138 (25.4) 618 (120) 998 (23.6) 606 (123)
20–24.99 5078 (58.3) 649 (130) 2576 (57.5) 655 (132) 2502 (59.1) 643 (127)
$25 1494 (17.2) 683 (142) 764 (17.1) 688 (142) 730 (17.3) 677 (141)
pa .000 .000 .000
Gestational weight gain (kg) 8262 4244 4018
,11 1911 (23.1) 620 (132) 909 (21.4) 623 (137) 1002 (25.0) 617 (128)
11–16.99 4310 (52.2) 645 (126) 2223 (52.4) 650 (125) 2087 (51.9) 640 (126)
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Table 2. Cont.
Potential Confounders and
Mental Health Outcomes Mean Placental Weight (g) (SD)
n (%) All n (%) Male n (%) Female
$17 2041 (24.7) 673 (136) 1112 (26.2) 679 (136) 929 (23.1) 666 (130)
pa .000 .000 .000
Smoking during pregnancy 8696 4455 4241
No 6989 (80.4) 649 (131) 3564 (80.0) 654 (133) 3425 (80.8) 644 (130)
Yes 1707 (19.6) 633 (130) 891 (20.0) 638 (131) 816 (19.2) 627 (129)
pa .000 .001 .001
Number of cigarettes (per day) 939 500 439
,10 cigarettes 556 (59.2) 630 (121) 293 (58.6) 634 (116) 263 (59.9) 626 (127)
$10 cigarettes 383 (40.8) 631 (138) 207 (41.4) 641 (138) 176 (40.1) 618 (137)
pa .968 .539 .544
Mental Health Outcomes
8-y-olds Rutter (teacher report)b
Probable psychiatric disturbance 8046 4097 3949
Yes 1139 (14.2) 651 (138) 800 (19.5) 660 (141) 339 (8.6) 632 (130)
No 6907 (85.8) 646 (129) 3297 (80.5) 651 (127) 3610 (91.4) 642 (129)
pa .245 .089 .145
Antisocial disorder 8046 4097 3949
Yes 724 (9.0) 659 (142) 569 (13.9) 663 (144) 155 (3.9) 646 (135)
No 7322 (91.0) 646 (129) 3528 (86.1) 651 (128) 3794 (96.1) 641 (129)
pa .010 .046 .683
Neurotic disorder 8046 4097 3949
Yes 328 (4.1) 641 (133) 171 (4.2) 660 (137) 157 (4.0) 621 (126)
No 7718 (95.9) 647 (130) 3926 (95.8) 652 (130) 3792 (96.0) 642 (130)
pa .419 .417 .041
Inattention- hyperactivity 8061 4103 3958
Yes 755 (9.4) 650 (138) 575 (14.0) 656 (136) 180 (4.5) 628 (140)
No 7306 (90.6) 647 (129) 3528 (86.0) 652 (129) 3778 (95.5) 642 (129)
pa .568 .442 .163
Inattentionc 8069 4108 3961
Yes 1703 (21.1) 650 (135) 1218 (29.6) 655 (135) 485 (12.2) 639 (132)
No 6366 (78.9) 646 (129) 2890 (70.4) 652 (128) 3476 (87.8) 642 (129)
pa .281 .496 .625
Hyperactivityd 8067 4105 3962
Yes 573 (7.1) 654 (137) 466 (11.4) 655 (138) 107 (2.7) 653 (132)
No 7494 (92.9) 646 (129) 3639 (88.6) 652 (129) 3855 (97.3) 641 (130)
pa .159 .677 .354
16-y-olds SWAN (parent report)b
Combined ADHD 6594 3275 3319
Yes 349 (5.3) 659 (138) 231 (7.1) 668 (144) 118 (3.6) 641 (123)
No 6245 (94.7) 647 (129) 3044 (92.9) 652 (128) 3201 (96.4) 642 (129)
pa .098 .076 .930
Inattentione 6488 3227 3261
Yes 332 (5.1) 663 (138) 230 (7.1) 666 (140) 102 (3.1) 656 (132)
No 6156 (94.9) 646 (128) 2997 (92.9) 652 (127) 3159 (96.9) 641 (129)
pa .024 .110 .256
Hyperactivity-impulsivityf 6455 3206 3249
Yes 306 (4.7) 650 (135) 197 (6.1) 660 (135) 109 (3.4) 632 (133)
No 6149 (95.3) 647 (129) 3009 (93.9) 652 (129) 3140 (96.6) 642 (128)
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Variation in the size of the placenta affects aspects of its
function, in particular the ability to transfer nutrients to the fetus
via changes in the exchange surface area [34]; in general, small
placentas are associated with small fetuses [35]. Placental size is
affected by maternal factors, such as BMI, gestational weight gain
and smoking [16], as well as various other medical and socio-
demographic factors, as demonstrated by our own results,
indicating that the placenta is receptive to the maternal
environment, and undergoes changes in size in an effort to
maintain fetal development under suboptimal conditions [7]. For
example, in response to maternal undernutrition, the placenta may
undergo compensatory enlargement [22]; although this adaptation
may improve the overall nutrient supply to the fetus, ensuring a
normal birth weight is achieved, the relative contribution of
specific nutrients to fetal organs may be altered, resulting in the
programming of developing organs [7]. Thus, placental compen-
satory mechanisms may often ensure a normal birth weight is
achieved in adverse circumstances, whilst the placenta itself may
be markedly affected [36] – reflecting the physiological stresses
which occurred during development. Therefore, compared to
birth weight and other common indices used to identify
suboptimal intrauterine conditions, placental phenotype can
provide additional insight into the intrauterine environment and
improve our understanding of the processes underlying fetal
programming. Furthermore, placental size may enhance the
ability to predict later disease, as several lines of evidence suggest
[36,37,38].
It is interesting to note that placental size was related to a range
of mental health problems (including general probable psychiatric
disturbance) in this study. This may correspond to the under-
standing that placental size is sensitive to various maternal
influences, and thus possibly represents an archive of gestational
insults, which could affect the developing brain non-specifically.
While there is evidence for a U-shaped relation between
placental size and various health outcomes [39], here we report a
positive linear association, which may be explained by factors
related to the direction of placental-fetal growth disproportion,
including maternal nutritional status and the timing of prenatal
insults. A study by Barker et al. found that in the offspring of tall,
middle-class mothers, who were likely to be well nourished,
Table 2. Cont.
Potential Confounders and
Mental Health Outcomes Mean Placental Weight (g) (SD)
n (%) All n (%) Male n (%) Female
pa .677 .402 .427
afor heterogeneity, analysis of variance.
bassessment of symptoms based on fulfilment of criteria according to the Rutter B2/Strengths and Weaknesses of ADHD symptoms and Normal behavior (SWAN) scale.
cassessment based on Rutter item number 16.
dassessment based on sum of Rutter items 1 and 3.
eSWAN subscale consisting of sum of 9 items.
fSWAN subscale consisting of sum of 9 items.
doi:10.1371/journal.pone.0040534.t002
Table 3. Logistic regression results for the association between male placental size (weight, surface area and placental-to-birth-
weight ratio) and mental health outcomes.
Behavior Male Placental Weight (100g) Male Placental Surface Area (10cm
2) Male Placental-to-Birth-Weight Ratio
Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjustedb
OR 95% CI n OR 95% CI OR 95% CI n OR 95% CI OR 95% CI n OR 95% CI
8-y-olds Rutter (teacher report)
Probable psychiatric
disturbance
1.05 .99–1.12 3276 1.14** 1.04–1.25 1.01 1.00–1.02 3236 1.01 1.00–1.03 1.04** 1.01–1.07 3276 1.04* 1.01–1.08
Antisocial disorder 1.07* 1.00–1.15 3276 1.14* 1.03–1.27 1.01 1.00–1.02 3236 1.02* 1.00–1.04 1.05** 1.02–1.08 3276 1.04* 1.01–1.08
Neurotic disorder 1.05 .93–1.18 3276 1.19 .99–1.42 1.00 .98–1.02 3236 1.00 .97–1.03 1.04 .98–1.09 3276 1.06 .99–1.13
Inattention-hyperactivity 1.03 .96–1.10 3282 1.11* 1.00–1.24 1.01 1.00–1.02 3242 1.02** 1.01–1.04 1.03 1.00–1.07 3282 1.03 .99–1.07
Inattention 1.02 .97–1.07 3286 1.11* 1.02–1.20 1.00 .99–1.01 3246 1.01 1.00–1.03 1.03** 1.01–1.06 3286 1.03* 1.00–1.06
Hyperactivity 1.02 .94–1.09 3283 1.12* 1.00–1.26 1.01 1.00–1.02 3243 1.03** 1.01–1.05 1.03 .99–1.06 3283 1.04 .99–1.08
16-y-olds SWAN (parent report)
Combined ADHD 1.10 .99–1.21 2754 1.19* 1.02–1.38 1.01 .99–1.03 2724 1.02 1.00–1.05 1.06* 1.01–1.11 2754 1.06* 1.00–1.11
Inattention 1.09 .98–1.20 2720 1.17* 1.00–1.37 1.01 .99–1.03 2691 1.03* 1.01–1.06 1.06* 1.01–1.11 2720 1.05 1.00–1.11
Hyperactivity-impulsivity 1.05 .94–1.17 2701 1.11 .94–1.31 1.01 .99–1.03 2672 1.02 1.00–1.05 1.03 1.00–1.08 2701 1.03 .97–1.09
aadjusted for gestational age, birth weight, socio-demographic factors (maternal age, family structure, education and social class) and medical factors (smoking during
pregnancy, parity, pre-pregnancy BMI and gestational weight gain).
badjusted as above, except for birth weight.
*p,.05; **p,.01.
doi:10.1371/journal.pone.0040534.t003
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hypertension was related to large placental size [40]. As Finland is
a high income country, it is likely that the general nutritional
standard of the nation is good. Furthermore, Finland has an
exemplary antenatal care system, along with very low infant and
maternal mortality rates [41]. Thus, it is likely that women in the
NFBC 1986 experienced compensatory placental growth in
response to adverse prenatal conditions. Extreme maternal
undernutrition at early and late stages of gestation have
respectively been associated with increased and reduced placental
size [22]. We speculate that prenatal insults related to socio-
demographic factors, which tend to be chronic, may induce a
trajectory for increased placental size from the start of pregnancy.
Acute gestational insults in late pregnancy may alone reduce
placental size; however such insults are less common than perhaps
chronic stressors, and so the effect of late gestational insults on
placental size may be diminished, thereby masking a potential
relationship between small placental size and mental health
problems.
In the present study, large placental size was associated with
psychiatric problems only in boys. Male placentas may be more
sensitive to prenatal insults, and more readily undergo compen-
satory growth in response to such disturbances [12]. Compared to
girls, boys grow faster throughout gestation [42], are usually longer
at any placental weight and have a smaller placental-to-birth-
weight ratio [43]; it has thus been postulated that male placentas
are more efficient but have less reserve capacity, causing them to
be more vulnerable to undernutrition [12], and presumably to
other forms of physiological stress. One study found that in
response to maternal asthma during pregnancy, there was no
change in the activity of the male placental hydroxysteroid (11-
beta) dehydrogenase 2 (HSD11B2) enzyme – the fetoplacental
barrier to maternal cortisol, and the fetus continued to grow [44].
In contrast, females showed reduced placental HSD11B2 activity
and decreased fetal growth. The authors suggested that the lack of
response by the male placenta may contribute to the increased risk
of morbidity and mortality of the male fetus. Furthermore, a study
in mice demonstrated that male placentas were more vulnerable to
prenatal stress, exhibiting an increase in the expression of placental
genes related to growth factors [45], which may lead to increased
male placental size.
The present study has a number of strengths, including use of
prospective data, derived from a large, longitudinal, population-
based cohort. Placental measurements were performed according
to standard procedures, by medical personnel at the time of birth.
Furthermore, mental health outcomes were assessed twice over an
8-year period, using validated screening instruments. Nevertheless,
the findings should be viewed in light of the following limitations.
First, placental weight included membranes and the umbilical
cord, and since these components are not involved in nutrient
exchange, this may in particular affect measurement of the
placental-to-birth weight ratio. Second, placental size provides
only limited insight into the role of the placenta in fetal
programming [8]. Recent work has found that the expression of
placental HSD11B2 mRNA is decreased in anxious pregnant
women [46]; since increased fetal exposure to cortisol has been
associated with neurodevelopmental disorders later in life [30], it is
possible that reduced placental HSD11B2 activity provides a link
between altered placental function and fetal programming [47]. In
animals, reduced HSD11B2 levels have been associated with
decreased placental weight [48]; it is of interest to investigate
whether this is also the case in humans, which should provide
further insight into how placental size relates to function. Third,
we only examined ADHD symptoms in adolescence due to limited
data availability. Fourth, we did not assess mental health diagnosis,
but rather whether children/adolescents screened positive for
probable diagnosis based on symptoms. This may help explain
why the frequencies of mental health problems in this study appear
somewhat high, in particular at 8 years, but are typical at the
symptom level for children of this age.
In conclusion, this study shows that placental size was associated
with mental health problems in boys during childhood and
adolescence. Placental enlargement may occur in response to
Table 4. Logistic regression results for the association between female placental size (weight, surface area and placental-to-birth-
weight ratio) and mental health outcomes.
Behavior Female Placental Weight (100g) Female Placental Surface Area (10cm
2) Female Placental-to-Birth-Weight Ratio
Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjustedb
OR 95% CI n OR 95% CI OR 95% CI n OR 95% CI OR 95% CI n OR 95% CI
8-y-olds Rutter (teacher report)
Probable psychiatric
disturbance
.94 .86–1.02 3176 .91 .79–1.04 1.00 .98–1.01 3140 1.00 .97–1.02 .99 .95–1.03 3176 .97 .92–1.01
Antisocial disorder 1.03 .91–1.16 3176 .97 .80–1.20 1.01 .99–1.03 3140 1.01 .99–1.04 1.00 .95–1.06 3176 .98 .92–1.05
Neurotic disorder .88 .77–.99 3176 .88 .72–1.10 .99 .97–1.02 3140 1.00 .96–1.02 .97 .92–1.03 3176 .96 .89–1.02
Inattention-hyperactivity .92 .82–1.04 3185 .90 .75–1.1 .99 .97–1.01 3149 .99 .96–1.02 .98 .93–1.03 3185 .95 .90–1.02
Inattention .98 .91–1.10 3187 1.01 .90–1.13 1.00 .99–1.01 3151 1.01 .99–1.03 1.02 .99–1.10 3187 1.00 .96–1.04
Hyperactivity 1.07 .93–1.24 3189 .95 .76–1.19 1.00 .97–1.03 3153 .99 .95–1.03 .99 .93–1.06 3189 .98 .90–1.06
16-y-olds SWAN (parent report)
Combined ADHD .99 .86–1.15 2779 .92 .74–1.15 1.01 .98–1.04 2745 1.01 .98–1.05 .99 .93–1.05 2779 .97 .90–1.05
Inattention 1.09 .94–1.27 2737 1.20 .95–1.50 1.01 .98–1.04 2702 1.02 .98–1.06 1.05 .98–1.11 2737 1.06 .98–1.14
Hyperactivity-impulsivity .94 .81–1.10 2725 .91 .73–1.15 1.00 .97–1.03 2690 1.01 .98–1.05 .98 .92–1.05 2725 .96 .89–1.04
aadjusted for gestational age, birth weight, socio-demographic factors (maternal age, family structure, education and social class) and medical factors (smoking during
pregnancy, parity, pre-pregnancy BMI and gestational weight gain).
badjusted as above, except for birth weight.
doi:10.1371/journal.pone.0040534.t004
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chronic adverse intrauterine conditions, and could lead to altered
fetal brain development, with long-term effects on mental health.
Future work is required to determine whether deviation in
placental size is causal or lies on the causal pathway linking
prenatal exposures to child psychopathology.
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